

Emulation of the EMPEROR-Preserved Heartfailure Trial in Healthcare Claims Data

NCT07599293

10th May, 2026

1. Title Page

| | |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title | Emulation of the EMPEROR-Preserved Heartfailure Trial in Healthcare Claims Data |
| Research question & Objectives | The EMPEROR-Preserved trial aims to evaluate the effect of Empagliflozin vs placebo on cardiovascular death and hospitalisation for heart failure among individuals with chronic heart failure with preserved ejection fraction. Our objective is to emulate the design of EMPEROR-Preserved using healthcare claims data and benchmark our results against the trial. |
| Protocol version | Version 1 |
| Last update date | May 10, 2026 |
| Contributors | Primary investigators contact information: Dr. Nils Krüger, nkruger1@bwh.harvard.edu Dr. Shirley Wang, swang1@bwh.harvard.edu Contributor names: Dr. Krüger implemented the study design in the Aetion Evidence Platform. He is responsible for the validity of the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform. |
| Study registration | Site: clinicaltrials.gov Identifier: NCT07599293 |
| Sponsor | Organization: Food and Drug Administration Contact: Dr. Marie Bradley, marie.bradley@fda.hhs.gov |
| Conflict of interest | Dr. Krüger has no conflict of interest. Dr. Wang has consulted for Cytel Inc, ICA Group, and MITRE an FFRDC for Centers for Medicare and Medicaid for unrelated work. |

Table of contents

| | |
|------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1. Title Page | 1 |
| 2. Abstract | 4 |
| 3. Amendments and updates | 4 |
| 4. Rationale and background | 5 |
| 5. Research question and objectives | 5 |
| Table 2. Primary and secondary research questions and objective | 5 |
| 6. Research methods | 7 |
| 6.1 Study design | 7 |
| 6.2 Study design diagram | 8 |
| 6.3 Setting | 9 |
| 6.3.1 Context and rationale for definition of time 0 (and other primary time anchors) for entry to the study population | 9 |
| 6.3.2 Context and rationale for study inclusion criteria: | 9 |
| 6.3.3 Context and rationale for study exclusion criteria | 9 |
| 6.4 Variables | 9 |
| 6.4.1 Context and rationale for exposure(s) of interest | 9 |
| 6.4.2 Context and rationale for outcome(s) of interest | 9 |
| 6.4.3 Context and rationale for follow up | 10 |
| Table 1. Operational Definitions of Follow Up | 10 |
| 6.4.4 Context and rationale for covariates (confounding variables and effect modifiers, e.g. risk factors, comorbidities, comedications) | 11 |
| Table 2. Operational Definitions of Covariates | 11 |
| 6.5 Data analysis | 30 |
| 6.5.1 Context and rationale for analysis plan | 30 |
| Table 3. Primary, secondary, and subgroup analysis specification | 30 |
| Table 4. Sensitivity analyses – rationale, strengths and limitations | 32 |
| 6.5.2 Comparison of Results Between Database Studies and RCTs | 33 |
| 6.6 Data sources | 33 |
| 6.6.1 Context and rationale for data sources | 33 |
| Table 5. Metadata about data sources and software | 34 |
| 6.7 Data management | 35 |
| 6.8 Quality control | 37 |
| 6.9 Study size and feasibility | 37 |
| 7. Limitation of the methods | 37 |

| | |
|--------------------------------------------------------------------------------|-----------|
| 8. Protection of human subjects | 38 |
| 9. References | 38 |
| 10. Appendices | 39 |
| 1 Target Trial Framework, Operational Definitions, and Data Fitness Assessment | 39 |
| 2 Code algorithms | 39 |
| 3 Flowchart for cohort assembly | 39 |
| 4 1st feasibility assessment | 39 |
| 5 2nd feasibility assessment | 39 |
| 6 Balance Assessment - PS Distribution and C-Statistic | 39 |
| 7 Balance Assessment - Table 1 | 39 |

2. Abstract

This is a non-randomized, non-interventional study that is part of the *Randomized Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology* (RCT-DUPLICATE) initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School.

This study is part of a series that applies the Benchmark, Expand, and Calibration (BenchExCal) approach, in which an initial trial emulation is benchmarked against a completed randomized controlled trial (RCT) to inform a subsequent database study for related clinical questions or expanded indications. In this empirical example, the related clinical question has also been evaluated in a completed randomized trial, allowing comparison of the expanded database emulation with the corresponding RCT findings.^{1,2}

It is intended to emulate, as closely as is possible in healthcare insurance claims data the EMPEROR-Preserved trial described below. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization cannot be achieved in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for emulation for a range of possible reasons and does not provide information on the validity of the original RCT finding.

The EMPEROR-Preserved trial is a superiority trial to evaluate the effect of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), vs placebo on cardiovascular death and hospitalisation for heart failure among individuals with chronic heart failure with preserved ejection fraction.

The database study is designed to emulate the EMPEROR-Preserved trial. It will be a new-user active-comparator cohort study, conducted using 3 national United States claims databases, where we compare the effect of empagliflozin vs sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP4i), on all-cause mortality and hospitalisation for heart failure in those with T2DM. While the EMPEROR-Preserved trial was conducted in participants with and without T2DM, both subgroups showed similar effect estimates in their results.³ Furthermore, while the trial compared empagliflozin to placebo, we chose to use sitagliptin as an active comparator proxy for placebo to minimize confounding by indication. Sitagliptin was specifically chosen because a major randomized controlled trial on cardiovascular outcomes demonstrated that it does not affect the cardiovascular outcomes under investigation. Furthermore, clinical guidelines during the study period recommended both SGLT2 inhibitors and DPP4 inhibitors as second- or third-line options for glucose lowering, and the therapies are similarly costly, reducing concerns about channelling of patients based on socioeconomic status.⁴ To capture preserved ejection fraction in healthcare claims data, we apply a validated algorithm that predicts ejection fraction. While the trial evaluated cardiovascular mortality, the database study captures all-cause mortality.

Optum: Eligible cohort entry period from August 1, 2014 to August 31, 2024.

Marketscan: Eligible cohort entry period from August 1, 2014 to September 30, 2023.

Medicare: Eligible cohort entry period from August 1, 2014 to September 30, 2020.

3. Amendments and updates

| Version date | Version number | Section of protocol | Amendment or update | Reason |
|--------------|----------------|---------------------|---------------------|--------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |

4. Rationale and background

The purpose of this protocol is to specify the emulation of the EMPEROR-Preserved trial ([NCT03057951](#)). empagliflozin became available on August 1, 2014, when it was approved to treat type 2 diabetes mellitus. Two years later, on December 2, 2016 empagliflozin was approved to reduce cardiovascular death in patients with type 2 diabetes mellitus and cardiovascular disease. Later on, empagliflozin was approved to treat heart failure with reduced ejection fraction (August 18, 2021) and preserved ejection fraction (February 25, 2022).

The EMPEROR-Preserved trial randomized 5,988 participants between February 2, 2017 and April 26, 2021. The trial design was event-driven, with a median follow-up period of 26.2 months and 239 of 1466 primary composite events occurring in the empagliflozin type 2 diabetes subgroup and 291 of 1472 composite events in the placebo type 2 diabetes subgroup. The trial was conducted with 90% power and a 0.05 type I error rate to confirm superiority.

In the emulation of the EMPEROR-Preserved trial, we chose sitagliptin as a cardiovascular outcome-neutral comparator because a major randomized controlled trial on cardiovascular outcomes demonstrated that it does not affect the cardiovascular outcomes under investigation.⁵ This contrasts with saxagliptin, which has raised concerns regarding potential increased risks of heart failure.⁶⁻⁹ Linagliptin is commonly prescribed for patients with renal impairment because it does not require dose modifications based on kidney function, which may lead to increased confounding compared to sitagliptin.^{10,11} Glucagon-like peptide-1 receptor agonists would not be a neutral comparator, as they significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.¹² Sulfonylureas (SUs), though inexpensive and widely used, are a poor comparator in cardiovascular outcome studies due to their association with hypoglycemia, weight gain, and channeling bias, as they are often prescribed to elderly, lower socioeconomic status patients with higher baseline cardiovascular risk, making direct comparisons to newer agents like SGLT2i less reliable.¹³

5. Research question and objectives

Table 2. Primary and secondary research questions and objective

A. Primary research question and objective

| | |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective: | To evaluate the comparative effect of empagliflozin vs sitagliptin on hospitalisation for heart failure or all-cause mortality in patients with heart failure and preserved ejection fraction. |
| Hypothesis: | We hypothesize that empagliflozin will be superior to sitagliptin in individuals with chronic heart failure and preserved ejection fraction at preventing all-cause mortality and hospitalization for heart failure. |
| Population (mention key inclusion-exclusion criteria): | Individuals aged 18 years or older with heart failure and preserved ejection fraction and type 2 diabetes. Additional eligibility criteria aligned with the EMPEROR-Preserved trial. |
| Exposure: | Empagliflozin. |
| Comparator: | Sitagliptin. |
| Outcome: | A composite of hospitalization for heart failure or all-cause mortality. |
| Time (when follow up begins and ends): | 1 day after cohort entry date until the first of outcome, disenrollment, end of study period, discontinuation (45 days grace and risk window), switch between the arms, start of any other SGLT2i or DPP4i. |
| Setting: | Patients may be treated in outpatient settings. The outcome will be measured from inpatient hospitalizations and death. |
| Main measure of effect: | Hazard ratio. |

B. Secondary research questions and objectives

| | |
|--------------------|-------------------------------------------------------------------------------------------------------------|
| Objective: | To evaluate the comparative effect of empagliflozin vs sitagliptin on the control outcome cataract surgery. |
| Hypothesis: | We hypothesize that empagliflozin will not have a different effect from sitagliptin. |

| | |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population (mention key inclusion-exclusion criteria): | Individuals aged 18 years or older with heart failure and preserved ejection fraction and type 2 diabetes. Additional eligibility criteria aligned with the EMPEROR-Preserved trial. |
| Exposure: | Empagliflozin. |
| Comparator: | Sitagliptin. |
| Outcome: | Cataract surgery. |
| Time (when follow up begins and ends): | 1 day after cohort entry date until the first of outcome, disenrollment, end of study period, discontinuation (45 days grace and risk window), switch between the arms, start of any other SGLT2i or DPP4i. |
| Setting: | Patients may be treated in inpatient or outpatient settings. The outcome will be measured using procedure codes in an inpatient or outpatient setting. |
| Main measure of effect: | Hazard ratio. |

| | |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective: | To evaluate the comparative effect of empagliflozin vs sitagliptin on the control outcome lumbar radiculopathy. |
| Hypothesis: | We hypothesize that empagliflozin will not have a different effect from sitagliptin. |
| Population (mention key inclusion-exclusion criteria): | Individuals aged 18 years or older with heart failure and preserved ejection fraction and type 2 diabetes. Additional eligibility criteria aligned with the EMPEROR-Preserved trial. |
| Exposure: | Empagliflozin. |
| Comparator: | Sitagliptin. |
| Outcome: | Lumbar radiculopathy (excluding patients with recent outcome prior to the follow-up time window (30 days)). |
| Time (when follow up begins and ends): | 1 day after cohort entry date until the first of outcome, disenrollment, end of study period, discontinuation (45 days grace and risk window), switch between the arms, start of any other SGLT2i or DPP4i. |
| Setting: | Patients may be treated in inpatient settings. The outcome will be measured using diagnosis and procedure codes in an inpatient setting. |

| | |
|--------------------------------|---------------|
| Main measure of effect: | Hazard ratio. |
|--------------------------------|---------------|

C.

| | |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective: | To evaluate the comparative effect of empagliflozin vs sitagliptin on the control outcome hernia. |
| Hypothesis: | We hypothesize that empagliflozin will not have a different effect from sitagliptin. |
| Population (mention key inclusion-exclusion criteria): | Individuals aged 18 years or older with heart failure and preserved ejection fraction and type 2 diabetes. Additional eligibility criteria aligned with the EMPEROR-Preserved trial. |
| Exposure: | Empagliflozin. |
| Comparator: | Sitagliptin. |
| Outcome: | Hernia (excluding patients with recent outcome prior to the follow-up time window (30 days)). |
| Time (when follow up begins and ends): | 1 day after cohort entry date until the first of outcome, disenrollment, end of study period, discontinuation (45 days grace and risk window), switch between the arms, start of any other SGLT2i or DPP4i. |
| Setting: | Patients may be treated in inpatient settings. The outcome will be measured using diagnosis and procedure codes in an inpatient setting. |
| Main measure of effect: | Hazard ratio. |

6. Research methods


6.1 Study design

Research design (e.g. cohort, case-control, etc.): New user active comparator cohort study.

Rationale for study design choice: The new user active-comparator design may be able to address confounding by indication. It accomplishes this, in large part, through judicious selection of an appropriate active-comparator group. While selection of an appropriate comparator in the design phase is crucial, cohort studies often require additional adjustment of measurable confounders. A common method for adjusting for confounding is via a propensity score.

6.2 Study design diagram

Figure 1. Exposure-based cohort entry where the cohort entry date is selected after application of exclusion criteria.



6.3 Setting

6.3.1 Context and rationale for definition of time 0 (and other primary time anchors) for entry to the study population

Time 0 in the database study was defined to emulate randomization to empagliflozin vs sitagliptin in the clinical trial design. See appendix tables 1 and 2a for operational definitions and detailed code algorithms.

6.3.2 Context and rationale for study inclusion criteria:

Study inclusion criteria were defined to emulate the inclusion criteria for the trial. See appendix tables 1 and 2 for operational definitions and detailed code algorithms. A flowchart of the study cohort assembly is provided in Appendix 3.

6.3.3 Context and rationale for study exclusion criteria

Study exclusion criteria were defined to emulate the exclusion criteria for the trial. See appendix tables 1 and 2 for operational definitions and detailed code algorithms. A flowchart of the study cohort assembly is provided in Appendix 3.

6.4 Variables

6.4.1 Context and rationale for exposure(s) of interest

The exposure and comparator were defined to emulate the agents compared for the trial, Empagliflozin vs Sitagliptin. See appendix tables 1 and 2 for operational definitions and detailed code algorithms.

Algorithm to define duration of exposure effect:

Assuming the effect of the drug lasts for 45 days after the days' supply, we allow a 45 days gap between the dispensation (grace period) and also add 45 days at the end of days' supply of dispensation (exposure risk window).

6.4.2 Context and rationale for outcome(s) of interest

The primary outcome for the database study was defined to emulate the primary outcome for the trial of cardiovascular death and hospitalization for heart failure. In our emulation, due to inability to capture cause of death, our modified composite endpoint was measured as all-cause mortality and hospitalization for heart failure. See appendix tables 1 and 2d for operational definitions and detailed code algorithms. Optum includes death information from the inpatient discharged dead status, social security death master file, and deaths scraped from obituaries or other sources. MarketScan includes information from the inpatient discharged dead status up until 2016. Medicare includes information from the inpatient discharged dead status, NDI cause of death, and social security death master file. PPV for HF diagnosis using ICD9 codes was 87% and for HHF 98%.^{14,15}

Control outcomes of interest include:

1. Cataract surgery. This is a negative control outcome where no difference in effect is expected for empagliflozin vs sitagliptin.
2. Lumbar radiculopathy. This is a negative control outcome where no difference in effect is expected for empagliflozin vs sitagliptin.
3. Hernia. This is a negative control outcome where no difference in effect is expected for empagliflozin vs sitagliptin.

6.4.3 Context and rationale for follow up

Both on-treatment (OT) and intention-to-treat (ITT) analyses will be conducted. Adherence in clinical practice databases is expected to be much worse than in the trial, therefore the OT analysis will be the primary analysis. The OT analysis targets the relative hazard of outcomes while on treatment and may more closely emulate the effect observed in highly adherent trial participants. Both OT and ITT will be conducted at 1-year follow-up and compared to the hazard ratio of cumulative incidence rates observed in the trial.

Table 1. Operational Definitions of Follow Up

| | | |
|------------------------------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------------|
| Follow up start | Day 1 | |
| Follow up end¹ | Select all that apply | Specify |
| Date of outcome | Yes | |
| Date of death | Yes | Part of the outcome. |
| End of observation in data | Yes | Date of disenrollment. |
| Day X following index date (specify day) | Yes | Day 365. |
| End of study period (specify date) | Yes | Optum: August 31, 2024; Marketscan: December 31, 2023; Medicare: December 31, 2020. |
| End of exposure (specify operational details, e.g. stockpiling algorithm, grace period) | Yes | 45 days grace window and 45 days risk window. |
| Date of add to/switch from exposure (specify algorithm) | Yes | Date of augmentation or switching from an exposure to a comparator and vice versa. |

| | | |
|----------------------|-----|---------------------------------------------------------------------------|
| Other date (specify) | Yes | Censor upon nursing home admission or starting any other SGLT2i or DPP4i. |
|----------------------|-----|---------------------------------------------------------------------------|

¹ Follow up ends at the first occurrence of any of the selected criteria that end follow up.

6.4.4 Context and rationale for covariates (confounding variables and effect modifiers, e.g. risk factors, comorbidities, comedications)

We identified a series of covariates that were likely confounders due to being strong risk factors for the primary outcome that were associated with choice of treatment. These include demographics, disease severity related variables, comorbid conditions, comedications, frailty, healthcare utilization and markers of health seeking behaviour. Covariate coding may be subject to changes before final treatment-effect estimation if propensity score diagnostics indicate sparse cells, unstable estimates, quasi-separation, or inadequate overlap.

Table 2. Operational Definitions of Covariates

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|---------------------|--------------------------------------------------------------------------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|----------------------|
| Demographics | | | | | | | | | |
| Age | Cohort entry year – year of birth, (last observed value in the baseline) | Continuous | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | n/a |
| Gender | Male, Female (last observed value in the baseline) | Categorical | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | n/a |
| Race | White, Asian, Black, Hispanic, Unknown/ | Categorical | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | n/a |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|---------------------------------------------------------|----------------------------------------------------------------------------------------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| | Missing/Other (last observed value in the baseline) | | | | | | | | |
| Region | Northeast, Midwest/Northern central, South, West (last observed value in the baseline) | Categorical | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | n/a |
| Lifestyle risk factors | | | | | | | | | |
| Smoking | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Overweight, if BMI is 25.0 to 29.9 | | Binary | [-730, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Class 1 (low-risk) obesity, if BMI is 30.0 to 34.9 | | Binary | [-730, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Class 2 (moderate-risk) obesity, if BMI is 35.0 to 39.9 | | Binary | [-730, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|-------------------------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Class 3 (high-risk) obesity if BMI is equal to or greater than 40 | | Binary | [-730, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Unspecified obesity | | Binary | [-730, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Diabetes complications | | | | | | | | | |
| Diabetes complications | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Skin infections | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Erectile dysfunction | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Urinary tract infections | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Genital infections | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hypoglycemia | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Hyperglycemia, DKA, HONK | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Cardiovascular-related conditions | | | | | | | | | |
| Unstable angina | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Stable angina | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hypertension | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hypotension | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hyperlipidemia | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Atrial fibrillation | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Previous MI | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| | | | | | | | Reference: Sitagliptin | | |
| Coronary atherosclerosis | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Previous cardiac procedure (CABG, PTCA, Stent) | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Cardiac conduction disorder | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Ischemic stroke | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| PVD diagnosis / surgery | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Other cardiac dysrhythmia | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Cardiomyopathy | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|---------------------------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Valve disorders | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Valve replacement | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| TIA | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Edema | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Venous thromboembolism (Deep vein thrombosis or pulmonary embolism) | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Pulmonary hypertension | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Renal-related conditions | | | | | | | | | |
| CKD stage 1-2 | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|-------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| | | | | | | | Reference: Sitagliptin | | |
| CKD stage 3-4 | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Unspecified CKD | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Acute kidney injury / Acute renal disease | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Urolithiasis (kidney and urinary stones) | | Binary | [-183, 0] | Any | ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Other renal conditions | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hypertensive nephropathy | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Other comorbidities | | | | | | | | | |
| COPD | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|---------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Asthma | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Obstructive sleep apnea | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Pneumonia | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Influenza | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hyperthyroidism and other thyroid gland disorders | | Binary | [-183, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hypothyroidism | | Binary | [-183, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Urinary incontinence | | Binary | [-183, 0] | Any | ICD-10-CM, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Serious infections | | Binary | [-183, 0] | Inpatient | ICD-10-CM, ICD-9-CM | Primary | Exposure: Empagliflozin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| | | | | | | | Reference: Sitagliptin | | |
| Liver disease | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Fractures/ Falls | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Osteoporosis | | Binary | [-183, 0] | Any | ICD-10-C, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Osteoarthritis | | Binary | [-183, 0] | Any | ICD-10-C, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Depression | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Anxiety | | Binary | [-183, 0] | Any | ICD-10-C, ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Sleep disorder | | Binary | [-183, 0] | Any | ICD-10-CM ICD-9-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|-----------------------------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Dementia | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Delirium | | Binary | [-183, 0] | Any | ICD-9-CM, ICD-10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Hyperkalemia | | Binary | [-183, 0] | n/a | ICD-9-CM, ICD-10-CM | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Anemia | | Binary | [-183, 0] | n/a | ICD-9-CM, ICD-10-CM | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Microalbuminuria | | Binary | [-183, 0] | n/a | CPT/HCPSCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Diabetes medications | | | | | | | | | |
| Number of antidiabetic drugs at cohort entry; median (iqr), mean (sd) | | Continuous | [0, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Concomitant use or initiation of metformin | | Binary | [0, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|----------------------------------------------------------------------------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Past use of metformin | | Binary | [-183, -1] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Past use of sulfonylureas | | Binary | [-183, -1] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Past use of GLP-1 receptor agonists | | Binary | [-183, -1] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Past use of insulin | | Binary | [-183, -1] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Past use of other antidiabetics (Meglitinides, Thiazolidones / Glitazones, Amylin analogs, Alpha-glucosidase (AGIs)) | | Binary | [-183, -1] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Heart failure medications | | | | | | | | | |
| ACEi / ARB | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|---------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| | | | | | | | Reference: Sitagliptin | | |
| ARNI | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Mineralocorticoid receptor antagonist | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Thiazide diuretics | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Beta-Blockers | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Calcium channel blockers | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Digoxin / Digitoxin | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Loop diuretics | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|--------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Other diuretics | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Intravenous diuretics | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Nitrates | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Other medications | | | | | | | | | |
| Number of distinct medications | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Antiarrhythmics | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Statins | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Other lipid-lowering drugs | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|---------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Antiplatelet agents | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Oral anticoagulants | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| COPD/Asthma medication | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| NSAIDs | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Oral corticosteroids | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Osteoporosis agents (incl. bisphosphonates) | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Opioids | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Antidepressants | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| | | | | | | | Reference: Sitagliptin | | |
| Benzodiazepines | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Dementia meds | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Antipsychotics | | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Healthcare utilization markers | | | | | | | | | |
| Emergency department visit | | Binary | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Office visit | | Continuous | [-183, 0] | OP | CPT/HCPCS | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Endocrinologist visit, median (iqr), mean (sd) | | Binary | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Endocrinologist visit, (within prior 30 d) | | Binary | [-30, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|------------------------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Endocrinologist visit, (31-183 d) | | Binary | [-183, -31] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Cardiologist visit, median (iqr), mean (sd) | | Binary | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Cardiologist visit, (within prior 30 d) | | Binary | [-30, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Cardiologist visit, (31-183 d) | | Binary | [-183, -31] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Internal medicine/family medicine visit, median (iqr), mean (sd) | | Binary | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Internal medicine/family medicine visit, (within prior 30 d) | | Binary | [-30, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Internal medicine/family medicine visit, (31-183 d) | | Binary | [-183, -31] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|-----------------------------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Pharmacy out-of-pocket cost, median (iqr), mean (sd) | | Continuous | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Unique brand medications, median (iqr), mean (sd)** | | Continuous | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Unique generic medications, median (iqr), mean (sd)** | | Continuous | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Ratio of unique brand to generic medications, median (iqr), mean (sd) | | Continuous | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Healthy behavior markers | | | | | | | | | |
| Electrocardiograms | | Binary | [-183, 0] | Any | CPT/HCPCS | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Echocardiograms | | Continuous | [-180, 0] | Any | CPT/HCPCS | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|-----------------------------------------------------------------|---------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| Flexible sigmoidoscopy or colonoscopy or CT virtual colonoscopy | | Binary | [-183, 0] | n/a | CPT/HCPCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Flu vaccine | | Binary | [-183, 0] | n/a | CPT/HCPCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Pneumococcal vaccine | | Binary | [-183, 0] | n/a | CPT/HCPCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Laboratory and diagnostic tests | | | | | | | | | |
| Glucose tests / HbA1c / oral glucose tolerance test | | Continuous | [-183, 0] | Any | CPT/HCPCS | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Lipid panel | | Continuous | [-183, 0] | Any | CPT/HCPCS | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Creatinine tests | | Continuous | [-183, 0] | Any | CPT/HCPCS | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Pap smear | | Binary | [-183, 0] | n/a | CPT/HCPCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|-------------------------------------------------------|----------------------------------------------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|-------------------------------------------|
| PSA test or prostate exam | | Binary | [-183, 0] | n/a | CPT/HCPCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Fecal Occult Blood Test | | Binary | [-183, 0] | n/a | CPT/HCPCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Urine test | | Binary | [-183, 0] | n/a | CPT/HCPCS | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |
| Burden of comorbidities | | | | | | | | | |
| Combined comorbidity score | | Continuous | [-183, 0] | Any | ICD10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Gagne et al., Sun et al. ^{16,17} |
| Frailty score | | Continuous | [-183, 0] | Any | ICD10-CM | Any | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Kim et al. ¹⁸ |
| Calendar year of cohort entry | | | | | | | | | |
| Cohort entry year | 2014-2018, 2019, 2020, 2021, 2022, 2023-2024 | Categorical | [0, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | n/a |
| Baseline hospitalizations and hospital metrics | | | | | | | | | |
| Number of any hospitalization | | Continuous | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin | n/a | |

| Characteristics | Details | Type of variable | Assessment window | Care Settings ¹ | Code Type ² | Diagnosis Position ³ | Applied to study populations: | Measurement characteristics/ validation | Source for algorithm |
|--------------------------------------------------------|----------------------------------------|------------------|-------------------|----------------------------|------------------------|---------------------------------|---------------------------------------------------|-----------------------------------------|---------------------------------|
| (0, 1, >1) | | | | | | | Reference: Sitagliptin | | |
| Number of hospitalization for heart failure (0, 1, >1) | | Continuous | [-183, 0] | n/a | n/a | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | |
| Dual status/low income subsidy | Dual Status code: 01/02/03/04/05/06/08 | Binary | [-183, 0] | n/a | generic | n/a | Exposure: Empagliflozin Reference: Sitagliptin | n/a | Appendix, Covariate – Algorithm |

¹IP = inpatient, OP = outpatient, ED = emergency department, OT = other, n/a = not applicable

²See appendix for listing of clinical codes for each study parameter

³Specify whether a diagnosis code is required to be in the primary position (main reason for encounter)

6.5 Data analysis

6.5.1 Context and rationale for analysis plan

The study will use a propensity score based overlap weighting method.¹⁹ This approach was selected because it covariate balance while preserving patients, thereby maximizing power. The propensity score will be estimated as the probability of initiating empagliflozin vs sitagliptin given the baseline patient characteristics using multivariable logistic regression models. As diagnostics for propensity score models, the study will evaluate distributional overlap, weight distribution, and covariate balance using standardized differences post-weighting. The study will estimate the hazard ratio for empagliflozin vs sitagliptin on the composite of heart failure hospitalisation or all-cause mortality in the weighted population using a Cox proportional hazards model with robust standard errors. Across all analyses, results from the three databases will be pooled via fixed effects meta-analysis.

Table 3. Primary, secondary, and subgroup analysis specification

A. Primary analysis

| | |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis: | Empagliflozin decreases the risk of the composite end point of hospitalization for heart failure or all-cause mortality in individuals with heart failure and preserved ejection fraction and type 2 diabetes. |
| Exposure contrast: | Empagliflozin vs sitagliptin. |
| Outcome: | Hospitalization for heart failure or all-cause death. |
| Analytic software: | Aetion, SAS 9.4, R.4.4.0 |
| Model(s): (provide details or code) | Outcome model: weighted Cox proportional hazards model using overlap weights. Follow-up time * status(0) = exposure |
| Confounding adjustment method | Name method and provide relevant details, e.g. bivariate, multivariable, propensity score matching (specify matching algorithm ratio and caliper), propensity score weighting (specify weight formula, trimming, truncation), propensity score stratification (specify strata definition), other. |
| | Overlap weighting based on the propensity score. Weights: 1-PS for treated patients and PS for untreated patients, where PS denotes the probability of receiving treatment conditional on baseline covariates. |
| Missing data methods | Name method and provide relevant details, e.g. missing indicators, complete case, last value carried forward, multiple imputation (specify model/variables), other. |
| | Assumption that if no relevant claims diagnoses/procedures are present, the condition is not present. |
| Subgroup Analyses | List all subgroups |
| | N/A. |

B. Secondary Analyses

| | |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis: | Empagliflozin has no increased or decreased risk of cataract surgery (control outcome) compared to sitagliptin. |
| Exposure contrast: | Empagliflozin vs sitagliptin |
| Outcome: | Cataract surgery (control outcome) |
| Analytic software: | Aetion, SAS 9.4, R.4.4.0 |
| Model(s): (provide details or code) | Outcome model: weighted Cox proportional hazards model using overlap weights. Follow-up time*status(0) = exposure |
| Confounding adjustment method | Name method and provide relevant details, e.g. bivariate, multivariable, propensity score matching (specify matching algorithm ratio and caliper), propensity score weighting (specify weight formula, trimming, truncation), propensity score stratification (specify strata definition), other. |
| | Overlap weighting based on the propensity score. Weights: 1-PS for treated patients and PS for untreated patients, where PS denotes the probability of receiving treatment conditional on baseline covariates. |
| Missing data methods | Name method and provide relevant details, e.g. missing indicators, complete case, last value carried forward, multiple imputation (specify model/variables), other. |
| | Assumption that if no relevant claims diagnoses/procedures are present, the condition is not present. |

| | |
|--------------------------|---------------------------|
| Subgroup Analyses | List all subgroups |
| | N/A. |

| | |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis: | Empagliflozin has no increased or decreased risk of lumbar radiculopathy (control outcome) compared to sitagliptin. |
| Exposure contrast: | Empagliflozin vs sitagliptin |
| Outcome: | Lumbar radiculopathy (excluding patients with recent outcome prior to the follow-up time window (30 days)) (negative control outcomes). |
| Analytic software: | Aetion, SAS 9.4, R.4.4.0 |
| Model(s): (provide details or code) | Outcome model: weighted Cox proportional hazards model using overlap weights. Follow-up time*status(0) = exposure |
| Confounding adjustment method | Name method and provide relevant details, e.g. bivariate, multivariable, propensity score matching (specify matching algorithm ratio and caliper), propensity score weighting (specify weight formula, trimming, truncation), propensity score stratification (specify strata definition), other. |
| | Overlap weighting based on the propensity score. Weights: 1-PS for treated patients and PS for untreated patients, where PS denotes the probability of receiving treatment conditional on baseline covariates. |
| Missing data methods | Name method and provide relevant details, e.g. missing indicators, complete case, last value carried forward, multiple imputation (specify model/variables), other. |
| | Assumption that if no relevant claims diagnoses/procedures are present, the condition is not present. |
| Subgroup Analyses | List all subgroups |
| | N/A. |

| | |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Hypothesis: | Empagliflozin has no increased or decreased risk of hernia (control outcome) compared to sitagliptin. |
| Exposure contrast: | Empagliflozin vs sitagliptin |
| Outcome: | Hernia (excluding patients with recent outcome prior to the follow-up time window (30 days)) (negative control outcomes). |
| Analytic software: | Aetion, SAS 9.4, R.4.4.0 |
| Model(s): (provide details or code) | Outcome model: weighted Cox proportional hazards model using overlap weights. Follow-up time*status(0) = exposure |

| | |
|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Confounding adjustment method | Name method and provide relevant details, e.g. bivariate, multivariable, propensity score matching (specify matching algorithm ratio and caliper), propensity score weighting (specify weight formula, trimming, truncation), propensity score stratification (specify strata definition), other. |
| | Overlap weighting based on the propensity score. Weights: 1-PS for treated patients and PS for untreated patients, where PS denotes the probability of receiving treatment conditional on baseline covariates. |
| Missing data methods | Name method and provide relevant details, e.g. missing indicators, complete case, last value carried forward, multiple imputation (specify model/variables), other. |
| | Assumption that if no relevant claims diagnoses/procedures are present, the condition is not present. |
| Subgroup Analyses | List all subgroups |
| | N/A. |

Table 4. Sensitivity analyses – rationale, strengths and limitations

| | What is being varied? How? | Why? (What do you expect to learn?) | Strengths of the sensitivity analysis compared to the primary | Limitations of the sensitivity analysis compared to the primary |
|----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Cataract surgery as negative control outcome | We are changing the outcome to cataract surgery, and outcome for which there is expected to be no causal effect from empagliflozin. | We will evaluate the potential impact of residual confounding on this outcome for which there is not expected to be a causal effect | The evaluates the robustness of the interpretation of the primary analysis by evaluating the potential magnitude of unmeasured confounding | This analysis assumes that the confounding structure is the same or similar for the negative control outcome as the outcome of interest |
| Hernia as a negative control outcome. | We are changing the outcome to hernia for which there is expected to be no causal effect from empagliflozin. | We will evaluate the potential impact of residual confounding on this outcome for which there is not expected to be a causal effect. | Evaluates the robustness of the interpretation of the primary analysis by evaluating the potential magnitude of unmeasured confounding. | This analysis assumes that the confounding structure is the same or similar for the negative control outcome as the outcome of interest. |
| Lumbar radiculopathy as a | We are changing the outcome to lumbar | We will evaluate the potential impact of residual | Evaluates the robustness of the interpretation of the | This analysis assumes that the confounding structure is the |

| | | | | |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| negative control outcome. | radiculopathy for which there is expected to be no causal effect from empagliflozin. | confounding on this outcome for which there is not expected to be a causal effect. | primary analysis by evaluating the potential magnitude of unmeasured confounding. | same or similar for the negative control outcome as the outcome of interest. |
| Broader definition of primary end point | Instead of requiring an inpatient discharge diagnosis in the primary position for heart failure, we will allow an inpatient diagnosis in any position for heart failure. All-cause mortality is unchanged. | Helps determine whether restricting to primary-position heart failure diagnoses omits relevant cases or whether including secondary diagnoses introduces misclassification. | Increases sensitivity for capturing hospitalizations for heart failure. | Some hospitalizations may primarily be for other conditions rather than heart failure itself. |
| Change in grace and risk windows | The grace period and exposure risk window will be varied by shortening and extending them to 30 days and 60 days, respectively. | To assess the potential impact of exposure misclassification arising from uncertainty in the duration of treatment effects and medication adherence. | Evaluates the robustness of the primary findings to alternative assumptions regarding exposure definition and risk attribution. | Alternative risk windows may not accurately reflect the true duration of drug exposure or biological effect. Shorter windows may underestimate treatment effects by missing delayed events, whereas longer windows may increase exposure misclassification by attributing events occurring after treatment discontinuation to the drug. |
| Re-weighted population distribution. | We will re-weight the population distribution of the pooled database study cohorts to reflect that of the RCT. | We will learn about potential effect modification due to different distributions of key characteristics such as age/sex in the RCT vs the database study. | The population distributions will be more aligned. | The measurement of these population characteristics may be measured differently in the RCT vs database study, with different levels of specificity and sensitivity. |
| Apply benchmark, expand, calibrate | We will use the observed difference in result from | We expect to learn about the performance of | The analysis will calibrate the primary result based on | The ability to appropriately calibrate the result depends on |

| | | | | |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (BenchExCal) sensitivity and tipping point analysis. | emulation of EMPEROR-Reduced to recalibrate the result from the database study emulation of EMPEROR-Preserved. We will conduct a tipping point analysis with a range of plausible estimates of the expected difference. | BenchExCal in an example where we emulate an RCT for an expanded indication and an RCT result for the expanded indication is available. | expected differences due to bias and/or design emulation differences and propagate uncertainty regarding the impact of these factors into the frequentist primary result. | how “close” the clinical context and confounding structure is between the initial and expanded indication. The approach assumes that the net effect of bias and design emulation differences is similar. |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

6.5.2 Comparison of Results Between Database Studies and RCTs

We will attempt to benchmark the results of the primary analysis from the database study against the composite end point of hospitalization for heart failure or all-cause mortality observed in the type 2 diabetes subgroup of the EMPEROR-Preserved trial. Consequently, failure to replicate the RCT findings is not necessarily indicative of the inadequacy of the healthcare claims data for emulation for a range of possible reasons, nor does failure to replicate provide information about the validity of the trial result.

Assessment of concordance in results between the database study-trial pair will use the metrics previously implemented in the RCT-DUPLICATE initiative, namely statistical significance agreement, estimate agreement, and standardized difference agreement. In this project, “full” statistical significance agreement was defined by estimates and confidence intervals on the same side of null; estimate agreement was defined by whether estimates for the trial emulation fell within the 95% CI for the trial results; standardized difference agreement between treatment effect estimates from trials and emulations was defined by standardized differences $|Z| < 1.96$ ($Z = \frac{(\theta_{RCT} - \theta_{RWE})}{\sqrt{\hat{\sigma}_{RCT}^2 + \hat{\sigma}_{RWE}^2}}$ where θ are the treatment effect estimates and the $\hat{\sigma}^2$ are associated variances). In addition, “partial” significance agreement was defined as meeting pre-specified non-inferiority criteria even though a more highly powered database study may have indicated superiority.^{20,21}

6.6 Data sources

6.6.1 Context and rationale for data sources

Reason for selection: The study will be conducted in 3 US health care claims databases: Optum Clinformatics (2004-2025), Merative Marketscan (2012-2023) and Medicare (2007-2020). Should additional Medicare data become available during the conduct of the study, more recent data may be incorporated into the analyses.

Strengths of data source(s): Each data source contains deidentified, longitudinal, date-stamped information on patient enrollment, demographics, inpatient/outpatient diagnosis and procedures, admission and discharge dates, and medication dispensation. The death data is captured in the Optum database from inpatient discharge status, social security death master file, and deaths scraped from obituaries or other sources. The death data in MarketScan is captured from the social security death master file and inpatient discharge status. It is recognized that the social security death master file has high specificity and positive predictive value for deaths. While this data resource has under captured deaths since 2011, the capture of deaths is not expected to be differential between compared exposure groups. The death data is captured in the Medicare database from inpatient discharge status, and social security death master file.^{22–24}

Limitations of data source(s): Patient healthcare encounters are only observable when they are enrolled in an insurance plan that contributes to the database. Patients may change insurance plans for multiple reasons. Both Optum Clinformatics and Merative MarketScan are primarily employer based insurance databases where patients may disenroll with job changes. Patients in Medicare may move in and out of fee-for-service plans. We are excluding person-time in health maintenance organization (HMO) plans due to concerns about the completeness of capture of diagnoses and procedures. This means that we require patients to be enrolled in Medicare parts AB and D during the baseline assessment window and censor patients if they switch to part C. In claims data, dispensing data for inpatient medication is unavailable. Diagnoses reflect billing practices, therefore algorithms (preferably validated) are needed for accurate phenotyping of patient conditions. Services that are not covered by insurance do not appear in the data. The trial evaluated cardiovascular deaths, however we will evaluate all cause death in the emulation because most deaths in this cohort of patients at high cardiovascular risk will likely be attributed to cardiovascular reasons, the cause of death is not recorded for databases not linked to NDI, and the performance of NDI at identifying cardiovascular causes of death may be suboptimal.²⁴ The completeness of death ascertainment differs across the three databases. Optum captures deaths from multiple sources, including inpatient discharge status, the Social Security Death Master File, and obituary-based sources, whereas Medicare includes death information from inpatient discharge records, the Social Security Death Master File, and National Death Index linkages. In contrast, death ascertainment in MarketScan is more limited and is primarily based on inpatient discharge status, resulting in undercapture of deaths occurring outside the hospital setting. Although this limitation may reduce the sensitivity of mortality ascertainment, it is not expected to differ systematically between treatment groups and therefore is unlikely to introduce substantial differential bias in comparative effect estimates.

Data source provenance/curation:

Information about Optum Clinformatics and Merative MarketScan can be found in data dictionaries and user guides that are provided to clients. Information about Medicare data provenance and curation can be found on the ResDac website.²⁵

Table 5. Metadata about data sources and software

| | Data 1 | Data 2 | Data 3 |
|-----------------|---------------------|---------------------|----------|
| Data Source(s): | Optum Clinformatics | Merative MarketScan | Medicare |

| | | | |
|-----------------------------------------------|----------------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Study Period: | January 1, 2004 - Aug 31, 2025 | December 31, 2012 - December 31, 2023 | January 1, 2007 - December 31, 2020 |
| Eligible Cohort Entry Period: | August 1, 2014 - August 31, 2024 | August 1, 2014 - September 30, 2023 | August 1, 2014 - September 30, 2020 |
| Data Version (or date of last update): | Jan 2026 | May 2025 | Jan 2024 |
| Data sampling/extraction criteria: | n/a | n/a | Patients were extracted on the basis of having a diabetes diagnosis or diabetes drug in any of the years of data |
| Type(s) of data: | Administrative claims | Administrative claims | Administrative claims |
| Data linkage: | n/a | n/a | Linkage to National Death Index |
| Conversion to CDM*: | n/a | n/a | n/a |
| Software for data management: | Aetion Evidence Platform® (2026) | Aetion Evidence Platform® (2026) | Aetion Evidence Platform® (2026) |

*CDM = Common Data Model

6.7 Data management

Tracking data: The Data Use Agreement (DUA) Custodian (Principal Investigator) and the Division Operations Manager (Winta Tekle) are responsible for receiving and creating a record of new data associated with the given request. The Operations Manager is responsible for all indexing and archiving of documents and electronic media related to data that the Division receives and will log data location, data contents, and associated DUA and Institutional Review Board (IRB) numbers in the Division's centralized tracking system.

Handling and storage: In-scope data will be stored utilizing Mass General Brigham approved information systems – i.e., Division servers and Mass General Brigham network storage.

Archiving: Data retention and any removal will be executed by the Division Operations Manager (Winta Tekle) and Data Manager (Todd MacGarvey). The Division follows Mass General Brigham enterprise record retention policies and follow the terms of the agreement through which the in-scope data was received.

Information security: The Division follows Mass General Brigham's Enterprise Information Security Program (EISP). The EISP helps by providing assurance that Mass General Brigham information and information systems are protected from unauthorized access, use, disclosure, duplication, modification, or destruction in order to maintain their confidentiality, integrity, and availability. To that end, the EISP policies, standards and procedures create an information security framework that is aligned with the recommendations of the International Organization for Standardization's (ISO)

publication 27001 and the National Institute of Standards and Technology's (NIST) publication 800-53 Family of Controls and MGB regulatory and legal requirements (as a HIPAA covered entity).

Mass General Brigham workforce members are required to complete new workforce privacy and information security training upon hire and annually thereafter. Refresh training is provided as appropriate. Mass General Brigham workforce members are required to review and sign a Confidentiality Agreement upon hire and annually thereafter. Additionally, we follow Enterprise Information Security and Privacy policies, including Managing Workforce Members Information Security Responsibilities Policy, which was developed to help assure that Mass General Brigham workforce members are competent and eligible to support the information security responsibilities associated with their role. Mass General Brigham workforce, including Division staff, are required to comply with Enterprise Information Security and Privacy Policies.

Facilities: The research team uses a highly secure, state-of-the-art, computing facility housed at Mass General Brigham's Corporate Data Centers in Needham and Marlborough, Massachusetts as well as Amazon Web Services (AWS). We maintain redundant storage for maximal data integrity and high-speed data access.

The Division uses Mass General Brigham corporate provisioned servers to analyze and store data in connection with this project. There are strict access controls enforced by technical means to ensure that only study staff who have been approved to conduct data analyses and contracted data engineers are able to access data (e.g., Mass General Brigham Authentication (Active Directory) utilized; auditing, logging, and monitoring enabled; firewalls enabled; etc.). All Division servers used in this study are accessible to only authorized staff only through the MGB network and utilizing VPN as appropriate (i.e., users must be on the network and logged into VPN to access). Mass General Brigham has a network information security monitoring team and in-scope servers are enrolled in enterprise security tools (e.g., vulnerability scanning service, antivirus, etc.).

The Division also uses AWS. In-scope AWS services / resources have undergone review and assessment by Mass General Brigham's Information Security Risk Assessment Team/ InfoSec Risk Management Team as required and in alignment with NIST 800-30: Guide for Conducting Risk Assessments. In-scope AWS servers are for our exclusive use (reserved instances), are covered under our organization's Business Associate Agreement with AWS. In-scope servers are housed in anonymous facilities that are not branded as AWS facilities. Physical access is strictly controlled both at the perimeter and at building ingress points by professional security staff utilizing video surveillance, intrusion detection systems, and other electronic means.

Security attributes and controls for the Division's use of in-scope AWS in connection with this project include: encryption at rest and in transit (industry standard AES-256 encryption, SSL/TSL), anti-malware, latest OS updates and patches as well as anti-virus; multi-factor authentication (MFA), Identity and Access Management, including SSO; auditing and logging; principle of least privilege, including for traffic and ports (e.g., deny all default configurations), use of VPC enabled Step functions, etc.; separation between environments; minimum necessary (out of the box AWS roles are not used as they can be overly permissive); all data would reside in the US domestic regions – use only US east HIPAA compliant region; performance monitoring enabled and reviewed as per internal processes; passwords compliant with enterprise password policy and, as appropriate, more protective password requirements; etc. Our Division's AWS use is also subject to ongoing evaluation and monitoring as well – e.g., vulnerability scanning and management, access review, etc.

A data file list will be maintained in Amazon S3 and tracked through Cloudtrail and Cloudwatch. Reporting of data file availability for any file stored in an S3 bucket will be controlled by MGB.

Amazon EC2, Amazon EBS, and Amazon VPC are integrated with AWS CloudTrail, a service that provides a record of actions taken by a user, role, or an AWS service in Amazon EC2, Amazon EBS, and Amazon VPC. CloudTrail captures all API calls for Amazon EC2, Amazon EBS, and Amazon VPC as events, including calls from the console and from code calls to the APIs. MGB IT/security staff have full access to CloudTrail to ensure that CloudTrail monitoring is available at all times. Amazon CloudWatch Events delivers a near-real-time stream of system events that describe changes in AWS resources. Amazon CloudTrail can log, continuously monitor, and retain account activity related to actions across the MGB AWS infrastructure. CloudTrail provides event history of MGB AWS account activity. This event history simplifies security analysis, resource change tracking, and troubleshooting and complies with requirements to ensure the data file inventory is controlled by MGB.

Backups: Backups are created using industry recognized Cryptographic mechanisms (e.g., 256-bit AES encryption) as appropriate and required. Data are backed up within the MGB network from the MGB Needham data center to the MGB Marlborough data center via replication/mirroring and volume-level snapshots. AWS Backup supports both instance-level backups as Amazon Machine Images (AMIs) and volume-level backups as separate snapshots based on the resource tags. AMIs allow MGB IT and security staff to create backups of all S3 and EC2 instances. This backup approach allows elimination of EC2 instances when access to CMS data files is no longer needed. Use of temporary instances will allow highest security control to be applied regarding for whom and when CMS data files are accessible.

In addition to the safeguards listed above, the Division follows enterprise privacy and information security policies and maintains internally procedures in connection with this project to safeguard the data in connection with this project as appropriate and required including: Physical Security and Environmental Controls for Electronic Information Policy; IT Access Control Standards for Users policy; Safeguarding Fax Copiers Printers Telephone Use and Pagers; Physical Removal and Transport of Protected Health Information and Personal Information policy, etc.

6.8 Quality control

Senior Programmers and Research Specialists perform QA/QC on raw or common data model converted data via SAS/R/Aetion software. The protocol will be iteratively developed and pre-specified data checks including feasibility counts and balance on baseline covariates will be conducted with outputs reviewed by both MGB and FDA team members. Team members will review code lists to ensure fidelity to intended algorithms.

6.9 Study size and feasibility

See appendix 4 (first feasibility matching on age, sex, comorbidity score) and appendix 5 (second feasibility matching on all predefined propensity score variables). Propensity score distribution plots with c-statistics are available in appendix 6. Table 1 showing prevalence of baseline characteristics and standardized differences in distribution are available in appendix 7.

7. Limitation of the methods

As we are using secondary data and the data were not collected for research purposes, some important variables may not be collected or will be measured imperfectly. We have selected validated algorithms when possible and we have created proxies for important variables that are not directly captured in the data to reduce confounding by unmeasured factors. One measurement difference is, for example, an inclusion criterion requiring left ventricular ejection fraction (LVEF). Since these measurements are not captured in claims, we proxied LVEF by applying a predictive algorithm for LVEF with high positive predictive value (PPV) of 91%. This algorithm has been used in other database studies.^{26–28}

When comparing results from an RCT to a database study that emulates the design, we assume that the findings from the single RCT are internally valid.

Although we plan to emulate the important features of each trial as closely as possible in healthcare claims, there may be some elements of the RCT design that are not emulable with a database study, which means that the real-world evidence obtained from the database study and trial will address slightly different clinical questions. For example, in routine clinical care, adherence to treatment is typically not as high as it is in an RCT with strong measures in place to encourage adherence to the study protocol. This means that there is more discontinuation and short-term medication use in the patients identified in claims databases than trial participants.

Apparent agreement between RCT and database study results could occur if the effects of multiple factors (chance, emulation differences, bias) cancel each other out.

8. Protection of human subjects

This study has been approved by the Brigham and Women's Hospital Institutional Review Board.

9. References

1. Wang SV, Russo M, Glynn RJ, et al. A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real-World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluation. *Clin Pharmacol Ther*. 2025;117(6):1820-1828. doi:10.1002/cpt.3621
2. Schneeweiss S, Krüger N. Non-Randomized Database Analyses to Complement Randomized Clinical Trials: Promising Approaches for Cardiovascular Medicine. *Circulation*. 2025;151(21):1495-1497. doi:10.1161/CIRCULATIONAHA.125.073235
3. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med*. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038
4. Summary. In: *Pharmacoeconomic Review Report: Empagliflozin (Jardiance) [Internet]*. Canadian Agency for Drugs and Technologies in Health; 2015. Accessed December 2, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK533795/>
5. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352

6. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. *N Engl J Med*. 2013;369(14):1317-1326. doi:10.1056/NEJMoa1307684
7. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. doi:10.1161/CIRCULATIONAHA.114.010389
8. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure | New England Journal of Medicine. Accessed December 2, 2024. <https://www-nejm-org.emedien.ub.uni-muenchen.de/doi/10.1056/NEJMoa1506115>
9. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study: *Annals of Internal Medicine*: Vol 164, No 11. Accessed December 2, 2024. <https://www.acpjournals.org/doi/10.7326/M15-2568>
10. Patorno E, Gopalakrishnan C, Bartels DB, Brodovicz KG, Liu J, Schneeweiss S. Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors. *Endocrinol Diabetes Metab*. 2018;1(1):e00005. doi:10.1002/edm2.5
11. Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. *Ther Adv Endocrinol Metab*. 2013;4(3):95-105. doi:10.1177/2042018813486165
12. Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*. Published online November 2024:S2213858724002717. doi:10.1016/S2213-8587(24)00271-7
13. Mohan V, Saboo B, Khader J, et al. Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines. *Clin Med Insights Endocrinol Diabetes*. 2022;15:11795514221074663. doi:10.1177/11795514221074663
14. Bates BA, Akhabue E, Nahass MM, et al. Validity of International Classification of Diseases (ICD)-10 Diagnosis Codes for Identification of Acute Heart Failure Hospitalization and Heart Failure with Reduced Versus Preserved Ejection Fraction in a National Medicare Sample. *Circ Cardiovasc Qual Outcomes*. 2023;16(2):e009078. doi:10.1161/CIRCOUTCOMES.122.009078
15. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of Heart Failure Diagnoses in Administrative Databases: A Systematic Review and Meta-Analysis. Guo Y, ed. *PLoS ONE*. 2014;9(8):e104519. doi:10.1371/journal.pone.0104519
16. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. *J Clin Epidemiol*. 2011;64(7):749-759. doi:10.1016/j.jclinepi.2010.10.004
17. Sun JW, Rogers JR, Her Q, et al. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care*. 2017;55(12):1046-1051. doi:10.1097/MLR.0000000000000824
18. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index - PubMed. Accessed December 18, 2024. <https://pubmed.ncbi.nlm.nih.gov/29244057/>
19. Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. *JAMA*. 2020;323(23):2417-2418. doi:10.1001/jama.2020.7819
20. Wang SV, Schneeweiss S, RCT-DUPLICATE Initiative. Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials. *JAMA*. 2023;329(16):1376-1385. doi:10.1001/jama.2023.4221

21. Franklin JM, Pawar A, Martin D, et al. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. *Clin Pharmacol Ther.* 2020;107(4):817-826. doi:10.1002/cpt.1633
22. Hill ME, Rosenwaike I. The Social Security Administration's Death Master File: the completeness of death reporting at older ages. *Soc Secur Bull.* 2001;64(1):45-51.
23. Death Information in the Research Identifiable Medicare Data | ResDAC. Accessed December 2, 2024. <https://resdac.org/articles/death-information-research-identifiable-medicare-data>
24. Olubowale OT, Safford MM, Brown TM, et al. Comparison of Expert Adjudicated Coronary Heart Disease and Cardiovascular Disease Mortality With the National Death Index: Results From the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. *J Am Heart Assoc.* 2017;6(5):e004966. doi:10.1161/JAHA.116.004966
25. Find, Request and Use CMS Data | ResDAC. Accessed December 2, 2024. <https://resdac.org/>
26. Desai RJ, Lin KJ, Patorno E, et al. Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. *Circ Cardiovasc Qual Outcomes.* 2018;11(12):e004700. doi:10.1161/CIRCOUTCOMES.118.004700
27. Abdel Jawad M, Spertus JA, Ikeaba U, et al. Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. *JAMA Cardiol.* 2025;10(1):89-94. doi:10.1001/jamacardio.2024.4489
28. Desai RJ, Solomon SD, Vaduganathan M. Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. *J Card Fail.* 2022;28(6):1035-1039. doi:10.1016/j.cardfail.2022.01.012

10. Appendices

See accompanying excel file.

1 Target Trial Framework, Operational Definitions, and Data Fitness Assessment

2 Code algorithms

- 2a Exposure
- 2b Inclusion
- 2c Exclusion
- 2d Outcome

3 Flowchart for cohort assembly

4 1st feasibility assessment

5 2nd feasibility assessment

6 Balance Assessment - PS Distribution and C-Statistic

7 Balance Assessment - Table 1

| | EMPEROR-Preserved | OPTUM | Medicare | MarketScan | Notes/Questions | Color coding | Score |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|-------|
| Treatment assignment (time 0) | Multicenter, parallel, blinded randomization to treatment with empagliflozin vs placebo | Non-randomized initiation of treatment with empagliflozin vs sitagliptin (first eligible entry to study population) | Non-randomized initiation of treatment with empagliflozin vs sitagliptin (first eligible entry to study population) | Non-randomized initiation of treatment with empagliflozin vs sitagliptin (first eligible entry to study population) | | | |
| Exposure | Empagliflozin 10 mg once daily | Code type: NDC Generic Care setting: Prescription Claims Diagnosis position: N/A Washout window: [-183, -1] Incident with respect to: Empagliflozin in any formulation or dose Assessment window: N/A Source of algorithm: N/A Measurement characteristics: N/A | Code type: NDC Generic Care setting: Prescription Claims Diagnosis position: N/A Washout window: [-183, -1] Incident with respect to: Empagliflozin in any formulation or dose Assessment window: N/A Source of algorithm: N/A Measurement characteristics: N/A | Code type: NDC Generic Care setting: Prescription Claims Diagnosis position: N/A Washout window: [-183, -1] Incident with respect to: Empagliflozin in any formulation or dose Assessment window: N/A Source of algorithm: N/A Measurement characteristics: N/A | | Good proxy definition | 3 |
| Comparator | Placebo, film-coated tablet once daily | Code type: NDC Generic Care setting: N/A Diagnosis position: N/A Washout window: [-183, -1] Incident with respect to: Sitagliptin in any formulation or dose Assessment window: N/A Source of algorithm: N/A Measurement characteristics: N/A | Code type: NDC Generic Care setting: N/A Diagnosis position: N/A Washout window: [-183, -1] Incident with respect to: Sitagliptin in any formulation or dose Assessment window: N/A Source of algorithm: N/A Measurement characteristics: N/A | Code type: NDC Generic Care setting: N/A Diagnosis position: N/A Washout window: [-183, -1] Incident with respect to: Sitagliptin in any formulation or dose Assessment window: N/A Source of algorithm: N/A Measurement characteristics: N/A | Rationale: Sitagliptin is being used as an active-comparator proxy for placebo in the database study | Moderate proxy definition | 2 |
| Primary Outcome | A composite of cardiovascular death or hospitalization for worsening heart failure. Due to inability to capture cause of death, our modified composite endpoint was measured as all-cause mortality and hospitalization for heart failure. | Code type: DX Care setting: Inpatient for Heart Failure Diagnosis position: Primary Washout window: N/A Source of algorithm: PROMISE Team, Validation studies, (Investigator reviewed codes) Measurement characteristics: Death includes information from the inpatient discharged dead status, social security death master file, and deaths scraped from obituaries or other sources. PPV for HF diagnosis using ICD9 codes was 87% and for HHF 98% https://pubmed.ncbi.nlm.nih.gov/25126761/ and https://pubmed.ncbi.nlm.nih.gov/36688301/ | Code type: DX Care setting: Inpatient for Heart Failure Diagnosis position: Primary Washout window: N/A Source of algorithm: PROMISE Team, Validation studies, (Investigator reviewed codes) Measurement characteristics: Death includes information from the inpatient discharged dead status, social security death master file, and deaths scraped from obituaries or other sources. PPV for HF diagnosis using ICD9 codes was 87% and for HHF 98% https://pubmed.ncbi.nlm.nih.gov/25126761/ and https://pubmed.ncbi.nlm.nih.gov/36688301/ | Code type: DX Care setting: Inpatient for Heart Failure Diagnosis position: Primary Washout window: N/A Source of algorithm: PROMISE Team, Validation studies, (Investigator reviewed codes) Measurement characteristics: Death includes information from the inpatient discharged dead status, social security death master file, and deaths scraped from obituaries or other sources. PPV for HF diagnosis using ICD9 codes was 87% and for HHF 98% https://pubmed.ncbi.nlm.nih.gov/25126761/ and https://pubmed.ncbi.nlm.nih.gov/36688301/ | | Poorly measured in database | 1 |
| Follow up start | Randomization date | One day after initiation of treatment with empagliflozin vs sitagliptin | One day after initiation of treatment with empagliflozin vs sitagliptin | One day after initiation of treatment with empagliflozin vs sitagliptin | | Poorly measured in database and not important | 0 |
| Follow up end | The primary outcome was assessed in a time-to-event analysis. Data were censored at the end of treatment for patients who completed the planned treatment period, up to 365 days, or at the last available follow-up visit (median time between follow/up visits was 84 days (interquartile range, 70 to 84)) for patients who discontinued. The median duration of follow-up for the primary outcome was 26.2 months (interquartile range, 18.1 to 33.1). | Earliest of: Outcome, End of observation in data, End of study period, discontinuation (45 days grace window and risk-window), switch to other SGLT2i or DPP4i, nursing home admission. | Earliest of: Outcome, End of observation in data, End of study period, discontinuation (45 days grace window and risk-window), switch to other SGLT2i or DPP4i, nursing home admission. | Earliest of: Outcome, End of observation in data, End of study period, discontinuation (45 days grace window and risk-window), switch to other SGLT2i or DPP4i, nursing home admission. | | | |
| Causal estimand | Intention-to-treat effect (treatment policy) | On-treatment effect | On-treatment effect | On-treatment effect | Rationale: Adherence in clinical practice databases is expected to be much worse than in the trial, therefore the OT analysis will be the primary analysis. The OT analysis targets the relative hazard of outcomes while on treatment and may more closely emulate the effect observed in highly adherent trial participants. | | |
| Effect estimation | Cox proportional hazards regression model | Cox proportional hazards regression model | Cox proportional hazards regression model | Cox proportional hazards regression model | | | |
| Inclusion criteria | | | | | | | |

| | | | | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | Male or female, age ≥ 18 years at screening. | Applied before/after selection of index date: Before Assessment window: [0, 0] Code type: N/A Care setting: N/A Diagnosis position: N/A Source of algorithm: N/A Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [0, 0] Code type: N/A Care setting: N/A Diagnosis position: N/A Source of algorithm: N/A Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [0, 0] Code type: N/A Care setting: N/A Diagnosis position: N/A Source of algorithm: N/A Measurement characteristics: N/A | |
| | Chronic HF diagnosed for at least 3 months before screening, and currently in HF NYHA class II-IV | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: https://pubmed.ncbi.nlm.nih.gov/25126761/ and https://pubmed.ncbi.nlm.nih.gov/36688301/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: https://pubmed.ncbi.nlm.nih.gov/25126761/ and https://pubmed.ncbi.nlm.nih.gov/36688301/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: https://pubmed.ncbi.nlm.nih.gov/25126761/ and https://pubmed.ncbi.nlm.nih.gov/36688301/ Measurement characteristics: N/A | |
| | Chronic HF with preserved EF defined as LVEF > 40 % and no prior measurement of LVEF ≤40% under stable conditions. | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX, PX, RX Care setting: Any Diagnosis position: Any Source of algorithm: EF algorithm, https://pubmed.ncbi.nlm.nih.gov/30562067/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX, PX, RX Care setting: Any Diagnosis position: Any Source of algorithm: EF algorithm, https://pubmed.ncbi.nlm.nih.gov/30562067/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX, PX, RX Care setting: Any Diagnosis position: Any Source of algorithm: EF algorithm, https://pubmed.ncbi.nlm.nih.gov/30562067/ Measurement characteristics: N/A | |
| | Elevated N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) > 300 pg/ml for patients without AF, OR > 900 pg/ml for patients with AF | Can't be measured in claims | Can't be measured in claims | Can't be measured in claims | |
| | At least one of the two (5.1 OR 5.2) conditions: | | | | |
| 5.1 | Structural heart disease (left atrial enlargement and/or left ventricular hypertrophy) documented by echocardiogram at Visit 1 or within 6 months prior to Visit 1, OR | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX, PX, RX Care setting: Any Diagnosis position: Any Source of algorithm: EF algorithm, https://pubmed.ncbi.nlm.nih.gov/30562067/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX, PX, RX Care setting: Any Diagnosis position: Any Source of algorithm: EF algorithm, https://pubmed.ncbi.nlm.nih.gov/30562067/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX, PX, RX Care setting: Any Diagnosis position: Any Source of algorithm: EF algorithm, https://pubmed.ncbi.nlm.nih.gov/30562067/ Measurement characteristics: N/A | Algorithm detail: The presence of left atrial enlargement and/or left ventricular hypertrophy will be proxied by the presence of HFpEF. |
| | Documented HHF within 12 months prior to Visit 1 | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: PROMISE team Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: PROMISE team Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: PROMISE team Measurement characteristics: N/A | |
| | Oral diuretics, if prescribed to patient according to local guidelines and discretion of the Investigator, should be stable for at least 1 week prior to Visit 2 | Applied before/after selection of index date: Before Assessment window: [-7, 0] Code type: NDC Care setting: Any Diagnosis position: Any Source of algorithm: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure https://pubmed.ncbi.nlm.nih.gov/35378257/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-7, 0] Code type: NDC Care setting: Any Diagnosis position: Any Source of algorithm: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure https://pubmed.ncbi.nlm.nih.gov/35378257/ Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-7, 0] Code type: NDC Care setting: Any Diagnosis position: Any Source of algorithm: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure https://pubmed.ncbi.nlm.nih.gov/35378257/ Measurement characteristics: N/A | |
| 6 | (Randomisation) | | | | Algorithm detail: Patients prescribed an oral diuretic in the 7 days before CED that has not been filled before should be excluded. Patients prescribed to an i.v. diuretic should be excluded. |

| | | | | | |
|--------------------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Exclusion Criteria | 7 | Body Mass Index (BMI) < 45 kg/m2 at Visit 1 | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX, LOINC</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX, LOINC</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX, LOINC</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data</p> <p>Measurement characteristics: N/A</p> |
| | 8 | Signed and dated written ICF in accordance with GCP and local legislation prior to admission to the trial | Can't be measured in claims | Can't be measured in claims | Can't be measured in claims |
| | 9 | Trial subgroup of patients with Type 2 Diabetes Mellitus (T2DM) | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team</p> <p>Measurement characteristics: N/A</p> |
| | 1 | Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischaemia or newly developed ischaemic ECG changes), coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 90 days | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> |
| | 2 | Heart transplant recipient or listed for heart transplant | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [Start of all available data, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [Start of all available data, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [Start of all available data, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> |
| | 3 | Implantation of cardioverter defibrillator (ICD) within 3 months | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> |
| | 4 | Cardiac resynchronisation therapy (CRT) | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [Start of all available data, 0]</p> <p>Code type: PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [Start of all available data, 0]</p> <p>Code type: PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [Start of all available data, 0]</p> <p>Code type: PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> |

| | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5 | Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial constriction | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Any Diagnosis position: Any Source of algorithm: Multiple sources (see "Algorithm Sources") Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Any Diagnosis position: Any Source of algorithm: Multiple sources (see "Algorithm Sources") Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Any Diagnosis position: Any Source of algorithm: Multiple sources (see "Algorithm Sources") Measurement characteristics: N/A |
| | | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| 6 | Any severe (obstructive or regurgitant) valvular heart disease expected to lead to surgery during the trial in the Investigator's opinion | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| | | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: PROMISE team Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: PROMISE team Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: PROMISE team Measurement characteristics: N/A |
| 7 | Acute decompensated HF (exacerbation of chronic HF) requiring intravenous (i.v.) diuretics, i.v. inotropes or i.v. vasodilators, or left ventricular assist device within 1 week from discharge to Visit 1, and during screening period until Visit 2 (Randomisation) | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| | | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| 8 | Atrial fibrillation or atrial flutter with a resting heart rate > 110 bpm documented by ECG at Visit 2 (Randomisation) | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| | | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-183, 0] Code type: DX Care setting: Inpatient Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg at Visit 2. If SBP >150 mmHg and <180 mmHg at Visit 2, the patient should be receiving at least 3 antihypertensive drugs | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| | | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-91, 0] Code type: DX Care setting: Any Diagnosis position: Any Source of algorithm: Investigator reviewed codes Measurement characteristics: N/A |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 2 | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A |
| | | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A |
| | | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A | Applied before/after selection of index date: Before Assessment window: [-365, 0] Code type: DX, PX Care setting: Inpatient, Outpatient Diagnosis position: Primary Source of algorithm: PROMISE team, Investigator reviewed codes Measurement characteristics: N/A |

Algorithm detail: Proxied by codes for malignant hypertension or hypertensive emergency/crisis

| | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | Algorithm detail: Based on diagnostic codes rather than laboratory values. |
| 13 | Impaired renal function, defined as eGFR < 20 mL/min/1.73 m ² (CKD-EPI) or requiring dialysis, as determined at Visit 1 | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | Algorithm detail: Proxied by codes for chronic kidney disease stage IV and V, end-stage renal disease and dialysis |
| 14 | Haemoglobin < 9 g/dl at Visit 1 | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0] for anemia, [-91, 0] for transfusion</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Primary, Any for transfusion</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0] for anemia, [-91, 0] for transfusion</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Primary, Any for transfusion</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0] for anemia, [-91, 0] for transfusion</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Primary, Any for transfusion</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | |
| 15 | History of ketoacidosis | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: PX</p> <p>Care setting: Inpatient</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | Algorithm detail: Major surgeries include craniotomy, colectomy, cholecystectomy, oesophagectomy, colostomy, ileostomy, pancreatectomy, ventral hernia repair, hip replacement, knee replacement, shoulder replacement, thorascopic pulmonary lobectomy, open pulmonary lobectomy, |
| 17 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-91, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team, <u>A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases</u>, Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | |

| | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-730, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-730, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-730, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: PROMISE team</p> <p>Measurement characteristics: N/A</p> | |
| 19 | Presence of any other disease than heart failure with a life expectancy of <1 year in the investigator's opinion | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Combined comorbidity score</p> <p>https://pubmed.ncbi.nlm.nih.gov/21208778/</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Combined comorbidity score</p> <p>https://pubmed.ncbi.nlm.nih.gov/21208778/</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Combined comorbidity score</p> <p>https://pubmed.ncbi.nlm.nih.gov/21208778/</p> <p>Measurement characteristics: N/A</p> | Algorithm detail: Proxied by CCI > 10 |
| 20 | Patients who must or wish to continue the intake of restricted medications (see Section 4.2.2) or any drug considered likely to interfere with the safe conduct of the trial | Can't be measured in claims | Can't be measured in claims | Can't be measured in claims | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted. | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: RX</p> <p>Care setting: N/A</p> <p>Diagnosis position: N/A</p> <p>Source of algorithm: N/A</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: RX</p> <p>Care setting: N/A</p> <p>Diagnosis position: N/A</p> <p>Source of algorithm: N/A</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-183, 0]</p> <p>Code type: RX</p> <p>Care setting: N/A</p> <p>Diagnosis position: N/A</p> <p>Source of algorithm: N/A</p> <p>Measurement characteristics: N/A</p> | Algorithm detail: Also exclude current or prior use of DPP4i |
| 22 | Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s). Patients participating in a purely observational trial will not be excluded | Can't be measured in claims | Can't be measured in claims | Can't be measured in claims | |
| 23 | Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors | Can't be measured in claims | Can't be measured in claims | Can't be measured in claims | |
| 24 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: <u>Validation of key, behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse, and tobacco use.</u> Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: <u>Validation of key, behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse, and tobacco use.</u> Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: <u>Validation of key, behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse, and tobacco use.</u> Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Pregnancy team</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Pregnancy team</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX, PX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Pregnancy team</p> <p>Measurement characteristics: N/A</p> | Algorithm detail: Proxied by codes indicative of pregnancy in baseline |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | <p>Applied before/after selection of index date: Before</p> <p>Assessment window: [-365, 0]</p> <p>Code type: DX</p> <p>Care setting: Any</p> <p>Diagnosis position: Any</p> <p>Source of algorithm: Investigator reviewed codes</p> <p>Measurement characteristics: N/A</p> | Algorithm detail: Proxied by codes indicative of non-compliance with treatment |

| Variable_Name | Code | Code_category | Code_type | Notes |
|---------------|----------------------------------------|---------------|-----------|-----------------------------------|
| Exposure | | | | |
| Empagliflozin | EMPAGLIFLOZIN | RX | Generic | NDC Route of Administration: ORAL |
| Empagliflozin | 00597015207 | RX | NDC | |
| Empagliflozin | 00597015230 | RX | NDC | |
| Empagliflozin | 00597015237 | RX | NDC | |
| Empagliflozin | 00597015270 | RX | NDC | |
| Empagliflozin | 00597015290 | RX | NDC | |
| Empagliflozin | 00597015307 | RX | NDC | |
| Empagliflozin | 00597015330 | RX | NDC | |
| Empagliflozin | 00597015337 | RX | NDC | |
| Empagliflozin | 00597015370 | RX | NDC | |
| Empagliflozin | 00597015390 | RX | NDC | |
| Empagliflozin | JARDIANCE | RX | Generic | |
| | EMPAGLIFLOZIN / METFORMIN | | | |
| Empagliflozin | HYDROCHLORIDE | RX | Generic | |
| Comparator | | | | |
| | SITAGLIPTIN PHOSPHATE/METFORMIN HCL | | | |
| Sitagliptin | | RX | Generic | NDC Route of Administration: ORAL |
| | SITAGLIPTIN PHOSPHATE | | | |
| Sitagliptin | | RX | Generic | |
| Sitagliptin | 00006011201 | RX | NDC | |
| Sitagliptin | 00006011228 | RX | NDC | |
| Sitagliptin | 00006011231 | RX | NDC | |
| Sitagliptin | 00006011254 | RX | NDC | |
| Sitagliptin | 00006022101 | RX | NDC | |
| Sitagliptin | 00006022128 | RX | NDC | |
| Sitagliptin | 0006022131 | RX | NDC | |
| Sitagliptin | 00006022154 | RX | NDC | |
| Sitagliptin | 00006027701 | RX | NDC | |

| | | | | |
|-------------|-------------|----|-----|-----------------------|
| Sitagliptin | 00006027702 | RX | NDC | |
| Sitagliptin | 00006027714 | RX | NDC | |
| Sitagliptin | 0006027727 | RX | NDC | |
| Sitagliptin | 00006027728 | RX | NDC | |
| Sitagliptin | 00006027730 | RX | NDC | |
| Sitagliptin | 00006027731 | RX | NDC | |
| Sitagliptin | 00006027733 | RX | NDC | |
| Sitagliptin | 0006027754 | RX | NDC | |
| Sitagliptin | 00006027782 | RX | NDC | |
| Sitagliptin | 00006057501 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057502 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057503 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057552 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057556 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057561 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057562 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057582 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 0006057701 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057702 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057703 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057752 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057756 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057761 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057762 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006057782 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006007814 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006007828 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006007861 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006007862 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006007882 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008014 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008028 | RX | NDC | Sitagliptin/metformin |

| | | | | |
|-------------|-------------|----|---------|-----------------------------------|
| Sitagliptin | 00006008061 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008062 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008082 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008107 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008114 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008131 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008154 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | 00006008182 | RX | NDC | Sitagliptin/metformin |
| Sitagliptin | JANUVIA | RX | Generic | NDC Route of Administration: ORAL |

| Category | Variable_name | Code | Code_category | Description | Code_type |
|----------|-----------------------|---------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 2 | Chronic heart failure | I09.81 | DX | RHEUMATIC HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I11.0 | DX | HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I13.0 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE | ICD-10-CM |
| 2 | Chronic heart failure | I13.2 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND WITH STAGE 5 CHRONIC KIDNEY DISEASE, OR END STAGE RENAL DISEASE | ICD-10-CM |
| 2 | Chronic heart failure | I50 | DX | HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.1 | DX | LEFT VENTRICULAR FAILURE, UNSPECIFIED | ICD-10-CM |
| 2 | Chronic heart failure | I50.2 | DX | SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.20 | DX | UNSPECIFIED SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.22 | DX | CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.23 | DX | ACUTE ON CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.3 | DX | DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.30 | DX | UNSPECIFIED DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.32 | DX | CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.33 | DX | ACUTE ON CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.4 | DX | COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.40 | DX | UNSPECIFIED COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.42 | DX | CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.43 | DX | ACUTE ON CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.8 | DX | OTHER HEART FAILURE | ICD-10-CM |
| 2 | Chronic heart failure | I50.810 | DX | RIGHT HEART FAILURE, UNSPECIFIED | ICD-10-CM |

| | | | | |
|-------------------------|---------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 2 Chronic heart failure | I50.812 | DX | CHRONIC RIGHT HEART FAILURE | ICD-10-CM |
| 2 Chronic heart failure | I50.813 | DX | ACUTE ON CHRONIC RIGHT HEART FAILURE | ICD-10-CM |
| 2 Chronic heart failure | I50.814 | DX | RIGHT HEART FAILURE DUE TO LEFT HEART FAILURE | ICD-10-CM |
| 2 Chronic heart failure | I50.82 | DX | BIVENTRICULAR HEART FAILURE | ICD-10-CM |
| 2 Chronic heart failure | I50.83 | DX | HIGH OUTPUT HEART FAILURE | ICD-10-CM |
| 2 Chronic heart failure | I50.84 | DX | END STAGE HEART FAILURE | ICD-10-CM |
| 2 Chronic heart failure | I50.89 | DX | OTHER HEART FAILURE | ICD-10-CM |
| 2 Chronic heart failure | I50.9 | DX | HEART FAILURE, UNSPECIFIED | ICD-10-CM |
| 2 Chronic heart failure | I97.130 | DX | POSTPROCEDURAL HEART FAILURE FOLLOWING CARDIAC SURGERY | ICD-10-CM |
| 2 Chronic heart failure | I97.131 | DX | POSTPROCEDURAL HEART FAILURE FOLLOWING OTHER SURGERY | ICD-10-CM |
| 2 Chronic heart failure | 398.91 | DX | RHEUMATIC HEART FAILURE (CONGESTIVE) | ICD-9-CM |
| 2 Chronic heart failure | 402.01 | DX | MALIGNANT HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM |
| 2 Chronic heart failure | 402.11 | DX | BENIGN HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM |
| 2 Chronic heart failure | 402.91 | DX | UNSPECIFIED HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM |
| 2 Chronic heart failure | 404.01 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM |
| 2 Chronic heart failure | 404.03 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 2 Chronic heart failure | 404.11 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM |
| 2 Chronic heart failure | 404.13 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |

| | | | | | | | |
|--------------------------------------------------------------------------------------|-----------------------------------|--------------|--|--|--|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 2 | Chronic heart failure | 404.91 | | | | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM |
| 2 | Chronic heart failure | 404.93 | | | | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 2 | Chronic heart failure | 428 | | | | HEART FAILURE | ICD-9-CM |
| 2 | Chronic heart failure | 428.0 | | | | CONGESTIVE HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 2 | Chronic heart failure | 428.1 | | | | LEFT HEART FAILURE | ICD-9-CM |
| 2 | Chronic heart failure | 428.2 | | | | SYSTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 2 | Chronic heart failure | 428.22 | | | | CHRONIC SYSTOLIC HEART FAILURE | ICD-9-CM |
| 2 | Chronic heart failure | 428.23 | | | | ACUTE ON CHRONIC SYSTOLIC HEART FAILURE | ICD-9-CM |
| 2 | Chronic heart failure | 428.3 | | | | DIASTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 2 | Chronic heart failure | 428.32 | | | | CHRONIC DIASTOLIC HEART FAILURE | ICD-9-CM |
| 2 | Chronic heart failure | 428.33 | | | | ACUTE ON CHRONIC DIASTOLIC HEART FAILURE | ICD-9-CM |
| 2 | Chronic heart failure | 428.4 | | | | COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 2 | Chronic heart failure | 428.42 | | | | CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM |
| 2 | Chronic heart failure | 428.43 | | | | ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM |
| Chronic HF with preserved EF defined as LVEF > 40 % and no prior measurement of LVEF | | | | | | | |
| 3 | ≤40% under stable conditions. | EF algorithm | | | | | |
| 5.1 | Structural heart disease | EF algorithm | | | | | |
| 5.2 | Hospitalisation for heart failure | I09.81 | | | | RHEUMATIC HEART FAILURE | ICD-10-CM |
| 5.2 | Hospitalisation for heart failure | I11.0 | | | | HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-10-CM |
| 5.2 | Hospitalisation for heart failure | I13.0 | | | | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE | ICD-10-CM |

| | | | |
|----------------------------------------------|----|--------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 5.2 Hospitalisation for heart failure I13.2 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND WITH STAGE 5 CHRONIC KIDNEY DISEASE, OR END STAGE RENAL DISEASE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50 | DX | HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.1 | DX | LEFT VENTRICULAR FAILURE, UNSPECIFIED | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.2 | DX | SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.20 | DX | UNSPECIFIED SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.21 | DX | ACUTE SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.22 | DX | CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.23 | DX | ACUTE ON CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.3 | DX | DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.30 | DX | UNSPECIFIED DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.31 | DX | ACUTE DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.32 | DX | CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.33 | DX | ACUTE ON CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.4 | DX | COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.40 | DX | UNSPECIFIED COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.41 | DX | ACUTE COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure I50.42 | DX | CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |

| | | | | |
|---------------------------------------|---------|----|------------------------------------------------------------------------------------------|-----------|
| 5.2 Hospitalisation for heart failure | I50.43 | DX | ACUTE ON CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.8 | DX | OTHER HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.810 | DX | RIGHT HEART FAILURE, UNSPECIFIED | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.811 | DX | ACUTE RIGHT HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.812 | DX | CHRONIC RIGHT HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.813 | DX | ACUTE ON CHRONIC RIGHT HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.814 | DX | RIGHT HEART FAILURE DUE TO LEFT HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.82 | DX | BIVENTRICULAR HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.83 | DX | HIGH OUTPUT HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.84 | DX | END STAGE HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.89 | DX | OTHER HEART FAILURE | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I50.9 | DX | HEART FAILURE, UNSPECIFIED | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I97.130 | DX | POSTPROCEDURAL HEART FAILURE FOLLOWING CARDIAC SURGERY | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | I97.131 | DX | POSTPROCEDURAL HEART FAILURE FOLLOWING OTHER SURGERY | ICD-10-CM |
| 5.2 Hospitalisation for heart failure | 398.91 | DX | RHEUMATIC HEART FAILURE (CONGESTIVE) | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 402.01 | DX | MALIGNANT HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 402.11 | DX | BENIGN HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 402.91 | DX | UNSPECIFIED HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM |

| | | | | |
|---------------------------------------|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 5.2 Hospitalisation for heart failure | 404.01 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 404.03 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 404.11 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 404.13 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 404.91 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 404.93 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 428 | DX | HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 428.0 | DX | CONGESTIVE HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 428.1 | DX | LEFT HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 428.2 | DX | SYSTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 428.21 | DX | ACUTE SYSTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 428.22 | DX | CHRONIC SYSTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure | 428.23 | DX | ACUTE ON CHRONIC SYSTOLIC HEART FAILURE | ICD-9-CM |

| | | | |
|----------------------------------------------|----|----------------------------------------------------------------|----------|
| 5.2 Hospitalisation for heart failure 428.3 | DX | DIASTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.31 | DX | ACUTE DIASTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.32 | DX | CHRONIC DIASTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.33 | DX | ACUTE ON CHRONIC DIASTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.4 | DX | COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.41 | DX | ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.42 | DX | CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.43 | DX | ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM |
| 5.2 Hospitalisation for heart failure 428.9 | DX | HEART FAILURE, UNSPECIFIED | ICD-9-CM |
| 6 Oral diuretics | RX | BENDROFLUMETHIAZIDE | Generic |
| 6 Oral diuretics | RX | CHLOROTHIAZIDE | Generic |
| 6 Oral diuretics | RX | CHLOROTHIAZIDE SODIUM | Generic |
| 6 Oral diuretics | RX | CHLORTHALIDONE | Generic |
| 6 Oral diuretics | RX | CLONIDINE HCL/CHLORTHALIDONE | Generic |
| 6 Oral diuretics | RX | HYDROCHLOROTHIAZIDE | Generic |
| 6 Oral diuretics | RX | POLYTHIAZIDE | Generic |
| 6 Oral diuretics | RX | PRAZOSIN HCL/POLYTHIAZIDE | Generic |
| 6 Oral diuretics | RX | RESERPINE/POLYTHIAZIDE | Generic |
| 6 Oral diuretics | RX | INDAPAMIDE | Generic |
| 6 Oral diuretics | RX | METOLAZONE | Generic |
| 6 Oral diuretics | RX | BUMETANIDE | Generic |
| 6 Oral diuretics | RX | FUROSEMIDE | Generic |
| 6 Oral diuretics | RX | FUROSEMIDE IN 0.9 % SODIUM CHLORIDE | Generic |
| 6 Oral diuretics | RX | FUROSEMIDE/DEXTROSE 5 % IN WATER | Generic |
| 6 Oral diuretics | RX | TORSEMIDE | Generic |
| 6 Oral diuretics | RX | AMILORIDE HCL | Generic |
| 6 Oral diuretics | RX | AMILORIDE HCL/HYDROCHLOROTHIAZIDE | Generic |
| 6 Oral diuretics | RX | TRIAMTERENE | Generic |

| | | | | |
|----------------------------|---------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 6 Oral diuretics | | RX | TRIAMTERENE/HYDROCHLOROTHIAZIDE | Generic |
| 6 Oral diuretics | | RX | EPLERENONE | Generic |
| 6 Oral diuretics | | RX | SPIRONOLACTONE | Generic |
| 6 Oral diuretics | | RX | SPIRONOLACTONE/HYDROCHLOROTHIAZIDE | Generic |
| 6 Oral diuretics | | RX | SPIRONOLACTONE/NIACINAMIDE | Generic |
| 6 Oral diuretics | | RX | FINERENONE | Generic |
| 6 Oral diuretics | | RX | TOLVAPTAN | Generic |
| 6 Oral diuretics | | RX | ACETAZOLAMIDE | Generic |
| 6 Oral diuretics | | RX | METHAZOLAMIDE | Generic |
| 6 Oral diuretics | J1120 | PX | INJECTION, ACETAZOLAMIDE SODIUM, UP TO 500 MG | CPT/HCPCS |
| 6 Oral diuretics | J1205 | PX | INJECTION, CHLOROTHIAZIDE SODIUM, PER 500 MG | CPT/HCPCS |
| 6 Oral diuretics | J1940 | PX | INJECTION, FUROSEMIDE, UP TO 20 MG | CPT/HCPCS |
| 6 Oral diuretics | J2150 | PX | INJECTION, MANNITOL, 25% IN 50 ML | CPT/HCPCS |
| 6 Oral diuretics | J3265 | PX | INJECTION, TORSEMIDE, 10 MG/ML | CPT/HCPCS |
| 6 Oral diuretics | J3350 | PX | INJECTION, UREA, UP TO 40 GM | CPT/HCPCS |
| 6 Oral diuretics | S0171 | PX | INJECTION, BUMETANIDE, 0.5 MG | CPT/HCPCS |
| | | | | |
| 6 Oral diuretics | S9361 | PX | HOME INFUSION THERAPY, DIURETIC INTRAVENOUS THERAPY; ADMINISTRATIVE SERVICES, PROFESSIONAL PHARMACY SERVICES, CARE COORDINATION, AND ALL NECESSARY SUPPLIES AND EQUIPMENT (DRUGS AND NURSING VISITS CODED SEPARATELY), PER DIEM | CPT/HCPCS |
| Body Mass Index (BMI) < 45 | | | | |
| 7 kg/m2 at Visit 1 | V85.42 | DX | BODY MASS INDEX 45.0-49.9, ADULT | ICD-9-CM |
| Body Mass Index (BMI) < 45 | | | | |
| 7 kg/m2 at Visit 2 | V85.43 | DX | BODY MASS INDEX 50.0-59.9, ADULT | ICD-9-CM |
| Body Mass Index (BMI) < 45 | | | | |
| 7 kg/m2 at Visit 3 | Z68.42 | DX | BODY MASS INDEX (BMI) 45.0-49.9, ADULT | ICD-10-CM |
| Body Mass Index (BMI) < 45 | | | | |
| 7 kg/m2 at Visit 4 | Z68.43 | DX | BODY MASS INDEX (BMI) 50-59.9, ADULT | ICD-10-CM |
| Body Mass Index (BMI) < 45 | | | | |
| 7 kg/m2 at Visit 5 | Z68.44 | DX | BODY MASS INDEX (BMI) 60.0-69.9, ADULT | ICD-10-CM |
| Body Mass Index (BMI) < 45 | | | | |
| 7 kg/m2 at Visit 6 | Z68.45 | DX | BODY MASS INDEX (BMI) 70 OR GREATER, ADULT | ICD-10-CM |
| Body Mass Index (BMI) < 45 | | | | |
| 7 kg/m2 at Visit 6 | 39156-5 | LOINC | BODY MASS INDEX (BMI) [Ratio] | |
| 9 Type 2 Diabetes mellitus | E11.0 | DX | TYPE 2 DIABETES MELLITUS WITH HYPEROSMOLARITY | ICD-10-CM |

| | | | | |
|----------------------------|----------|----|----------------------------------------------------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.00 | DX | TYPE 2 DIABETES MELLITUS WITH HYPEROSMOLARITY WITHOUT NONKETOTIC HYPERGLYCEMIC-HYPEROSMOLAR COMA (NKHHC) | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.01 | DX | TYPE 2 DIABETES MELLITUS WITH HYPEROSMOLARITY WITH COMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.1 | DX | TYPE 2 DIABETES MELLITUS WITH KETOACIDOSIS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.10 | DX | TYPE 2 DIABETES MELLITUS WITH KETOACIDOSIS WITHOUT COMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.11 | DX | TYPE 2 DIABETES MELLITUS WITH KETOACIDOSIS WITH COMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.2 | DX | TYPE 2 DIABETES MELLITUS WITH KIDNEY COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.21 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC NEPHROPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.22 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC CHRONIC KIDNEY DISEASE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.29 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC KIDNEY COMPLICATION | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3 | DX | TYPE 2 DIABETES MELLITUS WITH OPHTHALMIC COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.31 | DX | TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.311 | DX | TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITH MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.319 | DX | TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.32 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.321 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3211 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3212 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, LEFT EYE | ICD-10-CM |

| | | | | |
|----------------------------|----------|----|-----------------------------------------------------------------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.3213 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3219 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.329 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3291 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3292 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3293 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3299 | DX | TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.33 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.331 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3311 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3312 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3313 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, BILATERAL | ICD-10-CM |

| | | | | |
|----------------------------|----------|----|---------------------------------------------------------------------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.3319 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.339 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3391 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3392 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3393 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3399 | DX | TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.34 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.341 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3411 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3412 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3413 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3419 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |

| | | | | |
|----------------------------|----------|----|-----------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.349 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3491 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3492 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3493 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3499 | DX | TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.35 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.351 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3511 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3512 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3513 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3519 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.352 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT INVOLVING THE MACULA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3521 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT INVOLVING THE MACULA, RIGHT EYE | ICD-10-CM |

| | | | | |
|----------------------------|----------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.3522 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT INVOLVING THE MACULA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3523 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT INVOLVING THE MACULA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3529 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT INVOLVING THE MACULA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.353 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT NOT INVOLVING THE MACULA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3531 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT NOT INVOLVING THE MACULA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3532 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT NOT INVOLVING THE MACULA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3533 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT NOT INVOLVING THE MACULA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3539 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH TRACTION RETINAL DETACHMENT NOT INVOLVING THE MACULA, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.354 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH COMBINED TRACTION RETINAL DETACHMENT AND RHEGMATOGENOUS RETINAL DETACHMENT | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3541 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH COMBINED TRACTION RETINAL DETACHMENT AND RHEGMATOGENOUS RETINAL DETACHMENT, RIGHT EYE | ICD-10-CM |

| | | | | |
|----------------------------|----------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.3542 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH COMBINED TRACTION RETINAL DETACHMENT AND RHEGMATOGENOUS RETINAL DETACHMENT, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3543 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH COMBINED TRACTION RETINAL DETACHMENT AND RHEGMATOGENOUS RETINAL DETACHMENT, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3549 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH COMBINED TRACTION RETINAL DETACHMENT AND RHEGMATOGENOUS RETINAL DETACHMENT, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.355 | DX | TYPE 2 DIABETES MELLITUS WITH STABLE PROLIFERATIVE DIABETIC RETINOPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3551 | DX | TYPE 2 DIABETES MELLITUS WITH STABLE PROLIFERATIVE DIABETIC RETINOPATHY, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3552 | DX | TYPE 2 DIABETES MELLITUS WITH STABLE PROLIFERATIVE DIABETIC RETINOPATHY, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3553 | DX | TYPE 2 DIABETES MELLITUS WITH STABLE PROLIFERATIVE DIABETIC RETINOPATHY, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3559 | DX | TYPE 2 DIABETES MELLITUS WITH STABLE PROLIFERATIVE DIABETIC RETINOPATHY, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.359 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3591 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3592 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3593 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.3599 | DX | TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA, UNSPECIFIED EYE | ICD-10-CM |

| | | | | |
|----------------------------|----------|----|-----------------------------------------------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.36 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC CATARACT | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.37 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC MACULAR EDEMA, RESOLVED FOLLOWING TREATMENT | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.37X1 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC MACULAR EDEMA, RESOLVED FOLLOWING TREATMENT, RIGHT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.37X2 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC MACULAR EDEMA, RESOLVED FOLLOWING TREATMENT, LEFT EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.37X3 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC MACULAR EDEMA, RESOLVED FOLLOWING TREATMENT, BILATERAL | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.37X9 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC MACULAR EDEMA, RESOLVED FOLLOWING TREATMENT, UNSPECIFIED EYE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.39 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC OPHTHALMIC COMPLICATION | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.4 | DX | TYPE 2 DIABETES MELLITUS WITH NEUROLOGICAL COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.40 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC NEUROPATHY, UNSPECIFIED | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.41 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC MONONEUROPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.42 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.43 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC AUTONOMIC (POLY)NEUROPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.44 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC AMYOTROPHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.49 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC NEUROLOGICAL COMPLICATION | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.5 | DX | TYPE 2 DIABETES MELLITUS WITH CIRCULATORY COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.51 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITHOUT GANGRENE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.52 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITH GANGRENE | ICD-10-CM |

| | | | | |
|----------------------------|---------|----|----------------------------------------------------------------|-----------|
| 9 Type 2 Diabetes mellitus | E11.59 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER CIRCULATORY COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.6 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER SPECIFIED COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.61 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC ARTHROPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.610 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC NEUROPATHIC ARTHROPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.618 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC ARTHROPATHY | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.62 | DX | TYPE 2 DIABETES MELLITUS WITH SKIN COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.620 | DX | TYPE 2 DIABETES MELLITUS WITH DIABETIC DERMATITIS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.621 | DX | TYPE 2 DIABETES MELLITUS WITH FOOT ULCER | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.622 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER SKIN ULCER | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.628 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER SKIN COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.63 | DX | TYPE 2 DIABETES MELLITUS WITH ORAL COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.630 | DX | TYPE 2 DIABETES MELLITUS WITH PERIODONTAL DISEASE | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.638 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER ORAL COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.64 | DX | TYPE 2 DIABETES MELLITUS WITH HYPOGLYCEMIA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.641 | DX | TYPE 2 DIABETES MELLITUS WITH HYPOGLYCEMIA WITH COMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.649 | DX | TYPE 2 DIABETES MELLITUS WITH HYPOGLYCEMIA WITHOUT COMA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.65 | DX | TYPE 2 DIABETES MELLITUS WITH HYPERGLYCEMIA | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.69 | DX | TYPE 2 DIABETES MELLITUS WITH OTHER SPECIFIED COMPLICATION | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.8 | DX | TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED COMPLICATIONS | ICD-10-CM |
| 9 Type 2 Diabetes mellitus | E11.9 | DX | TYPE 2 DIABETES MELLITUS WITHOUT COMPLICATIONS | ICD-10-CM |

| | | | | |
|----------------------------|--------|----|------------------------------------------------------------------------------------------------------------|----------|
| 9 Type 2 Diabetes mellitus | 250.00 | DX | DIABETES MELLITUS WITHOUT MENTION OF COMPLICATION, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.02 | DX | DIABETES MELLITUS WITHOUT MENTION OF COMPLICATION, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.10 | DX | DIABETES WITH KETOACIDOSIS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.12 | DX | DIABETES WITH KETOACIDOSIS, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.20 | DX | DIABETES WITH HYPEROSMOLARITY, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.22 | DX | DIABETES WITH HYPEROSMOLARITY, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.30 | DX | DIABETES WITH OTHER COMA, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.32 | DX | DIABETES WITH OTHER COMA, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.40 | DX | DIABETES WITH RENAL MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.42 | DX | DIABETES WITH RENAL MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.50 | DX | DIABETES WITH OPHTHALMIC MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.52 | DX | DIABETES WITH OPHTHALMIC MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.60 | DX | DIABETES WITH NEUROLOGICAL MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.62 | DX | DIABETES WITH NEUROLOGICAL MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.70 | DX | DIABETES WITH PERIPHERAL CIRCULATORY DISORDERS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |

| | | | | |
|----------------------------|--------|----|-------------------------------------------------------------------------------------------------------------|----------|
| 9 Type 2 Diabetes mellitus | 250.72 | DX | DIABETES WITH PERIPHERAL CIRCULATORY DISORDERS, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.80 | DX | DIABETES WITH OTHER SPECIFIED MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.82 | DX | DIABETES WITH OTHER SPECIFIED MANIFESTATIONS, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.90 | DX | DIABETES WITH UNSPECIFIED COMPLICATION, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM |
| 9 Type 2 Diabetes mellitus | 250.92 | DX | DIABETES WITH UNSPECIFIED COMPLICATION, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM |

| Category | Variable_name | Variable_subtype | Code | Code_category | Description | Code_type | Notes |
|----------|---------------|------------------|----------|---------------|-----------------------------------------------------------------------------------------------|-----------|-------|
| 11 | Acute MI | | I21.0 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF ANTERIOR WALL | ICD-10-CM | |
| 11 | Acute MI | | I21.01 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION INVOLVING LEFT MAIN CORONARY ARTERY | ICD-10-CM | |
| 11 | Acute MI | | I21.02 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION INVOLVING LEFT ANTERIOR DESCENDING CORONARY ARTERY | ICD-10-CM | |
| 11 | Acute MI | | I21.09 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION INVOLVING OTHER CORONARY ARTERY OF ANTERIOR WALL | ICD-10-CM | |
| 11 | Acute MI | | I21 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF OTHER SITES | ICD-10-CM | |
| 11 | Acute MI | | I21.1 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF INFERIOR WALL | ICD-10-CM | |
| 11 | Acute MI | | I21.11 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION INVOLVING RIGHT CORONARY ARTERY | ICD-10-CM | |
| 11 | Acute MI | | I21.19 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION INVOLVING OTHER CORONARY ARTERY OF INFERIOR WALL | ICD-10-CM | |
| 11 | Acute MI | | I21.2 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF OTHER SITES | ICD-10-CM | |
| 11 | Acute MI | | I21.21 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION INVOLVING LEFT CIRCUMFLEX CORONARY ARTERY | ICD-10-CM | |
| 11 | Acute MI | | I21.29 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION INVOLVING OTHER SITES | ICD-10-CM | |
| 11 | Acute MI | | I21.3 | DX | ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF UNSPECIFIED SITE | ICD-10-CM | |
| 11 | Acute MI | | I21.4 | DX | NON-ST ELEVATION (NSTEMI) MYOCARDIAL INFARCTION | ICD-10-CM | |
| 11 | Acute MI | | I21.9 | DX | ACUTE MYOCARDIAL INFARCTION, UNSPECIFIED | ICD-10-CM | |
| 11 | Acute MI | | I21.A | DX | OTHER TYPE OF MYOCARDIAL INFARCTION | ICD-10-CM | |
| 11 | Acute MI | | I21.A1 | DX | MYOCARDIAL INFARCTION TYPE 2 | ICD-10-CM | |
| 11 | Acute MI | | I21.A9 | DX | OTHER MYOCARDIAL INFARCTION TYPE | ICD-10-CM | |
| 11 | Acute MI | | I22 | DX | SUBSEQUENT ST ELEVATION (STEMI) AND NON-ST ELEVATION (NSTEMI) MYOCARDIAL INFARCTION | ICD-10-CM | |
| 11 | Acute MI | | I22.0 | DX | SUBSEQUENT ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF ANTERIOR WALL | ICD-10-CM | |
| 11 | Acute MI | | I22.1 | DX | SUBSEQUENT ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF INFERIOR WALL | ICD-10-CM | |
| 11 | Acute MI | | I22.2 | DX | SUBSEQUENT NON-ST ELEVATION (NSTEMI) MYOCARDIAL INFARCTION | ICD-10-CM | |
| 11 | Acute MI | | I22.8 | DX | SUBSEQUENT ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF OTHER SITES | ICD-10-CM | |
| 11 | Acute MI | | I22.9 | DX | SUBSEQUENT ST ELEVATION (STEMI) MYOCARDIAL INFARCTION OF UNSPECIFIED SITE | ICD-10-CM | |
| 11 | Acute MI | | 410.0 | DX | ACUTE MYOCARDIAL INFARCTION OF ANTEROLATERAL WALL | ICD-9-CM | |
| 11 | Acute MI | | 410.00 | DX | ACUTE MYOCARDIAL INFARCTION OF ANTEROLATERAL WALL, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.01 | DX | ACUTE MYOCARDIAL INFARCTION OF ANTEROLATERAL WALL, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.1 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER ANTERIOR WALL | ICD-9-CM | |
| 11 | Acute MI | | 410.10 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER ANTERIOR WALL, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.11 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER ANTERIOR WALL, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.2 | DX | ACUTE MYOCARDIAL INFARCTION OF INFEROLATERAL WALL | ICD-9-CM | |
| 11 | Acute MI | | 410.20 | DX | ACUTE MYOCARDIAL INFARCTION OF INFEROLATERAL WALL, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.21 | DX | ACUTE MYOCARDIAL INFARCTION OF INFEROLATERAL WALL, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.3 | DX | ACUTE MYOCARDIAL INFARCTION OF INFEROPOSTERIOR WALL | ICD-9-CM | |
| 11 | Acute MI | | 410.30 | DX | ACUTE MYOCARDIAL INFARCTION OF INFEROPOSTERIOR WALL, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.31 | DX | ACUTE MYOCARDIAL INFARCTION OF INFEROPOSTERIOR WALL, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.4 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER INFERIOR WALL | ICD-9-CM | |
| 11 | Acute MI | | 410.40 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER INFERIOR WALL, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.41 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER INFERIOR WALL, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.5 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER LATERAL WALL | ICD-9-CM | |
| 11 | Acute MI | | 410.50 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER LATERAL WALL, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.51 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER LATERAL WALL, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.6 | DX | TRUE POSTERIOR WALL INFARCTION | ICD-9-CM | |
| 11 | Acute MI | | 410.60 | DX | TRUE POSTERIOR WALL INFARCTION, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.61 | DX | TRUE POSTERIOR WALL INFARCTION, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.7 | DX | SUBENDOCARDIAL INFARCTION | ICD-9-CM | |
| 11 | Acute MI | | 410.70 | DX | SUBENDOCARDIAL INFARCTION, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.71 | DX | SUBENDOCARDIAL INFARCTION, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.8 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER SPECIFIED SITES | ICD-9-CM | |
| 11 | Acute MI | | 410.80 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER SPECIFIED SITES, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.81 | DX | ACUTE MYOCARDIAL INFARCTION OF OTHER SPECIFIED SITES, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 11 | Acute MI | | 410.9 | DX | ACUTE MYOCARDIAL INFARCTION OF UNSPECIFIED SITE | ICD-9-CM | |
| 11 | Acute MI | | 410.90 | DX | ACUTE MYOCARDIAL INFARCTION OF UNSPECIFIED SITE, EPISODE OF CARE UNSPECIFIED | ICD-9-CM | |
| 11 | Acute MI | | 410.91 | DX | ACUTE MYOCARDIAL INFARCTION OF UNSPECIFIED SITE, INITIAL EPISODE OF CARE | ICD-9-CM | |
| 12 | CABG | | Z95.1 | DX | PRESENCE OF AORTOCORONARY BYPASS GRAFT | ICD-10-CM | |
| 12 | CABG | | T82.211A | DX | BREAKDOWN (MECHANICAL) OF CORONARY ARTERY BYPASS GRAFT, INITIAL ENCOUNTER | ICD-10-CM | |
| 12 | CABG | | T82.212A | DX | DISPLACEMENT OF CORONARY ARTERY BYPASS GRAFT, INITIAL ENCOUNTER | ICD-10-CM | |
| 12 | CABG | | T82.213A | DX | LEAKAGE OF CORONARY ARTERY BYPASS GRAFT, INITIAL ENCOUNTER | ICD-10-CM | |
| 12 | CABG | | T82.218A | DX | OTHER MECHANICAL COMPLICATION OF CORONARY ARTERY BYPASS GRAFT, INITIAL ENCOUNTER | ICD-10-CM | |
| 12 | CABG | | V45.81 | DX | AORTOCORONARY BYPASS STATUS | ICD-9-CM | |

| | | | | | |
|----|------|---------|----|--------------------------------------------------------------------------------------------------------------------|-----------|
| 12 | CABG | 996.03 | DX | MECHANICAL COMPLICATION DUE TO CORONARY BYPASS GRAFT | ICD-9-CM |
| 12 | CABG | 3610 | PX | AORTOCORONARY BYPASS FOR HEART REVASCULARIZATION, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 12 | CABG | 3611 | PX | (AORTO)CORONARY BYPASS OF ONE CORONARY ARTERY | ICD-9-CM |
| 12 | CABG | 3612 | PX | (AORTO)CORONARY BYPASS OF TWO CORONARY ARTERIES | ICD-9-CM |
| 12 | CABG | 3613 | PX | (AORTO)CORONARY BYPASS OF THREE CORONARY ARTERIES | ICD-9-CM |
| 12 | CABG | 3614 | PX | (AORTO)CORONARY BYPASS OF FOUR OR MORE CORONARY ARTERIES | ICD-9-CM |
| 12 | CABG | 3615 | PX | SINGLE INTERNAL MAMMARY-CORONARY ARTERY BYPASS | ICD-9-CM |
| 12 | CABG | 3616 | PX | DOUBLE INTERNAL MAMMARY-CORONARY ARTERY BYPASS | ICD-9-CM |
| 12 | CABG | 3617 | PX | ABDOMINAL-CORONARY ARTERY BYPASS | ICD-9-CM |
| 12 | CABG | 3619 | PX | OTHER BYPASS ANASTOMOSIS FOR HEART REVASCULARIZATION | ICD-9-CM |
| 12 | CABG | 362 | PX | HEART REVASCULARIZATION BY ARTERIAL IMPLANT | ICD-9-CM |
| 12 | CABG | 0210083 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM CORONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 0210088 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM RIGHT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 0210089 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM LEFT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 021008C | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM THORACIC ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 021008F | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM ABDOMINAL ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 021008W | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM AORTA WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 0210093 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM CORONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 0210098 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 0210099 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 021009C | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM THORACIC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 021009F | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM ABDOMINAL ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 021009W | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM AORTA WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100A3 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM CORONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100A8 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100A9 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100AC | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM THORACIC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100AF | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM ABDOMINAL ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100AW | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM AORTA WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100J3 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM CORONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100J8 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM RIGHT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100J9 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM LEFT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100JC | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM THORACIC ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100JF | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM ABDOMINAL ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100JW | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM AORTA WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100K3 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM CORONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100K8 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM RIGHT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 12 | CABG | 02100K9 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM LEFT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | |
|-----|------|---------|----|---------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.2 | CABG | 02104JW | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM AORTA WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104K3 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM CORONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104K8 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM RIGHT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104K9 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM LEFT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104KC | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM THORACIC ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104KF | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM ABDOMINAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104KW | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM AORTA WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104Z3 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM CORONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104Z8 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM RIGHT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104Z9 | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM LEFT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104ZC | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM THORACIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02104ZF | PX | BYPASS CORONARY ARTERY, ONE ARTERY FROM ABDOMINAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0211083 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0211088 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM RIGHT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0211089 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM LEFT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021108C | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM THORACIC ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021108F | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM ABDOMINAL ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021108W | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM AORTA WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0211093 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0211098 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0211099 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021109C | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021109F | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021109W | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM AORTA WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110A3 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110A8 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110A9 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110AC | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110AF | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110AW | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM AORTA WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110J3 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110J8 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM RIGHT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02110J9 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM LEFT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | |
|-----|------|---------|----|-----------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.2 | CABG | 02114AW | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM AORTA WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114D4 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114J3 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114J8 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM RIGHT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114J9 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM LEFT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114JC | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM THORACIC ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114JF | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM ABDOMINAL ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114JW | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM AORTA WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114K3 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114K8 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM RIGHT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114K9 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM LEFT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114KC | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM THORACIC ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114KF | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM ABDOMINAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114KW | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM AORTA WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114Z3 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM CORONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114Z8 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM RIGHT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114Z9 | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM LEFT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114ZC | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM THORACIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02114ZF | PX | BYPASS CORONARY ARTERY, TWO ARTERIES FROM ABDOMINAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212083 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212088 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212089 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021208C | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021208F | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021208W | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212093 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212098 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212099 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021209C | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021209F | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021209W | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120A3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120A8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |

| | | | | | |
|-----|------|---------|----|------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.2 | CABG | 02120A9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120AC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120AF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120AW | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120J3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120J8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120J9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120JC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120JF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120JW | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120K3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120K8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120K9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120KC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120KF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120KW | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120Z3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120Z8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120Z9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120ZC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02120ZF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212344 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY VEIN WITH DRUG-ELUTING INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.2 | CABG | 02123D4 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212444 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY VEIN WITH DRUG-ELUTING INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212483 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212488 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212489 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 021248C | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 021248F | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 021248W | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212493 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212498 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0212499 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 021249C | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | |
|-----|------|---------|----|-------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.2 | CABG | 021249F | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 021249W | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124A3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124A8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124A9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124AC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124AF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124AW | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124D4 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124J3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124J8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124J9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124JC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124JF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124JW | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124K3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124K8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124K9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124KC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124KF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124KW | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM AORTA WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124Z3 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM CORONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124Z8 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM RIGHT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124Z9 | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM LEFT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124ZC | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM THORACIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 02124ZF | PX | BYPASS CORONARY ARTERY, THREE ARTERIES FROM ABDOMINAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213083 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213088 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213089 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM LEFT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021308C | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM THORACIC ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021308F | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM ABDOMINAL ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021308W | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM AORTA WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213093 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |

| | | | | | |
|-----|------|---------|----|------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.2 | CABG | 0213098 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213099 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021309C | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021309F | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 021309W | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM AORTA WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130A3 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130A8 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130A9 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM LEFT INTERNAL MAMMARY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130AC | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM THORACIC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130AF | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM ABDOMINAL ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130AW | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM AORTA WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130J3 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130J8 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130J9 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM LEFT INTERNAL MAMMARY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130JC | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM THORACIC ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130JF | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM ABDOMINAL ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130JW | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM AORTA WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130K3 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130K8 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130K9 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM LEFT INTERNAL MAMMARY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130KC | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM THORACIC ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130KF | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM ABDOMINAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130KW | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM AORTA WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130Z3 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130Z8 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM RIGHT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130Z9 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM LEFT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130ZC | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM THORACIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 02130ZF | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM ABDOMINAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213344 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY VEIN WITH DRUG-ELUTING INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.2 | CABG | 02133D4 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213444 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY VEIN WITH DRUG-ELUTING INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213483 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM CORONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.2 | CABG | 0213488 | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM RIGHT INTERNAL MAMMARY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

[illegible]

| | | | | | |
|-----|------------------------|------------------------------------------------------------------------------------------------------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.2 | CABG | 02134ZF | PX | BYPASS CORONARY ARTERY, FOUR OR MORE ARTERIES FROM ABDOMINAL ARTERY, PERCUTANEOUS | ICD-10-CM |
| 1.2 | CABG | 33510 | PX | ENDOSCOPIC APPROACH | CPT/HCPCS |
| 1.2 | CABG | 33511 | PX | CORONARY ARTERY BYPASS, VEIN ONLY; SINGLE CORONARY VENOUS GRAFT | CPT/HCPCS |
| 1.2 | CABG | 33512 | PX | CORONARY ARTERY BYPASS, VEIN ONLY; 2 CORONARY VENOUS GRAFTS | CPT/HCPCS |
| 1.2 | CABG | 33513 | PX | CORONARY ARTERY BYPASS, VEIN ONLY; 3 CORONARY VENOUS GRAFTS | CPT/HCPCS |
| 1.2 | CABG | 33514 | PX | CORONARY ARTERY BYPASS, VEIN ONLY; 4 CORONARY VENOUS GRAFTS | CPT/HCPCS |
| 1.2 | CABG | 33516 | PX | CORONARY ARTERY BYPASS, VEIN ONLY; 5 CORONARY VENOUS GRAFTS | CPT/HCPCS |
| | | | | CORONARY ARTERY BYPASS, VEIN ONLY; 6 OR MORE CORONARY VENOUS GRAFTS | CPT/HCPCS |
| 1.2 | CABG | 33517 | PX | CORONARY ARTERY BYPASS, USING VENOUS GRAFT(S) AND ARTERIAL GRAFT(S); SINGLE VEIN GRAFT (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.2 | CABG | 33518 | PX | CORONARY ARTERY BYPASS, USING VENOUS GRAFT(S) AND ARTERIAL GRAFT(S); 2 VENOUS GRAFTS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.2 | CABG | 33519 | PX | CORONARY ARTERY BYPASS, USING VENOUS GRAFT(S) AND ARTERIAL GRAFT(S); 3 VENOUS GRAFTS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.2 | CABG | 33521 | PX | CORONARY ARTERY BYPASS, USING VENOUS GRAFT(S) AND ARTERIAL GRAFT(S); 4 VENOUS GRAFTS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.2 | CABG | 33522 | PX | CORONARY ARTERY BYPASS, USING VENOUS GRAFT(S) AND ARTERIAL GRAFT(S); 5 VENOUS GRAFTS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.2 | CABG | 33523 | PX | CORONARY ARTERY BYPASS, USING VENOUS GRAFT(S) AND ARTERIAL GRAFT(S); 6 OR MORE VENOUS GRAFTS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| | | | | REOPERATION, CORONARY ARTERY BYPASS PROCEDURE OR VALVE PROCEDURE, MORE THAN 1 MONTH AFTER ORIGINAL OPERATION (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.2 | CABG | 33530 | PX | CORONARY ARTERY BYPASS, USING ARTERIAL GRAFT(S); SINGLE ARTERIAL GRAFT | CPT/HCPCS |
| 1.2 | CABG | 33533 | PX | CORONARY ARTERY BYPASS, USING ARTERIAL GRAFT(S); 2 CORONARY ARTERIAL GRAFTS | CPT/HCPCS |
| 1.2 | CABG | 33534 | PX | CORONARY ARTERY BYPASS, USING ARTERIAL GRAFT(S); 3 CORONARY ARTERIAL GRAFTS | CPT/HCPCS |
| 1.2 | CABG | 33535 | PX | | |
| 1.2 | CABG | 33536 | PX | CORONARY ARTERY BYPASS, USING ARTERIAL GRAFT(S); 4 OR MORE CORONARY ARTERIAL GRAFTS | CPT/HCPCS |
| 1.2 | CABG | 33542 | PX | UNDER ARTERIAL GRAFTING FOR CORONARY ARTERY BYPASS | CPT/HCPCS |
| 1.2 | CABG | 33545 | PX | UNDER ARTERIAL GRAFTING FOR CORONARY ARTERY BYPASS | CPT/HCPCS |
| 1.2 | CABG | 33548 | PX | UNDER ARTERIAL GRAFTING FOR CORONARY ARTERY BYPASS | CPT/HCPCS |
| 1.2 | CABG | 33572 | PX | UNDER CORONARY ENDARTERECTOMY PROCEDURES | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33496 | PX | OTHER CARDIAC VALVULAR PROCEDURES | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33999 | PX | OTHER CARDIAC SURGERY PROCEDURES | CPT/HCPCS |
| | | source: https://codera.aapc.com/cpt-codes-range/906 | | | |
| 1.3 | Other Major CV surgery | 33460-33468 | PX | | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33361 | PX | SURGICAL PROCEDURES ON THE TRICUSPID VALVE | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33362 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; PERCUTANEOUS FEMORAL ARTERY APPROACH | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33363 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; OPEN FEMORAL ARTERY APPROACH | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33364 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; OPEN AXILLARY ARTERY APPROACH | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33365 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; OPEN ILIAC ARTERY APPROACH | CPT/HCPCS |
| | | | | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; TRANSAORTIC APPROACH (E.G., MEDIAN STERNOTOMY, MEDIASTINOTOMY) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33367 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; CARDIOPULMONARY BYPASS SUPPORT WITH PERCUTANEOUS PERIPHERAL ARTERIAL AND VENOUS CANNULATION (E.G., FEMORAL VESSELS) (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| | | | | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; CARDIOPULMONARY BYPASS SUPPORT WITH OPEN PERIPHERAL ARTERIAL AND VENOUS CANNULATION (E.G., FEMORAL, ILIAC, AXILLARY VESSELS) (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33369 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; CARDIOPULMONARY BYPASS SUPPORT WITH CENTRAL ARTERIAL AND VENOUS CANNULATION (E.G., AORTA, RIGHT ATRIUM, PULMONARY ARTERY) (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | 33477 | PX | TRANSCATHETER PULMONARY VALVE IMPLANTATION, PERCUTANEOUS APPROACH, INCLUDING PRE-STENTING OF THE VALVE DELIVERY SITE, WHEN PERFORMED | CPT/HCPCS |

| | | | | | | |
|-----|------------------------|-----------------|---------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | | 33418 | PX | TRANSCATHETER MITRAL VALVE REPAIR, PERCUTANEOUS APPROACH, INCLUDING TRANSSEPTAL PUNCTURE WHEN PERFORMED; INITIAL PROSTHESIS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33419 | PX | TRANSCATHETER MITRAL VALVE REPAIR, PERCUTANEOUS APPROACH, INCLUDING TRANSSEPTAL PUNCTURE WHEN PERFORMED; ADDITIONAL PROSTHESIS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33400 | PX | VALVULOPLASTY, AORTIC VALVE; OPEN, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33401 | PX | VALVULOPLASTY, AORTIC VALVE; OPEN, WITH INFLOW OCCLUSION | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33403 | PX | | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33405 | PX | REPLACEMENT, AORTIC VALVE, OPEN, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33406 | PX | REPLACEMENT, AORTIC VALVE, OPEN, WITH CARDIOPULMONARY BYPASS; WITH ALLOGRAFT VALVE (FREEHAND) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33410 | PX | REPLACEMENT, AORTIC VALVE, OPEN, WITH CARDIOPULMONARY BYPASS; WITH STENTLESS TISSUE VALVE | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33420 | PX | VALVOTOMY, MITRAL VALVE; CLOSED HEART | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33422 | PX | VALVOTOMY, MITRAL VALVE; OPEN HEART, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33425 | PX | VALVULOPLASTY, MITRAL VALVE, WITH CARDIOPULMONARY BYPASS; | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33426 | PX | VALVULOPLASTY, MITRAL VALVE, WITH CARDIOPULMONARY BYPASS; WITH PROSTHETIC RING | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33427 | PX | UNDER SURGICAL PROCEDURES ON THE MITRAL VALVE | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33430 | PX | REPLACEMENT, MITRAL VALVE, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33460 | PX | VALVECTOMY, TRICUSPID VALVE, WITH CARDIOPULMONARY BYPASS; | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33665 | PX | REPAIR OF INTERMEDIATE OR TRANSITIONAL ATRIOVENTRICULAR CANAL, WITH OR WITHOUT ATRIOVENTRICULAR VALVE REPAIR | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33463 | PX | VALVULOPLASTY, TRICUSPID VALVE, WITHOUT RING INSERTION | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33464 | PX | VALVULOPLASTY, TRICUSPID VALVE, WITH RING INSERTION | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33465 | PX | REPLACEMENT, TRICUSPID VALVE, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33468 | PX | TRICUSPID VALVE REPOSITIONING AND PLICATION FOR EBSTEIN ANOMALY | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33496 | PX | REPAIR OF NON-STRUCTURAL PROSTHETIC VALVE DYSFUNCTION WITH CARDIOPULMONARY BYPASS (SEPARATE PROCEDURE) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 33475 | PX | REPLACEMENT, PULMONARY VALVE | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 0257T | PX | IMPLANTATION OF CATHETER-DELIVERED PROSTHETIC AORTIC HEART VALVE; OPEN THORACIC APPROACH (EG, TRANSAPICAL, TRANSVENTRICULAR) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 0258T | PX | TRANSTHORACIC CARDIAC EXPOSURE (I.E. STERNOTOMY, THORACOTOMY, SUBXIPHOID) FOR CATHETER- DELIVERED AORTIC VALVE REPLACEMENT; WITHOUT CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 0259T | PX | TRANSTHORACIC CARDIAC EXPOSURE (I.E. STERNOTOMY, THORACOTOMY, SUBXIPHOID) FOR CATHETERDELIVERED AORTIC VALVE REPLACEMENT; WITH CARDIOPULMONARY BYPASS. | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 0262T | PX | MELODY TRANSCATHETER PULMONARY VALVE. | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | X2RF332 | PX | | ICD-10-CM |
| 1.3 | Other Major CV surgery | | X2RF032 | PX | | ICD-10-CM |
| 1.3 | Other Major CV surgery | | X2RF432 | PX | | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 0343T | PX | TRANSCATHETER MITRAL VALVE REPAIR PERCUTANEOUS APPROACH INCLUDING TRANSSEPTAL PUNCTURE WHEN PERFORMED; INITIAL PROSTHESIS (BEFORE 1/1/2015) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | | 0344T | PX | TRANSCATHETER MITRAL VALVE REPAIR PERCUTANEOUS APPROACH INCLUDING TRANSSEPTAL PUNCTURE WHEN PERFORMED; ADDITIONAL PROSTHESIS (ES) DURING SAME SESSION (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) BEFORE 1/1/2015 (EXCLUDE IF NOT PRESENT WITH 0343T) | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Lung transplant | V42.6 | DX | LUNG REPLACED BY TRANSPLANT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 996.84 | DX | COMPLICATIONS OF TRANSPLANTED LUNG | ICD-9-CM |
| 1.3 | Other Major CV surgery | Lung transplant | Z94.2 | DX | LUNG TRANSPLANT STATUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | Z94.3 | DX | HEART AND LUNGS TRANSPLANT STATUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | T86.810 | DX | LUNG TRANSPLANT REJECTION | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | T86.811 | DX | LUNG TRANSPLANT FAILURE | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | T86.819 | DX | UNSPECIFIED COMPLICATION OF LUNG TRANSPLANT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 33.5 | PX | LUNG TRANSPLANT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 33.50 | PX | LUNG TRANSPLANTATION, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 33.52 | PX | BILATERAL LUNG TRANSPLANTATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 33.51 | PX | UNILATERAL LUNG TRANSPLANTATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 33.6 | PX | COMBINED HEART-LUNG TRANSPLANTATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYC0Z0 | PX | TRANSPLANTATION OF RIGHT UPPER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYC0Z1 | PX | TRANSPLANTATION OF RIGHT UPPER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYC0Z2 | PX | TRANSPLANTATION OF RIGHT UPPER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYD0Z0 | PX | TRANSPLANTATION OF RIGHT MIDDLE LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYD0Z1 | PX | TRANSPLANTATION OF RIGHT MIDDLE LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYD0Z2 | PX | TRANSPLANTATION OF RIGHT MIDDLE LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYF0Z0 | PX | TRANSPLANTATION OF RIGHT LOWER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYF0Z1 | PX | TRANSPLANTATION OF RIGHT LOWER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYF0Z2 | PX | TRANSPLANTATION OF RIGHT LOWER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|--------------------------------|---------|----|-------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Lung transplant | 0BYG0Z0 | PX | TRANSPLANTATION OF LEFT UPPER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYG0Z1 | PX | TRANSPLANTATION OF LEFT UPPER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYG0Z2 | PX | TRANSPLANTATION OF LEFT UPPER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYH0Z0 | PX | TRANSPLANTATION OF LUNG LINGULA, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYH0Z1 | PX | TRANSPLANTATION OF LUNG LINGULA, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYH0Z2 | PX | TRANSPLANTATION OF LUNG LINGULA, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYJ0Z0 | PX | TRANSPLANTATION OF LEFT LOWER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYJ0Z1 | PX | TRANSPLANTATION OF LEFT LOWER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYJ0Z2 | PX | TRANSPLANTATION OF LEFT LOWER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYM0Z0 | PX | TRANSPLANTATION OF BILATERAL LUNGS, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYM0Z1 | PX | TRANSPLANTATION OF BILATERAL LUNGS, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYM0Z2 | PX | TRANSPLANTATION OF BILATERAL LUNGS, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYK0Z0 | PX | TRANSPLANTATION OF RIGHT LUNG, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYK0Z1 | PX | TRANSPLANTATION OF RIGHT LUNG, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYK0Z2 | PX | TRANSPLANTATION OF RIGHT LUNG, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYLOZ0 | PX | TRANSPLANTATION OF LEFT LUNG, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYLOZ1 | PX | TRANSPLANTATION OF LEFT LUNG, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 0BYLOZ2 | PX | TRANSPLANTATION OF LEFT LUNG, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Lung transplant | 32851 | PX | LUNG TRANSPLANT, SINGLE; WITHOUT CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Lung transplant | 32852 | PX | LUNG TRANSPLANT, SINGLE; WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Lung transplant | 32853 | PX | LUNG TRANSPLANT, DOUBLE (BILATERAL SEQUENTIAL OR EN BLOC); WITHOUT CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Lung transplant | 32854 | PX | LUNG TRANSPLANT, DOUBLE (BILATERAL SEQUENTIAL OR EN BLOC); WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Lung transplant | S2060 | PX | LOBAR LUNG TRANSPLANTATION | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Lung transplant | 33935 | PX | HEART-LUNG TRANSPLANT WITH RECIPIENT CARDIECTOMY-PNEUMONECTOMY | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | 33.6 | PX | COMBINED HEART-LUNG TRANSPLANTATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | T86.30 | DX | UNSPECIFIED COMPLICATION OF HEART-LUNG TRANSPLANT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | T86.31 | DX | HEART-LUNG TRANSPLANT REJECTION | ICD-10-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | T86.32 | DX | HEART-LUNG TRANSPLANT FAILURE | ICD-10-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | T86.33 | DX | HEART-LUNG TRANSPLANT INFECTION | ICD-10-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | T86.39 | DX | OTHER COMPLICATIONS OF HEART-LUNG TRANSPLANT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | Z94.3 | DX | HEART AND LUNGS TRANSPLANT STATUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | Z48.280 | DX | ENCOUNTER FOR AFTERCARE FOLLOWING HEART-LUNG TRANSPLANT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Combined heart-lung transplant | 33935 | PX | HEART-LUNG TRANSPLANT WITH RECIPIENT CARDIECTOMY-PNEUMONECTOMY | CPT/HCPCS |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.00 | PX | CLOSED HEART VALVOTOMY, UNSPECIFIED VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.01 | PX | CLOSED HEART VALVOTOMY, AORTIC VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.02 | PX | CLOSED HEART VALVOTOMY, MITRAL VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.03 | PX | CLOSED HEART VALVOTOMY, PULMONARY VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.04 | PX | CLOSED HEART VALVOTOMY, TRICUSPID VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NF3ZZ | PX | RELEASE AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NF4ZZ | PX | RELEASE AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NG3ZZ | PX | RELEASE MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NG4ZZ | PX | RELEASE MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NH3ZZ | PX | RELEASE PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NH4ZZ | PX | RELEASE PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NJ3ZZ | PX | RELEASE TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02NJ4ZZ | PX | RELEASE TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.05 | PX | ENDOVASCULAR REPLACEMENT OF AORTIC VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.06 | PX | TRANSAPICAL REPLACEMENT OF AORTIC VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.07 | PX | ENDOVASCULAR REPLACEMENT OF PULMONARY VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.08 | PX | TRANSAPICAL REPLACEMENT OF PULMONARY VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 35.09 | PX | ENDOVASCULAR REPLACEMENT OF UNSPECIFIED HEART VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF37Z | PX | REPLACEMENT OF AORTIC VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF38Z | PX | REPLACEMENT OF AORTIC VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF3JZ | PX | REPLACEMENT OF AORTIC VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------|---------|----|---------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF3KZ | PX | REPLACEMENT OF AORTIC VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF37H | PX | REPLACEMENT OF AORTIC VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF38H | PX | REPLACEMENT OF AORTIC VALVE WITH ZOOPLASTIC TISSUE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF3JH | PX | REPLACEMENT OF AORTIC VALVE WITH SYNTHETIC SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RF3KH | PX | REPLACEMENT OF AORTIC VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH37Z | PX | REPLACEMENT OF PULMONARY VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH38Z | PX | REPLACEMENT OF PULMONARY VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH3JZ | PX | REPLACEMENT OF PULMONARY VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH3KZ | PX | REPLACEMENT OF PULMONARY VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH37H | PX | REPLACEMENT OF PULMONARY VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH38H | PX | REPLACEMENT OF PULMONARY VALVE WITH ZOOPLASTIC TISSUE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH3JH | PX | REPLACEMENT OF PULMONARY VALVE WITH SYNTHETIC SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RH3KH | PX | REPLACEMENT OF PULMONARY VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG37H | PX | REPLACEMENT OF MITRAL VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG37Z | PX | REPLACEMENT OF MITRAL VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG38H | PX | REPLACEMENT OF MITRAL VALVE WITH ZOOPLASTIC TISSUE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG38Z | PX | REPLACEMENT OF MITRAL VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG3JH | PX | REPLACEMENT OF MITRAL VALVE WITH SYNTHETIC SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG3JZ | PX | REPLACEMENT OF MITRAL VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG3KH | PX | REPLACEMENT OF MITRAL VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RG3KZ | PX | REPLACEMENT OF MITRAL VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ37H | PX | REPLACEMENT OF TRICUSPID VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ37Z | PX | REPLACEMENT OF TRICUSPID VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ38H | PX | REPLACEMENT OF TRICUSPID VALVE WITH ZOOPLASTIC TISSUE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ38Z | PX | REPLACEMENT OF TRICUSPID VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ3JH | PX | REPLACEMENT OF TRICUSPID VALVE WITH SYNTHETIC SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ3JZ | PX | REPLACEMENT OF TRICUSPID VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ3KH | PX | REPLACEMENT OF TRICUSPID VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, TRANSAPICAL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Closed heart valvotomy | 02RJ3KZ | PX | REPLACEMENT OF TRICUSPID VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 3510 | PX | OPEN HEART VALVULOPLASTY WITHOUT REPLACEMENT, UNSPECIFIED VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 3511 | PX | OPEN HEART VALVULOPLASTY OF AORTIC VALVE WITHOUT REPLACEMENT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 3512 | PX | OPEN HEART VALVULOPLASTY OF MITRAL VALVE WITHOUT REPLACEMENT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 3513 | PX | OPEN HEART VALVULOPLASTY OF PULMONARY VALVE WITHOUT REPLACEMENT | ICD-9-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------|---------|----|----------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 3514 | PX | OPEN HEART VALVULOPLASTY OF TRICUSPID VALVE WITHOUT REPLACEMENT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QF0ZZ | PX | REPAIR AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QG0ZZ | PX | REPAIR MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QH0ZZ | PX | REPAIR PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QJ0ZZ | PX | REPAIR TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027F04Z | PX | DILATION OF AORTIC VALVE WITH DRUG-ELUTING INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027F0DZ | PX | DILATION OF AORTIC VALVE WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027F0ZZ | PX | DILATION OF AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02NF0ZZ | PX | RELEASE AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QF0ZZ | PX | REPAIR AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027G04Z | PX | DILATION OF MITRAL VALVE WITH DRUG-ELUTING INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027G0DZ | PX | DILATION OF MITRAL VALVE WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027G0ZZ | PX | DILATION OF MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02NG0ZZ | PX | RELEASE MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QG0ZZ | PX | REPAIR MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02VG0ZZ | PX | RESTRICTION OF MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027H04Z | PX | DILATION OF PULMONARY VALVE WITH DRUG-ELUTING INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027H0DZ | PX | DILATION OF PULMONARY VALVE WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027H0ZZ | PX | DILATION OF PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02NH0ZZ | PX | RELEASE PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QH0ZZ | PX | REPAIR PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027J04Z | PX | DILATION OF TRICUSPID VALVE WITH DRUG-ELUTING INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027J0DZ | PX | DILATION OF TRICUSPID VALVE WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 027J0ZZ | PX | DILATION OF TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02NJ0ZZ | PX | RELEASE TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02QJ0ZZ | PX | REPAIR TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.20 | PX | OPEN AND OTHER REPLACEMENT OF UNSPECIFIED HEART VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.21 | PX | OPEN AND OTHER REPLACEMENT OF AORTIC VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.22 | PX | OPEN AND OTHER REPLACEMENT OF AORTIC VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.23 | PX | OPEN AND OTHER REPLACEMENT OF MITRAL VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.24 | PX | OPEN AND OTHER REPLACEMENT OF MITRAL VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.25 | PX | OPEN AND OTHER REPLACEMENT OF PULMONARY VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.26 | PX | OPEN AND OTHER REPLACEMENT OF PULMONARY VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.27 | PX | OPEN AND OTHER REPLACEMENT OF TRICUSPID VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 35.28 | PX | OPEN AND OTHER REPLACEMENT OF TRICUSPID VALVE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF07Z | PX | REPLACEMENT OF AORTIC VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF08Z | PX | REPLACEMENT OF AORTIC VALVE WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF0JZ | PX | REPLACEMENT OF AORTIC VALVE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF0KZ | PX | REPLACEMENT OF AORTIC VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF47Z | PX | REPLACEMENT OF AORTIC VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF48Z | PX | REPLACEMENT OF AORTIC VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF4JZ | PX | REPLACEMENT OF AORTIC VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RF4KZ | PX | REPLACEMENT OF AORTIC VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG07Z | PX | REPLACEMENT OF MITRAL VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------|---------|----|-------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG08Z | PX | REPLACEMENT OF MITRAL VALVE WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG0JZ | PX | REPLACEMENT OF MITRAL VALVE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG0KZ | PX | REPLACEMENT OF MITRAL VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG47Z | PX | REPLACEMENT OF MITRAL VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG48Z | PX | REPLACEMENT OF MITRAL VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG4JZ | PX | REPLACEMENT OF MITRAL VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RG4KZ | PX | REPLACEMENT OF MITRAL VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH07Z | PX | REPLACEMENT OF PULMONARY VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH08Z | PX | REPLACEMENT OF PULMONARY VALVE WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH0JZ | PX | REPLACEMENT OF PULMONARY VALVE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH0KZ | PX | REPLACEMENT OF PULMONARY VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH47Z | PX | REPLACEMENT OF PULMONARY VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH48Z | PX | REPLACEMENT OF PULMONARY VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH4JZ | PX | REPLACEMENT OF PULMONARY VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RH4KZ | PX | REPLACEMENT OF PULMONARY VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ07Z | PX | REPLACEMENT OF TRICUSPID VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ08Z | PX | REPLACEMENT OF TRICUSPID VALVE WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ0JZ | PX | REPLACEMENT OF TRICUSPID VALVE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ0KZ | PX | REPLACEMENT OF TRICUSPID VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ47Z | PX | REPLACEMENT OF TRICUSPID VALVE WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ48Z | PX | REPLACEMENT OF TRICUSPID VALVE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ4JZ | PX | REPLACEMENT OF TRICUSPID VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|--------------------------------------------------|---------|----|-------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open heart valvuloplasty without replacement | 02RJ4KZ | PX | REPLACEMENT OF TRICUSPID VALVE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 35.3 | PX | OPERATIONS ON STRUCTURES ADJACENT TO HEART VALVES | ICD-9-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 35.31 | PX | OPERATIONS ON PAPILLARY MUSCLE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 35.32 | PX | OPERATIONS ON CHORDAE TENDINEAE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 35.33 | PX | ANNULOPLASTY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 35.34 | PX | INFUNDIBULECTOMY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 35.35 | PX | OPERATIONS ON TRABECULAE CARNEAE CORDIS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 35.39 | PX | OPERATIONS ON OTHER STRUCTURES ADJACENT TO VALVES OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 028D0ZZ | PX | DIVISION OF PAPILLARY MUSCLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 028D3ZZ | PX | DIVISION OF PAPILLARY MUSCLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 028D4ZZ | PX | DIVISION OF PAPILLARY MUSCLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QD0ZZ | PX | REPAIR PAPILLARY MUSCLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QD3ZZ | PX | REPAIR PAPILLARY MUSCLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QD4ZZ | PX | REPAIR PAPILLARY MUSCLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02890ZZ | PX | DIVISION OF CHORDAE TENDINEAE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02893ZZ | PX | DIVISION OF CHORDAE TENDINEAE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02894ZZ | PX | DIVISION OF CHORDAE TENDINEAE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02Q90ZZ | PX | REPAIR CHORDAE TENDINEAE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02Q93ZZ | PX | REPAIR CHORDAE TENDINEAE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02Q94ZZ | PX | REPAIR CHORDAE TENDINEAE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QF0ZZ | PX | REPAIR AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QF3ZZ | PX | REPAIR AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QF4ZZ | PX | REPAIR AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QG0ZZ | PX | REPAIR MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QG3ZZ | PX | REPAIR MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QG4ZZ | PX | REPAIR MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QH0ZZ | PX | REPAIR PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QH3ZZ | PX | REPAIR PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QH4ZZ | PX | REPAIR PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QJ0ZZ | PX | REPAIR TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QJ3ZZ | PX | REPAIR TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QJ4ZZ | PX | REPAIR TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------------------------------------------|---------|----|-----------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02BK0ZZ | PX | EXCISION OF RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02BK3ZZ | PX | EXCISION OF RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02BK4ZZ | PX | EXCISION OF RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02NK0ZZ | PX | RELEASE RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02NK3ZZ | PX | RELEASE RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02NK4ZZ | PX | RELEASE RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02NLOZZ | PX | RELEASE LEFT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02NL3ZZ | PX | RELEASE LEFT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02NL4ZZ | PX | RELEASE LEFT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QF0ZZ | PX | REPAIR AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QF3ZZ | PX | REPAIR AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Operation on structures adjacent to heart valves | 02QF4ZZ | PX | REPAIR AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 35.4 | PX | PRODUCTION OF SEPTAL DEFECT IN HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 35.41 | PX | ENLARGEMENT OF EXISTING ATRIAL SEPTAL DEFECT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 35.42 | PX | CREATION OF SEPTAL DEFECT IN HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 02QA0ZZ | PX | REPAIR HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 02QA3ZZ | PX | REPAIR HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 02QA4ZZ | PX | REPAIR HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 02B50ZZ | PX | EXCISION OF ATRIAL SEPTUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 02B53ZZ | PX | EXCISION OF ATRIAL SEPTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Production of septal defect in heart | 02B54ZZ | PX | EXCISION OF ATRIAL SEPTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.5 | PX | REPAIR OF UNSPECIFIED SEPTAL DEFECT OF HEART WITH PROSTHESIS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.51 | PX | REPAIR OF ATRIAL SEPTAL DEFECT WITH PROSTHESIS, OPEN TECHNIQUE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.52 | PX | REPAIR OF ATRIAL SEPTAL DEFECT WITH PROSTHESIS, CLOSED TECHNIQUE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.53 | PX | REPAIR OF VENTRICULAR SEPTAL DEFECT WITH PROSTHESIS, OPEN TECHNIQUE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.54 | PX | REPAIR OF ENDOCARDIAL CUSHION DEFECT WITH PROSTHESIS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.55 | PX | REPAIR OF VENTRICULAR SEPTAL DEFECT WITH PROSTHESIS, CLOSED TECHNIQUE | ICD-9-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM0JZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM4JZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U50JZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U53JZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U54JZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM0JZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U50JZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U53JZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U54JZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM0JZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM0JZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM3JZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM4JZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 024G0J2 | PX | CREATION OF MITRAL VALVE FROM COMMON ATRIOVENTRICULAR VALVE USING SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 024J0J2 | PX | CREATION OF TRICUSPID VALVE FROM COMMON ATRIOVENTRICULAR VALVE USING SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM4JZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.6 | PX | REPAIR OF UNSPECIFIED SEPTAL DEFECT OF HEART WITH TISSUE GRAFT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.61 | PX | REPAIR OF ATRIAL SEPTAL DEFECT WITH TISSUE GRAFT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.62 | PX | REPAIR OF VENTRICULAR SEPTAL DEFECT WITH TISSUE GRAFT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM07Z | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM0KZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM47Z | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM4KZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U507Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U508Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U50KZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U537Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U538Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH ZOOPLASTIC TISSUE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U53KZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U547Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U548Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U54KZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------------------------------------------|---------|----|------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM07Z | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM0KZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM37Z | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM3KZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM47Z | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM4KZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U507Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U508Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U50KZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U537Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U538Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH ZOOPLASTIC TISSUE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U53KZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U547Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U548Z | PX | SUPPLEMENT ATRIAL SEPTUM WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02U54KZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM07Z | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM0KZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM47Z | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02RM4KZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM07Z | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM0KZ | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM38Z | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH ZOOPLASTIC TISSUE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02UM48Z | PX | SUPPLEMENT VENTRICULAR SEPTUM WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.70 | PX | OTHER AND UNSPECIFIED REPAIR OF UNSPECIFIED SEPTAL DEFECT OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.71 | PX | OTHER AND UNSPECIFIED REPAIR OF ATRIAL SEPTAL DEFECT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 35.72 | PX | OTHER AND UNSPECIFIED REPAIR OF VENTRICULAR SEPTAL DEFECT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02Q50ZZ | PX | REPAIR ATRIAL SEPTUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02Q53ZZ | PX | REPAIR ATRIAL SEPTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02Q54ZZ | PX | REPAIR ATRIAL SEPTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02QM0ZZ | PX | REPAIR VENTRICULAR SEPTUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02QM3ZZ | PX | REPAIR VENTRICULAR SEPTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of atrial and ventricular septal defect of heart with prosthesis or tissue | 02QM4ZZ | PX | REPAIR VENTRICULAR SEPTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 35.8 | PX | TOTAL REPAIR OF CERTAIN CONGENITAL CARDIAC ANOMALIES | ICD-9-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 35.81 | PX | TOTAL REPAIR OF TETRALOGY OF FALLOT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 35.82 | PX | TOTAL REPAIR OF TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION | ICD-9-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 35.83 | PX | TOTAL REPAIR OF TRUNCUS ARTERIOSUS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 35.84 | PX | TOTAL CORRECTION OF TRANSPOSITION OF GREAT VESSELS, NOT ELSEWHERE CLASSIFIED | ICD-9-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02BK0ZZ | PX | EXCISION OF RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02NH0ZZ | PX | RELEASE PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02RM0JZ | PX | REPLACEMENT OF VENTRICULAR SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02RP0JZ | PX | REPLACEMENT OF PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02RQ0JZ | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02RR0JZ | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021708S | PX | BYPASS LEFT ATRIUM TO RIGHT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021708T | PX | BYPASS LEFT ATRIUM TO LEFT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021708U | PX | BYPASS LEFT ATRIUM TO PULMONARY VEIN CONFLUENCE WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021709S | PX | BYPASS LEFT ATRIUM TO RIGHT PULMONARY VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021709T | PX | BYPASS LEFT ATRIUM TO LEFT PULMONARY VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021709U | PX | BYPASS LEFT ATRIUM TO PULMONARY VEIN CONFLUENCE WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02170AS | PX | BYPASS LEFT ATRIUM TO RIGHT PULMONARY VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02170AT | PX | BYPASS LEFT ATRIUM TO LEFT PULMONARY VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02170AU | PX | BYPASS LEFT ATRIUM TO PULMONARY VEIN CONFLUENCE WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02170JS | PX | BYPASS LEFT ATRIUM TO RIGHT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02170JT | PX | BYPASS LEFT ATRIUM TO LEFT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02174ZS | PX | BYPASS LEFT ATRIUM TO RIGHT PULMONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02174ZT | PX | BYPASS LEFT ATRIUM TO LEFT PULMONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02174ZU | PX | BYPASS LEFT ATRIUM TO PULMONARY VEIN CONFLUENCE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V08S | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V08T | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V08U | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V09S | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V09T | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V09U | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0AS | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0AT | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0AU | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0JS | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0JT | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0JU | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0KS | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0KT | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0KU | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0ZS | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0ZT | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V0ZU | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V48S | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V48T | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V48U | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V49S | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V49T | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V49U | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4AS | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4AT | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4AU | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4JS | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4JT | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4JU | PX | BYPASS SUPERIOR VENA CAVA TO PULMONARY VEIN CONFLUENCE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4KS | PX | BYPASS SUPERIOR VENA CAVA TO RIGHT PULMONARY VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 021V4KT | PX | BYPASS SUPERIOR VENA CAVA TO LEFT PULMONARY VEIN WITH NONAUT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 024F07J | PX | CREATION OF AORTIC VALVE FROM TRUNCAL VALVE USING AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 024F08J | PX | CREATION OF AORTIC VALVE FROM TRUNCAL VALVE USING ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 024F0JJ | PX | CREATION OF AORTIC VALVE FROM TRUNCAL VALVE USING SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 024F0KJ | PX | CREATION OF AORTIC VALVE FROM TRUNCAL VALVE USING NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02S00ZZ | PX | REPOSITION CORONARY ARTERY, ONE ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02S10ZZ | PX | REPOSITION CORONARY ARTERY, TWO ARTERIES, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02SP0ZZ | PX | REPOSITION PULMONARY TRUNK, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02SW0ZZ | PX | REPOSITION THORACIC AORTA, DESCENDING, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Total Repair Of Certain Congenital Cardiac Anomalies | 02SX0ZZ | PX | REPOSITION THORACIC AORTA, ASCENDING/ARCH, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|-------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.9 | PX | OTHER OPERATIONS ON VALVES AND SEPTA OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.91 | PX | INTERATRIAL TRANSPOSITION OF VENOUS RETURN | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.92 | PX | CREATION OF CONDUIT BETWEEN RIGHT VENTRICLE AND PULMONARY ARTERY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.93 | PX | CREATION OF CONDUIT BETWEEN LEFT VENTRICLE AND AORTA | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.94 | PX | CREATION OF CONDUIT BETWEEN ATRIUM AND PULMONARY ARTERY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.95 | PX | REVISION OF CORRECTIVE PROCEDURE ON HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.96 | PX | PERCUTANEOUS BALLOON VALVULOPLASTY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.97 | PX | PERCUTANEOUS MITRAL VALVE REPAIR WITH IMPLANT | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.98 | PX | OTHER OPERATIONS ON SEPTA OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 35.99 | PX | OTHER OPERATIONS ON VALVES OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02U50JZ | PX | SUPPLEMENT ATRIAL SEPTUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K08P | PX | BYPASS RIGHT VENTRICLE TO PULMONARY TRUNK WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K08Q | PX | BYPASS RIGHT VENTRICLE TO RIGHT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K08R | PX | BYPASS RIGHT VENTRICLE TO LEFT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K09P | PX | BYPASS RIGHT VENTRICLE TO PULMONARY TRUNK WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K09Q | PX | BYPASS RIGHT VENTRICLE TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K09R | PX | BYPASS RIGHT VENTRICLE TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K0AP | PX | BYPASS RIGHT VENTRICLE TO PULMONARY TRUNK WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K0AQ | PX | BYPASS RIGHT VENTRICLE TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K0AR | PX | BYPASS RIGHT VENTRICLE TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K0JP | PX | BYPASS RIGHT VENTRICLE TO PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K0JQ | PX | BYPASS RIGHT VENTRICLE TO RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|-----------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K4ZP | PX | BYPASS RIGHT VENTRICLE TO PULMONARY TRUNK, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K4ZQ | PX | BYPASS RIGHT VENTRICLE TO RIGHT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021K4ZR | PX | BYPASS RIGHT VENTRICLE TO LEFT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH0CZ | PX | OCCLUSION OF PULMONARY VALVE WITH EXTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH0DZ | PX | OCCLUSION OF PULMONARY VALVE WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH0ZZ | PX | OCCLUSION OF PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH3CZ | PX | OCCLUSION OF PULMONARY VALVE WITH EXTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH3DZ | PX | OCCLUSION OF PULMONARY VALVE WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH3ZZ | PX | OCCLUSION OF PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH4CZ | PX | OCCLUSION OF PULMONARY VALVE WITH EXTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH4DZ | PX | OCCLUSION OF PULMONARY VALVE WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02LH4ZZ | PX | OCCLUSION OF PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021L0ZW | PX | BYPASS LEFT VENTRICLE TO AORTA, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021L4ZW | PX | BYPASS LEFT VENTRICLE TO AORTA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021648Q | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021648R | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021649P | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021649Q | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021649R | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164AP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164AQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164AR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164JP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164JQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164JR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164KP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164KQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164KR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164ZP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164ZQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02164ZR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021648P | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160ZR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160ZQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160ZP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160KR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160KQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160KP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160JR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160JQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160JP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160AR | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160AQ | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02160AP | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|-----------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021609R | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021609Q | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021609P | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021608R | PX | BYPASS RIGHT ATRIUM TO LEFT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021608Q | PX | BYPASS RIGHT ATRIUM TO RIGHT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 021608P | PX | BYPASS RIGHT ATRIUM TO PULMONARY TRUNK WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02W50JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN ATRIAL SEPTUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02W54JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN ATRIAL SEPTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF07Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF08Z | PX | REVISION OF ZOOPLASTIC TISSUE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF0JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WFOKZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF37Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF38Z | PX | REVISION OF ZOOPLASTIC TISSUE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF3JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF3KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF47Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF48Z | PX | REVISION OF ZOOPLASTIC TISSUE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF4JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WF4KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG07Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG08Z | PX | REVISION OF ZOOPLASTIC TISSUE IN MITRAL VALVE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG0JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG0KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG37Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG38Z | PX | REVISION OF ZOOPLASTIC TISSUE IN MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG3JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG3KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG47Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG48Z | PX | REVISION OF ZOOPLASTIC TISSUE IN MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG4JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WG4KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH07Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH08Z | PX | REVISION OF ZOOPLASTIC TISSUE IN PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH0JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH0KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH37Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH38Z | PX | REVISION OF ZOOPLASTIC TISSUE IN PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH3JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH3KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH47Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH48Z | PX | REVISION OF ZOOPLASTIC TISSUE IN PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH4JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WH4KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ07Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ08Z | PX | REVISION OF ZOOPLASTIC TISSUE IN TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ0JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ0KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ37Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ38Z | PX | REVISION OF ZOOPLASTIC TISSUE IN TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ3JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ3KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ47Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ48Z | PX | REVISION OF ZOOPLASTIC TISSUE IN TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ4JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WJ4KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WM0JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN VENTRICULAR SEPTUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02WM4JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN VENTRICULAR SEPTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027F3ZZ | PX | DILATION OF AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027F4ZZ | PX | DILATION OF AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027G3ZZ | PX | DILATION OF MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027G4ZZ | PX | DILATION OF MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027H3ZZ | PX | DILATION OF PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027H4ZZ | PX | DILATION OF PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027J3ZZ | PX | DILATION OF TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 027J4ZZ | PX | DILATION OF TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02UG3JZ | PX | SUPPLEMENT MITRAL VALVE WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02Q50ZZ | PX | REPAIR ATRIAL SEPTUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02Q53ZZ | PX | REPAIR ATRIAL SEPTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02Q54ZZ | PX | REPAIR ATRIAL SEPTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QM0ZZ | PX | REPAIR VENTRICULAR SEPTUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QM3ZZ | PX | REPAIR VENTRICULAR SEPTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QM4ZZ | PX | REPAIR VENTRICULAR SEPTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QF0ZJ | PX | REPAIR AORTIC VALVE CREATED FROM TRUNCAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QF0ZZ | PX | REPAIR AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QF3ZJ | PX | REPAIR AORTIC VALVE CREATED FROM TRUNCAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QF4ZJ | PX | REPAIR AORTIC VALVE CREATED FROM TRUNCAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QG0ZE | PX | REPAIR MITRAL VALVE CREATED FROM LEFT ATRIOVENTRICULAR VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QG0ZZ | PX | REPAIR MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QG3ZE | PX | REPAIR MITRAL VALVE CREATED FROM LEFT ATRIOVENTRICULAR VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QG4ZE | PX | REPAIR MITRAL VALVE CREATED FROM LEFT ATRIOVENTRICULAR VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QH0ZZ | PX | REPAIR PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QJ0ZG | PX | REPAIR TRICUSPID VALVE CREATED FROM RIGHT ATRIOVENTRICULAR VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QJ0ZZ | PX | REPAIR TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QJ3ZG | PX | REPAIR TRICUSPID VALVE CREATED FROM RIGHT ATRIOVENTRICULAR VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02QJ4ZG | PX | REPAIR TRICUSPID VALVE CREATED FROM RIGHT ATRIOVENTRICULAR VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02VG3ZZ | PX | RESTRICTION OF MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02VG4ZZ | PX | RESTRICTION OF MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------|---------|----|---------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 37.61 | PX | IMPLANT OF PULSATION BALLOON | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 37.65 | PX | IMPLANT OF SINGLE VENTRICULAR (EXTRACORPOREAL) EXTERNAL HEART ASSIST SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 5A02110 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING BALLOON PUMP, INTERMITTENT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 5A02210 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING BALLOON PUMP, CONTINUOUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02HA0RZ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 02HA4RZ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 5A02116 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, INTERMITTENT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on valves and septa of heart | 5A02216 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, CONTINUOUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 36.3 | PX | OTHER HEART REVASCULARIZATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | TMR | 36.31 | PX | OPEN CHEST TRANSMYOCARDIAL REVASCULARIZATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | TMR | 36.32 | PX | OTHER TRANSMYOCARDIAL REVASCULARIZATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | TMR | 36.33 | PX | ENDOSCOPIC TRANSMYOCARDIAL REVASCULARIZATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | TMR | 36.34 | PX | PERCUTANEOUS TRANSMYOCARDIAL REVASCULARIZATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | TMR | 36.39 | PX | OTHER HEART REVASCULARIZATION | ICD-9-CM |
| 1.3 | Other Major CV surgery | TMR | 021K0Z5 | PX | BYPASS RIGHT VENTRICLE TO CORONARY CIRCULATION, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K0Z8 | PX | BYPASS RIGHT VENTRICLE TO RIGHT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K0Z9 | PX | BYPASS RIGHT VENTRICLE TO LEFT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K0ZC | PX | BYPASS RIGHT VENTRICLE TO THORACIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K0ZF | PX | BYPASS RIGHT VENTRICLE TO ABDOMINAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K0ZW | PX | BYPASS RIGHT VENTRICLE TO AORTA, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K4Z5 | PX | BYPASS RIGHT VENTRICLE TO CORONARY CIRCULATION, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K4Z8 | PX | BYPASS RIGHT VENTRICLE TO RIGHT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K4Z9 | PX | BYPASS RIGHT VENTRICLE TO LEFT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K4ZC | PX | BYPASS RIGHT VENTRICLE TO THORACIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K4ZF | PX | BYPASS RIGHT VENTRICLE TO ABDOMINAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021K4ZW | PX | BYPASS RIGHT VENTRICLE TO AORTA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L08P | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L08Q | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L08R | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L09P | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L09Q | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L09R | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0AP | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0AQ | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0AR | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0JP | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0JQ | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----|----------|----|------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | TMR | 021L0JR | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0KP | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0KQ | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0KR | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0Z5 | PX | BYPASS LEFT VENTRICLE TO CORONARY CIRCULATION, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0Z8 | PX | BYPASS LEFT VENTRICLE TO RIGHT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0Z9 | PX | BYPASS LEFT VENTRICLE TO LEFT INTERNAL MAMMARY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0ZC | PX | BYPASS LEFT VENTRICLE TO THORACIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0ZF | PX | BYPASS LEFT VENTRICLE TO ABDOMINAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0ZP | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0ZQ | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L0ZR | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L48P | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L48Q | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L48R | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L49P | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L49Q | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L49R | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4A4P | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4A4Q | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4A4R | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4J4P | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4J4Q | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4J4R | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4K4P | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4K4Q | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4K4R | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4Z5 | PX | BYPASS LEFT VENTRICLE TO CORONARY CIRCULATION, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4Z8 | PX | BYPASS LEFT VENTRICLE TO CORONARY CIRCULATION, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4Z9 | PX | BYPASS LEFT VENTRICLE TO RIGHT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4ZC | PX | BYPASS LEFT VENTRICLE TO LEFT INTERNAL MAMMARY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4ZF | PX | BYPASS LEFT VENTRICLE TO THORACIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4ZP | PX | BYPASS LEFT VENTRICLE TO ABDOMINAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4ZQ | PX | BYPASS LEFT VENTRICLE TO PULMONARY TRUNK, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 021L4ZR | PX | BYPASS LEFT VENTRICLE TO RIGHT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QA0ZZ | PX | BYPASS LEFT VENTRICLE TO LEFT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QA3ZZ | PX | REPAIR HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QA4ZZ | PX | REPAIR HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QB0ZZ | PX | REPAIR RIGHT HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QB3ZZ | PX | REPAIR RIGHT HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QB4ZZ | PX | REPAIR RIGHT HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|--------------------------------------|---------|----|---------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | TMR | 02QC0ZZ | PX | REPAIR LEFT HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QC3ZZ | PX | REPAIR LEFT HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | TMR | 02QC4ZZ | PX | REPAIR LEFT HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 36.91 | PX | REPAIR OF ANEURYSM OF CORONARY VESSEL | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 36.99 | PX | OTHER OPERATIONS ON VESSELS OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02Q00ZZ | PX | REPAIR CORONARY ARTERY, ONE ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02Q03ZZ | PX | REPAIR CORONARY ARTERY, ONE ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02Q04ZZ | PX | REPAIR CORONARY ARTERY, ONE ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02Q40ZZ | PX | REPAIR CORONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02Q43ZZ | PX | REPAIR CORONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02Q44ZZ | PX | REPAIR CORONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02H40YZ | PX | INSERTION OF OTHER DEVICE INTO CORONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02H43YZ | PX | INSERTION OF OTHER DEVICE INTO CORONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02H44YZ | PX | INSERTION OF OTHER DEVICE INTO CORONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N00ZZ | PX | RELEASE CORONARY ARTERY, ONE ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N03ZZ | PX | RELEASE CORONARY ARTERY, ONE ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N04ZZ | PX | RELEASE CORONARY ARTERY, ONE ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N10ZZ | PX | RELEASE CORONARY ARTERY, TWO ARTERIES, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N13ZZ | PX | RELEASE CORONARY ARTERY, TWO ARTERIES, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N14ZZ | PX | RELEASE CORONARY ARTERY, TWO ARTERIES, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N20ZZ | PX | RELEASE CORONARY ARTERY, THREE ARTERIES, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N23ZZ | PX | RELEASE CORONARY ARTERY, THREE ARTERIES, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N24ZZ | PX | RELEASE CORONARY ARTERY, THREE ARTERIES, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N30ZZ | PX | RELEASE CORONARY ARTERY, FOUR OR MORE ARTERIES, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N33ZZ | PX | RELEASE CORONARY ARTERY, FOUR OR MORE ARTERIES, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Other operations on vessels of heart | 02N34ZZ | PX | RELEASE CORONARY ARTERY, FOUR OR MORE ARTERIES, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 37.0 | PX | PERICARDIOCENTESIS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9C30Z | PX | DRAINAGE OF MEDIASTINUM WITH DRAINAGE DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9C3ZZ | PX | DRAINAGE OF MEDIASTINUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9D30Z | PX | DRAINAGE OF PERICARDIAL CAVITY WITH DRAINAGE DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9D3ZX | PX | DRAINAGE OF PERICARDIAL CAVITY, PERCUTANEOUS APPROACH, DIAGNOSTIC | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9D3ZZ | PX | DRAINAGE OF PERICARDIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9D40Z | PX | DRAINAGE OF PERICARDIAL CAVITY WITH DRAINAGE DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9D4ZX | PX | DRAINAGE OF PERICARDIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH, DIAGNOSTIC | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiocentesis | 0W9D4ZZ | PX | DRAINAGE OF PERICARDIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 37.1 | PX | CARDIOTOMY AND PERICARDIOTOMY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 37.10 | PX | INCISION OF HEART, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 37.11 | PX | CARDIOTOMY | ICD-9-CM |

| | | | | | | |
|-----|------------------------|-------------------------------|---------|----|-----------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 37.12 | PX | PERICARDIOTOMY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02N60ZZ | PX | RELEASE RIGHT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02N63ZZ | PX | RELEASE RIGHT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02N64ZZ | PX | RELEASE RIGHT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02N70ZZ | PX | RELEASE LEFT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02N73ZZ | PX | RELEASE LEFT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02N74ZZ | PX | RELEASE LEFT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NK0ZZ | PX | RELEASE RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NK3ZZ | PX | RELEASE RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NK4ZZ | PX | RELEASE RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NL0ZZ | PX | RELEASE LEFT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NL3ZZ | PX | RELEASE LEFT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NL4ZZ | PX | RELEASE LEFT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C60ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C63ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C64ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C70ZZ | PX | EXTIRPATION OF MATTER FROM LEFT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C73ZZ | PX | EXTIRPATION OF MATTER FROM LEFT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C74ZZ | PX | EXTIRPATION OF MATTER FROM LEFT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C80ZZ | PX | EXTIRPATION OF MATTER FROM CONDUCTION MECHANISM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C83ZZ | PX | EXTIRPATION OF MATTER FROM CONDUCTION MECHANISM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C84ZZ | PX | EXTIRPATION OF MATTER FROM CONDUCTION MECHANISM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C90ZZ | PX | EXTIRPATION OF MATTER FROM CHORDAE TENDINEAE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C93ZZ | PX | EXTIRPATION OF MATTER FROM CHORDAE TENDINEAE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02C94ZZ | PX | EXTIRPATION OF MATTER FROM CHORDAE TENDINEAE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CK0ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CK3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CK4ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CL0ZZ | PX | EXTIRPATION OF MATTER FROM LEFT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CL3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CL4ZZ | PX | EXTIRPATION OF MATTER FROM LEFT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02PA0YZ | PX | REMOVAL OF OTHER DEVICE FROM HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02PA4YZ | PX | REMOVAL OF OTHER DEVICE FROM HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|---------------------------------------------|---------|----|------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02WA0YZ | PX | REVISION OF OTHER DEVICE IN HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02WA3YZ | PX | REVISION OF OTHER DEVICE IN HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02WA4YZ | PX | REVISION OF OTHER DEVICE IN HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CN0ZZ | PX | EXTIRPATION OF MATTER FROM PERICARDIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CN3ZZ | PX | EXTIRPATION OF MATTER FROM PERICARDIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02CN4ZZ | PX | EXTIRPATION OF MATTER FROM PERICARDIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NN0ZZ | PX | RELEASE PERICARDIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NN3ZZ | PX | RELEASE PERICARDIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 02NN4ZZ | PX | RELEASE PERICARDIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 0W9D00Z | PX | DRAINAGE OF PERICARDIAL CAVITY WITH DRAINAGE DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 0W9D0ZX | PX | DRAINAGE OF PERICARDIAL CAVITY, OPEN APPROACH, DIAGNOSTIC | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 0W9D0ZZ | PX | DRAINAGE OF PERICARDIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 0WCD0ZZ | PX | EXTIRPATION OF MATTER FROM PERICARDIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 0WCD3ZZ | PX | EXTIRPATION OF MATTER FROM PERICARDIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Cardiotomy and pericardiotomy | 0WCD4ZZ | PX | EXTIRPATION OF MATTER FROM PERICARDIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.3 | PX | PERICARDIECTOMY AND EXCISION OF LESION OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.31 | PX | PERICARDIECTOMY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.32 | PX | EXCISION OF ANEURYSM OF HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.33 | PX | EXCISION OR DESTRUCTION OF OTHER LESION OR TISSUE OF HEART, OPEN APPROACH | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.34 | PX | EXCISION OR DESTRUCTION OF OTHER LESION OR TISSUE OF HEART, ENDOVASCULAR APPROACH | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.36 | PX | EXCISION, DESTRUCTION, OR EXCLUSION OF LEFT ATRIAL APPENDAGE (LAA) | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.37 | PX | EXCISION OR DESTRUCTION OF OTHER LESION OR TISSUE OF HEART, THORACOSCOPIC APPROACH | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 37.35 | PX | PARTIAL VENTRICULECTOMY | ICD-9-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BN0ZZ | PX | EXCISION OF PERICARDIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BN3ZZ | PX | EXCISION OF PERICARDIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BN4ZZ | PX | EXCISION OF PERICARDIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02TN0ZZ | PX | RESECTION OF PERICARDIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02TN3ZZ | PX | RESECTION OF PERICARDIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02TN4ZZ | PX | RESECTION OF PERICARDIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B60ZZ | PX | EXCISION OF RIGHT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B63ZZ | PX | EXCISION OF RIGHT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B64ZZ | PX | EXCISION OF RIGHT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B70ZZ | PX | EXCISION OF LEFT ATRIUM, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|---------------------------------------------|---------|----|------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B73ZZ | PX | EXCISION OF LEFT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B74ZZ | PX | EXCISION OF LEFT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BK0ZZ | PX | EXCISION OF RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BK3ZZ | PX | EXCISION OF RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BK4ZZ | PX | EXCISION OF RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BL0ZZ | PX | EXCISION OF LEFT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BL3ZZ | PX | EXCISION OF LEFT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02BL4ZZ | PX | EXCISION OF LEFT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02560ZZ | PX | DESTRUCTION OF RIGHT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02570ZZ | PX | DESTRUCTION OF LEFT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 025K0ZZ | PX | DESTRUCTION OF RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 025L0ZZ | PX | DESTRUCTION OF LEFT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02T80ZZ | PX | RESECTION OF CONDUCTION MECHANISM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02563ZZ | PX | DESTRUCTION OF RIGHT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02573ZZ | PX | DESTRUCTION OF LEFT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 025K3ZZ | PX | DESTRUCTION OF RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 025L3ZZ | PX | DESTRUCTION OF LEFT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02570ZK | PX | DESTRUCTION OF LEFT ATRIAL APPENDAGE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02573ZK | PX | DESTRUCTION OF LEFT ATRIAL APPENDAGE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02574ZK | PX | DESTRUCTION OF LEFT ATRIAL APPENDAGE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B70ZK | PX | EXCISION OF LEFT ATRIAL APPENDAGE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B73ZK | PX | EXCISION OF LEFT ATRIAL APPENDAGE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02B74ZK | PX | EXCISION OF LEFT ATRIAL APPENDAGE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02L70ZK | PX | OCCLUSION OF LEFT ATRIAL APPENDAGE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02L73ZK | PX | OCCLUSION OF LEFT ATRIAL APPENDAGE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02L74ZK | PX | OCCLUSION OF LEFT ATRIAL APPENDAGE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02564ZZ | PX | DESTRUCTION OF RIGHT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 02574ZZ | PX | DESTRUCTION OF LEFT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 025K4ZZ | PX | DESTRUCTION OF RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Pericardiotomy and excision of heart lesion | 025L4ZZ | PX | DESTRUCTION OF LEFT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 37.4 | PX | REPAIR OF HEART AND PERICARDIUM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 37.41 | PX | IMPLANTATION OF PROSTHETIC CARDIAC SUPPORT DEVICE AROUND THE HEART | ICD-9-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 37.49 | PX | OTHER REPAIR OF HEART AND PERICARDIUM | ICD-9-CM |

| | | | | | | |
|-----|------------------------|---------------------------------|---------|----|------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02UA0JZ | PX | SUPPLEMENT HEART WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02UA3JZ | PX | SUPPLEMENT HEART WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02UA4JZ | PX | SUPPLEMENT HEART WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02163Z7 | PX | BYPASS RIGHT ATRIUM TO LEFT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02H60YZ | PX | INSERTION OF OTHER DEVICE INTO RIGHT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02H63YZ | PX | INSERTION OF OTHER DEVICE INTO RIGHT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02H64YZ | PX | INSERTION OF OTHER DEVICE INTO RIGHT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02H70YZ | PX | INSERTION OF OTHER DEVICE INTO LEFT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02H73YZ | PX | INSERTION OF OTHER DEVICE INTO LEFT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02H74YZ | PX | INSERTION OF OTHER DEVICE INTO LEFT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HA0YZ | PX | INSERTION OF OTHER DEVICE INTO HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HA3YZ | PX | INSERTION OF OTHER DEVICE INTO HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HA4YZ | PX | INSERTION OF OTHER DEVICE INTO HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HK0YZ | PX | INSERTION OF OTHER DEVICE INTO RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HK3YZ | PX | INSERTION OF OTHER DEVICE INTO RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HK4YZ | PX | INSERTION OF OTHER DEVICE INTO RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HLOYZ | PX | INSERTION OF OTHER DEVICE INTO LEFT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HL3YZ | PX | INSERTION OF OTHER DEVICE INTO LEFT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HL4YZ | PX | INSERTION OF OTHER DEVICE INTO LEFT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HN0YZ | PX | INSERTION OF OTHER DEVICE INTO PERICARDIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HN3YZ | PX | INSERTION OF OTHER DEVICE INTO PERICARDIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02HN4YZ | PX | INSERTION OF OTHER DEVICE INTO PERICARDIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02QA0ZZ | PX | REPAIR HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02QA3ZZ | PX | REPAIR HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02QA4ZZ | PX | REPAIR HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02QN0ZZ | PX | REPAIR PERICARDIUM, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02QN3ZZ | PX | REPAIR PERICARDIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Repair of Heart and Pericardium | 02QN4ZZ | PX | REPAIR PERICARDIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Heart replacement procedure | 37.5 | PX | HEART REPLACEMENT PROCEDURES | ICD-9-CM |
| 1.3 | Other Major CV surgery | Heart replacement procedure | 37.52 | PX | IMPLANTATION OF TOTAL INTERNAL BIVENTRICULAR HEART REPLACEMENT SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Heart replacement procedure | 37.53 | PX | REPLACEMENT OR REPAIR OF THORACIC UNIT OF (TOTAL) REPLACEMENT HEART SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Heart replacement procedure | 37.54 | PX | REPLACEMENT OR REPAIR OF OTHER IMPLANTABLE COMPONENT OF (TOTAL) REPLACEMENT HEART SYSTEM | ICD-9-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------------|---------|----|-----------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Removal of internal biventricular heart system | 37.55 | PX | REMOVAL OF INTERNAL BIVENTRICULAR HEART REPLACEMENT SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Heart replacement procedure | 02RK0JZ | PX | REPLACEMENT OF RIGHT VENTRICLE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Heart replacement procedure | 02RL0JZ | PX | REPLACEMENT OF LEFT VENTRICLE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Heart replacement procedure | 02WA0JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Removal of internal biventricular heart system | 02PA0JZ | PX | REMOVAL OF SYNTHETIC SUBSTITUTE FROM HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 37.60 | PX | IMPLANTATION OR INSERTION OF BIVENTRICULAR EXTERNAL HEART ASSIST SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 37.62 | PX | INSERTION OF TEMPORARY NON-IMPLANTABLE EXTRACORPOREAL CIRCULATORY ASSIST DEVICE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 37.63 | PX | REPAIR OF HEART ASSIST SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 37.64 | PX | REMOVAL OF EXTERNAL HEART ASSIST SYSTEM(S) OR DEVICE(S) | ICD-9-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 37.66 | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 37.67 | PX | IMPLANTATION OF CARDIOMYOSTIMULATION SYSTEM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 37.68 | PX | INSERTION OF PERCUTANEOUS EXTERNAL HEART ASSIST DEVICE | ICD-9-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA0RS | PX | INSERTION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA3RS | PX | INSERTION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA4RS | PX | INSERTION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA0RZ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA3RZ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA4RZ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 5A02116 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, INTERMITTENT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 5A02216 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, CONTINUOUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA0QZ | PX | REVISION OF IMPLANTABLE HEART ASSIST SYSTEM IN HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA0RS | PX | REVISION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM IN HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA0RZ | PX | REVISION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM IN HEART, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-----------------------------------------------------|---------|----|---------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA3QZ | PX | REVISION OF IMPLANTABLE HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA3RS | PX | REVISION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA3RZ | PX | REVISION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA4QZ | PX | REVISION OF IMPLANTABLE HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA4RS | PX | REVISION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02WA4RZ | PX | REVISION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA0QZ | PX | REMOVAL OF IMPLANTABLE HEART ASSIST SYSTEM FROM HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA0RS | PX | REMOVAL OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM FROM HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA0RZ | PX | REMOVAL OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM FROM HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA3QZ | PX | REMOVAL OF IMPLANTABLE HEART ASSIST SYSTEM FROM HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA3RZ | PX | REMOVAL OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM FROM HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA4QZ | PX | REMOVAL OF IMPLANTABLE HEART ASSIST SYSTEM FROM HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA4RS | PX | REMOVAL OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM FROM HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02PA4RZ | PX | REMOVAL OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM FROM HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA0QZ | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM INTO HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA3QZ | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA4QZ | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02QA0ZZ | PX | REPAIR HEART, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02QA3ZZ | PX | REPAIR HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02QA4ZZ | PX | REPAIR HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA0RJ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, INTRAOPERATIVE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA3RJ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, INTRAOPERATIVE, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|-------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 02HA4RJ | PX | INSERTION OF SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, INTRAOPERATIVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 5A02116 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, INTERMITTENT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 5A0211D | PX | ASSISTANCE WITH CARDIAC OUTPUT USING IMPELLER PUMP, INTERMITTENT | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 5A02216 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, CONTINUOUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | Implantation of heart and circulatory assist system | 5A0221D | PX | ASSISTANCE WITH CARDIAC OUTPUT USING IMPELLER PUMP, CONTINUOUS | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 38.34 | PX | RESECTION OF VESSEL WITH ANASTOMOSIS, AORTA | ICD-9-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 38.35 | PX | RESECTION OF VESSEL WITH ANASTOMOSIS, OTHER THORACIC VESSELS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BW0ZZ | PX | EXCISION OF THORACIC AORTA, DESCENDING, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BW4ZZ | PX | EXCISION OF THORACIC AORTA, DESCENDING, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BX0ZZ | PX | EXCISION OF THORACIC AORTA, ASCENDING/ARCH, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BX4ZZ | PX | EXCISION OF THORACIC AORTA, ASCENDING/ARCH, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 04B00ZZ | PX | EXCISION OF ABDOMINAL AORTA, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 04B04ZZ | PX | EXCISION OF ABDOMINAL AORTA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BP0ZZ | PX | EXCISION OF PULMONARY TRUNK, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BP4ZZ | PX | EXCISION OF PULMONARY TRUNK, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BQ0ZZ | PX | EXCISION OF RIGHT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BQ4ZZ | PX | EXCISION OF RIGHT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BR0ZZ | PX | EXCISION OF LEFT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BR4ZZ | PX | EXCISION OF LEFT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BS0ZZ | PX | EXCISION OF RIGHT PULMONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BS4ZZ | PX | EXCISION OF RIGHT PULMONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BT0ZZ | PX | EXCISION OF LEFT PULMONARY VEIN, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|-----------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BT4ZZ | PX | EXCISION OF LEFT PULMONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BV0ZZ | PX | EXCISION OF SUPERIOR VENA CAVA, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 02BV4ZZ | PX | EXCISION OF SUPERIOR VENA CAVA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B00ZZ | PX | EXCISION OF RIGHT INTERNAL MAMMARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B04ZZ | PX | EXCISION OF RIGHT INTERNAL MAMMARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B10ZZ | PX | EXCISION OF LEFT INTERNAL MAMMARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B14ZZ | PX | EXCISION OF LEFT INTERNAL MAMMARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B20ZZ | PX | EXCISION OF INNOMINATE ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B24ZZ | PX | EXCISION OF INNOMINATE ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B30ZZ | PX | EXCISION OF RIGHT SUBCLAVIAN ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B34ZZ | PX | EXCISION OF RIGHT SUBCLAVIAN ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B40ZZ | PX | EXCISION OF LEFT SUBCLAVIAN ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 03B44ZZ | PX | EXCISION OF LEFT SUBCLAVIAN ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B00ZZ | PX | EXCISION OF AZYGOS VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B04ZZ | PX | EXCISION OF AZYGOS VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B10ZZ | PX | EXCISION OF HEMIAZYGOS VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B14ZZ | PX | EXCISION OF HEMIAZYGOS VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B30ZZ | PX | EXCISION OF RIGHT INNOMINATE VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B34ZZ | PX | EXCISION OF RIGHT INNOMINATE VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B40ZZ | PX | EXCISION OF LEFT INNOMINATE VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B44ZZ | PX | EXCISION OF LEFT INNOMINATE VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B50ZZ | PX | EXCISION OF RIGHT SUBCLAVIAN VEIN, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|--------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B54ZZ | PX | EXCISION OF RIGHT SUBCLAVIAN VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B60ZZ | PX | EXCISION OF LEFT SUBCLAVIAN VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with anastomosis | 05B64ZZ | PX | EXCISION OF LEFT SUBCLAVIAN VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 38.36 | PX | RESECTION OF VESSEL WITH ANASTOMOSIS, ABDOMINAL ARTERIES | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B10ZZ | PX | EXCISION OF CELIAC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B14ZZ | PX | EXCISION OF CELIAC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B20ZZ | PX | EXCISION OF GASTRIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B24ZZ | PX | EXCISION OF GASTRIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B30ZZ | PX | EXCISION OF HEPATIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B34ZZ | PX | EXCISION OF HEPATIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B40ZZ | PX | EXCISION OF SPLENIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B44ZZ | PX | EXCISION OF SPLENIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B50ZZ | PX | EXCISION OF SUPERIOR MESENTERIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B54ZZ | PX | EXCISION OF SUPERIOR MESENTERIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B60ZZ | PX | EXCISION OF RIGHT COLIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B64ZZ | PX | EXCISION OF RIGHT COLIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B70ZZ | PX | EXCISION OF LEFT COLIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B74ZZ | PX | EXCISION OF LEFT COLIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B80ZZ | PX | EXCISION OF MIDDLE COLIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B84ZZ | PX | EXCISION OF MIDDLE COLIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B90ZZ | PX | EXCISION OF RIGHT RENAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B94ZZ | PX | EXCISION OF RIGHT RENAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BA0ZZ | PX | EXCISION OF LEFT RENAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BA4ZZ | PX | EXCISION OF LEFT RENAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BB0ZZ | PX | EXCISION OF INFERIOR MESENTERIC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BB4ZZ | PX | EXCISION OF INFERIOR MESENTERIC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BC0ZZ | PX | EXCISION OF RIGHT COMMON ILIAC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BC4ZZ | PX | EXCISION OF RIGHT COMMON ILIAC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BD0ZZ | PX | EXCISION OF LEFT COMMON ILIAC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BD4ZZ | PX | EXCISION OF LEFT COMMON ILIAC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BE0ZZ | PX | EXCISION OF RIGHT INTERNAL ILIAC ARTERY, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|-------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BE4ZZ | PX | EXCISION OF RIGHT INTERNAL ILIAC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BF0ZZ | PX | EXCISION OF LEFT INTERNAL ILIAC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BF4ZZ | PX | EXCISION OF LEFT INTERNAL ILIAC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BH0ZZ | PX | EXCISION OF RIGHT EXTERNAL ILIAC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BH4ZZ | PX | EXCISION OF RIGHT EXTERNAL ILIAC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BJ0ZZ | PX | EXCISION OF LEFT EXTERNAL ILIAC ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04BJ4ZZ | PX | EXCISION OF LEFT EXTERNAL ILIAC ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 38.44 | PX | RESECTION OF VESSEL WITH REPLACEMENT, AORTA, ABDOMINAL | ICD-9-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 38.45 | PX | RESECTION OF VESSEL WITH REPLACEMENT, THORACIC VESSELS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 04R007Z | PX | REPLACEMENT OF ABDOMINAL AORTA WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 04R00JZ | PX | REPLACEMENT OF ABDOMINAL AORTA WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 04R00KZ | PX | REPLACEMENT OF ABDOMINAL AORTA WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 04R047Z | PX | REPLACEMENT OF ABDOMINAL AORTA WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 04R04JZ | PX | REPLACEMENT OF ABDOMINAL AORTA WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 04R04KZ | PX | REPLACEMENT OF ABDOMINAL AORTA WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP07Z | PX | REPLACEMENT OF PULMONARY TRUNK WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP08Z | PX | REPLACEMENT OF PULMONARY TRUNK WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP0JZ | PX | REPLACEMENT OF PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP0KZ | PX | REPLACEMENT OF PULMONARY TRUNK WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP47Z | PX | REPLACEMENT OF PULMONARY TRUNK WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP48Z | PX | REPLACEMENT OF PULMONARY TRUNK WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP4JZ | PX | REPLACEMENT OF PULMONARY TRUNK WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RP4KZ | PX | REPLACEMENT OF PULMONARY TRUNK WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ07Z | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ08Z | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ0JZ | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ0KZ | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ47Z | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ48Z | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ4JZ | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RQ4KZ | PX | REPLACEMENT OF RIGHT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR07Z | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR08Z | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR0JZ | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR0KZ | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR47Z | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR48Z | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR4JZ | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RR4KZ | PX | REPLACEMENT OF LEFT PULMONARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS07Z | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS08Z | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS0JZ | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS0KZ | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS47Z | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS48Z | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS4JZ | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RS4KZ | PX | REPLACEMENT OF RIGHT PULMONARY VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT07Z | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT08Z | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT0JZ | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT0KZ | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT47Z | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT48Z | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH ZOOPLASTIC TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT4JZ | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 02RT4KZ | PX | REPLACEMENT OF LEFT PULMONARY VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R147Z | PX | REPLACEMENT OF LEFT INTERNAL MAMMARY ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R14JZ | PX | REPLACEMENT OF LEFT INTERNAL MAMMARY ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R14KZ | PX | REPLACEMENT OF LEFT INTERNAL MAMMARY ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R207Z | PX | REPLACEMENT OF INNOMINATE ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R20JZ | PX | REPLACEMENT OF INNOMINATE ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R20KZ | PX | REPLACEMENT OF INNOMINATE ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R247Z | PX | REPLACEMENT OF INNOMINATE ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R24JZ | PX | REPLACEMENT OF INNOMINATE ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R24KZ | PX | REPLACEMENT OF INNOMINATE ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R307Z | PX | REPLACEMENT OF RIGHT SUBCLAVIAN ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R30JZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R30KZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R347Z | PX | REPLACEMENT OF RIGHT SUBCLAVIAN ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|---------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R34JZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R34KZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R407Z | PX | REPLACEMENT OF LEFT SUBCLAVIAN ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R40JZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R40KZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R447Z | PX | REPLACEMENT OF LEFT SUBCLAVIAN ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R44JZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 03R44KZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R007Z | PX | REPLACEMENT OF AZYGOS VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R00JZ | PX | REPLACEMENT OF AZYGOS VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R00KZ | PX | REPLACEMENT OF AZYGOS VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R047Z | PX | REPLACEMENT OF AZYGOS VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R04JZ | PX | REPLACEMENT OF AZYGOS VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R04KZ | PX | REPLACEMENT OF AZYGOS VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R107Z | PX | REPLACEMENT OF HEMIAZYGOS VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R10JZ | PX | REPLACEMENT OF HEMIAZYGOS VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R10KZ | PX | REPLACEMENT OF HEMIAZYGOS VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R147Z | PX | REPLACEMENT OF HEMIAZYGOS VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R14JZ | PX | REPLACEMENT OF HEMIAZYGOS VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R14KZ | PX | REPLACEMENT OF HEMIAZYGOS VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R307Z | PX | REPLACEMENT OF RIGHT INNOMINATE VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R30JZ | PX | REPLACEMENT OF RIGHT INNOMINATE VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|------------------------------------------------------|---------|----|-------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R30KZ | PX | REPLACEMENT OF RIGHT INNOMINATE VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R347Z | PX | REPLACEMENT OF RIGHT INNOMINATE VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R34JZ | PX | REPLACEMENT OF RIGHT INNOMINATE VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R34KZ | PX | REPLACEMENT OF RIGHT INNOMINATE VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R407Z | PX | REPLACEMENT OF LEFT INNOMINATE VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R40JZ | PX | REPLACEMENT OF LEFT INNOMINATE VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R40KZ | PX | REPLACEMENT OF LEFT INNOMINATE VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R447Z | PX | REPLACEMENT OF LEFT INNOMINATE VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R44JZ | PX | REPLACEMENT OF LEFT INNOMINATE VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R44KZ | PX | REPLACEMENT OF LEFT INNOMINATE VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R507Z | PX | REPLACEMENT OF RIGHT SUBCLAVIAN VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R50JZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R50KZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R547Z | PX | REPLACEMENT OF RIGHT SUBCLAVIAN VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R54JZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R54KZ | PX | REPLACEMENT OF RIGHT SUBCLAVIAN VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R607Z | PX | REPLACEMENT OF LEFT SUBCLAVIAN VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R60JZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R60KZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R647Z | PX | REPLACEMENT OF LEFT SUBCLAVIAN VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Resection of aortic/thoracic vessel with replacement | 05R64JZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 05R64KZ | PX | REPLACEMENT OF LEFT SUBCLAVIAN VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 38.64 | PX | OTHER EXCISION OF VESSELS, AORTA, ABDOMINAL | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04500ZZ | PX | DESTRUCTION OF ABDOMINAL AORTA, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04503ZZ | PX | DESTRUCTION OF ABDOMINAL AORTA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04504ZZ | PX | DESTRUCTION OF ABDOMINAL AORTA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B00ZZ | PX | EXCISION OF ABDOMINAL AORTA, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B03ZZ | PX | EXCISION OF ABDOMINAL AORTA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04B04ZZ | PX | EXCISION OF ABDOMINAL AORTA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 39.73 | PX | ENDOVASCULAR IMPLANTATION OF GRAFT IN THORACIC AORTA | ICD-9-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 39.79 | PX | OTHER ENDOVASCULAR PROCEDURES ON OTHER VESSELS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02UW3JZ | PX | SUPPLEMENT THORACIC AORTA, DESCENDING WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02UW4JZ | PX | SUPPLEMENT THORACIC AORTA, DESCENDING WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02UX3JZ | PX | SUPPLEMENT THORACIC AORTA, ASCENDING/ARCH WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02UX4JZ | PX | SUPPLEMENT THORACIC AORTA, ASCENDING/ARCH WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VW0DZ | PX | RESTRICTION OF THORACIC AORTA, DESCENDING WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VW3DZ | PX | RESTRICTION OF THORACIC AORTA, DESCENDING WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VW4DZ | PX | RESTRICTION OF THORACIC AORTA, DESCENDING WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VX0DZ | PX | RESTRICTION OF THORACIC AORTA, ASCENDING/ARCH WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VX3DZ | PX | RESTRICTION OF THORACIC AORTA, ASCENDING/ARCH WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VX4DZ | PX | RESTRICTION OF THORACIC AORTA, ASCENDING/ARCH WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CW3ZZ | PX | EXTIRPATION OF MATTER FROM THORACIC AORTA, DESCENDING, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|---------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CX3ZZ | PX | EXTIRPATION OF MATTER FROM THORACIC AORTA, ASCENDING/ARCH, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04C03ZZ | PX | EXTIRPATION OF MATTER FROM ABDOMINAL AORTA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04L03ZZ | PX | OCCLUSION OF ABDOMINAL AORTA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04V03ZZ | PX | RESTRICTION OF ABDOMINAL AORTA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CC3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT COMMON ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CD3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT COMMON ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CE3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT INTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CF3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT INTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CH3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT EXTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CJ3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT EXTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LC0DZ | PX | OCCLUSION OF RIGHT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LC3DZ | PX | OCCLUSION OF RIGHT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LC3ZZ | PX | OCCLUSION OF RIGHT COMMON ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LC4DZ | PX | OCCLUSION OF RIGHT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LD0DZ | PX | OCCLUSION OF LEFT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LD3DZ | PX | OCCLUSION OF LEFT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|-----------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LD3ZZ | PX | OCCLUSION OF LEFT COMMON ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LD4DZ | PX | OCCLUSION OF LEFT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LE0DZ | PX | OCCLUSION OF RIGHT INTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LE3DZ | PX | OCCLUSION OF RIGHT INTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LE3ZZ | PX | OCCLUSION OF RIGHT INTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LE4DZ | PX | OCCLUSION OF RIGHT INTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LF0DZ | PX | OCCLUSION OF LEFT INTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LF3DZ | PX | OCCLUSION OF LEFT INTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LF3ZZ | PX | OCCLUSION OF LEFT INTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LF4DZ | PX | OCCLUSION OF LEFT INTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LH0DZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LH3DZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LH3ZZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LH4DZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LJ0DZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LJ3DZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LJ3ZZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LJ4DZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VC0DZ | PX | RESTRICTION OF RIGHT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VC0EZ | PX | RESTRICTION OF RIGHT COMMON ILIAC ARTERY WITH BRANCHED OR FENESTRATED INTRALUMINAL DEVICE, ONE OR TWO ARTERIES, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VC3DZ | PX | RESTRICTION OF RIGHT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VC3EZ | PX | RESTRICTION OF RIGHT COMMON ILIAC ARTERY WITH BRANCHED OR FENESTRATED INTRALUMINAL DEVICE, ONE OR TWO ARTERIES, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VC3ZZ | PX | RESTRICTION OF RIGHT COMMON ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VC4DZ | PX | RESTRICTION OF RIGHT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VC4EZ | PX | RESTRICTION OF RIGHT COMMON ILIAC ARTERY WITH BRANCHED OR FENESTRATED INTRALUMINAL DEVICE, ONE OR TWO ARTERIES, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VD0DZ | PX | RESTRICTION OF LEFT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VD0EZ | PX | RESTRICTION OF LEFT COMMON ILIAC ARTERY WITH BRANCHED OR FENESTRATED INTRALUMINAL DEVICE, ONE OR TWO ARTERIES, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VD3DZ | PX | RESTRICTION OF LEFT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VD3EZ | PX | RESTRICTION OF LEFT COMMON ILIAC ARTERY WITH BRANCHED OR FENESTRATED INTRALUMINAL DEVICE, ONE OR TWO ARTERIES, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VD3ZZ | PX | RESTRICTION OF LEFT COMMON ILIAC ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VD4DZ | PX | RESTRICTION OF LEFT COMMON ILIAC ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VD4EZ | PX | RESTRICTION OF LEFT COMMON ILIAC ARTERY WITH BRANCHED OR FENESTRATED INTRALUMINAL DEVICE, ONE OR TWO ARTERIES, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|---------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06CC3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT COMMON ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06CD3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT COMMON ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06CF3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT EXTERNAL ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06CG3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT EXTERNAL ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LC0DZ | PX | OCCLUSION OF RIGHT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LC3DZ | PX | OCCLUSION OF RIGHT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LC3ZZ | PX | OCCLUSION OF RIGHT COMMON ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LC4DZ | PX | OCCLUSION OF RIGHT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LD0DZ | PX | OCCLUSION OF LEFT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LD3DZ | PX | OCCLUSION OF LEFT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LD3ZZ | PX | OCCLUSION OF LEFT COMMON ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LD4DZ | PX | OCCLUSION OF LEFT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LF0DZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LF3DZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LF3ZZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LF4DZ | PX | OCCLUSION OF RIGHT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|-------------------------------------------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LG0DZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LG3DZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LG3ZZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LG4DZ | PX | OCCLUSION OF LEFT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VC0DZ | PX | RESTRICTION OF RIGHT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VC3DZ | PX | RESTRICTION OF RIGHT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VC3ZZ | PX | RESTRICTION OF RIGHT COMMON ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VC4DZ | PX | RESTRICTION OF RIGHT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VD0DZ | PX | RESTRICTION OF LEFT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VD3DZ | PX | RESTRICTION OF LEFT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VD3ZZ | PX | RESTRICTION OF LEFT COMMON ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VD4DZ | PX | RESTRICTION OF LEFT COMMON ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VF0DZ | PX | RESTRICTION OF RIGHT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VF3DZ | PX | RESTRICTION OF RIGHT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VF3ZZ | PX | RESTRICTION OF RIGHT EXTERNAL ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VF4DZ | PX | RESTRICTION OF RIGHT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VG0DZ | PX | RESTRICTION OF LEFT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VG3DZ | PX | RESTRICTION OF LEFT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VG3ZZ | PX | RESTRICTION OF LEFT EXTERNAL ILIAC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VG4DZ | PX | RESTRICTION OF LEFT EXTERNAL ILIAC VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03LH3ZZ | PX | OCCLUSION OF RIGHT COMMON CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03LJ3ZZ | PX | OCCLUSION OF LEFT COMMON CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03LK3ZZ | PX | OCCLUSION OF RIGHT INTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03LL3ZZ | PX | OCCLUSION OF LEFT INTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03LM3ZZ | PX | OCCLUSION OF RIGHT EXTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03LN3ZZ | PX | OCCLUSION OF LEFT EXTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03VJ3ZZ | PX | RESTRICTION OF LEFT COMMON CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03VK3ZZ | PX | RESTRICTION OF RIGHT INTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03VL3ZZ | PX | RESTRICTION OF LEFT INTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03VM3ZZ | PX | RESTRICTION OF RIGHT EXTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03VN3ZZ | PX | RESTRICTION OF LEFT EXTERNAL CAROTID ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CP3ZZ | PX | EXTIRPATION OF MATTER FROM PULMONARY TRUNK, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|---------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CQ3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT PULMONARY ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CR3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT PULMONARY ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CS3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT PULMONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CT3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT PULMONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CV3ZZ | PX | EXTIRPATION OF MATTER FROM SUPERIOR VENA CAVA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CW3ZZ | PX | EXTIRPATION OF MATTER FROM THORACIC AORTA, DESCENDING, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CX3ZZ | PX | EXTIRPATION OF MATTER FROM THORACIC AORTA, ASCENDING/ARCH, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02LS3DZ | PX | OCCLUSION OF RIGHT PULMONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02LS3ZZ | PX | OCCLUSION OF RIGHT PULMONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02LT3DZ | PX | OCCLUSION OF LEFT PULMONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02LT3ZZ | PX | OCCLUSION OF LEFT PULMONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VP3DZ | PX | RESTRICTION OF PULMONARY TRUNK WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VP3ZZ | PX | RESTRICTION OF PULMONARY TRUNK, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VQ3DZ | PX | RESTRICTION OF RIGHT PULMONARY ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VQ3ZZ | PX | RESTRICTION OF RIGHT PULMONARY ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VR3DT | PX | RESTRICTION OF DUCTUS ARTERIOSUS WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|---------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VR3DZ | PX | RESTRICTION OF LEFT PULMONARY ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VR3ZT | PX | RESTRICTION OF DUCTUS ARTERIOSUS, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VR3ZZ | PX | RESTRICTION OF LEFT PULMONARY ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VS3DZ | PX | RESTRICTION OF RIGHT PULMONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VS3ZZ | PX | RESTRICTION OF RIGHT PULMONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VT3DZ | PX | RESTRICTION OF LEFT PULMONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02VT3ZZ | PX | RESTRICTION OF LEFT PULMONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03C33ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT SUBCLAVIAN ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03C43ZZ | PX | EXTIRPATION OF MATTER FROM LEFT SUBCLAVIAN ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03L33ZZ | PX | OCCLUSION OF RIGHT SUBCLAVIAN ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03L43ZZ | PX | OCCLUSION OF LEFT SUBCLAVIAN ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V30DZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V33DZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V33ZZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V34DZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V40DZ | PX | RESTRICTION OF LEFT SUBCLAVIAN ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|--------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V43DZ | PX | RESTRICTION OF LEFT SUBCLAVIAN ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V43ZZ | PX | RESTRICTION OF LEFT SUBCLAVIAN ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V44DZ | PX | RESTRICTION OF LEFT SUBCLAVIAN ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05C53ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT SUBCLAVIAN VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05C63ZZ | PX | EXTIRPATION OF MATTER FROM LEFT SUBCLAVIAN VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05L53ZZ | PX | OCCLUSION OF RIGHT SUBCLAVIAN VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05L63ZZ | PX | OCCLUSION OF LEFT SUBCLAVIAN VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V50DZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V53DZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V53ZZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V54DZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V60DZ | PX | RESTRICTION OF LEFT SUBCLAVIAN VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V63DZ | PX | RESTRICTION OF LEFT SUBCLAVIAN VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V63ZZ | PX | RESTRICTION OF LEFT SUBCLAVIAN VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V64DZ | PX | RESTRICTION OF LEFT SUBCLAVIAN VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03C23ZZ | PX | EXTIRPATION OF MATTER FROM INNOMINATE ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|-------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03L23ZZ | PX | OCCLUSION OF INNOMINATE ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V20DZ | PX | RESTRICTION OF INNOMINATE ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V23DZ | PX | RESTRICTION OF INNOMINATE ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V23ZZ | PX | RESTRICTION OF INNOMINATE ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 03V24DZ | PX | RESTRICTION OF INNOMINATE ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05C33ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT INNOMINATE VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05C43ZZ | PX | EXTIRPATION OF MATTER FROM LEFT INNOMINATE VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05L33ZZ | PX | OCCLUSION OF RIGHT INNOMINATE VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05L43ZZ | PX | OCCLUSION OF LEFT INNOMINATE VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V30DZ | PX | RESTRICTION OF RIGHT INNOMINATE VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V33DZ | PX | RESTRICTION OF RIGHT INNOMINATE VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V33ZZ | PX | RESTRICTION OF RIGHT INNOMINATE VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V34DZ | PX | RESTRICTION OF RIGHT INNOMINATE VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V40DZ | PX | RESTRICTION OF LEFT INNOMINATE VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V43DZ | PX | RESTRICTION OF LEFT INNOMINATE VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V43ZZ | PX | RESTRICTION OF LEFT INNOMINATE VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 05V44DZ | PX | RESTRICTION OF LEFT INNOMINATE VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 02CV3ZZ | PX | EXTIRPATION OF MATTER FROM SUPERIOR VENA CAVA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06C03ZZ | PX | EXTIRPATION OF MATTER FROM INFERIOR VENA CAVA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CK3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04CL3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LK0DZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LK3DZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LK3ZZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LK4DZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LL0DZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LL3DZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LL3ZZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04LL4DZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VK0DZ | PX | RESTRICTION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VK3DZ | PX | RESTRICTION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VK3ZZ | PX | RESTRICTION OF RIGHT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VK4DZ | PX | RESTRICTION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VL0DZ | PX | RESTRICTION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VL3DZ | PX | RESTRICTION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VL3ZZ | PX | RESTRICTION OF LEFT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 04VL4DZ | PX | RESTRICTION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06CM3ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT FEMORAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06CN3ZZ | PX | EXTIRPATION OF MATTER FROM LEFT FEMORAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LM0DZ | PX | OCCLUSION OF RIGHT FEMORAL VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LM3DZ | PX | OCCLUSION OF RIGHT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LM3ZZ | PX | OCCLUSION OF RIGHT FEMORAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LM4DZ | PX | OCCLUSION OF RIGHT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LN0DZ | PX | OCCLUSION OF LEFT FEMORAL VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LN3DZ | PX | OCCLUSION OF LEFT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LN3ZZ | PX | OCCLUSION OF LEFT FEMORAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06LN4DZ | PX | OCCLUSION OF LEFT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VM0DZ | PX | RESTRICTION OF RIGHT FEMORAL VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|----------------------------------------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VM3DZ | PX | RESTRICTION OF RIGHT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VM3ZZ | PX | RESTRICTION OF RIGHT FEMORAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VM4DZ | PX | RESTRICTION OF RIGHT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VN0DZ | PX | RESTRICTION OF LEFT FEMORAL VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VN3DZ | PX | RESTRICTION OF LEFT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VN3ZZ | PX | RESTRICTION OF LEFT FEMORAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Endovascular implantation of graft in thoracic aorta / other vessels | 06VN4DZ | PX | RESTRICTION OF LEFT FEMORAL VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 39.25 | PX | AORTA-ILIAC-FEMORAL BYPASS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 0410096 | PX | BYPASS ABDOMINAL AORTA TO RIGHT COMMON ILIAC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 0410097 | PX | BYPASS ABDOMINAL AORTA TO LEFT COMMON ILIAC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 0410098 | PX | BYPASS ABDOMINAL AORTA TO BILATERAL COMMON ILIAC ARTERIES WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 0410099 | PX | BYPASS ABDOMINAL AORTA TO RIGHT INTERNAL ILIAC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009B | PX | BYPASS ABDOMINAL AORTA TO LEFT INTERNAL ILIAC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009C | PX | BYPASS ABDOMINAL AORTA TO BILATERAL INTERNAL ILIAC ARTERIES WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009D | PX | BYPASS ABDOMINAL AORTA TO RIGHT EXTERNAL ILIAC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009F | PX | BYPASS ABDOMINAL AORTA TO LEFT EXTERNAL ILIAC ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009G | PX | BYPASS ABDOMINAL AORTA TO BILATERAL EXTERNAL ILIAC ARTERIES WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009H | PX | BYPASS ABDOMINAL AORTA TO RIGHT FEMORAL ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009J | PX | BYPASS ABDOMINAL AORTA TO LEFT FEMORAL ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009K | PX | BYPASS ABDOMINAL AORTA TO BILATERAL FEMORAL ARTERIES WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009Q | PX | BYPASS ABDOMINAL AORTA TO LOWER EXTREMITY ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041009R | PX | BYPASS ABDOMINAL AORTA TO LOWER ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04100A6 | PX | BYPASS ABDOMINAL AORTA TO RIGHT COMMON ILIAC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04100A7 | PX | BYPASS ABDOMINAL AORTA TO LEFT COMMON ILIAC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04100A8 | PX | BYPASS ABDOMINAL AORTA TO BILATERAL COMMON ILIAC ARTERIES WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 04100A9 | PX | BYPASS ABDOMINAL AORTA TO RIGHT INTERNAL ILIAC ARTERY WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|-----|------------------------|---------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041J4KJ | PX | BYPASS LEFT EXTERNAL ILIAC ARTERY TO LEFT FEMORAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041J4KK | PX | BYPASS LEFT EXTERNAL ILIAC ARTERY TO BILATERAL FEMORAL ARTERIES WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041J4ZH | PX | BYPASS LEFT EXTERNAL ILIAC ARTERY TO RIGHT FEMORAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041J4ZJ | PX | BYPASS LEFT EXTERNAL ILIAC ARTERY TO LEFT FEMORAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 041J4ZK | PX | BYPASS LEFT EXTERNAL ILIAC ARTERY TO BILATERAL FEMORAL ARTERIES, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 39.52 | PX | OTHER REPAIR OF ANEURYSM | ICD-9-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VP0DZ | PX | RESTRICTION OF PULMONARY TRUNK WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VP0ZZ | PX | RESTRICTION OF PULMONARY TRUNK, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VP4DZ | PX | RESTRICTION OF PULMONARY TRUNK WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VP4ZZ | PX | RESTRICTION OF PULMONARY TRUNK, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VQ0DZ | PX | RESTRICTION OF RIGHT PULMONARY ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VQ0ZZ | PX | RESTRICTION OF RIGHT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VQ4DZ | PX | RESTRICTION OF RIGHT PULMONARY ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VQ4ZZ | PX | RESTRICTION OF RIGHT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR0DT | PX | RESTRICTION OF DUCTUS ARTERIOSUS WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR0DZ | PX | RESTRICTION OF LEFT PULMONARY ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR0ZT | PX | RESTRICTION OF DUCTUS ARTERIOSUS, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR0ZZ | PX | RESTRICTION OF LEFT PULMONARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR4DT | PX | RESTRICTION OF DUCTUS ARTERIOSUS WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR4DZ | PX | RESTRICTION OF LEFT PULMONARY ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR4ZT | PX | RESTRICTION OF DUCTUS ARTERIOSUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VR4ZZ | PX | RESTRICTION OF LEFT PULMONARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VS0DZ | PX | RESTRICTION OF RIGHT PULMONARY VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VS0ZZ | PX | RESTRICTION OF RIGHT PULMONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VS4DZ | PX | RESTRICTION OF RIGHT PULMONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VS4ZZ | PX | RESTRICTION OF RIGHT PULMONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VT0DZ | PX | RESTRICTION OF LEFT PULMONARY VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VT0ZZ | PX | RESTRICTION OF LEFT PULMONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VT4DZ | PX | RESTRICTION OF LEFT PULMONARY VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VT4ZZ | PX | RESTRICTION OF LEFT PULMONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VW0ZZ | PX | RESTRICTION OF THORACIC AORTA, DESCENDING, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VW4DZ | PX | RESTRICTION OF THORACIC AORTA, DESCENDING WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VW4ZZ | PX | RESTRICTION OF THORACIC AORTA, DESCENDING, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|---------------------------------------|---------|----|----------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VX0ZZ | PX | RESTRICTION OF THORACIC AORTA, ASCENDING/ARCH, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VX4DZ | PX | RESTRICTION OF THORACIC AORTA, ASCENDING/ARCH WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 02VX4ZZ | PX | RESTRICTION OF THORACIC AORTA, ASCENDING/ARCH, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V00ZZ | PX | RESTRICTION OF RIGHT INTERNAL MAMMARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V04ZZ | PX | RESTRICTION OF RIGHT INTERNAL MAMMARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V10ZZ | PX | RESTRICTION OF LEFT INTERNAL MAMMARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V14ZZ | PX | RESTRICTION OF LEFT INTERNAL MAMMARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V20ZZ | PX | RESTRICTION OF INNOMINATE ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V24ZZ | PX | RESTRICTION OF INNOMINATE ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V30ZZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V34ZZ | PX | RESTRICTION OF RIGHT SUBCLAVIAN ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V40ZZ | PX | RESTRICTION OF LEFT SUBCLAVIAN ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V44ZZ | PX | RESTRICTION OF LEFT SUBCLAVIAN ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V50ZZ | PX | RESTRICTION OF RIGHT AXILLARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V54ZZ | PX | RESTRICTION OF RIGHT AXILLARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V60ZZ | PX | RESTRICTION OF LEFT AXILLARY ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V64ZZ | PX | RESTRICTION OF LEFT AXILLARY ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V70ZZ | PX | RESTRICTION OF RIGHT BRACHIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V74ZZ | PX | RESTRICTION OF RIGHT BRACHIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V80ZZ | PX | RESTRICTION OF LEFT BRACHIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V84ZZ | PX | RESTRICTION OF LEFT BRACHIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V90ZZ | PX | RESTRICTION OF RIGHT ULNAR ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03V94ZZ | PX | RESTRICTION OF RIGHT ULNAR ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VA0ZZ | PX | RESTRICTION OF LEFT ULNAR ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VA4ZZ | PX | RESTRICTION OF LEFT ULNAR ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VB0ZZ | PX | RESTRICTION OF RIGHT RADIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VB4ZZ | PX | RESTRICTION OF RIGHT RADIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VC0ZZ | PX | RESTRICTION OF LEFT RADIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VC4ZZ | PX | RESTRICTION OF LEFT RADIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VD0ZZ | PX | RESTRICTION OF RIGHT HAND ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VD4ZZ | PX | RESTRICTION OF RIGHT HAND ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VF0ZZ | PX | RESTRICTION OF LEFT HAND ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 03VF4ZZ | PX | RESTRICTION OF LEFT HAND ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|-----|------------------------|---------------------------------------|---------|----|--------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 05VV0ZZ | PX | RESTRICTION OF LEFT FACE VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 05VV4ZZ | PX | RESTRICTION OF LEFT FACE VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 05VY0DZ | PX | RESTRICTION OF UPPER VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 05VY0ZZ | PX | RESTRICTION OF UPPER VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 05VY4DZ | PX | RESTRICTION OF UPPER VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 05VY4ZZ | PX | RESTRICTION OF UPPER VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V10ZZ | PX | RESTRICTION OF SPLENIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V14ZZ | PX | RESTRICTION OF SPLENIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V20ZZ | PX | RESTRICTION OF GASTRIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V24ZZ | PX | RESTRICTION OF GASTRIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V30ZZ | PX | RESTRICTION OF ESOPHAGEAL VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V34ZZ | PX | RESTRICTION OF ESOPHAGEAL VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V40ZZ | PX | RESTRICTION OF HEPATIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V44ZZ | PX | RESTRICTION OF HEPATIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V50ZZ | PX | RESTRICTION OF SUPERIOR MESENTERIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V54ZZ | PX | RESTRICTION OF SUPERIOR MESENTERIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V60ZZ | PX | RESTRICTION OF INFERIOR MESENTERIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V64ZZ | PX | RESTRICTION OF INFERIOR MESENTERIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V70ZZ | PX | RESTRICTION OF COLIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V74ZZ | PX | RESTRICTION OF COLIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V80ZZ | PX | RESTRICTION OF PORTAL VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V84ZZ | PX | RESTRICTION OF PORTAL VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V90ZZ | PX | RESTRICTION OF RIGHT RENAL VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06V94ZZ | PX | RESTRICTION OF RIGHT RENAL VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VB0ZZ | PX | RESTRICTION OF LEFT RENAL VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VB4ZZ | PX | RESTRICTION OF LEFT RENAL VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VC0ZZ | PX | RESTRICTION OF RIGHT COMMON ILIAC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VC4ZZ | PX | RESTRICTION OF RIGHT COMMON ILIAC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VD0ZZ | PX | RESTRICTION OF LEFT COMMON ILIAC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VD4ZZ | PX | RESTRICTION OF LEFT COMMON ILIAC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VF0ZZ | PX | RESTRICTION OF RIGHT EXTERNAL ILIAC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VF4ZZ | PX | RESTRICTION OF RIGHT EXTERNAL ILIAC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VG0ZZ | PX | RESTRICTION OF LEFT EXTERNAL ILIAC VEIN, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|-----|------------------------|---------------------------------------|---------|----|-----------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VG4ZZ | PX | RESTRICTION OF LEFT EXTERNAL ILIAC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VH0ZZ | PX | RESTRICTION OF RIGHT HYPOGASTRIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VH4ZZ | PX | RESTRICTION OF RIGHT HYPOGASTRIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VJ0ZZ | PX | RESTRICTION OF LEFT HYPOGASTRIC VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VJ4ZZ | PX | RESTRICTION OF LEFT HYPOGASTRIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VM0ZZ | PX | RESTRICTION OF RIGHT FEMORAL VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VM4ZZ | PX | RESTRICTION OF RIGHT FEMORAL VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VN0ZZ | PX | RESTRICTION OF LEFT FEMORAL VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VN4ZZ | PX | RESTRICTION OF LEFT FEMORAL VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VP0ZZ | PX | RESTRICTION OF RIGHT SAPHENOUS VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VP4ZZ | PX | RESTRICTION OF RIGHT SAPHENOUS VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VQ0ZZ | PX | RESTRICTION OF LEFT SAPHENOUS VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VQ4ZZ | PX | RESTRICTION OF LEFT SAPHENOUS VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VT0ZZ | PX | RESTRICTION OF RIGHT FOOT VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VT4ZZ | PX | RESTRICTION OF RIGHT FOOT VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VV0ZZ | PX | RESTRICTION OF LEFT FOOT VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VV4ZZ | PX | RESTRICTION OF LEFT FOOT VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VY0DZ | PX | RESTRICTION OF LOWER VEIN WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VY0ZZ | PX | RESTRICTION OF LOWER VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VY4DZ | PX | RESTRICTION OF LOWER VEIN WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 06VY4ZZ | PX | RESTRICTION OF LOWER VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Open Abdominal Aortic Aneurysm Repair | 39.29 | PX | OTHER (PERIPHERAL) VASCULAR SHUNT OR BYPASS | ICD-9-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312091 | PX | BYPASS INNOMINATE ARTERY TO LEFT UPPER ARM ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312092 | PX | BYPASS INNOMINATE ARTERY TO BILATERAL UPPER ARM ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312093 | PX | BYPASS INNOMINATE ARTERY TO RIGHT LOWER ARM ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312094 | PX | BYPASS INNOMINATE ARTERY TO LEFT LOWER ARM ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312095 | PX | BYPASS INNOMINATE ARTERY TO BILATERAL LOWER ARM ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312096 | PX | BYPASS INNOMINATE ARTERY TO RIGHT UPPER LEG ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312097 | PX | BYPASS INNOMINATE ARTERY TO LEFT UPPER LEG ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312098 | PX | BYPASS INNOMINATE ARTERY TO BILATERAL UPPER LEG ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 0312099 | PX | BYPASS INNOMINATE ARTERY TO RIGHT LOWER LEG ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 031209B | PX | BYPASS INNOMINATE ARTERY TO LEFT LOWER LEG ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 031209C | PX | BYPASS INNOMINATE ARTERY TO BILATERAL LOWER LEG ARTERY WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|-----|------------------------|-------------------------------|---------|----|-----------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 061Q47Y | PX | BYPASS LEFT SAPHENOUS VEIN TO LOWER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 061Q49Y | PX | BYPASS LEFT SAPHENOUS VEIN TO LOWER VEIN WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 061Q4AY | PX | BYPASS LEFT SAPHENOUS VEIN TO LOWER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 061Q4JY | PX | BYPASS LEFT SAPHENOUS VEIN TO LOWER VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 061Q4KY | PX | BYPASS LEFT SAPHENOUS VEIN TO LOWER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 061Q4ZY | PX | BYPASS LEFT SAPHENOUS VEIN TO LOWER VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 38.88 | PX | OTHER SURGICAL OCCLUSION OF VESSELS, LOWER LIMB ARTERIES | ICD-9-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK0CZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH EXTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK0DZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK0ZZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK3CZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK3DZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK3ZZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK4CZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK4DZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LK4ZZ | PX | OCCLUSION OF RIGHT FEMORAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL0CZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH EXTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL0DZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL0ZZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL3CZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL3DZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL3ZZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL4CZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL4DZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LL4ZZ | PX | OCCLUSION OF LEFT FEMORAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM0CZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY WITH EXTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM0DZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM0ZZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM3CZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM3DZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM3ZZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM4CZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LM4DZ | PX | OCCLUSION OF RIGHT POPLITEAL ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|-----|------------------------|-------------------------------|---------|----|--------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LV0ZZ | PX | OCCLUSION OF RIGHT FOOT ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LV3CZ | PX | OCCLUSION OF RIGHT FOOT ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LV3DZ | PX | OCCLUSION OF RIGHT FOOT ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LV3ZZ | PX | OCCLUSION OF RIGHT FOOT ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LV4CZ | PX | OCCLUSION OF RIGHT FOOT ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LV4DZ | PX | OCCLUSION OF RIGHT FOOT ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LV4ZZ | PX | OCCLUSION OF RIGHT FOOT ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW0CZ | PX | OCCLUSION OF LEFT FOOT ARTERY WITH EXTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW0DZ | PX | OCCLUSION OF LEFT FOOT ARTERY WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW0ZZ | PX | OCCLUSION OF LEFT FOOT ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW3CZ | PX | OCCLUSION OF LEFT FOOT ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW3DZ | PX | OCCLUSION OF LEFT FOOT ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW3ZZ | PX | OCCLUSION OF LEFT FOOT ARTERY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW4CZ | PX | OCCLUSION OF LEFT FOOT ARTERY WITH EXTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW4DZ | PX | OCCLUSION OF LEFT FOOT ARTERY WITH INTRALUMINAL DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04LW4ZZ | PX | OCCLUSION OF LEFT FOOT ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 38.48 | PX | RESECTION OF VESSEL WITH REPLACEMENT, LOWER LIMB ARTERIES | ICD-9-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RL07Z | PX | REPLACEMENT OF LEFT FEMORAL ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RL0JZ | PX | REPLACEMENT OF LEFT FEMORAL ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RL0KZ | PX | REPLACEMENT OF LEFT FEMORAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RL47Z | PX | REPLACEMENT OF LEFT FEMORAL ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RL4JZ | PX | REPLACEMENT OF LEFT FEMORAL ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RL4KZ | PX | REPLACEMENT OF LEFT FEMORAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RM07Z | PX | REPLACEMENT OF RIGHT POPLITEAL ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RM0JZ | PX | REPLACEMENT OF RIGHT POPLITEAL ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RM0KZ | PX | REPLACEMENT OF RIGHT POPLITEAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RM47Z | PX | REPLACEMENT OF RIGHT POPLITEAL ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RM4JZ | PX | REPLACEMENT OF RIGHT POPLITEAL ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RM4KZ | PX | REPLACEMENT OF RIGHT POPLITEAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RN07Z | PX | REPLACEMENT OF LEFT POPLITEAL ARTERY WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RN0JZ | PX | REPLACEMENT OF LEFT POPLITEAL ARTERY WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RN0KZ | PX | REPLACEMENT OF LEFT POPLITEAL ARTERY WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04RK4JZ | PX | REPLACEMENT OF RIGHT FEMORAL ARTERY WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|-----|------------------------|-------------------------------|---------|----|-------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BM0ZZ | PX | EXCISION OF RIGHT POPLITEAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BM4ZZ | PX | EXCISION OF RIGHT POPLITEAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BN0ZZ | PX | EXCISION OF LEFT POPLITEAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BN4ZZ | PX | EXCISION OF LEFT POPLITEAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BP0ZZ | PX | EXCISION OF RIGHT ANTERIOR TIBIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BP4ZZ | PX | EXCISION OF RIGHT ANTERIOR TIBIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BQ0ZZ | PX | EXCISION OF LEFT ANTERIOR TIBIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BQ4ZZ | PX | EXCISION OF LEFT ANTERIOR TIBIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BR0ZZ | PX | EXCISION OF RIGHT POSTERIOR TIBIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BR4ZZ | PX | EXCISION OF RIGHT POSTERIOR TIBIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BS0ZZ | PX | EXCISION OF LEFT POSTERIOR TIBIAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BS4ZZ | PX | EXCISION OF LEFT POSTERIOR TIBIAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BT0ZZ | PX | EXCISION OF RIGHT PERONEAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BT4ZZ | PX | EXCISION OF RIGHT PERONEAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BU0ZZ | PX | EXCISION OF LEFT PERONEAL ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BU4ZZ | PX | EXCISION OF LEFT PERONEAL ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BV0ZZ | PX | EXCISION OF RIGHT FOOT ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BV4ZZ | PX | EXCISION OF RIGHT FOOT ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BW0ZZ | PX | EXCISION OF LEFT FOOT ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BW4ZZ | PX | EXCISION OF LEFT FOOT ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BY0ZZ | PX | EXCISION OF LOWER ARTERY, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | Infrainguinal Arterial Bypass | 04BY4ZZ | PX | EXCISION OF LOWER ARTERY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG07Y | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG09Y | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG0AY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG0JY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG0KY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG0ZY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG47Y | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG49Y | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG4AY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG4JY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG4KY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | | 05IG4ZY | PX | BYPASS RIGHT HAND VEIN TO UPPER VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | |
|-----|------------------------|---------|----|-------------------------------------------------------------------------------------------------------------|-----------|
| 1.3 | Other Major CV surgery | 051H07Y | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H09Y | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H0AY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H0JY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H0KY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H0ZY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H47Y | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H49Y | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H4AY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H4JY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H4KY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 051H4ZY | PX | BYPASS LEFT HAND VEIN TO UPPER VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T07Y | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T09Y | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T0AY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T0JY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T0KY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T0ZY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T47Y | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T49Y | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T4AY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T4JY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T4KY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061T4ZY | PX | BYPASS RIGHT FOOT VEIN TO LOWER VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V07Y | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V09Y | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS VENOUS TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V0AY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V0JY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V0KY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V0ZY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN, OPEN APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V47Y | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V49Y | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS VENOUS TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V4AY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH AUTOLOGOUS ARTERIAL TISSUE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V4JY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V4KY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.3 | Other Major CV surgery | 061V4ZY | PX | BYPASS LEFT FOOT VEIN TO LOWER VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 1.4 | Stroke | 430 | DX | SUBARACHNOID HEMORRHAGE | ICD-9-CM |
| 1.4 | Stroke | 431 | DX | INTRACEREBRAL HEMORRHAGE | ICD-9-CM |
| 1.4 | Stroke | 433.01 | DX | OCCLUSION AND STENOSIS OF BASILAR ARTERY WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 433.11 | DX | OCCLUSION AND STENOSIS OF CAROTID ARTERY WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 433.21 | DX | OCCLUSION AND STENOSIS OF VERTEBRAL ARTERY WITH CEREBRAL INFARCTION | ICD-9-CM |

| | | | | | |
|-----|--------|---------|----|------------------------------------------------------------------------------------------------|-----------|
| 1.4 | Stroke | 433.31 | DX | OCCLUSION AND STENOSIS OF MULTIPLE AND BILATERAL PRECEREBRAL ARTERIES WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 433.81 | DX | OCCLUSION AND STENOSIS OF OTHER SPECIFIED PRECEREBRAL ARTERY WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 433.91 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED PRECEREBRAL ARTERY WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 434.01 | DX | CEREBRAL THROMBOSIS WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 434.11 | DX | CEREBRAL EMBOLISM WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 434.91 | DX | CEREBRAL ARTERY OCCLUSION, UNSPECIFIED WITH CEREBRAL INFARCTION | ICD-9-CM |
| 1.4 | Stroke | 436 | DX | ACUTE, BUT ILL-DEFINED, CEREBROVASCULAR DISEASE | ICD-9-CM |
| 1.4 | Stroke | 997.02 | DX | IATROGENIC CEREBROVASCULAR INFARCTION OR HEMORRHAGE | ICD-9-CM |
| 1.4 | Stroke | G43.609 | DX | PERSISTENT MIGRAINE AURA WITH CEREBRAL INFARCTION, NOT INTRACTABLE, WITHOUT STATUS MIGRAINOSUS | ICD-10-CM |
| 1.4 | Stroke | G43.619 | DX | PERSISTENT MIGRAINE AURA WITH CEREBRAL INFARCTION, INTRACTABLE, WITHOUT STATUS MIGRAINOSUS | ICD-10-CM |
| 1.4 | Stroke | G46.3 | DX | BRAIN STEM STROKE SYNDROME | ICD-10-CM |
| 1.4 | Stroke | G46.4 | DX | CEREBELLAR STROKE SYNDROME | ICD-10-CM |
| 1.4 | Stroke | I60 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE | ICD-10-CM |
| 1.4 | Stroke | I60.0 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM CAROTID SIPHON AND BIFURCATION | ICD-10-CM |
| 1.4 | Stroke | I60.00 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM UNSPECIFIED CAROTID SIPHON AND BIFURCATION | ICD-10-CM |
| 1.4 | Stroke | I60.01 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM RIGHT CAROTID SIPHON AND BIFURCATION | ICD-10-CM |
| 1.4 | Stroke | I60.02 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM LEFT CAROTID SIPHON AND BIFURCATION | ICD-10-CM |
| 1.4 | Stroke | I60.1 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.10 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM UNSPECIFIED MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.11 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM RIGHT MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.12 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM LEFT MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.2 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM ANTERIOR COMMUNICATING ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.3 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM POSTERIOR COMMUNICATING ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.30 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM UNSPECIFIED POSTERIOR COMMUNICATING ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.31 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM RIGHT POSTERIOR COMMUNICATING ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.32 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM LEFT POSTERIOR COMMUNICATING ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.4 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM BASILAR ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.5 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.50 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM UNSPECIFIED VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.51 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM RIGHT VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.52 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM LEFT VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.6 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM OTHER INTRACRANIAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | I60.7 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE FROM UNSPECIFIED INTRACRANIAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I60.8 | DX | OTHER NONTRAUMATIC SUBARACHNOID HEMORRHAGE | ICD-10-CM |
| 1.4 | Stroke | I60.9 | DX | NONTRAUMATIC SUBARACHNOID HEMORRHAGE, UNSPECIFIED | ICD-10-CM |
| 1.4 | Stroke | I61 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE | ICD-10-CM |
| 1.4 | Stroke | I61.0 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE IN HEMISPHERE, SUBCORTICAL | ICD-10-CM |
| 1.4 | Stroke | I61.1 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE IN HEMISPHERE, CORTICAL | ICD-10-CM |
| 1.4 | Stroke | I61.2 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE IN HEMISPHERE, UNSPECIFIED | ICD-10-CM |
| 1.4 | Stroke | I61.3 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE IN BRAIN STEM | ICD-10-CM |
| 1.4 | Stroke | I61.4 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE IN CEREBELLUM | ICD-10-CM |
| 1.4 | Stroke | I61.5 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE, INTRAVENTRICULAR | ICD-10-CM |
| 1.4 | Stroke | I61.6 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE, MULTIPLE LOCALIZED | ICD-10-CM |
| 1.4 | Stroke | I61.8 | DX | OTHER NONTRAUMATIC INTRACEREBRAL HEMORRHAGE | ICD-10-CM |
| 1.4 | Stroke | I61.9 | DX | NONTRAUMATIC INTRACEREBRAL HEMORRHAGE, UNSPECIFIED | ICD-10-CM |
| 1.4 | Stroke | I63 | DX | CEREBRAL INFARCTION | ICD-10-CM |
| 1.4 | Stroke | I63.0 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF PRECEREBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | I63.01 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I63.011 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF RIGHT VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I63.012 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF LEFT VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | I63.013 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF BILATERAL VERTEBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | I63.019 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF UNSPECIFIED VERTEBRAL ARTER | ICD-10-CM |
| 1.4 | Stroke | I63.02 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF BASILAR ARTERY | ICD-10-CM |
| 1.4 | Stroke | I63.03 | DX | CEREBRAL INFARCTION DUE TO THROMBOSIS OF CAROTID ARTERY | ICD-10-CM |

[illegible]

| | | | | | | |
|-----|-----------------------|-----------------------|---------|----|-----------------------------------------------------------------------------------------------|-----------|
| 1.4 | Stroke | | 163.543 | DX | CEREBRAL INFARCTION DUE TO UNSPECIFIED OCCLUSION OR STENOSIS OF BILATERAL CEREBELLAR ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 163.549 | DX | CEREBRAL INFARCTION DUE TO UNSPECIFIED OCCLUSION OR STENOSIS OF UNSPECIFIED CEREBELLAR ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 163.59 | DX | CEREBRAL INFARCTION DUE TO UNSPECIFIED OCCLUSION OR STENOSIS OF OTHER CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 163.6 | DX | CEREBRAL INFARCTION DUE TO CEREBRAL VENOUS THROMBOSIS, NONPYOGENIC | ICD-10-CM |
| 1.4 | Stroke | | 163.8 | DX | OTHER CEREBRAL INFARCTION | ICD-10-CM |
| 1.4 | Stroke | | 163.81 | DX | OTHER CEREBRAL INFARCTION DUE TO OCCLUSION OR STENOSIS OF SMALL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 163.89 | DX | OTHER CEREBRAL INFARCTION | ICD-10-CM |
| 1.4 | Stroke | | 163.9 | DX | CEREBRAL INFARCTION, UNSPECIFIED | ICD-10-CM |
| 1.4 | Stroke | | 165.0 | DX | OCCLUSION AND STENOSIS OF VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.01 | DX | OCCLUSION AND STENOSIS OF RIGHT VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.02 | DX | OCCLUSION AND STENOSIS OF LEFT VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.03 | DX | OCCLUSION AND STENOSIS OF BILATERAL VERTEBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 165.09 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED VERTEBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.1 | DX | OCCLUSION AND STENOSIS OF BASILAR ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.2 | DX | OCCLUSION AND STENOSIS OF CAROTID ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.21 | DX | OCCLUSION AND STENOSIS OF RIGHT CAROTID ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.22 | DX | OCCLUSION AND STENOSIS OF LEFT CAROTID ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.23 | DX | OCCLUSION AND STENOSIS OF BILATERAL CAROTID ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 165.29 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED CAROTID ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 165.8 | DX | OCCLUSION AND STENOSIS OF OTHER PRECEREBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 165.9 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED PRECEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.0 | DX | OCCLUSION AND STENOSIS OF MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.01 | DX | OCCLUSION AND STENOSIS OF RIGHT MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.02 | DX | OCCLUSION AND STENOSIS OF LEFT MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.03 | DX | OCCLUSION AND STENOSIS OF BILATERAL MIDDLE CEREBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 166.09 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED MIDDLE CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.1 | DX | OCCLUSION AND STENOSIS OF ANTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.11 | DX | OCCLUSION AND STENOSIS OF RIGHT ANTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.12 | DX | OCCLUSION AND STENOSIS OF LEFT ANTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.13 | DX | OCCLUSION AND STENOSIS OF BILATERAL ANTERIOR CEREBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 166.19 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED ANTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.2 | DX | OCCLUSION AND STENOSIS OF POSTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.21 | DX | OCCLUSION AND STENOSIS OF RIGHT POSTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.22 | DX | OCCLUSION AND STENOSIS OF LEFT POSTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.23 | DX | OCCLUSION AND STENOSIS OF BILATERAL POSTERIOR CEREBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 166.29 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED POSTERIOR CEREBRAL ARTERY | ICD-10-CM |
| 1.4 | Stroke | | 166.3 | DX | OCCLUSION AND STENOSIS OF CEREBELLAR ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 166.8 | DX | OCCLUSION AND STENOSIS OF OTHER CEREBRAL ARTERIES | ICD-10-CM |
| 1.4 | Stroke | | 166.9 | DX | OCCLUSION AND STENOSIS OF UNSPECIFIED CEREBRAL ARTERY | ICD-10-CM |
| 1.5 | TIA | | 435 | DX | TRANSIENT CEREBRAL ISCHEMIA | ICD-9-CM |
| 1.5 | TIA | | 435.0 | DX | BASILAR ARTERY SYNDROME | ICD-9-CM |
| 1.5 | TIA | | 435.1 | DX | VERTEBRAL ARTERY SYNDROME | ICD-9-CM |
| 1.5 | TIA | | 435.2 | DX | SUBCLAVIAN STEAL SYNDROME | ICD-9-CM |
| 1.5 | TIA | | 435.3 | DX | VERTEBROBASILAR ARTERY SYNDROME | ICD-9-CM |
| 1.5 | TIA | | 435.8 | DX | OTHER SPECIFIED TRANSIENT CEREBRAL ISCHEMIAS | ICD-9-CM |
| 1.5 | TIA | | 435.9 | DX | UNSPECIFIED TRANSIENT CEREBRAL ISCHEMIA | ICD-9-CM |
| 1.5 | TIA | | G45.0 | DX | VERTEBRO-BASILAR ARTERY SYNDROME | ICD-10-CM |
| 1.5 | TIA | | G45.1 | DX | CAROTID ARTERY SYNDROME (HEMISPHERIC) | ICD-10-CM |
| 1.5 | TIA | | G45.2 | DX | MULTIPLE AND BILATERAL PRECEREBRAL ARTERY SYNDROMES | ICD-10-CM |
| 1.5 | TIA | | G45.8 | DX | OTHER TRANSIENT CEREBRAL ISCHEMIC ATTACKS AND RELATED SYNDROMES | ICD-10-CM |
| 1.5 | TIA | | G45.9 | DX | TRANSIENT CEREBRAL ISCHEMIC ATTACK, UNSPECIFIED | ICD-10-CM |
| 1.5 | TIA | | G46.0 | DX | MIDDLE CEREBRAL ARTERY SYNDROME | ICD-10-CM |
| 1.5 | TIA | | G46.1 | DX | ANTERIOR CEREBRAL ARTERY SYNDROME | ICD-10-CM |
| 1.5 | TIA | | G46.2 | DX | POSTERIOR CEREBRAL ARTERY SYNDROME | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | V42.1 | DX | HEART REPLACED BY TRANSPLANT | ICD-9-CM |
| 2 | Heart transplantation | Heart transplantation | 996.83 | DX | COMPLICATIONS OF TRANSPLANTED HEART | ICD-9-CM |
| 2 | Heart transplantation | Heart transplantation | T86.20 | DX | UNSPECIFIED COMPLICATION OF HEART TRANSPLANT | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.21 | DX | HEART TRANSPLANT REJECTION | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.22 | DX | HEART TRANSPLANT FAILURE | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.23 | DX | HEART TRANSPLANT INFECTION | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.290 | DX | CARDIAC ALLOGRAFT VASCULOPATHY | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.298 | DX | OTHER COMPLICATIONS OF HEART TRANSPLANT | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.30 | DX | UNSPECIFIED COMPLICATION OF HEART-LUNG TRANSPLANT | ICD-10-CM |

| | | | | | | |
|---|-----------------------|-----------------------------|---------|----|--------------------------------------------------------------------------------------------------------------------------------|-----------|
| 2 | Heart transplantation | Heart transplantation | T86.31 | DX | HEART-LUNG TRANSPLANT REJECTION | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.32 | DX | HEART-LUNG TRANSPLANT FAILURE | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.33 | DX | HEART-LUNG TRANSPLANT INFECTION | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | T86.39 | DX | OTHER COMPLICATIONS OF HEART-LUNG TRANSPLANT | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | Z94.1 | DX | HEART TRANSPLANT STATUS | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | Z94.3 | DX | HEART AND LUNGS TRANSPLANT STATUS | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | Z48.21 | DX | ENCOUNTER FOR AFTERCARE FOLLOWING HEART TRANSPLANT | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | Z48.280 | DX | ENCOUNTER FOR AFTERCARE FOLLOWING HEART-LUNG TRANSPLANT | ICD-10-CM |
| 2 | Heart transplantation | Listed for heart transplant | V49.83 | DX | AWAITING ORGAN TRANSPLANT STATUS | ICD-9-CM |
| 2 | Heart transplantation | Listed for heart transplant | Z76.82 | DX | AWAITING ORGAN TRANSPLANT STATUS | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | 33.6 | PX | COMBINED HEART-LUNG TRANSPLANTATION | ICD-9-CM |
| 2 | Heart transplantation | Heart transplantation | 37.51 | PX | HEART TRANSPLANTATION | ICD-9-CM |
| 2 | Heart transplantation | Heart transplantation | 02YA0Z0 | PX | TRANSPLANTATION OF HEART, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | 02YA0Z1 | PX | TRANSPLANTATION OF HEART, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | 02YA0Z2 | PX | TRANSPLANTATION OF HEART, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 2 | Heart transplantation | Heart transplantation | 33927 | PX | IMPLANTATION OF A TOTAL REPLACEMENT HEART SYSTEM (ARTIFICIAL HEART) WITH RECIPIENT CARDIOTOMY. | CPT/HCPSC |
| 2 | Heart transplantation | Heart transplantation | 33928 | PX | REMOVAL AND REPLACEMENT OF TOTAL REPLACEMENT HEART SYSTEM (ARTIFICIAL HEART) | CPT/HCPSC |
| 2 | Heart transplantation | Heart transplantation | 33929 | PX | REMOVAL OF A TOTAL REPLACEMENT HEART SYSTEM (ARTIFICIAL HEART) FOR HEART TRANSPLANTATION | CPT/HCPSC |
| 2 | Heart transplantation | Heart transplantation | 33935 | PX | HEART-LUNG TRANSPLANT WITH RECIPIENT CARDIOTOMY-PNEUMONECTOMY | CPT/HCPSC |
| 2 | Heart transplantation | Heart transplantation | 33945 | PX | HEART TRANSPLANT, WITH OR WITHOUT RECIPIENT CARDIOTOMY | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | V43.2 | DX | HEART REPLACED BY OTHER MEANS | ICD-9-CM |
| 2 | Heart transplantation | LVAD | V43.21 | DX | ORGAN OR TISSUE REPLACED BY OTHER MEANS, HEART ASSIST DEVICE | ICD-9-CM |
| 2 | Heart transplantation | LVAD | V43.22 | DX | ORGAN OR TISSUE REPLACED BY OTHER MEANS, FULLY IMPLANTABLE ARTIFICIAL HEART | ICD-9-CM |
| 2 | Heart transplantation | LVAD | Z95.811 | DX | PRESENCE OF HEART ASSIST DEVICE | ICD-10-CM |
| 2 | Heart transplantation | LVAD | Z95.812 | DX | PRESENCE OF FULLY IMPLANTABLE ARTIFICIAL HEART | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 37.60 | PX | IMPLANTATION OR INSERTION OF BIVENTRICULAR EXTERNAL HEART ASSIST SYSTEM | ICD-9-CM |
| 2 | Heart transplantation | LVAD | 37.63 | PX | REPAIR OF HEART ASSIST SYSTEM | ICD-9-CM |
| 2 | Heart transplantation | LVAD | 37.65 | PX | IMPLANT OF SINGLE VENTRICULAR (EXTRACORPOREAL) EXTERNAL HEART ASSIST SYSTEM | ICD-9-CM |
| 2 | Heart transplantation | LVAD | 37.66 | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM | ICD-9-CM |
| 2 | Heart transplantation | LVAD | 02HA0RS | PX | INSERTION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, OPEN APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02HA3RS | PX | INSERTION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02HA4RS | PX | INSERTION OF BIVENTRICULAR SHORT-TERM EXTERNAL HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 5A02116 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, INTERMITTENT | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 5A02216 | PX | ASSISTANCE WITH CARDIAC OUTPUT USING OTHER PUMP, CONTINUOUS | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02HA0QZ | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM INTO HEART, OPEN APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02HA3QZ | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02HA4QZ | PX | INSERTION OF IMPLANTABLE HEART ASSIST SYSTEM INTO HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02WA0QZ | PX | REVISION OF IMPLANTABLE HEART ASSIST SYSTEM IN HEART, OPEN APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02WA3QZ | PX | REVISION OF IMPLANTABLE HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 02WA4QZ | PX | REVISION OF IMPLANTABLE HEART ASSIST SYSTEM IN HEART, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 2 | Heart transplantation | LVAD | 33975 | PX | INSERTION OF VENTRICULAR ASSIST DEVICE; EXTRACORPOREAL, SINGLE VENTRICLE | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33976 | PX | INSERTION OF VENTRICULAR ASSIST DEVICE; EXTRACORPOREAL, BIVENTRICULAR | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33977 | PX | REMOVAL OF VENTRICULAR ASSIST DEVICE; EXTRACORPOREAL, SINGLE VENTRICLE | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33978 | PX | REMOVAL OF VENTRICULAR ASSIST DEVICE; EXTRACORPOREAL, BIVENTRICULAR | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33979 | PX | INSERTION OF VENTRICULAR ASSIST DEVICE, IMPLANTABLE, INTRACORPOREAL, SINGLE VENTRICLE | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33980 | PX | REMOVAL OF VENTRICULAR ASSIST DEVICE, IMPLANTABLE INTRACORPOREAL, SINGLE VENTRICLE | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33881 | PX | REPLACEMENT OF EXTRACORPOREAL VENTRICULAR ASSIST DEVICE, SINGLE OR BIVENTRICULAR, PUMP(S), SINGLE OR EACH PUMP | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33982 | PX | REPLACEMENT OF VENTRICULAR ASSIST DEVICE PUMP(S); IMPLANTABLE INTRACORPOREAL, SINGLE VENTRICLE, WITHOUT CARDIOPULMONARY BYPASS | CPT/HCPSC |
| 2 | Heart transplantation | LVAD | 33983 | PX | REPLACEMENT OF VENTRICULAR ASSIST DEVICE PUMP(S); IMPLANTABLE INTRACORPOREAL, SINGLE VENTRICLE, WITH CARDIOPULMONARY BYPASS | CPT/HCPSC |
| 3 | ICD | | V45.02 | DX | AUTOMATIC IMPLANTABLE CARDIAC DEFIBRILLATOR IN SITU | ICD-9-CM |
| 3 | ICD | | Z95.810 | DX | PRESENCE OF AUTOMATIC (IMPLANTABLE) CARDIAC DEFIBRILLATOR | ICD-10-CM |

| | | | | | |
|---|-----|---------|----|----------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 3 | ICD | 37.94 | PX | IMPLANTATION OR REPLACEMENT OF AUTOMATIC CARDIOVERTER/DEFIBRILLATOR, TOTAL SYSTEM [AICD] | ICD-9-CM |
| 3 | ICD | 37.95 | PX | IMPLANTATION OF AUTOMATIC CARDIOVERTER/DEFIBRILLATOR LEAD(S) ONLY | ICD-9-CM |
| 3 | ICD | 37.96 | PX | IMPLANTATION OF AUTOMATIC CARDIOVERTER/DEFIBRILLATOR PULSE GENERATOR ONLY | ICD-9-CM |
| 3 | ICD | 37.97 | PX | REPLACEMENT OF AUTOMATIC CARDIOVERTER/DEFIBRILLATOR LEAD(S) ONLY | ICD-9-CM |
| 3 | ICD | 37.98 | PX | REPLACEMENT OF AUTOMATIC CARDIOVERTER/DEFIBRILLATOR PULSE GENERATOR ONLY | ICD-9-CM |
| 3 | ICD | 02H43KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO CORONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 02H40KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO CORONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 02H44KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO CORONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 3 | ICD | 02H60KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 02H63KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 02H64KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 3 | ICD | 02H70KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO LEFT ATRIUM, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 02H73KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO LEFT ATRIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 02H74KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO LEFT ATRIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 3 | ICD | 02HK0KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 02HK3KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 02HK4KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 3 | ICD | 02HL0KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO LEFT VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 02HL3KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO LEFT VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 02HL4KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO LEFT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 3 | ICD | 02HN0KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO PERICARDIUM, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 02HN3KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO PERICARDIUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 02HN4KZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO PERICARDIUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 3 | ICD | 0JH608Z | PX | INSERTION OF DEFIBRILLATOR GENERATOR INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 0JH60FZ | PX | INSERTION OF SUBCUTANEOUS DEFIBRILLATOR LEAD INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 0JH638Z | PX | INSERTION OF DEFIBRILLATOR GENERATOR INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 0JH63FZ | PX | INSERTION OF SUBCUTANEOUS DEFIBRILLATOR LEAD INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 0JH808Z | PX | INSERTION OF DEFIBRILLATOR GENERATOR INTO ABDOMEN SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 0JH838Z | PX | INSERTION OF DEFIBRILLATOR GENERATOR INTO ABDOMEN SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 0JPT0FZ | PX | REMOVAL OF SUBCUTANEOUS DEFIBRILLATOR LEAD FROM TRUNK SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 0JPT3FZ | PX | REMOVAL OF SUBCUTANEOUS DEFIBRILLATOR LEAD FROM TRUNK SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 02H40JZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO CORONARY VEIN, OPEN APPROACH | ICD-10-CM |
| 3 | ICD | 02H43JZ | PX | INSERTION OF DEFIBRILLATOR LEAD INTO CORONARY VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 3 | ICD | 33223 | PX | RELOCATION OF SKIN POCKET FOR SINGLE OR DUAL CHAMBER PACING CARDIOVERTER-DEFIBRILLATOR | CPT/HCPCS |
| 3 | ICD | 33230 | PX | INSERTION OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR ONLY; WITH EXISTING DUAL LEADS | CPT/HCPCS |
| 3 | ICD | 33231 | PX | INSERTION OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR ONLY; WITH EXISTING MULTIPLE LEADS | CPT/HCPCS |
| 3 | ICD | 33240 | PX | INSERTION OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR ONLY; WITH EXISTING SINGLE LEAD | CPT/HCPCS |
| 3 | ICD | 33241 | PX | REMOVAL OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR ONLY | CPT/HCPCS |
| 3 | ICD | 33243 | PX | REMOVAL OF SINGLE OR DUAL CHAMBER IMPLANTABLE DEFIBRILLATOR ELECTRODE(S); BY THORACOTOMY | CPT/HCPCS |
| 3 | ICD | 33244 | PX | REMOVAL OF SINGLE OR DUAL CHAMBER IMPLANTABLE DEFIBRILLATOR ELECTRODE(S); BY TRANSVENOUS EXTRACTION | CPT/HCPCS |
| 3 | ICD | 33249 | PX | INSERTION OR REPLACEMENT OF PERMANENT IMPLANTABLE DEFIBRILLATOR SYSTEM, WITH TRANSVENOUS LEAD(S), SINGLE OR DUAL CHAMBER | CPT/HCPCS |
| 3 | ICD | 33262 | PX | REMOVAL OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR WITH REPLACEMENT OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR; SINGLE LEAD SYSTEM | CPT/HCPCS |

| | | | | | | |
|-----|----------------|-----------------|---------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 3 | ICD | | 33263 | PX | REMOVAL OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR WITH REPLACEMENT OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR; DUAL LEAD SYSTEM | CPT/HCPSC |
| 3 | ICD | | 33264 | PX | REMOVAL OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR WITH REPLACEMENT OF IMPLANTABLE DEFIBRILLATOR PULSE GENERATOR; MULTIPLE LEAD SYSTEM | CPT/HCPSC |
| 3 | ICD | | 33270 | PX | INSERTION OR REPLACEMENT OF PERMANENT SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR SYSTEM, WITH SUBCUTANEOUS ELECTRODE, INCLUDING DEFIBRILLATION THRESHOLD EVALUATION, INDUCTION OF ARRHYTHMIA, EVALUATION OF SENSING FOR ARRHYTHMIA TERMINATION, AND PROGRAMMING OR REPROGRAMMING OF SENSING OR THERAPEUTIC PARAMETERS, WHEN PERFORMED | CPT/HCPSC |
| 3 | ICD | | 33271 | PX | INSERTION OF SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR ELECTRODE | CPT/HCPSC |
| 3 | ICD | | 33272 | PX | REMOVAL OF SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR ELECTRODE | CPT/HCPSC |
| 3 | ICD | | 33273 | PX | REPOSITIONING OF PREVIOUSLY IMPLANTED SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR ELECTRODE | CPT/HCPSC |
| 4 | CRT | CRT-P | 00.50 | PX | IMPLANTATION OF CARDIAC RESYNCHRONIZATION PACEMAKER WITHOUT MENTION OF DEFIBRILLATION, TOTAL SYSTEM [CRT-P] | ICD-9-CM |
| 4 | CRT | CRT-D | 00.51 | PX | IMPLANTATION OF CARDIAC RESYNCHRONIZATION DEFIBRILLATOR, TOTAL SYSTEM [CRT-D] | ICD-9-CM |
| 4 | CRT | CRT-P | 00.53 | PX | IMPLANTATION OR REPLACEMENT OF CARDIAC RESYNCHRONIZATION PACEMAKER PULSE GENERATOR ONLY [CRT-P] | ICD-9-CM |
| 4 | CRT | CRT-D | 00.54 | PX | IMPLANTATION OR REPLACEMENT OF CARDIAC RESYNCHRONIZATION DEFIBRILLATOR PULSE GENERATOR ONLY [CRT-D] | ICD-9-CM |
| 4 | CRT | CRT-P | 0JH607Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION PACEMAKER PULSE GENERATOR INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 4 | CRT | CRT-P | 0JH637Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION PACEMAKER PULSE GENERATOR INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 4 | CRT | CRT-P | 0JH807Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION PACEMAKER PULSE GENERATOR INTO ABDOMEN SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 4 | CRT | CRT-P | 0JH837Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION PACEMAKER PULSE GENERATOR INTO ABDOMEN SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 4 | CRT | CRT-D | 0JH609Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION DEFIBRILLATOR PULSE GENERATOR INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 4 | CRT | CRT-D | 0JH639Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION DEFIBRILLATOR PULSE GENERATOR INTO CHEST SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 4 | CRT | CRT-D | 0JH809Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION DEFIBRILLATOR PULSE GENERATOR INTO ABDOMEN SUBCUTANEOUS TISSUE AND FASCIA, OPEN APPROACH | ICD-10-CM |
| 4 | CRT | CRT-D | 0JH839Z | PX | INSERTION OF CARDIAC RESYNCHRONIZATION DEFIBRILLATOR PULSE GENERATOR INTO ABDOMEN SUBCUTANEOUS TISSUE AND FASCIA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | 425.7 | DX | NUTRITIONAL AND METABOLIC CARDIOMYOPATHY | ICD-9-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | 425.8 | DX | CARDIOMYOPATHY IN OTHER DISEASES CLASSIFIED ELSEWHERE | ICD-9-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | 425.9 | DX | SECONDARY CARDIOMYOPATHY, UNSPECIFIED | ICD-9-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | 425.11 | DX | HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY | ICD-9-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | I42.1 | DX | OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY | ICD-10-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | I42.5 | DX | OTHER RESTRICTIVE CARDIOMYOPATHY | ICD-10-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | I42.7 | DX | CARDIOMYOPATHY DUE TO DRUG AND EXTERNAL AGENT | ICD-10-CM |
| 5.1 | Cardiomyopathy | Cardiomyopathy | I43 | DX | CARDIOMYOPATHY IN DISEASES CLASSIFIED ELSEWHERE | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | 277.3 | DX | AMYLOIDOSIS | ICD-9-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | 277.30 | DX | AMYLOIDOSIS, UNSPECIFIED | ICD-9-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | 277.39 | DX | OTHER AMYLOIDOSIS | ICD-9-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85 | DX | AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.0 | DX | NON-NEUROPATHIC HEREDOFAMILIAL AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.1 | DX | NEUROPATHIC HEREDOFAMILIAL AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.2 | DX | HEREDOFAMILIAL AMYLOIDOSIS, UNSPECIFIED | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.3 | DX | SECONDARY SYSTEMIC AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.4 | DX | ORGAN-LIMITED AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.8 | DX | OTHER AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.81 | DX | LIGHT CHAIN (AL) AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.82 | DX | WILD-TYPE TRANS THYRETIN-RELATED (ATTR) AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.89 | DX | OTHER AMYLOIDOSIS | ICD-10-CM |
| 5.2 | Cardiomyopathy | Amyloidosis | E85.9 | DX | AMYLOIDOSIS, UNSPECIFIED | ICD-10-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | 275.01 | DX | HEREDITARY HEMOCHROMATOSIS | ICD-9-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | 275.02 | DX | HEMOCHROMATOSIS DUE TO REPEATED RED BLOOD CELL TRANSFUSIONS | ICD-9-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | 275.03 | DX | OTHER HEMOCHROMATOSIS | ICD-9-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | 275.09 | DX | OTHER DISORDERS OF IRON METABOLISM | ICD-9-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | E83.11 | DX | HEMOCHROMATOSIS | ICD-10-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | E83.110 | DX | HEREDITARY HEMOCHROMATOSIS | ICD-10-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | E83.111 | DX | HEMOCHROMATOSIS DUE TO REPEATED RED BLOOD CELL TRANSFUSIONS | ICD-10-CM |

| | | | | | | |
|-----|------------------------|--------------------------|----------|----|-------------------------------------------------------------------------------------------------------------|-----------|
| 5.3 | Cardiomyopathy | Hemochromatosis | E83.118 | DX | OTHER HEMOCHROMATOSIS | ICD-10-CM |
| 5.3 | Cardiomyopathy | Hemochromatosis | E83.119 | DX | HEMOCHROMATOSIS, UNSPECIFIED | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | 359.0 | DX | CONGENITAL HEREDITARY MUSCULAR DYSTROPHY | ICD-9-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | 359.1 | DX | HEREDITARY PROGRESSIVE MUSCULAR DYSTROPHY | ICD-9-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.0 | DX | MUSCULAR DYSTROPHY | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.00 | DX | MUSCULAR DYSTROPHY, UNSPECIFIED | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.01 | DX | DUCHENNE OR BECKER MUSCULAR DYSTROPHY | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.02 | DX | FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.03 | DX | LIMB GIRDLE MUSCULAR DYSTROPHIES | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.031 | DX | AUTOSOMAL DOMINANT LIMB GIRDLE MUSCULAR DYSTROPHY | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.032 | DX | AUTOSOMAL RECESSIVE LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO CALPAIN-3 DYSFUNCTION | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.033 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO DYSFERLIN DYSFUNCTION | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.034 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO SARCOGLYCAN DYSFUNCTION | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.0340 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO SARCOGLYCAN DYSFUNCTION, UNSPECIFIED | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.0341 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO ALPHA SARCOGLYCAN DYSFUNCTION | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.0342 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO BETA SARCOGLYCAN DYSFUNCTION | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.0349 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO OTHER SARCOGLYCAN DYSFUNCTION | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.035 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY DUE TO ANOCTAMIN-5 DYSFUNCTION | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.038 | DX | OTHER LIMB GIRDLE MUSCULAR DYSTROPHY | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.039 | DX | LIMB GIRDLE MUSCULAR DYSTROPHY, UNSPECIFIED | ICD-10-CM |
| 5.4 | Cardiomyopathy | Muscular dystrophies | G71.09 | DX | OTHER SPECIFIED MUSCULAR DYSTROPHIES | ICD-10-CM |
| 5.5 | Cardiomyopathy | Takotsubo syndrome | 429.83 | DX | TAKOTSUBO SYNDROME | ICD-9-CM |
| 5.5 | Cardiomyopathy | Takotsubo syndrome | I51.81 | DX | TAKOTSUBO SYNDROME | ICD-10-CM |
| 5.6 | Cardiomyopathy | Pericardial constriction | 423.2 | DX | CONSTRUCTIVE PERICARDITIS | ICD-9-CM |
| 5.6 | Cardiomyopathy | Pericardial constriction | I31.1 | DX | CHRONIC CONSTRUCTIVE PERICARDITIS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | 394.0 | DX | MITRAL STENOSIS | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 394.1 | DX | RHEUMATIC MITRAL INSUFFICIENCY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 394.2 | DX | MITRAL STENOSIS WITH INSUFFICIENCY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 394.9 | DX | OTHER AND UNSPECIFIED MITRAL VALVE DISEASES | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 395.0 | DX | RHEUMATIC AORTIC STENOSIS | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 395.1 | DX | RHEUMATIC AORTIC INSUFFICIENCY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 395.2 | DX | RHEUMATIC AORTIC STENOSIS WITH INSUFFICIENCY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 395.9 | DX | OTHER AND UNSPECIFIED RHEUMATIC AORTIC DISEASES | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 396.0 | DX | MITRAL VALVE STENOSIS AND AORTIC VALVE STENOSIS | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 396.1 | DX | MITRAL VALVE STENOSIS AND AORTIC VALVE INSUFFICIENCY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 396.2 | DX | MITRAL VALVE INSUFFICIENCY AND AORTIC VALVE STENOSIS | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 396.3 | DX | MITRAL VALVE INSUFFICIENCY AND AORTIC VALVE INSUFFICIENCY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 396.8 | DX | MULTIPLE INVOLVEMENT OF MITRAL AND AORTIC VALVES | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 396.9 | DX | MITRAL AND AORTIC VALVE DISEASES, UNSPECIFIED | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 397.0 | DX | DISEASES OF TRICUSPID VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 397.1 | DX | RHEUMATIC DISEASES OF PULMONARY VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 397.9 | DX | RHEUMATIC DISEASES OF ENDOCARDIUM, VALVE UNSPECIFIED | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 424.0 | DX | MITRAL VALVE DISORDER | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 424.1 | DX | AORTIC VALVE DISORDER | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 424.2 | DX | TRICUSPID VALVE DISORDERS, SPECIFIED AS NONRHEUMATIC | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 424.3 | DX | PULMONARY VALVE DISORDERS | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 424.90 | DX | ENDOCARDITIS, VALVE UNSPECIFIED, UNSPECIFIED CAUSE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 424.99 | DX | OTHER ENDOCARDITIS, VALVE UNSPECIFIED | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.00 | DX | CONGENITAL PULMONARY VALVE ANOMALY, UNSPECIFIED | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.01 | DX | ATRESIA OF PULMONARY VALVE, CONGENITAL | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.02 | DX | STENOSIS OF PULMONARY VALVE, CONGENITAL | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.09 | DX | OTHER CONGENITAL ANOMALIES OF PULMONARY VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.1 | DX | TRICUSPID ATRESIA AND STENOSIS, CONGENITAL | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.2 | DX | EBSTEIN'S ANOMALY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.3 | DX | CONGENITAL STENOSIS OF AORTIC VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.4 | DX | CONGENITAL INSUFFICIENCY OF AORTIC VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.5 | DX | CONGENITAL MITRAL STENOSIS | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 746.6 | DX | CONGENITAL MITRAL INSUFFICIENCY | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | I05.0 | DX | RHEUMATIC MITRAL STENOSIS (MITRAL VALVE OBSTRUCTION, RHEUMATIC) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I05.1 | DX | RHEUMATIC MITRAL INSUFFICIENCY (RHEUMATIC MITRAL INCOMPETENCE, RHEUMATIC MITRAL REGURGITATION) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I05.2 | DX | RHEUMATIC MITRAL STENOSIS WITH INSUFFICIENCY (RHEUMATIC MITRAL STENOSIS WITH INCOMPETENCE OR REGURGITATION) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I05.8 | DX | OTHER RHEUMATIC MITRAL VALVE DISEASES (RHEUMATIC MITRAL VALVE FAILURE) | ICD-10-CM |

| | | | | | | |
|---|------------------------|------------------------|--------|----|---------------------------------------------------------------------------------------------|-----------|
| 6 | Valvular heart disease | Valvular heart disease | I05.9 | DX | RHEUMATIC MITRAL VALVE DISEASE, UNSPECIFIED (RHEUMATIC MITRAL VALVE DISORDER (CHRONIC) NOS) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I06 | DX | RHEUMATIC AORTIC VALVE DISEASES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I06.0 | DX | RHEUMATIC AORTIC STENOSIS (RHEUMATIC AORTIC VALVE OBSTRUCTION) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I06.1 | DX | RHEUMATIC AORTIC INSUFFICIENCY (RHEUMATIC AORTIC INCOMPETENCE OR REGURGITATION) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I06.2 | DX | RHEUMATIC AORTIC STENOSIS WITH INSUFFICIENCY (INCOMPETENCE OR REGURGITATION) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I06.8 | DX | OTHER RHEUMATIC AORTIC VALVE DISEASES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I06.9 | DX | RHEUMATIC AORTIC VALVE DISEASE, UNSPECIFIED (RHEUMATIC AORTIC VALVE DISEASE NOS) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I07 | DX | RHEUMATIC TRICUSPID VALVE DISEASES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I07.0 | DX | RHEUMATIC TRICUSPID STENOSIS (TRICUSPID VALVE STENOSIS, RHEUMATIC) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I07.1 | DX | RHEUMATIC TRICUSPID INSUFFICIENCY (TRICUSPID VALVE INSUFFICIENCY, RHEUMATIC) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I07.2 | DX | RHEUMATIC TRICUSPID STENOSIS AND INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I07.8 | DX | OTHER RHEUMATIC TRICUSPID VALVE DISEASES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I07.9 | DX | RHEUMATIC TRICUSPID VALVE DISEASE, UNSPECIFIED (RHEUMATIC TRICUSPID VALVE DISORDER NOS) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I08 | DX | MULTIPLE VALVE DISEASES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I08.0 | DX | RHEUMATIC DISORDERS OF BOTH MITRAL AND AORTIC VALVES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I08.1 | DX | RHEUMATIC DISORDERS OF BOTH MITRAL AND TRICUSPID VALVES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I08.2 | DX | RHEUMATIC DISORDERS OF BOTH AORTIC AND TRICUSPID VALVES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I08.3 | DX | COMBINED RHEUMATIC DISORDERS OF MITRAL, AORTIC, AND TRICUSPID VALVES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I08.8 | DX | OTHER RHEUMATIC MULTIPLE VALVE DISEASES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I08.9 | DX | RHEUMATIC MULTIPLE VALVE DISEASE, UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I09.1 | DX | RHEUMATIC DISEASES OF ENDOCARDIUM, VALVE UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34 | DX | NONRHEUMATIC MITRAL VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34.0 | DX | NONRHEUMATIC MITRAL (VALVE) INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34.1 | DX | NONRHEUMATIC MITRAL (VALVE) PROLAPSE | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34.2 | DX | NONRHEUMATIC MITRAL (VALVE) STENOSIS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34.8 | DX | OTHER NONRHEUMATIC MITRAL VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34.81 | DX | NONRHEUMATIC MITRAL (VALVE) ANNULUS CALCIFICATION | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34.89 | DX | OTHER NONRHEUMATIC MITRAL VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I34.9 | DX | NONRHEUMATIC MITRAL VALVE DISORDER, UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I35 | DX | NONRHEUMATIC AORTIC VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I35.0 | DX | NONRHEUMATIC AORTIC (VALVE) STENOSIS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I35.1 | DX | NONRHEUMATIC AORTIC (VALVE) INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I35.2 | DX | NONRHEUMATIC AORTIC (VALVE) STENOSIS WITH INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I35.8 | DX | OTHER NONRHEUMATIC AORTIC VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I35.9 | DX | NONRHEUMATIC AORTIC VALVE DISORDER, UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I36 | DX | NONRHEUMATIC TRICUSPID VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I36.0 | DX | NONRHEUMATIC TRICUSPID (VALVE) STENOSIS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I36.1 | DX | NONRHEUMATIC TRICUSPID (VALVE) INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I36.2 | DX | NONRHEUMATIC TRICUSPID (VALVE) STENOSIS WITH INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I36.8 | DX | OTHER NONRHEUMATIC TRICUSPID VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I36.9 | DX | NONRHEUMATIC TRICUSPID VALVE DISORDER, UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I37 | DX | NONRHEUMATIC PULMONARY VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I37.0 | DX | NONRHEUMATIC PULMONARY VALVE STENOSIS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I37.1 | DX | NONRHEUMATIC PULMONARY VALVE INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I37.2 | DX | NONRHEUMATIC PULMONARY VALVE STENOSIS WITH INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I37.8 | DX | OTHER NONRHEUMATIC PULMONARY VALVE DISORDERS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I37.9 | DX | NONRHEUMATIC PULMONARY VALVE DISORDER, UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I38 | DX | ENDOCARDITIS, VALVE UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | I39 | DX | ENDOCARDITIS AND HEART VALVE DISORDERS IN DISEASES CLASSIFIED ELSEWHERE | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | 421.1 | DX | ACUTE AND SUBACUTE INFECTIVE ENDOCARDITIS IN DISEASES CLASSIFIED ELSEWHERE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | 424.91 | DX | ENDOCARDITIS IN DISEASES CLASSIFIED ELSEWHERE | ICD-9-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.0 | DX | PULMONARY VALVE ATRESIA | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.1 | DX | CONGENITAL PULMONARY VALVE STENOSIS | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.2 | DX | CONGENITAL PULMONARY VALVE INSUFFICIENCY (CONGENITAL PULMONARY VALVE REGURGITATION) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.3 | DX | OTHER CONGENITAL MALFORMATIONS OF PULMONARY VALVE (SUPERNUMERARY CUSPS OF PULMONARY VALVE) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.4 | DX | CONGENITAL TRICUSPID STENOSIS (CONGENITAL TRICUSPID ATRESIA) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.5 | DX | EBSTEIN'S ANOMALY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.6 | DX | HYPOPLASTIC RIGHT HEART SYNDROME | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.8 | DX | OTHER CONGENITAL MALFORMATIONS OF TRICUSPID VALVE | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q22.9 | DX | CONGENITAL MALFORMATION OF TRICUSPID VALVE, UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23 | DX | CONGENITAL MALFORMATIONS OF AORTIC AND MITRAL VALVES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.0 | DX | CONGENITAL STENOSIS OF AORTIC VALVE (CONGENITAL AORTIC ATRESIA) | ICD-10-CM |

| | | | | | | |
|---|------------------------|------------------------|---------|----|------------------------------------------------------------------------------------------------|-----------|
| 6 | Valvular heart disease | Valvular heart disease | Q23.1 | DX | CONGENITAL INSUFFICIENCY OF AORTIC VALVE (CONGENITAL AORTIC INSUFFICIENCY) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.2 | DX | CONGENITAL MITRAL STENOSIS (CONGENITAL MITRAL ATRESIA) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.3 | DX | CONGENITAL MITRAL INSUFFICIENCY | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.8 | DX | OTHER CONGENITAL MALFORMATIONS OF AORTIC AND MITRAL VALVES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.81 | DX | BICUSPID AORTIC VALVE (CONGENITAL BICUSPID AORTIC VALVE, UNICUSPID AORTIC VALVE) | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.82 | DX | CONGENITAL MITRAL VALVE CLEFT LEAFLET | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.88 | DX | OTHER CONGENITAL MALFORMATIONS OF AORTIC AND MITRAL VALVES | ICD-10-CM |
| 6 | Valvular heart disease | Valvular heart disease | Q23.9 | DX | CONGENITAL MALFORMATION OF AORTIC AND MITRAL VALVES, UNSPECIFIED | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 35.00 | PX | CLOSED HEART VALVOTOMY, UNSPECIFIED VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.01 | PX | CLOSED HEART VALVOTOMY, AORTIC VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.02 | PX | CLOSED HEART VALVOTOMY, MITRAL VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.03 | PX | CLOSED HEART VALVOTOMY, PULMONARY VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.04 | PX | CLOSED HEART VALVOTOMY, TRICUSPID VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.05 | PX | ENDOVASCULAR REPLACEMENT OF AORTIC VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.06 | PX | TRANSAPICAL REPLACEMENT OF AORTIC VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.07 | PX | ENDOVASCULAR REPLACEMENT OF PULMONARY VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.08 | PX | TRANSAPICAL REPLACEMENT OF PULMONARY VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.09 | PX | ENDOVASCULAR REPLACEMENT OF UNSPECIFIED HEART VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.10 | PX | OPEN HEART VALVULOPLASTY WITHOUT REPLACEMENT, UNSPECIFIED VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.11 | PX | OPEN HEART VALVULOPLASTY OF AORTIC VALVE WITHOUT REPLACEMENT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.12 | PX | OPEN HEART VALVULOPLASTY OF MITRAL VALVE WITHOUT REPLACEMENT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.13 | PX | OPEN HEART VALVULOPLASTY OF PULMONARY VALVE WITHOUT REPLACEMENT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.14 | PX | OPEN HEART VALVULOPLASTY OF TRICUSPID VALVE WITHOUT REPLACEMENT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.20 | PX | OPEN AND OTHER REPLACEMENT OF UNSPECIFIED HEART VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.21 | PX | OPEN AND OTHER REPLACEMENT OF AORTIC VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.22 | PX | OPEN AND OTHER REPLACEMENT OF AORTIC VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.23 | PX | OPEN AND OTHER REPLACEMENT OF MITRAL VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.24 | PX | OPEN AND OTHER REPLACEMENT OF MITRAL VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.25 | PX | OPEN AND OTHER REPLACEMENT OF PULMONARY VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.26 | PX | OPEN AND OTHER REPLACEMENT OF PULMONARY VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.27 | PX | OPEN AND OTHER REPLACEMENT OF TRICUSPID VALVE WITH TISSUE GRAFT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.28 | PX | OPEN AND OTHER REPLACEMENT OF TRICUSPID VALVE | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.95 | PX | REVISION OF CORRECTIVE PROCEDURE ON HEART | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 35.97 | PX | PERCUTANEOUS MITRAL VALVE REPAIR WITH IMPLANT | ICD-9-CM |
| 6 | Valvular heart disease | Valve replacement | 02NF0ZZ | PX | RELEASE AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NF3ZZ | PX | RELEASE AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NF4ZZ | PX | RELEASE AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NG0ZZ | PX | RELEASE MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NG3ZZ | PX | RELEASE MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NG4ZZ | PX | RELEASE MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NH0ZZ | PX | RELEASE PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NH3ZZ | PX | RELEASE PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NH4ZZ | PX | RELEASE PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NJ0ZZ | PX | RELEASE TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NJ3ZZ | PX | RELEASE TRICUSPID VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02NJ4ZZ | PX | RELEASE TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QF0ZJ | PX | REPAIR AORTIC VALVE CREATED FROM TRUNCAL VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QF0ZZ | PX | REPAIR AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QF3ZJ | PX | REPAIR AORTIC VALVE CREATED FROM TRUNCAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QF3ZZ | PX | REPAIR AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QF4ZJ | PX | REPAIR AORTIC VALVE CREATED FROM TRUNCAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QF4ZZ | PX | REPAIR AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QG0ZE | PX | REPAIR MITRAL VALVE CREATED FROM LEFT ATRIOVENTRICULAR VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QG0ZZ | PX | REPAIR MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QG3ZE | PX | REPAIR MITRAL VALVE CREATED FROM LEFT ATRIOVENTRICULAR VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QG3ZZ | PX | REPAIR MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QG4ZE | PX | REPAIR MITRAL VALVE CREATED FROM LEFT ATRIOVENTRICULAR VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QG4ZZ | PX | REPAIR MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QJ0ZG | PX | REPAIR TRICUSPID VALVE CREATED FROM RIGHT ATRIOVENTRICULAR VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QJ0ZZ | PX | REPAIR TRICUSPID VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02QJ3ZG | PX | REPAIR TRICUSPID VALVE CREATED FROM RIGHT ATRIOVENTRICULAR VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|---|------------------------|-------------------|---------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 6 | Valvular heart disease | Valve replacement | 027J4ZZ | PX | DILATION OF TRICUSPID VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 027H04Z | PX | DILATION OF PULMONARY VALVE WITH DRUG-ELUTING INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 027H0DZ | PX | DILATION OF PULMONARY VALVE WITH INTRALUMINAL DEVICE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 027H0ZZ | PX | DILATION OF PULMONARY VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 027H3ZZ | PX | DILATION OF PULMONARY VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 027H4ZZ | PX | DILATION OF PULMONARY VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | X2RF33Z | PX | REPLACEMENT OF AORTIC VALVE USING ZOOPLASTIC TISSUE, RAPID DEPLOYMENT TECHNIQUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 2 | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | X2RF03Z | PX | REPLACEMENT OF AORTIC VALVE USING ZOOPLASTIC TISSUE, RAPID DEPLOYMENT TECHNIQUE, OPEN APPROACH, NEW TECHNOLOGY GROUP 2 | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | X2RF43Z | PX | REPLACEMENT OF AORTIC VALVE USING ZOOPLASTIC TISSUE, RAPID DEPLOYMENT TECHNIQUE, PERCUTANEOUS ENDOSCOPIC APPROACH, NEW TECHNOLOGY GROUP 2 | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02VG0ZZ | PX | RESTRICTION OF MITRAL VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02VG3ZZ | PX | RESTRICTION OF MITRAL VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02VG4ZZ | PX | RESTRICTION OF MITRAL VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF07Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF08Z | PX | REVISION OF ZOOPLASTIC TISSUE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF0JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF0KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, OPEN APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF37Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF38Z | PX | REVISION OF ZOOPLASTIC TISSUE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF3JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF3KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF47Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF48Z | PX | REVISION OF ZOOPLASTIC TISSUE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF4JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 02WF4KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN AORTIC VALVE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 6 | Valvular heart disease | Valve replacement | 33361 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; PERCUTANEOUS FEMORAL ARTERY APPROACH | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33362 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; OPEN FEMORAL ARTERY APPROACH | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33363 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; OPEN AXILLARY ARTERY APPROACH | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33364 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; OPEN ILIAC ARTERY APPROACH | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33365 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; TRANSAORTIC APPROACH (E.G., MEDIAN STERNOTOMY, MEDIASTINOTOMY) | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33367 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; CARDIOPULMONARY BYPASS SUPPORT WITH PERCUTANEOUS PERIPHERAL ARTERIAL AND VENOUS CANNULATION (E.G., FEMORAL VESSELS) (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33368 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; CARDIOPULMONARY BYPASS SUPPORT WITH OPEN PERIPHERAL ARTERIAL AND VENOUS CANNULATION (E.G., FEMORAL, ILIAC, AXILLARY VESSELS) (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33369 | PX | TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR/TAVI) WITH PROSTHETIC VALVE; CARDIOPULMONARY BYPASS SUPPORT WITH CENTRAL ARTERIAL AND VENOUS CANNULATION (E.G., AORTA, RIGHT ATRIUM, PULMONARY ARTERY) (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33400 | PX | VALVULOPLASTY, AORTIC VALVE; OPEN, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33401 | PX | VALVULOPLASTY, AORTIC VALVE; OPEN, WITH INFLOW OCCLUSION | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33403 | PX | VALVULOPLASTY, AORTIC VALVE; USING TRANSVENTRICULAR DILATION, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33405 | PX | REPLACEMENT, AORTIC VALVE, OPEN, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33406 | PX | REPLACEMENT, AORTIC VALVE, OPEN, WITH CARDIOPULMONARY BYPASS; WITH ALLOGRAFT VALVE (FREEHAND) | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33410 | PX | REPLACEMENT, AORTIC VALVE, OPEN, WITH CARDIOPULMONARY BYPASS; WITH STENTLESS TISSUE VALVE | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33418 | PX | TRANSCATHETER MITRAL VALVE REPAIR, PERCUTANEOUS APPROACH, INCLUDING TRANSSEPTAL PUNCTURE WHEN PERFORMED; INITIAL PROSTHESIS | CPT/HCPCS |

| | | | | | | |
|---|------------------------------------------|---------------------|---------|----|--------------------------------------------------------------------------------------------------------------------------------|-----------|
| 6 | Valvular heart disease | Valve replacement | 33419 | PX | TRANSCATHETER MITRAL VALVE REPAIR, PERCUTANEOUS APPROACH, INCLUDING TRANSSEPTAL PUNCTURE WHEN PERFORMED; ADDITIONAL PROSTHESIS | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33420 | PX | VALVOTOMY, MITRAL VALVE; CLOSED HEART | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33422 | PX | VALVOTOMY, MITRAL VALVE; OPEN HEART, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33425 | PX | VALVULOPLASTY, MITRAL VALVE, WITH CARDIOPULMONARY BYPASS; | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33426 | PX | VALVULOPLASTY, MITRAL VALVE, WITH CARDIOPULMONARY BYPASS; WITH PROSTHETIC RING | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33427 | PX | UNDER SURGICAL PROCEDURES ON THE MITRAL VALVE | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33430 | PX | REPLACEMENT, MITRAL VALVE, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33460 | PX | VALVECTOMY, TRICUSPID VALVE, WITH CARDIOPULMONARY BYPASS; | CPT/HCPCS |
| | | | | | REPAIR OF INTERMEDIATE OR TRANSITIONAL ATRIOVENTRICULAR CANAL, WITH OR WITHOUT | |
| 6 | Valvular heart disease | Valve replacement | 33665 | PX | ATRIOVENTRICULAR VALVE REPAIR | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33463 | PX | VALVULOPLASTY, TRICUSPID VALVE, WITHOUT RING INSERTION | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33464 | PX | VALVULOPLASTY, TRICUSPID VALVE, WITH RING INSERTION | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33465 | PX | REPLACEMENT, TRICUSPID VALVE, WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33468 | PX | TRICUSPID VALVE REPOSITIONING AND PLICATION FOR EBSTEIN ANOMALY | CPT/HCPCS |
| | | | | | REPAIR OF NON-STRUCTURAL PROSTHETIC VALVE DYSFUNCTION WITH CARDIOPULMONARY | |
| 6 | Valvular heart disease | Valve replacement | 33496 | PX | BYPASS (SEPARATE PROCEDURE) | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 33475 | PX | REPLACEMENT, PULMONARY VALVE | CPT/HCPCS |
| | | | | | TRANSCATHETER PULMONARY VALVE IMPLANTATION, PERCUTANEOUS APPROACH, INCLUDING PRE- | |
| 6 | Valvular heart disease | Valve replacement | 33477 | PX | STENTING OF THE VALVE DELIVERY SITE, WHEN PERFORMED | CPT/HCPCS |
| | | | | | IMPLANTATION OF CATHETER-DELIVERED PROSTHETIC AORTIC HEART VALVE; OPEN THORACIC | |
| 6 | Valvular heart disease | Valve replacement | 0257T | PX | APPROACH (EG, TRANSAPICAL, TRANSVENTRICULAR) | CPT/HCPCS |
| | | | | | TRANSTHORACIC CARDIAC EXPOSURE (I.E. STERNOTOMY, THORACOTOMY, SUBXIPHOID) FOR | |
| 6 | Valvular heart disease | Valve replacement | 0258T | PX | CATHETER- DELIVERED AORTIC VALVE REPLACEMENT; WITHOUT CARDIOPULMONARY BYPASS | CPT/HCPCS |
| | | | | | TRANSTHORACIC CARDIAC EXPOSURE (I.E. STERNOTOMY, THORACOTOMY, SUBXIPHOID) FOR | |
| 6 | Valvular heart disease | Valve replacement | 0259T | PX | CATHETERDELIVERED AORTIC VALVE REPLACEMENT; WITH CARDIOPULMONARY BYPASS. | CPT/HCPCS |
| 6 | Valvular heart disease | Valve replacement | 0262T | PX | MELODY TRANSCATHETER PULMONARY VALVE. | CPT/HCPCS |
| | | | | | TRANSCATHETER MITRAL VALVE REPAIR PERCUTANEOUS APPROACH INCLUDING | |
| 6 | Valvular heart disease | Valve replacement | 0343T | PX | TRANSSEPTAL PUNCTURE WHEN PERFORMED; INITIAL PROSTHESIS (BEFORE 1/1/2015) | CPT/HCPCS |
| | | | | | TRANSCATHETER MITRAL VALVE REPAIR PERCUTANEOUS APPROACH INCLUDING | |
| | | | | | TRANSSEPTAL PUNCTURE WHEN PERFORMED; ADDITIONAL PROSTHESIS (ES) DURING | |
| 6 | Valvular heart disease | Valve replacement | 0344T | PX | SAME SESSION (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) | CPT/HCPCS |
| 7 | Acute decompensated HF | | 428.23 | DX | BEFORE 1/1/2015 (EXCLUDE IF NOT PRESENT WITH 0343T) | ICD-9-CM |
| 7 | Acute decompensated HF | | 428.41 | DX | ACUTE ON CHRONIC SYSTOLIC HEART FAILURE | ICD-9-CM |
| 7 | Acute decompensated HF | | 428.33 | DX | ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM |
| 7 | Acute decompensated HF | | 428.43 | DX | ACUTE ON CHRONIC DIASTOLIC HEART FAILURE | ICD-9-CM |
| 7 | Acute decompensated HF | | 150.21 | DX | ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM |
| 7 | Acute decompensated HF | | 150.23 | DX | ACUTE SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 7 | Acute decompensated HF | | 150.31 | DX | ACUTE ON CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 7 | Acute decompensated HF | | 150.33 | DX | ACUTE DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| 7 | Acute decompensated HF | | 150.41 | DX | ACUTE ON CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM |
| | | | | | ACUTE COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | |
| 7 | Acute decompensated HF | | 150.43 | DX | ACUTE ON CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART | ICD-10-CM |
| 7 | Acute decompensated HF | | 150.811 | DX | FAILURE | ICD-10-CM |
| 7 | Acute decompensated HF | | 150.813 | DX | ACUTE RIGHT HEART FAILURE | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial fibrillation | 427.31 | DX | ACUTE ON CHRONIC RIGHT HEART FAILURE | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial fibrillation | 148.0 | DX | ATRIAL FIBRILLATION | ICD-9-CM |
| 8 | Atrial fibrillation / flutter | Atrial fibrillation | 148.1 | DX | PAROXYSMAL ATRIAL FIBRILLATION | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial fibrillation | 148.19 | DX | PERSISTENT ATRIAL FIBRILLATION | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial fibrillation | 148.2 | DX | OTHER PERSISTENT ATRIAL FIBRILLATION | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial fibrillation | 148.91 | DX | CHRONIC ATRIAL FIBRILLATION | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial flutter | 427.32 | DX | UNSPECIFIED ATRIAL FIBRILLATION | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial flutter | 148.3 | DX | ATRIAL FLUTTER | ICD-9-CM |
| 8 | Atrial fibrillation / flutter | Atrial flutter | 148.4 | DX | TYPICAL ATRIAL FLUTTER | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Atrial flutter | 148.92 | DX | ATYPICAL ATRIAL FLUTTER | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Tachycardia | 427.0 | DX | UNSPECIFIED ATRIAL FLUTTER | ICD-10-CM |
| 8 | Atrial fibrillation / flutter | Tachycardia | 427.1 | DX | PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA | ICD-9-CM |
| 8 | Atrial fibrillation / flutter | Tachycardia | 147.1 | DX | PAROXYSMAL VENTRICULAR TACHYCARDIA | ICD-9-CM |
| 8 | Atrial fibrillation / flutter | Tachycardia | 147.2 | DX | SUPRAVENTRICULAR TACHYCARDIA | ICD-10-CM |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 401.0 | DX | VENTRICULAR TACHYCARDIA | ICD-10-CM |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 402.00 | DX | MALIGNANT ESSENTIAL HYPERTENSION | ICD-9-CM |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 402.01 | DX | MALIGNANT HYPERTENSIVE HEART DISEASE WITHOUT HEART FAILURE | ICD-9-CM |
| | | | | | MALIGNANT HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 403.00 | DX | HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH CHRONIC KIDNEY DISEASE STAGE I | ICD-9-CM |
| | | | | | THROUGH STAGE IV, OR UNSPECIFIED | |

| | | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------------------------------------------------------|
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 403.01 | DX | HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 404.00 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 404.01 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 404.02 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 404.03 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 405.01 | DX | MALIGNANT RENOVASCULAR HYPERTENSION | ICD-9-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | 405.09 | DX | OTHER MALIGNANT SECONDARY HYPERTENSION | ICD-9-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | I16.0 | DX | HYPERTENSIVE URGENCY | ICD-10-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | I16.1 | DX | HYPERTENSIVE EMERGENCY | ICD-10-CM | |
| 9 | Systolic blood pressure (SBP) ≥ 180 mmHg | Hypertensive crisis | I16.9 | DX | HYPERTENSIVE CRISIS, UNSPECIFIED | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 2 | Hypotension | 458.0 | DX | ORTHOSTATIC HYPOTENSION | ICD-9-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 3 | Hypotension | 458.1 | DX | CHRONIC HYPOTENSION | ICD-9-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 4 | Hypotension | 458.21 | DX | HYPOTENSION OF HEMODIALYSIS | ICD-9-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 5 | Hypotension | 458.29 | DX | OTHER IATROGENIC HYPOTENSION | ICD-9-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 6 | Hypotension | 458.8 | DX | OTHER SPECIFIED HYPOTENSION | ICD-9-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | 458.9 | DX | HYPOTENSION, UNSPECIFIED | ICD-9-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95 | DX | HYPOTENSION | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.0 | DX | IDIOPATHIC HYPOTENSION | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.1 | DX | ORTHOSTATIC HYPOTENSION | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.2 | DX | HYPOTENSION DUE TO DRUGS | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.3 | DX | HYPOTENSION OF HEMODIALYSIS | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.8 | DX | OTHER HYPOTENSION | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.81 | DX | POSTPROCEDURAL HYPOTENSION | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.89 | DX | OTHER HYPOTENSION | ICD-10-CM | |
| 10 | Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 7 | Hypotension | I95.9 | DX | HYPOTENSION, UNSPECIFIED | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 491 | DX | SIMPLE CHRONIC BRONCHITIS | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 491.1 | DX | MUCOPURULENT CHRONIC BRONCHITIS | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 491.2 | DX | OBSTRUCTIVE CHRONIC BRONCHITIS WITHOUT EXACERBATION | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 491.21 | DX | OBSTRUCTIVE CHRONIC BRONCHITIS WITH (ACUTE) EXACERBATION | ICD-9-CM | Also include in outpatient setting (primary position) |

| | | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|--------|----|------------------------------------------------------|----------|-------------------------------------------------------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 491.22 | DX | OBSTRUCTIVE CHRONIC BRONCHITIS WITH ACUTE BRONCHITIS | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 491.8 | DX | OTHER CHRONIC BRONCHITIS | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 491.9 | DX | UNSPECIFIED CHRONIC BRONCHITIS | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 492 | DX | EMPHYSEMATOUS BLEB | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 492.8 | DX | OTHER EMPHYSEMA | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 493.2 | DX | CHRONIC OBSTRUCTIVE ASTHMA, UNSPECIFIED | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 493.21 | DX | CHRONIC OBSTRUCTIVE ASTHMA WITH STATUS ASTHMATICUS | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 493.22 | DX | CHRONIC OBSTRUCTIVE ASTHMA WITH (ACUTE) EXACERBATION | ICD-9-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 496 | DX | CHRONIC AIRWAY OBSTRUCTION, NOT ELSEWHERE CLASSIFIED | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 518.83 | DX | CHRONIC RESPIRATORY FAILURE | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | 518.84 | DX | ACUTE AND CHRONIC RESPIRATORY FAILURE | ICD-9-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary Hypertension | 416 | DX | PRIMARY PULMONARY HYPERTENSION | ICD-9-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary arterial hypertension | 416.1 | DX | KYPHOSCOLIOTIC HEART DISEASE | ICD-9-CM | |

| | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--------|----|-------------------------------------------------------|-----------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic thromboembolic pulmonary hypertension | 416.2 | DX | CHRONIC PULMONARY EMBOLISM | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary arterial hypertension | 416.8 | DX | OTHER CHRONIC PULMONARY HEART DISEASE | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary Hypertension | 416.9 | DX | CHRONIC PULMONARY HEART DISEASE, UNSPECIFIED | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | 162.2 | DX | MALIGNANT NEOPLASM OF MAIN BRONCHUS | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | 162.3 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, BRONCHUS OR LUNG | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | 162.4 | DX | MALIGNANT NEOPLASM OF MIDDLE LOBE, BRONCHUS OR LUNG | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | 162.5 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, BRONCHUS OR LUNG | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | 162.8 | DX | MALIGNANT NEOPLASM OF OTHER PARTS OF BRONCHUS OR LUNG | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | 162.9 | DX | MALIGNANT NEOPLASM OF BRONCHUS AND LUNG, UNSPECIFIED | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | 231.2 | DX | CARCINOMA IN SITU OF BRONCHUS AND LUNG | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | V42.6 | DX | LUNG REPLACED BY TRANSPLANT | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 996.84 | DX | COMPLICATIONS OF TRANSPLANTED LUNG | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J41 | DX | SIMPLE AND MUCOPURULENT CHRONIC BRONCHITIS | ICD-10-CM |

| | | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------|----|--------------------------------------------------------------------------------|-----------|-------------------------------------------------------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J41.0 | DX | SIMPLE CHRONIC BRONCHITIS | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J41.1 | DX | MUCOPURULENT CHRONIC BRONCHITIS | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J41.8 | DX | MIXED SIMPLE AND MUCOPURULENT CHRONIC BRONCHITIS | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J42 | DX | UNSPECIFIED CHRONIC BRONCHITIS | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J43.0 | DX | UNILATERAL PULMONARY EMPHYSEMA [MACLEOD'S SYNDROME] | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J43.1 | DX | PANLOBULAR EMPHYSEMA | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J43.2 | DX | CENTRIOBULAR EMPHYSEMA | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J43.8 | DX | OTHER EMPHYSEMA | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J43.9 | DX | EMPHYSEMA, UNSPECIFIED | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.0 | DX | CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH (ACUTE) LOWER RESPIRATORY INFECTION | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.1 | DX | CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH (ACUTE) EXACERBATION | ICD-10-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.10 | DX | CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH (ACUTE) EXACERBATION | ICD-10-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.11 | DX | CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH (ACUTE) EXACERBATION | ICD-10-CM | Also include in outpatient setting (primary position) |

| | | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------|----|------------------------------------------------------------------------------|-----------|-------------------------------------------------------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.8 | DX | OTHER SPECIFIED CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.81 | DX | BRONCHIOLITIS OBLITERANS AND BRONCHIOLITIS OBLITERANS SYNDROME | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.89 | DX | OTHER SPECIFIED CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | COPD/Tuberculosis | J44.9 | DX | CHRONIC OBSTRUCTIVE PULMONARY DISEASE, UNSPECIFIED | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.1 | DX | CHRONIC RESPIRATORY FAILURE | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.10 | DX | CHRONIC RESPIRATORY FAILURE, UNSPECIFIED WHETHER WITH HYPOXIA OR HYPERCAPNIA | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.11 | DX | CHRONIC RESPIRATORY FAILURE WITH HYPOXIA | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.12 | DX | CHRONIC RESPIRATORY FAILURE WITH HYPERCAPNIA | ICD-10-CM | |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.2 | DX | CHRONIC RESPIRATORY ACIDOSIS | ICD-10-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.20 | DX | ACUTE AND CHRONIC RESPIRATORY FAILURE | ICD-10-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.21 | DX | ACUTE AND CHRONIC RESPIRATORY FAILURE WITH HYPOXIA | ICD-10-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic respiratory failure | J96.22 | DX | ACUTE AND CHRONIC RESPIRATORY FAILURE WITH HYPERCAPNIA | ICD-10-CM | Also include in outpatient setting (primary position) |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary Hypertension | I27.0 | DX | PRIMARY PULMONARY HYPERTENSION | ICD-10-CM | |

| | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--------|----|----------------------------------------------------------------|-----------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary arterial hypertension | I27.1 | DX | KYPHOSCOLIOTIC HEART DISEASE | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary arterial hypertension | I27.23 | DX | PULMONARY HYPERTENSION DUE TO LUNG DISEASES AND HYPOXIA | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Chronic thromboembolic pulmonary hypertension | I27.24 | DX | CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary arterial hypertension | I27.82 | DX | CHRONIC PULMONARY EMBOLISM | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary arterial hypertension | I27.83 | DX | EISENMENGER'S SYNDROME | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Pulmonary Hypertension | I27.81 | DX | COR PULMONALE (CHRONIC) | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34 | DX | MALIGNANT NEOPLASM OF BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.0 | DX | MALIGNANT NEOPLASM OF MAIN BRONCHUS | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.00 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED MAIN BRONCHUS | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.01 | DX | MALIGNANT NEOPLASM OF RIGHT MAIN BRONCHUS | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.02 | DX | MALIGNANT NEOPLASM OF LEFT MAIN BRONCHUS | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.1 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.10 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, UNSPECIFIED BRONCHUS OR LUNG | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------|----|--------------------------------------------------------------------------|-----------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.11 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, RIGHT BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.12 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, LEFT BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.2 | DX | MALIGNANT NEOPLASM OF MIDDLE LOBE, BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.3 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.30 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, UNSPECIFIED BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.31 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, RIGHT BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.32 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, LEFT BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.80 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF UNSPECIFIED BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.81 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF RIGHT BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.82 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF LEFT BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.9 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.90 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF UNSPECIFIED BRONCHUS OR LUNG | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------|----|------------------------------------------------------------------|-----------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.91 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF RIGHT BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | C34.92 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF LEFT BRONCHUS OR LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | D02.2 | DX | CARCINOMA IN SITU OF BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | D02.20 | DX | CARCINOMA IN SITU OF UNSPECIFIED BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | D02.21 | DX | CARCINOMA IN SITU OF RIGHT BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung/Pulmonary Malignancies | D02.22 | DX | CARCINOMA IN SITU OF LEFT BRONCHUS AND LUNG | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | Z94.2 | DX | LUNG TRANSPLANT STATUS | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | Z94.3 | DX | HEART AND LUNGS TRANSPLANT STATUS | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | T86.810 | DX | LUNG TRANSPLANT REJECTION | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | T86.811 | DX | LUNG TRANSPLANT FAILURE | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | T86.819 | DX | UNSPECIFIED COMPLICATION OF LUNG TRANSPLANT | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 33.5 | PX | LUNG TRANSPLANT | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 33.5 | PX | LUNG TRANSPLANTATION, NOT OTHERWISE SPECIFIED | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------|----|----------------------------------------------------------------------|-----------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 33.52 | PX | BILATERAL LUNG TRANSPLANTATION | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 33.6 | PX | COMBINED HEART-LUNG TRANSPLANTATION | ICD-9-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYC0Z0 | PX | TRANSPLANTATION OF RIGHT UPPER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYC0Z1 | PX | TRANSPLANTATION OF RIGHT UPPER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYC0Z2 | PX | TRANSPLANTATION OF RIGHT UPPER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYD0Z0 | PX | TRANSPLANTATION OF RIGHT MIDDLE LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYD0Z1 | PX | TRANSPLANTATION OF RIGHT MIDDLE LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYD0Z2 | PX | TRANSPLANTATION OF RIGHT MIDDLE LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYF0Z0 | PX | TRANSPLANTATION OF RIGHT LOWER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYF0Z1 | PX | TRANSPLANTATION OF RIGHT LOWER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYF0Z2 | PX | TRANSPLANTATION OF RIGHT LOWER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYG0Z0 | PX | TRANSPLANTATION OF LEFT UPPER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYG0Z1 | PX | TRANSPLANTATION OF LEFT UPPER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------|----|--------------------------------------------------------------------|-----------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYG0Z2 | PX | TRANSPLANTATION OF LEFT UPPER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYH0Z0 | PX | TRANSPLANTATION OF LUNG LINGULA, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYH0Z1 | PX | TRANSPLANTATION OF LUNG LINGULA, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYH0Z2 | PX | TRANSPLANTATION OF LUNG LINGULA, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYJ0Z0 | PX | TRANSPLANTATION OF LEFT LOWER LUNG LOBE, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYJ0Z1 | PX | TRANSPLANTATION OF LEFT LOWER LUNG LOBE, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYJ0Z2 | PX | TRANSPLANTATION OF LEFT LOWER LUNG LOBE, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYM0Z0 | PX | TRANSPLANTATION OF BILATERAL LUNGS, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYM0Z1 | PX | TRANSPLANTATION OF BILATERAL LUNGS, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYM0Z2 | PX | TRANSPLANTATION OF BILATERAL LUNGS, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYK0Z0 | PX | TRANSPLANTATION OF RIGHT LUNG, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYK0Z1 | PX | TRANSPLANTATION OF RIGHT LUNG, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYK0Z2 | PX | TRANSPLANTATION OF RIGHT LUNG, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------|----|-----------------------------------------------------------------------------------------------|-----------|
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYLOZ0 | PX | TRANSPLANTATION OF LEFT LUNG, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYLOZ1 | PX | TRANSPLANTATION OF LEFT LUNG, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 0BYLOZ2 | PX | TRANSPLANTATION OF LEFT LUNG, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 32851 | PX | LUNG TRANSPLANT, SINGLE; WITHOUT CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 32852 | PX | LUNG TRANSPLANT, SINGLE; WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 32853 | PX | LUNG TRANSPLANT, DOUBLE (BILATERAL SEQUENTIAL OR EN BLOC); WITHOUT CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 32854 | PX | LUNG TRANSPLANT, DOUBLE (BILATERAL SEQUENTIAL OR EN BLOC); WITH CARDIOPULMONARY BYPASS | CPT/HCPCS |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | S2060 | PX | LOBAR LUNG TRANSPLANTATION | CPT/HCPCS |
| 11 | Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | Lung transplant | 33935 | PX | HEART-LUNG TRANSPLANT WITH RECIPIENT CARDIECTOMY-PNEUMONECTOMY | CPT/HCPCS |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.0 | DX | VIRAL HEPATITIS A WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.2 | DX | | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.20 | DX | VIRAL HEPATITIS B WITH HEPATIC COMA, ACUTE OR UNSPECIFIED, WITHOUT MENTION OF HEPATITIS DELTA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.21 | DX | VIRAL HEPATITIS B WITH HEPATIC COMA, ACUTE OR UNSPECIFIED, WITH HEPATITIS DELTA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.22 | DX | CHRONIC VIRAL HEPATITIS B WITH HEPATIC COMA WITHOUT HEPATITIS DELTA | ICD-9-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------|----|---------------------------------------------------------------------------------|----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.23 | DX | CHRONIC VIRAL HEPATITIS B WITH HEPATIC COMA WITH HEPATITIS DELTA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.4 | DX | OTHER SPECIFIED VIRAL HEPATITIS WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.41 | DX | ACUTE HEPATITIS C WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.42 | DX | HEPATITIS DELTA WITHOUT MENTION OF ACTIVE HEPATITIS B DISEASE WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.43 | DX | HEPATITIS E WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.44 | DX | CHRONIC HEPATITIS C WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.49 | DX | OTHER SPECIFIED VIRAL HEPATITIS WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.6 | DX | UNSPECIFIED VIRAL HEPATITIS WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 070.71 | DX | UNSPECIFIED VIRAL HEPATITIS C WITH HEPATIC COMA | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | 572.2 | DX | HEPATIC ENCEPHALOPATHY | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | 571.2 | DX | ALCOHOLIC CIRRHOSIS OF LIVER | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | 571.41 | DX | CHRONIC PERSISTENT HEPATITIS | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | 571.42 | DX | AUTOIMMUNE HEPATITIS | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | 571.49 | DX | OTHER CHRONIC HEPATITIS | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | 571.5 | DX | CIRRHOSIS OF LIVER WITHOUT MENTION OF ALCOHOL | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | 571.6 | DX | BILIARY CIRRHOSIS | ICD-9-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------|----|--------------------------------------------------------------------|----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | 571.9 | DX | UNSPECIFIED CHRONIC LIVER DISEASE WITHOUT MENTION OF ALCOHOL | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | 155.0 | DX | MALIGNANT NEOPLASM OF LIVER, PRIMARY | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | 155.1 | DX | MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | 155.2 | DX | MALIGNANT NEOPLASM OF LIVER, NOT SPECIFIED AS PRIMARY OR SECONDARY | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatorenal syndrome | 572.4 | DX | HEPATORENAL SYNDROME | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | V42.7 | DX | LIVER REPLACED BY TRANSPLANT | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 996.82 | DX | COMPLICATIONS OF TRANSPLANTED LIVER | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 50.5 | PX | LIVER TRANSPLANT | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 50.51 | PX | AUXILIARY LIVER TRANSPLANT | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 50.59 | PX | OTHER TRANSPLANT OF LIVER | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 275.1 | DX | DISORDERS OF COPPER METABOLISM BUDD-CHIARI SYNDROME | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 453.0 | DX | | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 571.8 | DX | OTHER CHRONIC NONALCOHOLIC LIVER DISEASE | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 789.51 | DX | MALIGNANT ASCITES | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 572.8 | DX | OTHER SEQUELAE OF CHRONIC LIVER DISEASE | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 573.1 | DX | HEPATITIS IN VIRAL DISEASES CLASSIFIED ELSEWHERE | ICD-9-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------|----|-----------------------------------------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 573.0 | DX | CHRONIC PASSIVE CONGESTION OF LIVER | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | 573.8 | DX | OTHER SPECIFIED DISORDERS OF LIVER | ICD-9-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B15 | DX | ACUTE HEPATITIS A | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | B15.0 | DX | HEPATITIS A WITH HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B15.9 | DX | HEPATITIS A WITHOUT HEPATIC COMA (HEPATITIS A (ACUTE)(VIRAL) NOS) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B16 | DX | ACUTE HEPATITIS B | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | B16.0 | DX | ACUTE HEPATITIS B WITH DELTA-AGENT WITH HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B16.1 | DX | ACUTE HEPATITIS B WITH DELTA-AGENT WITHOUT HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | B16.2 | DX | ACUTE HEPATITIS B WITHOUT DELTA-AGENT WITH HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B17 | DX | OTHER ACUTE VIRAL HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B17.0 | DX | ACUTE DELTA-(SUPER) INFECTION OF HEPATITIS B CARRIER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B17.1 | DX | ACUTE HEPATITIS C | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B17.10 | DX | ACUTE HEPATITIS C WITHOUT HEPATIC COMA (ACUTE HEPATITIS C NOS) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | B17.11 | DX | ACUTE HEPATITIS C WITH HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B17.2 | DX | ACUTE HEPATITIS E | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B17.8 | DX | OTHER SPECIFIED ACUTE VIRAL HEPATITIS (HEPATITIS NON-A NON-B (ACUTE) (VIRAL) NEC) | ICD-10-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------|----|---------------------------------------------------------------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B17.9 | DX | ACUTE VIRAL HEPATITIS, UNSPECIFIED (ACUTE HEPATITIS NOS, ACUTE INFECTIOUS HEPATITIS NOS) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B18 | DX | CHRONIC VIRAL HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B18.0 | DX | CHRONIC VIRAL HEPATITIS B WITH DELTA-AGENT | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B18.1 | DX | CHRONIC VIRAL HEPATITIS B WITHOUT DELTA-AGENT (CARRIER OF VIRAL HEPATITIS B, CHRONIC VIRAL HEPATITIS B) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B18.2 | DX | CHRONIC VIRAL HEPATITIS C (CARRIER OF VIRAL HEPATITIS C) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B18.8 | DX | OTHER CHRONIC VIRAL HEPATITIS (CARRIER OF OTHER VIRAL HEPATITIS) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B18.9 | DX | CHRONIC VIRAL HEPATITIS, UNSPECIFIED (CARRIER OF UNSPECIFIED VIRAL HEPATITIS) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B19 | DX | UNSPECIFIED VIRAL HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | B19.0 | DX | UNSPECIFIED VIRAL HEPATITIS WITH HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B19.1 | DX | UNSPECIFIED VIRAL HEPATITIS B | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B19.10 | DX | UNSPECIFIED VIRAL HEPATITIS B WITHOUT HEPATIC COMA (UNSPECIFIED VIRAL HEPATITIS B NOS) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | B19.11 | DX | UNSPECIFIED VIRAL HEPATITIS B WITH HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B19.2 | DX | UNSPECIFIED VIRAL HEPATITIS C | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B19.20 | DX | UNSPECIFIED VIRAL HEPATITIS C WITHOUT HEPATIC COMA (VIRAL HEPATITIS C NOS) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | B19.21 | DX | UNSPECIFIED VIRAL HEPATITIS C WITH HEPATIC COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Viral Hepatitis | B19.9 | DX | UNSPECIFIED VIRAL HEPATITIS WITHOUT HEPATIC COMA (VIRAL HEPATITIS NOS) | ICD-10-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------|----|-------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K72 | DX | HEPATIC FAILURE, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K72.0 | DX | ACUTE AND SUBACUTE HEPATIC FAILURE | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K72.00 | DX | ACUTE AND SUBACUTE HEPATIC FAILURE WITHOUT COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | K72.01 | DX | ACUTE AND SUBACUTE HEPATIC FAILURE WITH COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K72.1 | DX | CHRONIC HEPATIC FAILURE | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | K72.11 | DX | CHRONIC HEPATIC FAILURE WITH COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K72.9 | DX | HEPATIC FAILURE, UNSPECIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | K72.90 | DX | HEPATIC FAILURE, UNSPECIFIED WITHOUT COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Encephalopathy/Coma | K72.91 | DX | HEPATIC FAILURE, UNSPECIFIED WITH COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K76.82 | DX | HEPATIC ENCEPHALOPATHY | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K70.2 | DX | ALCOHOLIC FIBROSIS AND SCLEROSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K70.3 | DX | ALCOHOLIC CIRRHOSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K70.30 | DX | ALCOHOLIC CIRRHOSIS OF LIVER WITHOUT ASCITES | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K70.31 | DX | ALCOHOLIC CIRRHOSIS OF LIVER WITH ASCITES | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K70.4 | DX | ALCOHOLIC HEPATIC FAILURE | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K70.40 | DX | ALCOHOLIC HEPATIC FAILURE WITHOUT COMA | ICD-10-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------|----|--------------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K70.41 | DX | ALCOHOLIC HEPATIC FAILURE WITH COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K73 | DX | CHRONIC HEPATITIS, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K73.0 | DX | CHRONIC PERSISTENT HEPATITIS, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K73.1 | DX | CHRONIC LOBULAR HEPATITIS, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K73.2 | DX | CHRONIC ACTIVE HEPATITIS, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K73.8 | DX | OTHER CHRONIC HEPATITIS, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K73.9 | DX | CHRONIC HEPATITIS, UNSPECIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74 | DX | FIBROSIS AND CIRRHOSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.00 | DX | HEPATIC FIBROSIS, UNSPECIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.01 | DX | HEPATIC FIBROSIS, EARLY FIBROSIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.02 | DX | HEPATIC FIBROSIS, ADVANCED FIBROSIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.1 | DX | HEPATIC SCLEROSIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.2 | DX | HEPATIC FIBROSIS WITH HEPATIC SCLEROSIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.3 | DX | PRIMARY BILIARY CIRRHOSIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.4 | DX | SECONDARY BILIARY CIRRHOSIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.5 | DX | BILIARY CIRRHOSIS, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|--------|----|--------------------------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.6 | DX | OTHER AND UNSPECIFIED CIRRHOSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.60 | DX | UNSPECIFIED CIRRHOSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K74.69 | DX | OTHER CIRRHOSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K75.2 | DX | NONSPECIFIC REACTIVE HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K75.3 | DX | GRANULOMATOUS HEPATITIS, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Cirrhosis/Chronic hepatic disease | K75.4 | DX | AUTOIMMUNE HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22 | DX | MALIGNANT NEOPLASM OF LIVER AND INTRAHEPATIC BILE DUCTS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.0 | DX | LIVER CELL CARCINOMA (HEPATOCELLULAR CARCINOMA, HEPATOMA) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.1 | DX | INTRAHEPATIC BILE DUCT CARCINOMA (CHOLANGIOCARCINOMA) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.2 | DX | HEPATOBLASTOMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.3 | DX | ANGIOSARCOMA OF LIVER (KUPFFER CELL SARCOMA) | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.4 | DX | OTHER SARCOMAS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.7 | DX | OTHER SPECIFIED CARCINOMAS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.8 | DX | MALIGNANT NEOPLASM OF LIVER, PRIMARY, UNSPECIFIED AS TO TYPE | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatic Cancer | C22.9 | DX | MALIGNANT NEOPLASM OF LIVER, NOT SPECIFIED AS PRIMARY OR SECONDARY | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Hepatorenal syndrome | K76.7 | DX | HEPATORENAL SYNDROME | ICD-10-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|---------|----|------------------------------------------------------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | Z94.4 | DX | LIVER TRANSPLANT STATUS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | Z48.23 | DX | ENCOUNTER FOR AFTERCARE FOLLOWING LIVER TRANSPLANT | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | T86.40 | DX | UNSPECIFIED COMPLICATION OF LIVER TRANSPLANT | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | T86.41 | DX | LIVER TRANSPLANT REJECTION | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | T86.42 | DX | LIVER TRANSPLANT FAILURE | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | T86.43 | DX | LIVER TRANSPLANT INFECTION | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | T86.49 | DX | OTHER COMPLICATIONS OF LIVER TRANSPLANT | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 0FY00Z0 | PX | TRANSPLANTATION OF LIVER, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 0FY00Z1 | PX | TRANSPLANTATION OF LIVER, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 0FY00Z2 | PX | TRANSPLANTATION OF LIVER, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Liver transplant | 47135 | PX | LIVER ALLOTRANSPLANTATION, ORTHOTOPIC, PARTIAL OR WHOLE, FROM CADAVER OR LIVING DONOR, ANY AGE | CPT/HCPCS |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | E83.00 | DX | DISORDER OF COPPER METABOLISM, UNSPECIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | E83.01 | DX | WILSON'S DISEASE | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | E83.09 | DX | OTHER DISORDERS OF COPPER METABOLISM BUDD-CHIARI SYNDROME | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | I82.0 | DX | | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71 | DX | TOXIC LIVER DISEASE INCLUDES DRUG-INDUCED IDIOSYNCRATIC OR TOXIC LIVER DISEASE | ICD-10-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------|----|-------------------------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.0 | DX | TOXIC LIVER DISEASE WITH CHOLESTASIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.1 | DX | TOXIC LIVER DISEASE WITH HEPATIC NECROSIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.10 | DX | TOXIC LIVER DISEASE WITH HEPATIC NECROSIS, WITHOUT COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.11 | DX | TOXIC LIVER DISEASE WITH HEPATIC NECROSIS, WITH COMA | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.2 | DX | TOXIC LIVER DISEASE WITH ACUTE HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.3 | DX | TOXIC LIVER DISEASE WITH CHRONIC PERSISTENT HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.4 | DX | TOXIC LIVER DISEASE WITH CHRONIC LOBULAR HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.5 | DX | TOXIC LIVER DISEASE WITH CHRONIC ACTIVE HEPATITIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.50 | DX | TOXIC LIVER DISEASE WITH CHRONIC ACTIVE HEPATITIS WITHOUT ASCITES | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.51 | DX | TOXIC LIVER DISEASE WITH CHRONIC ACTIVE HEPATITIS WITH ASCITES | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.6 | DX | TOXIC LIVER DISEASE WITH HEPATITIS, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.7 | DX | TOXIC LIVER DISEASE WITH FIBROSIS AND CIRRHOSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.8 | DX | TOXIC LIVER DISEASE WITH OTHER DISORDERS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K71.9 | DX | TOXIC LIVER DISEASE, UNSPECIFIED | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | R18.0 | DX | MALIGNANT ASCITES | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K72.10 | DX | CHRONIC HEPATIC FAILURE WITHOUT COMA | ICD-10-CM |

| | | | | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K76.1 | DX | CHRONIC PASSIVE CONGESTION OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K76.2 | DX | CENTRAL HEMORRHAGIC NECROSIS OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K76.3 | DX | INFARCTION OF LIVER | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K76.4 | DX | PELIOSIS HEPATIS | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K76.5 | DX | HEPATIC VENO-OCCLUSIVE DISEASE | ICD-10-CM |
| 12 | Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 | Other hepatic diseases | K76.81 | DX | HEPATOPULMONARY SYNDROME | ICD-10-CM |
| 13 | Impaired renal function | CKD Stage IV and V | 585.4 | DX | CHRONIC KIDNEY DISEASE, STAGE IV (SEVERE) | ICD-9-CM |
| 13 | Impaired renal function | CKD Stage IV and V | 585.5 | DX | CHRONIC KIDNEY DISEASE, STAGE V | ICD-9-CM |
| 13 | Impaired renal function | ESRD | 585.6 | DX | END STAGE RENAL DISEASE | ICD-9-CM |
| 13 | Impaired renal function | Stage V or ESRD | 403.01 | DX | HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 13 | Impaired renal function | Stage V or ESRD | 403.11 | DX | HYPERTENSIVE CHRONIC KIDNEY DISEASE, BENIGN, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 13 | Impaired renal function | Stage V or ESRD | 403.91 | DX | HYPERTENSIVE CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 13 | Impaired renal function | Stage V or ESRD | 404.03 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 13 | Impaired renal function | Stage V or ESRD | 404.13 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 13 | Impaired renal function | Stage V or ESRD | 404.93 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V45.1 | DX | POSTSURGICAL RENAL DIALYSIS STATUS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V45.11 | DX | RENAL DIALYSIS STATUS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V45.12 | DX | NONCOMPLIANCE WITH RENAL DIALYSIS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V56 | DX | ENCOUNTER FOR DIALYSIS AND DIALYSIS CATHETER CARE | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V56.0 | DX | ENCOUNTER FOR EXTRACORPOREAL DIALYSIS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V56.1 | DX | FITTING AND ADJUSTMENT OF EXTRACORPOREAL DIALYSIS CATHETER | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V56.2 | DX | FITTING AND ADJUSTMENT OF PERITONEAL DIALYSIS CATHETER | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V56.31 | DX | ENCOUNTER FOR ADEQUACY TESTING FOR HEMODIALYSIS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V56.32 | DX | ENCOUNTER FOR ADEQUACY TESTING FOR PERITONEAL DIALYSIS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | V56.8 | DX | ENCOUNTER FOR OTHER DIALYSIS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 792.5 | DX | CLOUDY (HEMODIALYSIS) (PERITONEAL) DIALYSIS EFFLUENT | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 996.56 | DX | MECHANICAL COMPLICATION DUE TO PERITONEAL DIALYSIS CATHETER | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 996.68 | DX | INFECTION AND INFLAMMATORY REACTION DUE TO PERITONEAL DIALYSIS CATHETER | ICD-9-CM |

| | | | | | | |
|----|-------------------------|----------------------------------|----------|----|----------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 996.73 | DX | OTHER COMPLICATIONS DUE TO RENAL DIALYSIS DEVICE, IMPLANT, AND GRAFT | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | E879.1 | DX | KIDNEY DIALYSIS AS THE CAUSE OF ABNORMAL REACTION OF PATIENT, OR OF LATER COMPLICATION, WITHOUT MENTION OF MISADVENTURE AT TIME OF PROCEDURE | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 39.95 | PX | HEMODIALYSIS | ICD-9-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 54.98 | PX | PERITONEAL DIALYSIS | ICD-9-CM |
| 13 | Impaired renal function | Kidney Transplant | V42.0 | DX | KIDNEY REPLACED BY TRANSPLANT | ICD-9-CM |
| 13 | Impaired renal function | Kidney Transplant | 996.81 | DX | COMPLICATIONS OF TRANSPLANTED KIDNEY | ICD-9-CM |
| 13 | Impaired renal function | Kidney Transplant | 55.53 | PX | REMOVAL OF TRANSPLANTED OR REJECTED KIDNEY | ICD-9-CM |
| 13 | Impaired renal function | Kidney Transplant | 55.6 | PX | TRANSPLANT OF KIDNEY | ICD-9-CM |
| 13 | Impaired renal function | Kidney Transplant | 55.61 | PX | RENAL AUTOTRANSPLANTATION | ICD-9-CM |
| 13 | Impaired renal function | Kidney Transplant | 55.69 | PX | OTHER KIDNEY TRANSPLANTATION | ICD-9-CM |
| 13 | Impaired renal function | CKD Stage IV and V | N18.4 | DX | CHRONIC KIDNEY DISEASE, STAGE 4 (SEVERE) | ICD-10-CM |
| 13 | Impaired renal function | CKD Stage IV and V | N18.5 | DX | CHRONIC KIDNEY DISEASE, STAGE 5 | ICD-10-CM |
| 13 | Impaired renal function | ESRD | N18.6 | DX | END STAGE RENAL DISEASE | ICD-10-CM |
| 13 | Impaired renal function | Stage V or ESRD | I12.0 | DX | HYPERTENSIVE CHRONIC KIDNEY DISEASE WITH STAGE 5 CHRONIC KIDNEY DISEASE OR END STAGE RENAL DISEASE | ICD-10-CM |
| 13 | Impaired renal function | Stage V or ESRD | I13.2 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND WITH STAGE 5 CHRONIC KIDNEY DISEASE, OR END STAGE RENAL DISEASE | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z49 | DX | ENCOUNTER FOR CARE INVOLVING RENAL DIALYSIS | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z49.0 | DX | PREPARATORY CARE FOR RENAL DIALYSIS | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z49.3 | DX | ENCOUNTER FOR ADEQUACY TESTING FOR DIALYSIS | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z49.31 | DX | ENCOUNTER FOR ADEQUACY TESTING FOR HEMODIALYSIS | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z49.32 | DX | ENCOUNTER FOR ADEQUACY TESTING FOR PERITONEAL DIALYSIS | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z49.01 | DX | ENCOUNTER FOR FITTING AND ADJUSTMENT OF EXTRACORPOREAL DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z49.02 | DX | ENCOUNTER FOR FITTING AND ADJUSTMENT OF PERITONEAL DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z9115 | DX | PATIENT'S NONCOMPLIANCE WITH RENAL DIALYSIS | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Z99.2 | DX | DEPENDENCE ON RENAL DIALYSIS | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | R88.0 | DX | CLOUDY (HEMODIALYSIS) (PERITONEAL) DIALYSIS EFFLUENT | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.41 | DX | BREAKDOWN (MECHANICAL) OF VASCULAR DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.41XA | DX | BREAKDOWN (MECHANICAL) OF VASCULAR DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.41XD | DX | BREAKDOWN (MECHANICAL) OF VASCULAR DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.41XS | DX | BREAKDOWN (MECHANICAL) OF VASCULAR DIALYSIS CATHETER, SEQUELA | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.42 | DX | DISPLACEMENT OF VASCULAR DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.42XA | DX | DISPLACEMENT OF VASCULAR DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.42XD | DX | DISPLACEMENT OF VASCULAR DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.42XS | DX | DISPLACEMENT OF VASCULAR DIALYSIS CATHETER, SEQUELA | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.43 | DX | LEAKAGE OF VASCULAR DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.43XA | DX | LEAKAGE OF VASCULAR DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.43XD | DX | LEAKAGE OF VASCULAR DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.43XS | DX | LEAKAGE OF VASCULAR DIALYSIS CATHETER, SEQUELA | ICD-10-CM |

| | | | | | | |
|----|-------------------------|----------------------------------|----------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.49 | DX | OTHER COMPLICATION OF VASCULAR DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.49XA | DX | OTHER COMPLICATION OF VASCULAR DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.49XD | DX | OTHER COMPLICATION OF VASCULAR DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T82.49XS | DX | OTHER COMPLICATION OF VASCULAR DIALYSIS CATHETER, SEQUELA | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.611 | DX | BREAKDOWN (MECHANICAL) OF INTRAPERITONEAL DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.611A | DX | BREAKDOWN (MECHANICAL) OF INTRAPERITONEAL DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.611D | DX | BREAKDOWN (MECHANICAL) OF INTRAPERITONEAL DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.611S | DX | BREAKDOWN (MECHANICAL) OF INTRAPERITONEAL DIALYSIS CATHETER, SEQUELA | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.621 | DX | DISPLACEMENT OF INTRAPERITONEAL DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.621A | DX | DISPLACEMENT OF INTRAPERITONEAL DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.621D | DX | DISPLACEMENT OF INTRAPERITONEAL DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.621S | DX | DISPLACEMENT OF INTRAPERITONEAL DIALYSIS CATHETER, SEQUELA | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.631 | DX | LEAKAGE OF INTRAPERITONEAL DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.631A | DX | LEAKAGE OF INTRAPERITONEAL DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.631D | DX | LEAKAGE OF INTRAPERITONEAL DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.631S | DX | LEAKAGE OF INTRAPER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.691 | DX | OTHER MECHANICAL COMPLICATION OF INTRAPERITONEAL DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.691A | DX | OTHER MECHANICAL COMPLICATION OF INTRAPERITONEAL DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.691D | DX | OTHER MECHANICAL COMPLICATION OF INTRAPERITONEAL DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.691S | DX | OTHER MECHANICAL COMPLICATION OF INTRAPERITONEAL DIALYSIS CATHETER, SEQUELA | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.71 | DX | INFECTION AND INFLAMMATORY REACTION DUE TO PERITONEAL DIALYSIS CATHETER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.71XA | DX | INFECTION AND INFLAMMATORY REACTION DUE TO PERITONEAL DIALYSIS CATHETER, INITIAL ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.71XD | DX | INFECTION AND INFLAMMATORY REACTION DUE TO PERITONEAL DIALYSIS CATHETER, SUBSEQUENT ENCOUNTER | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | T85.71XS | DX | INFECTION AND INFLAMMATORY REACTION DUE TO PERITONEAL DIALYSIS CATHETER, SEQUELA | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | Y84.1 | DX | KIDNEY DIALYSIS AS THE CAUSE OF ABNORMAL REACTION OF THE PATIENT, OR OF LATER COMPLICATION, WITHOUT MENTION OF MISADVENTURE AT THE TIME OF THE PROCEDURE | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 5A1D70Z | PX | PERFORMANCE OF URINARY FILTRATION, INTERMITTENT, LESS THAN 6 HOURS PER DAY | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 5A1D80Z | PX | PERFORMANCE OF URINARY FILTRATION, PROLONGED INTERMITTENT, 6-18 HOURS PER DAY | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 5A1D90Z | PX | PERFORMANCE OF URINARY FILTRATION, CONTINUOUS, GREATER THAN 18 HOURS PER DAY | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 5A1D00Z | PX | PERFORMANCE OF URINARY FILTRATION, SINGLE | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 5A1D60Z | PX | PERFORMANCE OF URINARY FILTRATION, MULTIPLE | ICD-10-CM |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 3E1M39Z | PX | IRRIGATION OF PERITONEAL CAVITY USING DIALYSATE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | Z94.0 | DX | KIDNEY TRANSPLANT STATUS | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | T86.1 | DX | COMPLICATIONS OF KIDNEY TRANSPLANT | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | T86.10 | DX | UNSPECIFIED COMPLICATION OF KIDNEY TRANSPLANT | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | T86.11 | DX | KIDNEY TRANSPLANT REJECTION | ICD-10-CM |

| | | | | | | |
|----|-------------------------|----------------------------------|---------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 13 | Impaired renal function | Kidney Transplant | T86.12 | DX | KIDNEY TRANSPLANT FAILURE | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | T86.13 | DX | KIDNEY TRANSPLANT INFECTION | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | T86.19 | DX | OTHER COMPLICATION OF KIDNEY TRANSPLANT | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | Z48.22 | DX | ENCOUNTER FOR AFTERCARE FOLLOWING KIDNEY TRANSPLANT | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TY00Z0 | PX | TRANSPLANTATION OF RIGHT KIDNEY, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TY00Z1 | PX | TRANSPLANTATION OF RIGHT KIDNEY, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TY00Z2 | PX | TRANSPLANTATION OF RIGHT KIDNEY, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TY10Z0 | PX | TRANSPLANTATION OF LEFT KIDNEY, ALLOGENEIC, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TY10Z1 | PX | TRANSPLANTATION OF LEFT KIDNEY, SYNGENEIC, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TY10Z2 | PX | TRANSPLANTATION OF LEFT KIDNEY, ZOOPLASTIC, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TS00ZZ | PX | REPOSITION RIGHT KIDNEY, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 0TS10ZZ | PX | REPOSITION LEFT KIDNEY, OPEN APPROACH | ICD-10-CM |
| 13 | Impaired renal function | Kidney Transplant | 50360 | PX | RENAL ALLOTRANSPLANTATION, IMPLANTATION OF GRAFT; WITHOUT RECIPIENT NEPHRECTOMY | CPT/HCPCS |
| 13 | Impaired renal function | Kidney Transplant | 50365 | PX | RENAL ALLOTRANSPLANTATION, IMPLANTATION OF GRAFT; WITH RECIPIENT NEPHRECTOMY | CPT/HCPCS |
| 13 | Impaired renal function | Kidney Transplant | 50370 | PX | REMOVAL OF TRANSPLANTED RENAL ALLOGRAFT | CPT/HCPCS |
| 13 | Impaired renal function | Impaired renal function | 50380 | PX | RENAL AUTOTRANSPLANTATION, REIMPLANTATION OF KIDNEY | CPT/HCPCS |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | G0257 | PX | UNSCHEDULED OR EMERGENCY DIALYSIS TREATMENT FOR AN ESRD PATIENT IN A HOSPITAL OUTPATIENT DEPARTMENT THAT IS NOT CERTIFIED AS AN ESRD FACILITY | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | G0319 | PX | END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS 20 YEARS OF AGE AND OVER; WITH 1 FACE-TO-FACE PHYSICIAN VISIT PER MONTH / END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS 20 YEARS OF AGE AND OVER; WITH 1 FACE-TO-FACE PHYSICIAN VISIT PER MONTH | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | G0326 | PX | END STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS BETWEEN TWELVE AND NINETEEN YEARS OF AGE / END STAGE RENAL DISEASE (ESRD) RELATED SERVICES LESS THAN FULL MONTH, PER DAY; FOR PATIENTS BETWEEN TWELVE AND NINETEEN YEARS OF AGE | CPT/HCPCS |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | S9335 | PX | HOME THERAPY, HEMODIALYSIS; ADMINISTRATIVE SERVICES, PROFESSIONAL PHARMACY SERVICES, CARE COORDINATION, AND ALL NECESSARY SUPPLIES AND EQUIPMENT (DRUGS AND NURSING SERVICES CODED SEPARATELY), PER DIEM | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90920 | PX | END STAGE RENAL DISEASE (ESRD) RELATED SERVICES PER FULL MONTH; FOR PATIENTS BETWEEN TWELVE AND NINETEEN YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES PER FULL MONTH; FOR PATIENTS BETWEEN TWELVE AND NINETEEN YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90921 | PX | END STAGE RENAL DISEASE (ESRD) RELATED SERVICES PER FULL MONTH; FOR PATIENTS TWENTY YEARS OF AGE AND OVER / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES PER FULL MONTH; FOR PATIENTS TWENTY YEARS OF AGE AND OLDER / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES PER FULL MONTH; FOR PATIENTS TWENTY YEARS OF AGE AND OVER | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90924 | PX | END STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS BETWEEN TWELVE AND NINETEEN YEARS OF AGE / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS BETWEEN TWELVE AND NINETEEN YEARS OF AGE | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90925 | PX | END STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS TWENTY YEARS OF AGE AND OVER / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS TWENTY YEARS OF AGE AND OLDER / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS TWENTY YEARS OF AGE AND OVER | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90935 | PX | HEMODIALYSIS PROCEDURE WITH SINGLE EVALUATION BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90937 | PX | HEMODIALYSIS PROCEDURE REQUIRING REPEATED EVALUATION(S) WITH OR WITHOUT SUBSTANTIAL REVISION OF DIALYSIS PRESCRIPTION | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90939 | PX | HEMODIALYSIS ACCESS FLOW STUDY TO DETERMINE BLOOD FLOW IN GRAFTS AND ARTERIOVENOUS FISTULAE BY AN INDICATOR DILUTION METHOD, HOOK-UP; TRANSCUTANEOUS MEASUREMENT AND DISCONNECTION | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90940 | PX | HEMODIALYSIS ACCESS FLOW STUDY TO DETERMINE BLOOD FLOW IN GRAFTS AND ARTERIOVENOUS FISTULAE BY AN INDICATOR METHOD | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90945 | PX | DIALYSIS PROCEDURE OTHER THAN HEMODIALYSIS (EG, PERITONEAL DIALYSIS, HEMOFILTRATION, OR OTHER CONTINUOUS RENAL REPLACEMENT THERAPIES), WITH SINGLE EVALUATION BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL | CPT/HCPCS |
| 13 | Impaired renal function | ESRD | 90947 | PX | DIALYSIS PROCEDURE OTHER THAN HEMODIALYSIS (EG, PERITONEAL DIALYSIS, HEMOFILTRATION, OR OTHER CONTINUOUS RENAL REPLACEMENT THERAPIES) REQUIRING REPEATED EVALUATIONS BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL, WITH OR WITHOUT SUBSTANTIAL REVISION OF DIALYSIS PRESCRIPTION | CPT/HCPCS |

| | | | | | | | |
|----|-------------------------|----------------------------------|-------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------|
| 13 | Impaired renal function | ESRD | 90957 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES MONTHLY, FOR PATIENTS 12-19 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 4 OR MORE FACE-TO-FACE VISITS BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL PER MONTH | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90958 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES MONTHLY, FOR PATIENTS 12-19 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 2-3 FACE-TO-FACE VISITS BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL PER MONTH | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90959 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES MONTHLY, FOR PATIENTS 12-19 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 1 FACE-TO-FACE VISIT BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL PER MONTH | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90960 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES MONTHLY, FOR PATIENTS 20 YEARS OF AGE AND OLDER; WITH 4 OR MORE FACE-TO-FACE VISITS BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL PER MONTH | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90961 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES MONTHLY, FOR PATIENTS 20 YEARS OF AGE AND OLDER; WITH 2-3 FACE-TO-FACE VISITS BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL PER MONTH | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90962 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES MONTHLY, FOR PATIENTS 20 YEARS OF AGE AND OLDER; WITH 1 FACE-TO-FACE VISIT BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL PER MONTH | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90965 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS PER FULL MONTH, FOR PATIENTS 12-19 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90966 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS PER FULL MONTH, FOR PATIENTS 20 YEARS OF AGE AND OLDER | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90969 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR DIALYSIS LESS THAN A FULL MONTH OF SERVICE, PER DAY; FOR PATIENTS 12-19 YEARS OF AGE | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90970 | PX | END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR DIALYSIS LESS THAN A FULL MONTH OF SERVICE, PER DAY; FOR PATIENTS 20 YEARS OF AGE AND OLDER | CPT/HCPCS | |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 90989 | PX | DIALYSIS TRAINING, PATIENT, INCLUDING HELPER WHERE APPLICABLE, ANY MODE, COMPLETED COURSE | CPT/HCPCS | |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 90993 | PX | DIALYSIS TRAINING, PATIENT, INCLUDING HELPER WHERE APPLICABLE, ANY MODE, COURSE NOT COMPLETED, PER TRAINING SESSION | CPT/HCPCS | |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 90999 | PX | UNLISTED DIALYSIS PROCEDURE, INPATIENT OR OUTPATIENT | CPT/HCPCS | |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 99512 | PX | HOME VISIT FOR HEMODIALYSIS | CPT/HCPCS | |
| 13 | Impaired renal function | Hemodialysis/Peritoneal dialysis | 99559 | PX | HOME INFUSION OF PERITONEAL DIALYSIS, PER DIEM / HOME INFUSION OF PERITONEAL DIALYSIS, PER VISIT | CPT/HCPCS | |
| 13 | Impaired renal function | ESRD | 90925 | PX | END STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS TWENTY YEARS OF AGE AND OVER / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS TWENTY YEARS OF AGE AND OLDER / END-STAGE RENAL DISEASE (ESRD) RELATED SERVICES (LESS THAN FULL MONTH), PER DAY; FOR PATIENTS TWENTY YEARS OF AGE AND OVER | CPT/HCPCS | |
| 14 | Hb < 9mg/dl | Nutritional anemias | 280.0 | DX | IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC) | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 280.1 | DX | IRON DEFICIENCY ANEMIA SECONDARY TO INADEQUATE DIETARY IRON INTAKE | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 280.8 | DX | OTHER SPECIFIED IRON DEFICIENCY ANEMIAS | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 280.9 | DX | IRON DEFICIENCY ANEMIA, UNSPECIFIED | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 281.0 | DX | PERNICIOUS ANEMIA | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 281.1 | DX | OTHER VITAMIN B12 DEFICIENCY ANEMIA | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 281.2 | DX | FOLATE-DEFICIENCY ANEMIA | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 281.3 | DX | OTHER SPECIFIED MEGALOBlastic ANEMIAS NOT ELSEWHERE CLASSIFIED | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 281.4 | DX | PROTEIN-DEFICIENCY ANEMIA | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | 281.8 | DX | ANEMIA ASSOCIATED WITH OTHER SPECIFIED NUTRITIONAL DEFICIENCY | ICD-9-CM | In primary position only, 183 days before CED |

| | | | | | | | |
|----|-------------|---------------------|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------|
| 14 | Hb < 9mg/dl | Nutritional anemias | 2819 | DX | UNSPECIFIED DEFICIENCY ANEMIA | ICD-9-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D50 | DX | IRON DEFICIENCY ANEMIA INCLUDES ASIDEROTIC ANEMIA HYPOCHROMIC ANEMIA | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D50.0 | DX | IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC) POSTHEMORRHAGIC ANEMIA (CHRONIC) EXCLUDES1 ACUTE POSTHEMORRHAGIC ANEMIA (D62) CONGENITAL ANEMIA FROM FETAL BLOOD LOSS (P61.3) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D50.1 | DX | SIDEROPENIC DYSPHAGIA KELLY-PATERSON SYNDROME PLUMMER-VINSON SYNDROME | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D50.8 | DX | OTHER IRON DEFICIENCY ANEMIAS IRON DEFICIENCY ANEMIA DUE TO INADEQUATE DIETARY IRON INTAKE | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D50.9 | DX | IRON DEFICIENCY ANEMIA, UNSPECIFIED | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D51 | DX | VITAMIN B12 DEFICIENCY ANEMIA EXCLUDES1 VITAMIN B12 DEFICIENCY (E53.8) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D51.0 | DX | VITAMIN B12 DEFICIENCY ANEMIA DUE TO INTRINSIC FACTOR DEFICIENCY ADDISON ANEMIA BIERMER ANEMIA PERNICIOUS (CONGENITAL) ANEMIA CONGENITAL INTRINSIC FACTOR DEFICIENCY | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D51.1 | DX | VITAMIN B12 DEFICIENCY ANEMIA DUE TO SELECTIVE VITAMIN B12 MALABSORPTION WITH PROTEINURIA IMERSLUND (GRÄSBECK) SYNDROME MEGALOBlastic HEREDITARY ANEMIA | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D51.2 | DX | TRANSCOBALAMIN II DEFICIENCY | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D51.3 | DX | OTHER DIETARY VITAMIN B12 DEFICIENCY ANEMIA VEGAN ANEMIA | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D51.8 | DX | OTHER VITAMIN B12 DEFICIENCY ANEMIAS | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D51.9 | DX | VITAMIN B12 DEFICIENCY ANEMIA, UNSPECIFIED | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D52 | DX | FOLATE DEFICIENCY ANEMIA EXCLUDES1 FOLATE DEFICIENCY WITHOUT ANEMIA (E53.8) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D52.0 | DX | DIETARY FOLATE DEFICIENCY ANEMIA NUTRITIONAL MEGALOBlastic ANEMIA | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D52.1 | DX | DRUG-INDUCED FOLATE DEFICIENCY ANEMIA USE ADDITIONAL CODE FOR ADVERSE EFFECT, IF APPLICABLE, TO IDENTIFY DRUG (T36-T50 WITH FIFTH OR SIXTH CHARACTER 5) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D52.8 | DX | OTHER FOLATE DEFICIENCY ANEMIAS | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D52.9 | DX | FOLATE DEFICIENCY ANEMIA, UNSPECIFIED FOLIC ACID DEFICIENCY ANEMIA NOS | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D53 | DX | OTHER NUTRITIONAL ANEMIAS INCLUDES MEGALOBlastic ANEMIA UNRESPONSIVE TO VITAMIN B12 OR FOLATE THERAPY | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D53.0 | DX | PROTEIN DEFICIENCY ANEMIA AMINO-ACID DEFICIENCY ANEMIA OROTACIDURIC ANEMIA EXCLUDES1 LESCH-NYHAN SYNDROME (E79.1) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D53.1 | DX | OTHER MEGALOBlastic ANEMIAS, NOT ELSEWHERE CLASSIFIED MEGALOBlastic ANEMIA NOS EXCLUDES1 DI GUGLIELMO'S DISEASE (C94.0) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D53.2 | DX | SCORBUTIC ANEMIA EXCLUDES1 SCURVY (E54) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D53.8 | DX | OTHER SPECIFIED NUTRITIONAL ANEMIAS ANEMIA ASSOCIATED WITH DEFICIENCY OF COPPER ANEMIA ASSOCIATED WITH DEFICIENCY OF MOLYBDENUM ANEMIA ASSOCIATED WITH DEFICIENCY OF ZINC EXCLUDES1 NUTRITIONAL DEFICIENCIES WITHOUT ANEMIA, SUCH AS COPPER DEFICIENCY NOS (E61.0) MOLYBDENUM DEFICIENCY NOS (E61.5) ZINC DEFICIENCY NOS (E60) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Nutritional anemias | D53.9 | DX | NUTRITIONAL ANEMIA, UNSPECIFIED SIMPLE CHRONIC ANEMIA EXCLUDES1 ANEMIA NOS (D64.9) | ICD-10-CM | In primary position only, 183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.0 | DX | HEMOLYTIC ANEMIAS (D55-D59) | ICD-10-CM | |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.1 | DX | HEREDITARY SPHEROCYTOSIS | ICD-9-CM | Any position, 183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.2 | DX | HEREDITARY ELLIPTOCYTOSIS | ICD-9-CM | Any position, 183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.3 | DX | ANEMIAS DUE TO DISORDERS OF GLUTATHIONE METABOLISM | ICD-9-CM | Any position, 183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.4 | DX | OTHER HEMOLYTIC ANEMIAS DUE TO ENZYME DEFICIENCY | ICD-9-CM | Any position, 183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.41 | DX | THALASSEMIA, UNSPECIFIED | ICD-9-CM | Any position, 183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | | DX | SICKLE-CELL THALASSEMIA WITHOUT CRISIS | ICD-9-CM | Any position, 183 days before CED |

| | | | | | | | |
|----|-------------|--------------------|--------|----|------------------------------------------------------|-----------|----------------------------------|
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.42 | DX | SICKLE-CELL THALASSEMIA WITH CRISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.43 | DX | ALPHA THALASSEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.44 | DX | BETA THALASSEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.45 | DX | DELTA-BETA THALASSEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.46 | DX | THALASSEMIA MINOR | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.47 | DX | HEMOGLOBIN E-BETA THALASSEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.49 | DX | OTHER THALASSEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.5 | DX | SICKLE-CELL TRAIT | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.6 | DX | SICKLE-CELL DISEASE, UNSPECIFIED | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.61 | DX | HB-SS DISEASE WITHOUT CRISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.62 | DX | HB-SS DISEASE WITH CRISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.63 | DX | SICKLE-CELL/HB-C DISEASE WITHOUT CRISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.64 | DX | SICKLE-CELL/HB-C DISEASE WITH CRISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.68 | DX | OTHER SICKLE-CELL DISEASE WITHOUT CRISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.69 | DX | OTHER SICKLE-CELL DISEASE WITH CRISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.7 | DX | OTHER HEMOGLOBINOPATHIES | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.8 | DX | OTHER SPECIFIED HEREDITARY HEMOLYTIC ANEMIAS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 282.9 | DX | HEREDITARY HEMOLYTIC ANEMIA, UNSPECIFIED | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 283.0 | DX | AUTOIMMUNE HEMOLYTIC ANEMIAS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 283.1 | DX | NON-AUTOIMMUNE HEMOLYTIC ANEMIA, UNSPECIFIED | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 283.11 | DX | HEMOLYTIC-UREMIC SYNDROME | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 283.19 | DX | OTHER NON-AUTOIMMUNE HEMOLYTIC ANEMIAS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 283.2 | DX | HEMOGLOBINURIA DUE TO HEMOLYSIS FROM EXTERNAL CAUSES | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | 283.9 | DX | ACQUIRED HEMOLYTIC ANEMIA, UNSPECIFIED | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56 | DX | THALASSEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.0 | DX | ALPHA THALASSEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.1 | DX | BETA THALASSEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.2 | DX | DELTA-BETA THALASSEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.3 | DX | THALASSEMIA MINOR | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.4 | DX | HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN [HPFH] | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.5 | DX | HEMOGLOBIN E-BETA THALASSEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.8 | DX | OTHER THALASSEMIAS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D56.9 | DX | THALASSEMIA, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |

| | | | | | | | |
|----|-------------|--------------------|---------|----|-------------------------------------------------------------------------------------|-----------|----------------------------------|
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57 | DX | SICKLE-CELL DISORDERS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.0 | DX | HB-SS DISEASE WITH CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.00 | DX | HB-SS DISEASE WITH CRISIS, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.01 | DX | HB-SS DISEASE WITH ACUTE CHEST SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.02 | DX | HB-SS DISEASE WITH SPLENIC SEQUESTRATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.03 | DX | HB-SS DISEASE WITH CEREBRAL VASCULAR INVOLVEMENT | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.04 | DX | HB-SS DISEASE WITH DACTYLITIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.09 | DX | HB-SS DISEASE WITH CRISIS WITH OTHER SPECIFIED COMPLICATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.1 | DX | SICKLE-CELL DISEASE WITHOUT CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.2 | DX | SICKLE-CELL/HB-C DISEASE | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.20 | DX | SICKLE-CELL/HB-C DISEASE WITHOUT CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.21 | DX | SICKLE-CELL/HB-C DISEASE WITH CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.211 | DX | SICKLE-CELL/HB-C DISEASE WITH ACUTE CHEST SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.212 | DX | SICKLE-CELL/HB-C DISEASE WITH SPLENIC SEQUESTRATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.213 | DX | SICKLE-CELL/HB-C DISEASE WITH CEREBRAL VASCULAR INVOLVEMENT | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.214 | DX | SICKLE-CELL/HB-C DISEASE WITH DACTYLITIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.218 | DX | SICKLE-CELL/HB-C DISEASE WITH CRISIS WITH OTHER SPECIFIED COMPLICATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.219 | DX | SICKLE-CELL/HB-C DISEASE WITH CRISIS, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.3 | DX | SICKLE-CELL TRAIT | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.4 | DX | SICKLE-CELL THALASSEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.40 | DX | SICKLE-CELL THALASSEMIA WITHOUT CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.41 | DX | SICKLE-CELL THALASSEMIA, UNSPECIFIED, WITH CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.411 | DX | SICKLE-CELL THALASSEMIA, UNSPECIFIED, WITH ACUTE CHEST SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.412 | DX | SICKLE-CELL THALASSEMIA, UNSPECIFIED, WITH SPLENIC SEQUESTRATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.413 | DX | SICKLE-CELL THALASSEMIA, UNSPECIFIED, WITH CEREBRAL VASCULAR INVOLVEMENT | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.414 | DX | SICKLE-CELL THALASSEMIA, UNSPECIFIED, WITH DACTYLITIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.418 | DX | SICKLE-CELL THALASSEMIA, UNSPECIFIED, WITH CRISIS WITH OTHER SPECIFIED COMPLICATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.419 | DX | SICKLE-CELL THALASSEMIA, UNSPECIFIED, WITH CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.42 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITHOUT CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.43 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITH CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.431 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITH ACUTE CHEST SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.432 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITH SPLENIC SEQUESTRATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.433 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITH CEREBRAL VASCULAR INVOLVEMENT | ICD-10-CM | Any position,183 days before CED |

| | | | | | | | |
|----|-------------|--------------------|---------|----|---------------------------------------------------------------------------------|-----------|----------------------------------|
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.434 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITH DACTYLITIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.438 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITH CRISIS WITH OTHER SPECIFIED COMPLICATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.439 | DX | SICKLE-CELL THALASSEMIA BETA ZERO WITH CRISIS, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.44 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITHOUT CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.45 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITH CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.451 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITH ACUTE CHEST SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.452 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITH SPLENIC SEQUESTRATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.453 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITH CEREBRAL VASCULAR INVOLVEMENT | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.454 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITH DACTYLITIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.458 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITH CRISIS WITH OTHER SPECIFIED COMPLICATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.459 | DX | SICKLE-CELL THALASSEMIA BETA PLUS WITH CRISIS, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.8 | DX | OTHER SICKLE-CELL DISORDERS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.80 | DX | OTHER SICKLE-CELL DISORDERS WITHOUT CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.81 | DX | OTHER SICKLE-CELL DISORDERS WITH CRISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.811 | DX | OTHER SICKLE-CELL DISORDERS WITH ACUTE CHEST SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.812 | DX | OTHER SICKLE-CELL DISORDERS WITH SPLENIC SEQUESTRATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.813 | DX | OTHER SICKLE-CELL DISORDERS WITH CEREBRAL VASCULAR INVOLVEMENT | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.814 | DX | OTHER SICKLE-CELL DISORDERS WITH DACTYLITIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.818 | DX | OTHER SICKLE-CELL DISORDERS WITH CRISIS WITH OTHER SPECIFIED COMPLICATION | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D57.819 | DX | OTHER SICKLE-CELL DISORDERS WITH CRISIS, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D58 | DX | OTHER HEREDITARY HEMOLYTIC ANEMIAS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D58.0 | DX | HEREDITARY SPHEROCYTOSIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D58.1 | DX | HEREDITARY ELLIPTOCYTOSIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D58.2 | DX | OTHER HEMOGLOBINOPATHIES | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D58.8 | DX | OTHER SPECIFIED HEREDITARY HEMOLYTIC ANEMIAS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D58.9 | DX | HEREDITARY HEMOLYTIC ANEMIA, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59 | DX | ACQUIRED HEMOLYTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.0 | DX | DRUG-INDUCED AUTOIMMUNE HEMOLYTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.1 | DX | OTHER AUTOIMMUNE HEMOLYTIC ANEMIAS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.10 | DX | AUTOIMMUNE HEMOLYTIC ANEMIA, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.11 | DX | WARM AUTOIMMUNE HEMOLYTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.12 | DX | COLD AUTOIMMUNE HEMOLYTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.13 | DX | MIXED TYPE AUTOIMMUNE HEMOLYTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |

| | | | | | | | |
|----|-------------|--------------------|--------|----|----------------------------------------------------------------|-----------|----------------------------------|
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.19 | DX | OTHER AUTOIMMUNE HEMOLYTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.2 | DX | DRUG-INDUCED NONAUTOIMMUNE HEMOLYTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.3 | DX | HEMOLYTIC-UREMIC SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.30 | DX | HEMOLYTIC-UREMIC SYNDROME, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.31 | DX | INFECTION-ASSOCIATED HEMOLYTIC-UREMIC SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.32 | DX | HEREDITARY HEMOLYTIC-UREMIC SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.39 | DX | OTHER HEMOLYTIC-UREMIC SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.4 | DX | OTHER NONAUTOIMMUNE HEMOLYTIC ANEMIAS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.5 | DX | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.6 | DX | HEMOGLOBINURIA DUE TO HEMOLYSIS FROM OTHER EXTERNAL CAUSES | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.8 | DX | OTHER ACQUIRED HEMOLYTIC ANEMIAS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Haemolytic anemias | D59.9 | DX | ACQUIRED HEMOLYTIC ANEMIA, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.01 | DX | CONSTITUTIONAL RED BLOOD CELL APLASIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.09 | DX | OTHER CONSTITUTIONAL APLASTIC ANEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.11 | DX | ANTINEOPLASTIC CHEMOTHERAPY INDUCED PANCYTOPENIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.12 | DX | OTHER DRUG-INDUCED PANCYTOPENIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.19 | DX | OTHER PANCYTOPENIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.2 | DX | MYELOPHTHISIS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.81 | DX | RED CELL APLASIA (ACQUIRED)(ADULT)(WITH THYMOMA) | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.89 | DX | OTHER SPECIFIED APLASTIC ANEMIAS | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | 284.9 | DX | APLASTIC ANEMIA, UNSPECIFIED | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D60 | DX | ACQUIRED PURE RED CELL APLASIA [ERYTHROBLASTOPENIA] | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D60.0 | DX | CHRONIC ACQUIRED PURE RED CELL APLASIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D60.1 | DX | TRANSIENT ACQUIRED PURE RED CELL APLASIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D60.8 | DX | OTHER ACQUIRED PURE RED CELL APLASIAS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D60.9 | DX | ACQUIRED PURE RED CELL APLASIA, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61 | DX | OTHER APLASTIC ANEMIAS AND OTHER BONE MARROW FAILURE SYNDROMES | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.0 | DX | CONSTITUTIONAL APLASTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.01 | DX | CONSTITUTIONAL (PURE) RED BLOOD CELL APLASIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.02 | DX | SHWACHMAN-DIAMOND SYNDROME | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.03 | DX | FANCONI ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.09 | DX | OTHER CONSTITUTIONAL APLASTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.1 | DX | DRUG-INDUCED APLASTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |

| | | | | | | | |
|----|-------------|--------------------------------|---------|----|--------------------------------------------------------------------------|-----------|----------------------------------------------|
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.2 | DX | APLASTIC ANEMIA DUE TO OTHER EXTERNAL AGENTS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.3 | DX | IDIOPATHIC APLASTIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.8 | DX | OTHER SPECIFIED APLASTIC ANEMIAS AND OTHER BONE MARROW FAILURE SYNDROMES | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.81 | DX | PANCYTOPENIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.810 | DX | ANTINEOPLASTIC CHEMOTHERAPY INDUCED PANCYTOPENIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.811 | DX | OTHER DRUG-INDUCED PANCYTOPENIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.818 | DX | OTHER PANCYTOPENIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.82 | DX | MYELOPHTHISIS | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.89 | DX | OTHER SPECIFIED APLASTIC ANEMIAS AND OTHER BONE MARROW FAILURE SYNDROMES | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Aplastic anemia | D61.9 | DX | APLASTIC ANEMIA, UNSPECIFIED | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Hemorrhagic anemia | 285.1 | DX | ACUTE POSTHEMORRHAGIC ANEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Hemorrhagic anemia | D62 | DX | ACUTE POSTHEMORRHAGIC ANEMIA | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Anemia due to chronic diseases | 285.21 | DX | ANEMIA IN CHRONIC KIDNEY DISEASE | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Anemia due to chronic diseases | 285.22 | DX | ANEMIA IN NEOPLASTIC DISEASE | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Anemia due to chronic diseases | 285.29 | DX | ANEMIA OF OTHER CHRONIC DISEASE | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Anemia due to chronic diseases | D63 | DX | ANEMIA IN CHRONIC DISEASES CLASSIFIED ELSEWHERE | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Anemia due to chronic diseases | D63.1 | DX | ANEMIA IN CHRONIC KIDNEY DISEASE | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Anemia due to chronic diseases | D63.8 | DX | ANEMIA IN OTHER CHRONIC DISEASES CLASSIFIED ELSEWHERE | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Cancer related anemia | 285.3 | DX | ANTINEOPLASTIC CHEMOTHERAPY INDUCED ANEMIA | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Cancer related anemia | 285.22 | DX | ANEMIA IN NEOPLASTIC DISEASE | ICD-9-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Cancer related anemia | D63.0 | DX | ANEMIA IN NEOPLASTIC DISEASE | ICD-10-CM | Any position,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | 285.0 | DX | SIDEROBLASTIC ANEMIA | ICD-9-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | 285.8 | DX | OTHER SPECIFIED ANEMIAS | ICD-9-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | 285.9 | DX | ANEMIA, UNSPECIFIED | ICD-9-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.0 | DX | HEREDITARY SIDEROBLASTIC ANEMIA | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.1 | DX | SECONDARY SIDEROBLASTIC ANEMIA DUE TO DISEASE | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.2 | DX | SECONDARY SIDEROBLASTIC ANEMIA DUE TO DRUGS AND TOXINS | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.3 | DX | OTHER SIDEROBLASTIC ANEMIAS | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.4 | DX | CONGENITAL DYSERYTHROPOIETIC ANEMIA | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.8 | DX | OTHER SPECIFIED ANEMIAS | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.81 | DX | ANEMIA DUE TO ANTINEOPLASTIC CHEMOTHERAPY | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.89 | DX | OTHER SPECIFIED ANEMIAS | ICD-10-CM | In primary position only,183 days before CED |
| 14 | Hb < 9mg/dl | Other anemia | D64.9 | DX | ANEMIA, UNSPECIFIED | ICD-10-CM | In primary position only,183 days before CED |

| | | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|----|-------------------------------------------------------------------------------------------|-----------|----------------------------------|
| 14 | Hb < 9mg/dl | Transfusion | 99.00 | PX | PERIOPERATIVE AUTOLOGOUS TRANSFUSION OF WHOLE BLOOD OR BLOOD COMPONENTS | ICD-9-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30233H0 | PX | TRANSFUSION OF AUTOLOGOUS WHOLE BLOOD INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30233N0 | PX | TRANSFUSION OF AUTOLOGOUS RED BLOOD CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30243H0 | PX | TRANSFUSION OF AUTOLOGOUS WHOLE BLOOD INTO CENTRAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30243N0 | PX | TRANSFUSION OF AUTOLOGOUS RED BLOOD CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 99.01 | PX | EXCHANGE TRANSFUSION | ICD-9-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30233H1 | PX | TRANSFUSION OF NONAUTOLOGOUS WHOLE BLOOD INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30243H1 | PX | TRANSFUSION OF NONAUTOLOGOUS WHOLE BLOOD INTO CENTRAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 99.02 | PX | TRANSFUSION OF PREVIOUSLY COLLECTED AUTOLOGOUS BLOOD | ICD-9-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30233W0 | PX | TRANSFUSION OF AUTOLOGOUS FACTOR IX INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30243W0 | PX | TRANSFUSION OF AUTOLOGOUS FACTOR IX INTO CENTRAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 99.03 | PX | OTHER TRANSFUSION OF WHOLE BLOOD | ICD-9-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 99.04 | PX | TRANSFUSION OF PACKED CELLS | ICD-9-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30233N1 | PX | TRANSFUSION OF NONAUTOLOGOUS RED BLOOD CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30233P1 | PX | TRANSFUSION OF NONAUTOLOGOUS FROZEN RED CELLS INTO PERIPHERAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30243N1 | PX | TRANSFUSION OF NONAUTOLOGOUS RED BLOOD CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 14 | Hb < 9mg/dl | Transfusion | 30243P1 | PX | TRANSFUSION OF NONAUTOLOGOUS FROZEN RED CELLS INTO CENTRAL VEIN, PERCUTANEOUS APPROACH | ICD-10-CM | Any position, 91 days before CED |
| 15 | History of ketoacidosis | | 2491 | DX | SECONDARY DIABETES MELLITUS WITH KETOACIDOSIS | ICD-9-CM | |
| 15 | History of ketoacidosis | | 2491.10 | DX | SECONDARY DIABETES MELLITUS WITH KETOACIDOSIS, NOT STATED AS UNCONTROLLED, OR UNSPECIFIED | ICD-9-CM | |
| 15 | History of ketoacidosis | | 2491.11 | DX | SECONDARY DIABETES MELLITUS WITH KETOACIDOSIS, UNCONTROLLED | ICD-9-CM | |
| 15 | History of ketoacidosis | | 250.10 | DX | DIABETES WITH KETOACIDOSIS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED | ICD-9-CM | |
| 15 | History of ketoacidosis | | 250.11 | DX | DIABETES WITH KETOACIDOSIS, TYPE I [JUVENILE TYPE], NOT STATED AS UNCONTROLLED | ICD-9-CM | |
| 15 | History of ketoacidosis | | 250.12 | DX | DIABETES WITH KETOACIDOSIS, TYPE II OR UNSPECIFIED TYPE, UNCONTROLLED | ICD-9-CM | |
| 15 | History of ketoacidosis | | 250.13 | DX | DIABETES WITH KETOACIDOSIS, TYPE I [JUVENILE TYPE], UNCONTROLLED | ICD-9-CM | |
| 15 | History of ketoacidosis | | E08.10 | DX | DIABETES MELLITUS DUE TO UNDERLYING CONDITION WITH KETOACIDOSIS WITHOUT COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E08.11 | DX | DIABETES MELLITUS DUE TO UNDERLYING CONDITION WITH KETOACIDOSIS WITH COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E09.10 | DX | DRUG OR CHEMICAL INDUCED DIABETES MELLITUS WITH KETOACIDOSIS WITHOUT COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E09.11 | DX | DRUG OR CHEMICAL INDUCED DIABETES MELLITUS WITH KETOACIDOSIS WITH COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E10.10 | DX | TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS WITHOUT COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E10.11 | DX | TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS WITH COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E11.10 | DX | TYPE 2 DIABETES MELLITUS WITH KETOACIDOSIS WITHOUT COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E11.11 | DX | TYPE 2 DIABETES MELLITUS WITH KETOACIDOSIS WITH COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E13.10 | DX | OTHER SPECIFIED DIABETES MELLITUS WITH KETOACIDOSIS WITHOUT COMA | ICD-10-CM | |
| 15 | History of ketoacidosis | | E13.11 | DX | OTHER SPECIFIED DIABETES MELLITUS WITH KETOACIDOSIS WITH COMA | ICD-10-CM | |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.2 | PX | CRANIOTOMY AND CRANIECTOMY | ICD-9-CM | |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.20 | PX | CRANIAL IMPLANTATION OR REPLACEMENT OF NEUROSTIMULATOR PULSE GENERATOR | ICD-9-CM | |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.21 | PX | INCISION AND DRAINAGE OF CRANIAL SINUS | ICD-9-CM | |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.22 | PX | REMOVAL OF INTRACRANIAL NEUROSTIMULATOR LEAD(S) | ICD-9-CM | |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.23 | PX | REOPENING OF CRANIOTOMY SITE | ICD-9-CM | |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.24 | PX | OTHER CRANIOTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.25 | PX | OTHER CRANIECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.26 | PX | INSERTION OF CATHETER(S) INTO CRANIAL CAVITY OR TISSUE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.27 | PX | REMOVAL OF CATHETER(S) FROM CRANIAL CAVITY OR TISSUE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.28 | PX | PLACEMENT OF INTRACEREBRAL CATHETER(S) VIA BURR HOLE(S) | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.29 | PX | REMOVAL OF CRANIAL NEUROSTIMULATOR PULSE GENERATOR | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.3 | PX | INCISION OF BRAIN AND CEREBRAL MENINGES | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.31 | PX | INCISION OF CEREBRAL MENINGES | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.32 | PX | LOBOTOMY AND TRACTOTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.39 | PX | OTHER INCISION OF BRAIN | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.5 | PX | OTHER EXCISION OR DESTRUCTION OF BRAIN AND MENINGES | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.51 | PX | EXCISION OF LESION OR TISSUE OF CEREBRAL MENINGES | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.52 | PX | HEMISPHERECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.53 | PX | LOBECTOMY OF BRAIN | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 01.59 | PX | OTHER EXCISION OR DESTRUCTION OF LESION OR TISSUE OF BRAIN | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0N500ZZ | PX | DESTRUCTION OF SKULL, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|-----------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0N964ZZ | PX | DRAINAGE OF LEFT TEMPORAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0N9700Z | PX | DRAINAGE OF OCCIPITAL BONE WITH DRAINAGE DEVICE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0N970ZZ | PX | DRAINAGE OF OCCIPITAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0N9740Z | PX | DRAINAGE OF OCCIPITAL BONE WITH DRAINAGE DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0N974ZZ | PX | DRAINAGE OF OCCIPITAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB00ZZ | PX | EXCISION OF SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB03ZZ | PX | EXCISION OF SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB04ZZ | PX | EXCISION OF SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB10ZZ | PX | EXCISION OF FRONTAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB13ZZ | PX | EXCISION OF FRONTAL BONE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB14ZZ | PX | EXCISION OF FRONTAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB30ZZ | PX | EXCISION OF RIGHT PARIETAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB33ZZ | PX | EXCISION OF RIGHT PARIETAL BONE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB34ZZ | PX | EXCISION OF RIGHT PARIETAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB40ZZ | PX | EXCISION OF LEFT PARIETAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0NB43ZZ | PX | EXCISION OF LEFT PARIETAL BONE, PERCUTANEOUS APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|----------------------------------------------------------------------------------|-----------|
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC40ZZ | PX | EXTIRPATION OF MATTER FROM LEFT PARIETAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC43ZZ | PX | EXTIRPATION OF MATTER FROM LEFT PARIETAL BONE, PERCUTANEOUS APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC44ZZ | PX | EXTIRPATION OF MATTER FROM LEFT PARIETAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC50ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT TEMPORAL BONE, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC53ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT TEMPORAL BONE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC54ZZ | PX | EXTIRPATION OF MATTER FROM RIGHT TEMPORAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC60ZZ | PX | EXTIRPATION OF MATTER FROM LEFT TEMPORAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC63ZZ | PX | EXTIRPATION OF MATTER FROM LEFT TEMPORAL BONE, PERCUTANEOUS APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC64ZZ | PX | EXTIRPATION OF MATTER FROM LEFT TEMPORAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC70ZZ | PX | EXTIRPATION OF MATTER FROM OCCIPITAL BONE, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC73ZZ | PX | EXTIRPATION OF MATTER FROM OCCIPITAL BONE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONC74ZZ | PX | EXTIRPATION OF MATTER FROM OCCIPITAL BONE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONH00MZ | PX | INSERTION OF BONE GROWTH STIMULATOR INTO SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONH00NZ | PX | INSERTION OF NEUROSTIMULATOR GENERATOR INTO SKULL, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONH03MZ | PX | INSERTION OF BONE GROWTH STIMULATOR INTO SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONH04MZ | PX | INSERTION OF BONE GROWTH STIMULATOR INTO SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|----------------------------------------------------------------------------------|-----------|
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP000Z | PX | REMOVAL OF DRAINAGE DEVICE FROM SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP004Z | PX | REMOVAL OF INTERNAL FIXATION DEVICE FROM SKULL, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP005Z | PX | REMOVAL OF EXTERNAL FIXATION DEVICE FROM SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP007Z | PX | REMOVAL OF AUTOLOGOUS TISSUE SUBSTITUTE FROM SKULL, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP00KZ | PX | REMOVAL OF NONAUTOLOGOUS TISSUE SUBSTITUTE FROM SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP00MZ | PX | REMOVAL OF BONE GROWTH STIMULATOR FROM SKULL, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP00NZ | PX | REMOVAL OF NEUROSTIMULATOR GENERATOR FROM SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP00SZ | PX | REMOVAL OF HEARING DEVICE FROM SKULL, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP030Z | PX | REMOVAL OF DRAINAGE DEVICE FROM SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP034Z | PX | REMOVAL OF INTERNAL FIXATION DEVICE FROM SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP037Z | PX | REMOVAL OF AUTOLOGOUS TISSUE SUBSTITUTE FROM SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP03KZ | PX | REMOVAL OF NONAUTOLOGOUS TISSUE SUBSTITUTE FROM SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP03MZ | PX | REMOVAL OF BONE GROWTH STIMULATOR FROM SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP03SZ | PX | REMOVAL OF HEARING DEVICE FROM SKULL, PERCUTANEOUS APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP040Z | PX | REMOVAL OF DRAINAGE DEVICE FROM SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP044Z | PX | REMOVAL OF INTERNAL FIXATION DEVICE FROM SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|-----------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP047Z | PX | REMOVAL OF AUTOLOGOUS TISSUE SUBSTITUTE FROM SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP04KZ | PX | REMOVAL OF NONAUTOLOGOUS TISSUE SUBSTITUTE FROM SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP04MZ | PX | REMOVAL OF BONE GROWTH STIMULATOR FROM SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP04SZ | PX | REMOVAL OF HEARING DEVICE FROM SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP0X4Z | PX | REMOVAL OF INTERNAL FIXATION DEVICE FROM SKULL, EXTERNAL APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP0XMZ | PX | REMOVAL OF BONE GROWTH STIMULATOR FROM SKULL, EXTERNAL APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONP0XSZ | PX | REMOVAL OF HEARING DEVICE FROM SKULL, EXTERNAL APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONT10ZZ | PX | RESECTION OF FRONTAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONT30ZZ | PX | RESECTION OF RIGHT PARIETAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONT40ZZ | PX | RESECTION OF LEFT PARIETAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONT50ZZ | PX | RESECTION OF RIGHT TEMPORAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONT60ZZ | PX | RESECTION OF LEFT TEMPORAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONT70ZZ | PX | RESECTION OF OCCIPITAL BONE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONW000Z | PX | REVISION OF DRAINAGE DEVICE IN SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONW004Z | PX | REVISION OF INTERNAL FIXATION DEVICE IN SKULL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | ONW005Z | PX | REVISION OF EXTERNAL FIXATION DEVICE IN SKULL, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0NW045Z PX | REVISION OF EXTERNAL FIXATION DEVICE IN SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0NW047Z PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0NW04JZ PX | REVISION OF SYNTHETIC SUBSTITUTE IN SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0NW04KZ PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0NW04MZ PX | REVISION OF BONE GROWTH STIMULATOR IN SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0NW04SZ PX | REVISION OF HEARING DEVICE IN SKULL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0W9100Z PX | DRAINAGE OF CRANIAL CAVITY WITH DRAINAGE DEVICE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0W910ZZ PX | DRAINAGE OF CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0W9130Z PX | DRAINAGE OF CRANIAL CAVITY WITH DRAINAGE DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0W913ZZ PX | DRAINAGE OF CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0W9140Z PX | DRAINAGE OF CRANIAL CAVITY WITH DRAINAGE DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0W914ZZ PX | DRAINAGE OF CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0WC10ZZ PX | EXTIRPATION OF MATTER FROM CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0WC13ZZ PX | EXTIRPATION OF MATTER FROM CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0WC14ZZ PX | EXTIRPATION OF MATTER FROM CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Craniotomy | 0WH103Z PX | INSERTION OF INFUSION DEVICE INTO CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WH10YZ | PX | INSERTION OF OTHER DEVICE INTO CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WH133Z | PX | INSERTION OF INFUSION DEVICE INTO CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WH13YZ | PX | INSERTION OF OTHER DEVICE INTO CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WH143Z | PX | INSERTION OF INFUSION DEVICE INTO CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WH14YZ | PX | INSERTION OF OTHER DEVICE INTO CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WJ10ZZ | PX | INSPECTION OF CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP100Z | PX | REMOVAL OF DRAINAGE DEVICE FROM CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP101Z | PX | REMOVAL OF RADIOACTIVE ELEMENT FROM CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP103Z | PX | REMOVAL OF INFUSION DEVICE FROM CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP10JZ | PX | REMOVAL OF SYNTHETIC SUBSTITUTE FROM CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP10YZ | PX | REMOVAL OF OTHER DEVICE FROM CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP130Z | PX | REMOVAL OF DRAINAGE DEVICE FROM CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP131Z | PX | REMOVAL OF RADIOACTIVE ELEMENT FROM CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP133Z | PX | REMOVAL OF INFUSION DEVICE FROM CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP13JZ | PX | REMOVAL OF SYNTHETIC SUBSTITUTE FROM CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 0WP13YZ | PX | REMOVAL OF OTHER DEVICE FROM CRANIAL CAVITY, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWP140Z | PX | REMOVAL OF DRAINAGE DEVICE FROM CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWP141Z | PX | REMOVAL OF RADIOACTIVE ELEMENT FROM CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWP143Z | PX | REMOVAL OF INFUSION DEVICE FROM CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWP14JZ | PX | REMOVAL OF SYNTHETIC SUBSTITUTE FROM CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWP14YZ | PX | REMOVAL OF OTHER DEVICE FROM CRANIAL CAVITY, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWP1X3Z | PX | REMOVAL OF INFUSION DEVICE FROM CRANIAL CAVITY, EXTERNAL APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWQF0ZZ | PX | REPAIR ABDOMINAL WALL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWQF3ZZ | PX | REPAIR ABDOMINAL WALL, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWQF4ZZ | PX | REPAIR ABDOMINAL WALL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWUF07Z | PX | SUPPLEMENT ABDOMINAL WALL WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWUF0JZ | PX | SUPPLEMENT ABDOMINAL WALL WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWUF0KZ | PX | SUPPLEMENT ABDOMINAL WALL WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWUF47Z | PX | SUPPLEMENT ABDOMINAL WALL WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWUF4JZ | PX | SUPPLEMENT ABDOMINAL WALL WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWUF4KZ | PX | SUPPLEMENT ABDOMINAL WALL WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | OWW100Z | PX | REVISION OF DRAINAGE DEVICE IN CRANIAL CAVITY, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 005D3ZZ | PX | DESTRUCTION OF MEDULLA OBLONGATA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 005D4ZZ | PX | DESTRUCTION OF MEDULLA OBLONGATA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00800ZZ | PX | DIVISION OF BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00803ZZ | PX | DIVISION OF BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00804ZZ | PX | DIVISION OF BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00870ZZ | PX | DIVISION OF CEREBRAL HEMISPHERE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00873ZZ | PX | DIVISION OF CEREBRAL HEMISPHERE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00874ZZ | PX | DIVISION OF CEREBRAL HEMISPHERE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009000Z | PX | DRAINAGE OF BRAIN WITH DRAINAGE DEVICE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00900ZZ | PX | DRAINAGE OF BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009030Z | PX | DRAINAGE OF BRAIN WITH DRAINAGE DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00903ZZ | PX | DRAINAGE OF BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009040Z | PX | DRAINAGE OF BRAIN WITH DRAINAGE DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00904ZZ | PX | DRAINAGE OF BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009100Z | PX | DRAINAGE OF CEREBRAL MENINGES WITH DRAINAGE DEVICE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00910ZZ | PX | DRAINAGE OF CEREBRAL MENINGES, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009D0ZZ | PX | DRAINAGE OF MEDULLA OBLONGATA, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009D30Z | PX | DRAINAGE OF MEDULLA OBLONGATA WITH DRAINAGE DEVICE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009D3ZZ | PX | DRAINAGE OF MEDULLA OBLONGATA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009D40Z | PX | DRAINAGE OF MEDULLA OBLONGATA WITH DRAINAGE DEVICE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 009D4ZZ | PX | DRAINAGE OF MEDULLA OBLONGATA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B00ZZ | PX | EXCISION OF BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B03ZZ | PX | EXCISION OF BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B04ZZ | PX | EXCISION OF BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B10ZZ | PX | EXCISION OF CEREBRAL MENINGES, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B13ZZ | PX | EXCISION OF CEREBRAL MENINGES, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B14ZZ | PX | EXCISION OF CEREBRAL MENINGES, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B20ZZ | PX | EXCISION OF DURA MATER, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B23ZZ | PX | EXCISION OF DURA MATER, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B24ZZ | PX | EXCISION OF DURA MATER, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B60ZZ | PX | EXCISION OF CEREBRAL VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B63ZZ | PX | EXCISION OF CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B64ZZ | PX | EXCISION OF CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B70ZZ | PX | EXCISION OF CEREBRAL HEMISPHERE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B73ZZ | PX | EXCISION OF CEREBRAL HEMISPHERE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00B74ZZ | PX | EXCISION OF CEREBRAL HEMISPHERE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BB0ZZ | PX | EXCISION OF PONS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BB3ZZ | PX | EXCISION OF PONS, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BB4ZZ | PX | EXCISION OF PONS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BC0ZZ | PX | EXCISION OF CEREBELLUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BC3ZZ | PX | EXCISION OF CEREBELLUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BC4ZZ | PX | EXCISION OF CEREBELLUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BD0ZZ | PX | EXCISION OF MEDULLA OBLONGATA, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BD3ZZ | PX | EXCISION OF MEDULLA OBLONGATA, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00BD4ZZ | PX | EXCISION OF MEDULLA OBLONGATA, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00C00ZZ | PX | EXTIRPATION OF MATTER FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00C03ZZ | PX | EXTIRPATION OF MATTER FROM BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00C04ZZ | PX | EXTIRPATION OF MATTER FROM BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00H632Z | PX | INSERTION OF MONITORING DEVICE INTO CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00H633Z | PX | INSERTION OF INFUSION DEVICE INTO CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00H63YZ | PX | INSERTION OF OTHER DEVICE INTO CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00H642Z | PX | INSERTION OF MONITORING DEVICE INTO CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00H643Z | PX | INSERTION OF INFUSION DEVICE INTO CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00H64YZ | PX | INSERTION OF OTHER DEVICE INTO CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00J00ZZ | PX | INSPECTION OF BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P000Z | PX | REMOVAL OF DRAINAGE DEVICE FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P002Z | PX | REMOVAL OF MONITORING DEVICE FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P003Z | PX | REMOVAL OF INFUSION DEVICE FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P007Z | PX | REMOVAL OF AUTOLOGOUS TISSUE SUBSTITUTE FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P00JZ | PX | REMOVAL OF SYNTHETIC SUBSTITUTE FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P00KZ | PX | REMOVAL OF NONAUTOLOGOUS TISSUE SUBSTITUTE FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P00MZ | PX | REMOVAL OF NEUROSTIMULATOR LEAD FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P00YZ | PX | REMOVAL OF OTHER DEVICE FROM BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00P030Z | PX | REMOVAL OF DRAINAGE DEVICE FROM BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00T70ZZ | PX | RESECTION OF CEREBRAL HEMISPHERE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00T73ZZ | PX | RESECTION OF CEREBRAL HEMISPHERE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00T74ZZ | PX | RESECTION OF CEREBRAL HEMISPHERE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W000Z | PX | REVISION OF DRAINAGE DEVICE IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W002Z | PX | REVISION OF MONITORING DEVICE IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W003Z | PX | REVISION OF INFUSION DEVICE IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W007Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W00JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W00KZ | PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W00MZ | PX | REVISION OF NEUROSTIMULATOR LEAD IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W00YZ | PX | REVISION OF OTHER DEVICE IN BRAIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W030Z | PX | REVISION OF DRAINAGE DEVICE IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W032Z | PX | REVISION OF MONITORING DEVICE IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W033Z | PX | REVISION OF INFUSION DEVICE IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W037Z | PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W03JZ | PX | REVISION OF SYNTHETIC SUBSTITUTE IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------------|-----------|
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W03KZ PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W03MZ PX | REVISION OF NEUROSTIMULATOR LEAD IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W03YZ PX | REVISION OF OTHER DEVICE IN BRAIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W04OZ PX | REVISION OF DRAINAGE DEVICE IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W042Z PX | REVISION OF MONITORING DEVICE IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W043Z PX | REVISION OF INFUSION DEVICE IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W047Z PX | REVISION OF AUTOLOGOUS TISSUE SUBSTITUTE IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W04JZ PX | REVISION OF SYNTHETIC SUBSTITUTE IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W04KZ PX | REVISION OF NONAUTOLOGOUS TISSUE SUBSTITUTE IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W04MZ PX | REVISION OF NEUROSTIMULATOR LEAD IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W04YZ PX | REVISION OF OTHER DEVICE IN BRAIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W60OZ PX | REVISION OF DRAINAGE DEVICE IN CEREBRAL VENTRICLE, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W602Z PX | REVISION OF MONITORING DEVICE IN CEREBRAL VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W603Z PX | REVISION OF INFUSION DEVICE IN CEREBRAL VENTRICLE, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W60MZ PX | REVISION OF NEUROSTIMULATOR LEAD IN CEREBRAL VENTRICLE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W60YZ PX | REVISION OF OTHER DEVICE IN CEREBRAL VENTRICLE, OPEN APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W630Z | PX | REVISION OF DRAINAGE DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W632Z | PX | REVISION OF MONITORING DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W633Z | PX | REVISION OF INFUSION DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W63MZ | PX | REVISION OF NEUROSTIMULATOR LEAD IN CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W63YZ | PX | REVISION OF OTHER DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W640Z | PX | REVISION OF DRAINAGE DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W642Z | PX | REVISION OF MONITORING DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W643Z | PX | REVISION OF INFUSION DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W64MZ | PX | REVISION OF NEUROSTIMULATOR LEAD IN CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Craniotomy | 00W64YZ | PX | REVISION OF OTHER DEVICE IN CEREBRAL VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.3 | PX | LAPAROSCOPIC PARTIAL EXCISION OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.31 | PX | LAPAROSCOPIC MULTIPLE SEGMENTAL RESECTION OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.32 | PX | LAPAROSCOPIC CECECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.33 | PX | LAPAROSCOPIC RIGHT HEMICOLECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.34 | PX | LAPAROSCOPIC RESECTION OF TRANSVERSE COLON | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.35 | PX | LAPAROSCOPIC LEFT HEMICOLECTOMY | ICD-9-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------|----|--------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.36 | PX | LAPAROSCOPIC SIGMOIDECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 51.2 | PX | CHOLECYSTECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 51.21 | PX | OTHER PARTIAL CHOLECYSTECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 51.22 | PX | CHOLECYSTECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 51.23 | PX | LAPAROSCOPIC CHOLECYSTECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 51.24 | PX | LAPAROSCOPIC PARTIAL CHOLECYSTECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0F540ZZ | PX | DESTRUCTION OF GALLBLADDER, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0F543ZZ | PX | DESTRUCTION OF GALLBLADDER, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0F544ZZ | PX | DESTRUCTION OF GALLBLADDER, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0F548ZZ | PX | DESTRUCTION OF GALLBLADDER, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FB40ZZ | PX | EXCISION OF GALLBLADDER, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FB43ZZ | PX | EXCISION OF GALLBLADDER, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FB44ZZ | PX | EXCISION OF GALLBLADDER, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FB48ZZ | PX | EXCISION OF GALLBLADDER, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FT40ZZ | PX | RESECTION OF GALLBLADDER, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FT44ZZ | PX | RESECTION OF GALLBLADDER, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------|----|----------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FTG0ZZ | PX | RESECTION OF PANCREAS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Cholecystectomy | 0FTG4ZZ | PX | RESECTION OF PANCREAS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 42.4 | PX | EXCISION OF ESOPHAGUS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 42.4 | PX | ESOPHAGECTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 42.41 | PX | PARTIAL ESOPHAGECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 42.42 | PX | TOTAL ESOPHAGECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 42.9 | PX | OTHER OPERATIONS ON ESOPHAGUS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 42.99 | PX | OTHER OPERATIONS ON ESOPHAGUS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DB50ZZ | PX | EXCISION OF ESOPHAGUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DB53ZZ | PX | EXCISION OF ESOPHAGUS, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DB57ZZ | PX | EXCISION OF ESOPHAGUS, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT50ZZ | PX | RESECTION OF ESOPHAGUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT54ZZ | PX | RESECTION OF ESOPHAGUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT57ZZ | PX | RESECTION OF ESOPHAGUS, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT58ZZ | PX | RESECTION OF ESOPHAGUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DB10ZZ | PX | EXCISION OF UPPER ESOPHAGUS, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|---------|----|----------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT30ZZ | PX | RESECTION OF LOWER ESOPHAGUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT34ZZ | PX | RESECTION OF LOWER ESOPHAGUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT37ZZ | PX | RESECTION OF LOWER ESOPHAGUS, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DT38ZZ | PX | RESECTION OF LOWER ESOPHAGUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DQ50ZZ | PX | REPAIR ESOPHAGUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DQ53ZZ | PX | REPAIR ESOPHAGUS, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DQ54ZZ | PX | REPAIR ESOPHAGUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DQ57ZZ | PX | REPAIR ESOPHAGUS, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Oesophagectomy | 0DQ58ZZ | PX | REPAIR ESOPHAGUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 17.39 | PX | OTHER LAPAROSCOPIC PARTIAL EXCISION OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.41 | PX | EXCISION OF LESION OR TISSUE OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.42 | PX | ENDOSCOPIC POLYPECTOMY OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.5 | PX | ISOLATION OF INTESTINAL SEGMENT, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.52 | PX | ISOLATION OF SEGMENT OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 44.61 | PX | SUTURE OF LACERATION OF STOMACH | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.7 | PX | OPEN AND OTHER PARTIAL EXCISION OF LARGE INTESTINE | ICD-9-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|----|----------------------------------------------------------------|----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.71 | PX | OPEN AND OTHER MULTIPLE SEGMENTAL RESECTION OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.72 | PX | OPEN AND OTHER CECECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.73 | PX | OPEN AND OTHER RIGHT HEMICOLECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.74 | PX | OPEN AND OTHER RESECTION OF TRANSVERSE COLON | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.75 | PX | OPEN AND OTHER LEFT HEMICOLECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.76 | PX | OPEN AND OTHER SIGMOIDECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.79 | PX | OTHER AND UNSPECIFIED PARTIAL EXCISION OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.8 | PX | TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.9 | PX | INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.92 | PX | ANASTOMOSIS OF SMALL INTESTINE TO RECTAL STUMP | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.9 | PX | INTESTINAL ANASTOMOSIS, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.91 | PX | SMALL-TO-SMALL INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.93 | PX | OTHER SMALL-TO-LARGE INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.94 | PX | LARGE-TO-LARGE INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.95 | PX | ANASTOMOSIS TO ANUS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.81 | PX | LAPAROSCOPIC TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|----------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.82 | PX | OPEN TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 45.83 | PX | OTHER AND UNSPECIFIED TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 46.04 | PX | RESECTION OF EXTERIORIZED SEGMENT OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 46.71 | PX | SUTURE OF LACERATION OF DUODENUM | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 46.73 | PX | SUTURE OF LACERATION OF SMALL INTESTINE; EXCEPT DUODENUM | |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 48.61 | PX | TRANSSACRAL RECTOSIGMOIDECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ90ZZ | PX | REPAIR DUODENUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ93ZZ | PX | REPAIR DUODENUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ94ZZ | PX | REPAIR DUODENUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ97ZZ | PX | REPAIR DUODENUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ98ZZ | PX | REPAIR DUODENUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ80ZZ | PX | REPAIR SMALL INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ83ZZ | PX | REPAIR SMALL INTESTINE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ84ZZ | PX | REPAIR SMALL INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ87ZZ | PX | REPAIR SMALL INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ88ZZ | PX | REPAIR SMALL INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|-----------------------------------------------------------------------------------|-----------|
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD1H8ZP | PX | BYPASS CECUM TO RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD190Z9 | PX | BYPASS DUODENUM TO DUODENUM, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD190ZA | PX | BYPASS DUODENUM TO JEJUNUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD190ZB | PX | BYPASS DUODENUM TO ILEUM, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD190ZL | PX | BYPASS DUODENUM TO TRANSVERSE COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD194Z9 | PX | BYPASS DUODENUM TO DUODENUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD194ZA | PX | BYPASS DUODENUM TO JEJUNUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD194ZB | PX | BYPASS DUODENUM TO ILEUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD194ZL | PX | BYPASS DUODENUM TO TRANSVERSE COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD198Z9 | PX | BYPASS DUODENUM TO DUODENUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD198ZA | PX | BYPASS DUODENUM TO JEJUNUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD198ZB | PX | BYPASS DUODENUM TO ILEUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD198ZL | PX | BYPASS DUODENUM TO TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD1A0ZA | PX | BYPASS JEJUNUM TO JEJUNUM, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD1A0ZB | PX | BYPASS JEJUNUM TO ILEUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | OD1A0ZH | PX | BYPASS JEJUNUM TO CECUM, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|----------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZK | PX | BYPASS JEJUNUM TO ASCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZL | PX | BYPASS JEJUNUM TO TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZM | PX | BYPASS JEJUNUM TO DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZN | PX | BYPASS JEJUNUM TO SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZP | PX | BYPASS JEJUNUM TO RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZB | PX | BYPASS ILEUM TO ILEUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZH | PX | BYPASS ILEUM TO CECUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZK | PX | BYPASS ILEUM TO ASCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZL | PX | BYPASS ILEUM TO TRANSVERSE COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZM | PX | BYPASS ILEUM TO DESCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZN | PX | BYPASS ILEUM TO SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZP | PX | BYPASS ILEUM TO RECTUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZB | PX | BYPASS ILEUM TO ILEUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZH | PX | BYPASS ILEUM TO CECUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZK | PX | BYPASS ILEUM TO ASCENDING COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZL | PX | BYPASS ILEUM TO TRANSVERSE COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|--------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZM | PX | BYPASS ILEUM TO DESCENDING COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZN | PX | BYPASS ILEUM TO SIGMOID COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZP | PX | BYPASS ILEUM TO RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZB | PX | BYPASS ILEUM TO ILEUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZH | PX | BYPASS ILEUM TO CECUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZK | PX | BYPASS ILEUM TO ASCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZL | PX | BYPASS ILEUM TO TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZM | PX | BYPASS ILEUM TO DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZN | PX | BYPASS ILEUM TO SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZP | PX | BYPASS ILEUM TO RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1H0ZH | PX | BYPASS CECUM TO CECUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1H0ZK | PX | BYPASS CECUM TO ASCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1H0ZL | PX | BYPASS CECUM TO TRANSVERSE COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1H0ZM | PX | BYPASS CECUM TO DESCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1H0ZN | PX | BYPASS CECUM TO SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1H0ZP | PX | BYPASS CECUM TO RECTUM, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|-------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M4ZP | PX | BYPASS DESCENDING COLON TO RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M8ZM | PX | BYPASS DESCENDING COLON TO DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M8ZN | PX | BYPASS DESCENDING COLON TO SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M8ZP | PX | BYPASS DESCENDING COLON TO RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N0Z4 | PX | BYPASS SIGMOID COLON TO CUTANEOUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N0ZN | PX | BYPASS SIGMOID COLON TO SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N0ZP | PX | BYPASS SIGMOID COLON TO RECTUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N4Z4 | PX | BYPASS SIGMOID COLON TO CUTANEOUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N4ZN | PX | BYPASS SIGMOID COLON TO SIGMOID COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N4ZP | PX | BYPASS SIGMOID COLON TO RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N8ZN | PX | BYPASS SIGMOID COLON TO SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N8ZP | PX | BYPASS SIGMOID COLON TO RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D190Z9 | PX | BYPASS DUODENUM TO DUODENUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D190ZA | PX | BYPASS DUODENUM TO JEJUNUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D190ZB | PX | BYPASS DUODENUM TO ILEUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D194Z9 | PX | BYPASS DUODENUM TO DUODENUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|-----------------------------------------------------------------------------------|-----------|
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D190ZL | PX | BYPASS DUODENUM TO TRANSVERSE COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D194ZL | PX | BYPASS DUODENUM TO TRANSVERSE COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D198ZL | PX | BYPASS DUODENUM TO TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A0ZH | PX | BYPASS JEJUNUM TO CECUM, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A0ZK | PX | BYPASS JEJUNUM TO ASCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A0ZL | PX | BYPASS JEJUNUM TO TRANSVERSE COLON, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A0ZM | PX | BYPASS JEJUNUM TO DESCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A0ZN | PX | BYPASS JEJUNUM TO SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A4ZH | PX | BYPASS JEJUNUM TO CECUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A4ZK | PX | BYPASS JEJUNUM TO ASCENDING COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A4ZL | PX | BYPASS JEJUNUM TO TRANSVERSE COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A4ZM | PX | BYPASS JEJUNUM TO DESCENDING COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A4ZN | PX | BYPASS JEJUNUM TO SIGMOID COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZK | PX | BYPASS JEJUNUM TO ASCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZL | PX | BYPASS JEJUNUM TO TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1A8ZM | PX | BYPASS JEJUNUM TO DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|-------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M4ZP | PX | BYPASS DESCENDING COLON TO RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M8ZM | PX | BYPASS DESCENDING COLON TO DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M8ZN | PX | BYPASS DESCENDING COLON TO SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1M8ZP | PX | BYPASS DESCENDING COLON TO RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N0ZN | PX | BYPASS SIGMOID COLON TO SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N0ZP | PX | BYPASS SIGMOID COLON TO RECTUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N4ZN | PX | BYPASS SIGMOID COLON TO SIGMOID COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N4ZP | PX | BYPASS SIGMOID COLON TO RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N8ZN | PX | BYPASS SIGMOID COLON TO SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1N8ZP | PX | BYPASS SIGMOID COLON TO RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B0ZQ | PX | BYPASS ILEUM TO ANUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B4ZQ | PX | BYPASS ILEUM TO ANUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0D1B8ZQ | PX | BYPASS ILEUM TO ANUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBE0ZZ | PX | EXCISION OF LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBE3ZZ | PX | EXCISION OF LARGE INTESTINE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBE4ZZ | PX | EXCISION OF LARGE INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|-------------------------------------------------------------------------------------------------------------|-----------|
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBE7ZZ | PX | EXCISION OF LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBE8ZZ | PX | EXCISION OF LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBF0ZZ | PX | EXCISION OF RIGHT LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBF3ZZ | PX | EXCISION OF RIGHT LARGE INTESTINE, PERCUTANEOUS APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBF4ZZ | PX | EXCISION OF RIGHT LARGE INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBF7ZZ | PX | EXCISION OF RIGHT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBF8ZZ | PX | EXCISION OF RIGHT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBG0ZZ | PX | EXCISION OF LEFT LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBG3ZZ | PX | EXCISION OF LEFT LARGE INTESTINE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBG4ZZ | PX | EXCISION OF LEFT LARGE INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBG7ZZ | PX | EXCISION OF LEFT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBG8ZZ | PX | EXCISION OF LEFT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBGFZZ | PX | EXCISION OF LEFT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING WITH PERCUTANEOUS ENDOSCOPIC ASSISTANCE | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBH0ZZ | PX | EXCISION OF CECUM, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBH3ZZ | PX | EXCISION OF CECUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBH4ZZ | PX | EXCISION OF CECUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|---------------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBM7ZZ | PX | EXCISION OF DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBM8ZZ | PX | EXCISION OF DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBMFZZ | PX | EXCISION OF DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING WITH PERCUTANEOUS ENDOSCOPIC ASSISTANCE | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBN0ZZ | PX | EXCISION OF SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBN3ZZ | PX | EXCISION OF SIGMOID COLON, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBN4ZZ | PX | EXCISION OF SIGMOID COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBN7ZZ | PX | EXCISION OF SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBN8ZZ | PX | EXCISION OF SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DBNFZZ | PX | EXCISION OF SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING WITH PERCUTANEOUS ENDOSCOPIC ASSISTANCE | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DTE0ZZ | PX | RESECTION OF LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DTE4ZZ | PX | RESECTION OF LARGE INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DTE7ZZ | PX | RESECTION OF LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DTE8ZZ | PX | RESECTION OF LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DTF0ZZ | PX | RESECTION OF RIGHT LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DTF4ZZ | PX | RESECTION OF RIGHT LARGE INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DTF7ZZ | PX | RESECTION OF RIGHT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|--------------------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTF8ZZ | PX | RESECTION OF RIGHT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTG0ZZ | PX | RESECTION OF LEFT LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTG4ZZ | PX | RESECTION OF LEFT LARGE INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTG7ZZ | PX | RESECTION OF LEFT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTG8ZZ | PX | RESECTION OF LEFT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTGFZZ | PX | RESECTION OF LEFT LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING WITH PERCUTANEOUS ENDOSCOPIC ASSISTANCE | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTH0ZZ | PX | RESECTION OF CECUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTH4ZZ | PX | RESECTION OF CECUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTH7ZZ | PX | RESECTION OF CECUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTH8ZZ | PX | RESECTION OF CECUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTK0ZZ | PX | RESECTION OF ASCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTK4ZZ | PX | RESECTION OF ASCENDING COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTK7ZZ | PX | RESECTION OF ASCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTK8ZZ | PX | RESECTION OF ASCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTL0ZZ | PX | RESECTION OF TRANSVERSE COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | ODTL4ZZ | PX | RESECTION OF TRANSVERSE COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|----------------------------------------------------------------------------------------------------------|-----------|
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTL7ZZ | PX | RESECTION OF TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTL8ZZ | PX | RESECTION OF TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTLFZZ | PX | RESECTION OF TRANSVERSE COLON, VIA NATURAL OR ARTIFICIAL OPENING WITH PERCUTANEOUS ENDOSCOPIC ASSISTANCE | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTM0ZZ | PX | RESECTION OF DESCENDING COLON, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTM4ZZ | PX | RESECTION OF DESCENDING COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTM7ZZ | PX | RESECTION OF DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTM8ZZ | PX | RESECTION OF DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTMFZZ | PX | RESECTION OF DESCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING WITH PERCUTANEOUS ENDOSCOPIC ASSISTANCE | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTN0ZZ | PX | RESECTION OF SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTN4ZZ | PX | RESECTION OF SIGMOID COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTN7ZZ | PX | RESECTION OF SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTN8ZZ | PX | RESECTION OF SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODTNFZZ | PX | RESECTION OF SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING WITH PERCUTANEOUS ENDOSCOPIC ASSISTANCE | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODQ60ZZ | PX | REPAIR STOMACH, OPEN APPROACH | ICD-10-CM |
| | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODQ63ZZ | PX | REPAIR STOMACH, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colecotomy | ODQ64ZZ | PX | REPAIR STOMACH, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|-----------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ67ZZ | PX | REPAIR STOMACH, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQ68ZZ | PX | REPAIR STOMACH, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 44.91 | PX | LIGATION OF GASTRIC VARICES | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 06L20ZZ | PX | OCCLUSION OF GASTRIC VEIN, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 06L23ZZ | PX | OCCLUSION OF GASTRIC VEIN, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 06L24ZZ | PX | OCCLUSION OF GASTRIC VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.10 | PX | COLOSTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.11 | PX | TEMPORARY COLOSTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.13 | PX | PERMANENT COLOSTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.14 | PX | DELAYED OPENING OF COLOSTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1H0Z4 | PX | BYPASS CECUM TO CUTANEOUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1H4Z4 | PX | BYPASS CECUM TO CUTANEOUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1H8Z4 | PX | BYPASS CECUM TO CUTANEOUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1K0Z4 | PX | BYPASS ASCENDING COLON TO CUTANEOUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1K4Z4 | PX | BYPASS ASCENDING COLON TO CUTANEOUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1K8Z4 | PX | BYPASS ASCENDING COLON TO CUTANEOUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1L0Z4 | PX | BYPASS TRANSVERSE COLON TO CUTANEOUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1L4Z4 | PX | BYPASS TRANSVERSE COLON TO CUTANEOUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1L8Z4 | PX | BYPASS TRANSVERSE COLON TO CUTANEOUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1N0Z4 | PX | BYPASS SIGMOID COLON TO CUTANEOUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1N4Z4 | PX | BYPASS SIGMOID COLON TO CUTANEOUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1N8Z4 | PX | BYPASS SIGMOID COLON TO CUTANEOUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0H87XZZ | PX | DIVISION OF ABDOMEN SKIN, EXTERNAL APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.2 | PX | ILEOSTOMY, OPEN APPROACH | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.21 | PX | TEMPORARY ILEOSTOMY, OPEN APPROACH | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.22 | PX | CONTINENT ILEOSTOMY, OPEN APPROACH | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.23 | PX | OTHER PERMANENT ILEOSTOMY, OPEN APPROACH | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.24 | PX | DELAYED OPENING OF ILEOSTOMY, OPEN APPROACH | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 46.20 | PX | ILEOSTOMY, NOT OTHERWISE SPECIFIED, OPEN APPROACH | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1B0Z4 | PX | BYPASS ILEUM TO CUTANEOUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1B4Z4 | PX | BYPASS ILEUM TO CUTANEOUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1B8Z4 | PX | BYPASS ILEUM TO CUTANEOUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1B0Z4 | PX | BYPASS ILEUM TO CUTANEOUS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1B4Z4 | PX | BYPASS ILEUM TO CUTANEOUS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colostomy | 0D1B8Z4 | PX | BYPASS ILEUM TO CUTANEOUS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 46.3 | PX | OTHER ENTEROSTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 46.32 | PX | PERCUTANEOUS (ENDOSCOPIC) JEJUNOSTOMY [PEJ] | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 46.31 | PX | DELAYED OPENING OF OTHER ENTEROSTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 46.39 | PX | OTHER ENTEROSTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH80UZ | PX | INSERTION OF FEEDING DEVICE INTO SMALL INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH83UZ | PX | INSERTION OF FEEDING DEVICE INTO SMALL INTESTINE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH84UZ | PX | INSERTION OF FEEDING DEVICE INTO SMALL INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH87UZ | PX | INSERTION OF FEEDING DEVICE INTO SMALL INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH88UZ | PX | INSERTION OF FEEDING DEVICE INTO SMALL INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH90UZ | PX | INSERTION OF FEEDING DEVICE INTO DUODENUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH93UZ | PX | INSERTION OF FEEDING DEVICE INTO DUODENUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH94UZ | PX | INSERTION OF FEEDING DEVICE INTO DUODENUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH97UZ | PX | INSERTION OF FEEDING DEVICE INTO DUODENUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|-----------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DH98UZ | PX | INSERTION OF FEEDING DEVICE INTO DUODENUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DHA0UZ | PX | INSERTION OF FEEDING DEVICE INTO JEJUNUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DHA7UZ | PX | INSERTION OF FEEDING DEVICE INTO JEJUNUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DHA3UZ | PX | INSERTION OF FEEDING DEVICE INTO JEJUNUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DHA4UZ | PX | INSERTION OF FEEDING DEVICE INTO JEJUNUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ileostomy | 0DHA8UZ | PX | INSERTION OF FEEDING DEVICE INTO JEJUNUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 46.75 | PX | SUTURE OF LACERATION OF LARGE INTESTINE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQE0ZZ | PX | REPAIR LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQE3ZZ | PX | REPAIR LARGE INTESTINE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQE4ZZ | PX | REPAIR LARGE INTESTINE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQE7ZZ | PX | REPAIR LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQE8ZZ | PX | REPAIR LARGE INTESTINE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQH0ZZ | PX | REPAIR CECUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQH3ZZ | PX | REPAIR CECUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQH4ZZ | PX | REPAIR CECUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQH7ZZ | PX | REPAIR CECUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|----------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQH8ZZ | PX | REPAIR CECUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQK0ZZ | PX | REPAIR ASCENDING COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQK3ZZ | PX | REPAIR ASCENDING COLON, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQK4ZZ | PX | REPAIR ASCENDING COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQK7ZZ | PX | REPAIR ASCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQK8ZZ | PX | REPAIR ASCENDING COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQN0ZZ | PX | REPAIR SIGMOID COLON, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQN3ZZ | PX | REPAIR SIGMOID COLON, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQN4ZZ | PX | REPAIR SIGMOID COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQN7ZZ | PX | REPAIR SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQN8ZZ | PX | REPAIR SIGMOID COLON, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 48.3 | PX | LOCAL EXCISION OR DESTRUCTION OF LESION OR TISSUE OF RECTUM | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 48.32 | PX | OTHER ELECTROCOAGULATION OF RECTAL LESION OR TISSUE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 48.33 | PX | DESTRUCTION OF RECTAL LESION OR TISSUE BY LASER | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 48.34 | PX | DESTRUCTION OF RECTAL LESION OR TISSUE BY CRYOSURGERY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 48.35 | PX | LOCAL EXCISION OF RECTAL LESION OR TISSUE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------|----|---------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 48.36 | PX | [ENDOSCOPIC] POLYPECTOMY OF RECTUM | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 48.31 | PX | RADICAL ELECTROCOAGULATION OF RECTAL LESION OR TISSUE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D5P0ZZ | PX | DESTRUCTION OF RECTUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D5P3ZZ | PX | DESTRUCTION OF RECTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D5P4ZZ | PX | DESTRUCTION OF RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D5P7ZZ | PX | DESTRUCTION OF RECTUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0D5P8ZZ | PX | DESTRUCTION OF RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBP3ZZ | PX | EXCISION OF RECTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBP7ZZ | PX | EXCISION OF RECTUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBP8ZZ | PX | EXCISION OF RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBP4ZZ | PX | EXCISION OF RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DBP8ZZ | PX | EXCISION OF RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 48.71 | PX | SUTURE OF LACERATION OF RECTUM | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DQP0ZZ | PX | REPAIR RECTUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DQP3ZZ | PX | REPAIR RECTUM, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Colectomy | 0DQP4ZZ | PX | REPAIR RECTUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-----------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQP7ZZ | PX | REPAIR RECTUM, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Colectomy | 0DQP8ZZ | PX | REPAIR RECTUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 44604 | PX | SUTURE OF LARGE INTESTINE (COLORRHAPHY) FOR PERFORATED ULCER, DIVERTICULUM, WOUND, INJURY OR RUPTURE (SINGLE OR MULTIPLE PERFORATIONS); WITHOUT COLOSTOMY / WITH COLOSTOMY | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 44605 | PX | SUTURE OF LARGE INTESTINE (COLORRHAPHY) FOR PERFORATED ULCER, DIVERTICULUM, WOUND, INJURY OR RUPTURE (SINGLE OR MULTIPLE PERFORATIONS); WITHOUT COLOSTOMY / WITH COLOSTOMY | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 43460 | PX | ESOPHOAGSTRIC TAMPONADE WITH BALLOON | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 43840 | PX | GASTRORRAPHY, SUTURE OF PERFORATED DUODENAL OR GASTRIC ULCER, WOUND, OR INJURY | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 52.5 | PX | PARTIAL PANCREATECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 52.51 | PX | PROXIMAL PANCREATECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 52.52 | PX | DISTAL PANCREATECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 52.53 | PX | RADICAL SUBTOTAL PANCREATECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 52.59 | PX | OTHER PARTIAL PANCREATECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 52.6 | PX | TOTAL PANCREATECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0FBG0ZZ | PX | EXCISION OF PANCREAS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0FBG3ZZ | PX | EXCISION OF PANCREAS, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0FBG4ZZ | PX | EXCISION OF PANCREAS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0FBG8ZZ | PX | EXCISION OF PANCREAS, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------|----|-------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 52.7 | PX | RADICAL PANCREATICODUODENECTOMY | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0FTG0ZZ | PX | RESECTION OF PANCREAS, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0FTG4ZZ | PX | RESECTION OF PANCREAS, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0D1607A | PX | BYPASS STOMACH TO JEJUNUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0D160JA | PX | BYPASS STOMACH TO JEJUNUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0D160KA | PX | BYPASS STOMACH TO JEJUNUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0D160ZA | PX | BYPASS STOMACH TO JEJUNUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0DT90ZZ | PX | RESECTION OF DUODENUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0F190Z3 | PX | BYPASS COMMON BILE DUCT TO DUODENUM, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Pancreatectomy | 0F1G0ZC | PX | BYPASS PANCREAS TO LARGE INTESTINE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 53.51 | PX | INCISIONAL HERNIA REPAIR | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 53.61 | PX | OTHER OPEN INCISIONAL HERNIA REPAIR WITH GRAFT OR PROSTHESIS | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 53.62 | PX | LAPAROSCOPIC INCISIONAL HERNIA REPAIR WITH GRAFT | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | | 68.8 | PX | PELVIC EVISCERATION | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WQF0ZZ | PX | REPAIR ABDOMINAL WALL, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WQF3ZZ | PX | REPAIR ABDOMINAL WALL, PERCUTANEOUS APPROACH | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WQF4ZZ | PX | REPAIR ABDOMINAL WALL, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WUF07Z | PX | SUPPLEMENT ABDOMINAL WALL WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WUF0JZ | PX | SUPPLEMENT ABDOMINAL WALL WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WUF0KZ | PX | SUPPLEMENT ABDOMINAL WALL WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WUF47Z | PX | SUPPLEMENT ABDOMINAL WALL WITH AUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WUF4JZ | PX | SUPPLEMENT ABDOMINAL WALL WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Ventral Hernia Repair | 0WUF4KZ | PX | SUPPLEMENT ABDOMINAL WALL WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Lower GI | 44140 | PX | COLECTOMY, PARTIAL; WITH ANASTOMOSIS | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Lower GI | 44202-44208 | PX | COLECTOMY | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Upper GI | 43501 | PX | GASTROTOMY; WITH SUTURE REPAIR OF BLEEDING ULCER | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Upper GI | 43502 | PX | GASTROTOMY; WITH SUTURE REPAIR OF PRE-EXISTING ESOPHAGOGASTRIC LACERATION (EG, MALLORY-WEISS) | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Upper GI | 44602-3 | PX | SUTURE OF SMALL INTESTINE (ENTERORRHAPHY) FOR PERFORATED ULCER, DIVERTICULUM, WOUND, INJURY OR RUPTURE; SINGLE PERFORATION/MULTIPLE PERFORATIONS | CPT/HCPCS |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Hip replacement | 81.51 | PX | TOTAL HIP REPLACEMENT | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Hip replacement | 81.52 | PX | PARTIAL HIP REPLACEMENT | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Hip replacement | 0SR90J9 | PX | REPLACEMENT OF RIGHT HIP JOINT WITH SYNTHETIC SUBSTITUTE, CEMENTED, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Hip replacement | 0SR90JA | PX | REPLACEMENT OF RIGHT HIP JOINT WITH SYNTHETIC SUBSTITUTE, UNCEMENTED, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|---------|----|-------------------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Hip replacement | OSRS0JZ | PX | REPLACEMENT OF LEFT HIP JOINT, FEMORAL SURFACE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Hip replacement | OSRS0KZ | PX | REPLACEMENT OF LEFT HIP JOINT, FEMORAL SURFACE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | 8L54 | PX | TOTAL KNEE REPLACEMENT | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRC06Z | PX | REPLACEMENT OF RIGHT KNEE JOINT WITH OXIDIZED ZIRCONIUM ON POLYETHYLENE SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRC07Z | PX | REPLACEMENT OF RIGHT KNEE JOINT WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRC0JZ | PX | REPLACEMENT OF RIGHT KNEE JOINT WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRC0KZ | PX | REPLACEMENT OF RIGHT KNEE JOINT WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRC0LZ | PX | REPLACEMENT OF RIGHT KNEE JOINT WITH MEDIAL UNICONDYLAR SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRD06Z | PX | REPLACEMENT OF LEFT KNEE JOINT WITH OXIDIZED ZIRCONIUM ON POLYETHYLENE SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRD07Z | PX | REPLACEMENT OF LEFT KNEE JOINT WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRD0JZ | PX | REPLACEMENT OF LEFT KNEE JOINT WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRD0KZ | PX | REPLACEMENT OF LEFT KNEE JOINT WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRD0LZ | PX | REPLACEMENT OF LEFT KNEE JOINT WITH MEDIAL UNICONDYLAR SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRT07Z | PX | REPLACEMENT OF RIGHT KNEE JOINT, FEMORAL SURFACE WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRT0JZ | PX | REPLACEMENT OF RIGHT KNEE JOINT, FEMORAL SURFACE WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Knee replacement | OSRT0KZ | PX | REPLACEMENT OF RIGHT KNEE JOINT, FEMORAL SURFACE WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |

[illegible]

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------|----|------------------------------------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Knee replacement | 0SRU0JA | PX | REPLACEMENT OF LEFT KNEE JOINT, FEMORAL SURFACE WITH SYNTHETIC SUBSTITUTE, UNCEMENTED, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Knee replacement | 0SRV0J9 | PX | REPLACEMENT OF RIGHT KNEE JOINT, TIBIAL SURFACE WITH SYNTHETIC SUBSTITUTE, CEMENTED, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Knee replacement | 0SRV0JA | PX | REPLACEMENT OF RIGHT KNEE JOINT, TIBIAL SURFACE WITH SYNTHETIC SUBSTITUTE, UNCEMENTED, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Knee replacement | 0SRW0J9 | PX | REPLACEMENT OF LEFT KNEE JOINT, TIBIAL SURFACE WITH SYNTHETIC SUBSTITUTE, CEMENTED, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Knee replacement | 0SRW0JA | PX | REPLACEMENT OF LEFT KNEE JOINT, TIBIAL SURFACE WITH SYNTHETIC SUBSTITUTE, UNCEMENTED, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 81.80 | PX | OTHER TOTAL SHOULDER REPLACEMENT | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 81.88 | PX | REVERSE TOTAL SHOULDER REPLACEMENT | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRJ0Z7 | PX | REPLACEMENT OF RIGHT SHOULDER JOINT WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRJ0JZ | PX | REPLACEMENT OF RIGHT SHOULDER JOINT WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRJ0KZ | PX | REPLACEMENT OF RIGHT SHOULDER JOINT WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRK0Z7 | PX | REPLACEMENT OF LEFT SHOULDER JOINT WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRK0JZ | PX | REPLACEMENT OF LEFT SHOULDER JOINT WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRK0KZ | PX | REPLACEMENT OF LEFT SHOULDER JOINT WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRJ00Z | PX | REPLACEMENT OF RIGHT SHOULDER JOINT WITH REVERSE BALL AND SOCKET SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Shoulder replacement | 0RRK0JZ | PX | REPLACEMENT OF LEFT SHOULDER JOINT WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 32.20 | PX | THORACOSCOPIC EXCISION OF LESION OR TISSUE OF LUNG | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------|----|-------------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 32.24 | PX | PERCUTANEOUS ABLATION OF LUNG LESION OR TISSUE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 32.26 | PX | OTHER AND UNSPECIFIED ABLATION OF LUNG LESION OR TISSUE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 32.30 | PX | THORACOSCOPIC SEGMENTAL RESECTION OF LUNG | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 32.41 | PX | THORACOSCOPIC LOBECTOMY OF LUNG | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 0BBC4ZZ | PX | EXCISION OF RIGHT UPPER LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 0BBD4ZZ | PX | EXCISION OF RIGHT MIDDLE LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 0BBF4ZZ | PX | EXCISION OF RIGHT LOWER LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 0BBG4ZZ | PX | EXCISION OF LEFT UPPER LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Thorascopic pulmonary lobectomy | 0BBJ4ZZ | PX | EXCISION OF LEFT LOWER LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 32.23 | PX | OPEN ABLATION OF LUNG LESION OR TISSUE | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 32.29 | PX | OTHER LOCAL EXCISION OR DESTRUCTION OF LESION OR TISSUE OF LUNG | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 32.49 | PX | OTHER LOBECTOMY OF LUNG | ICD-9-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0B5C0ZZ | PX | DESTRUCTION OF RIGHT UPPER LUNG LOBE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0B5C3ZZ | PX | DESTRUCTION OF RIGHT UPPER LUNG LOBE, PERCUTANEOUS APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0B5C7ZZ | PX | DESTRUCTION OF RIGHT UPPER LUNG LOBE, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (eg. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0B5D0ZZ | PX | DESTRUCTION OF RIGHT MIDDLE LUNG LOBE, OPEN APPROACH | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------|----|-----------------------------------------------------------------------|-----------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTD4ZZ | PX | RESECTION OF RIGHT MIDDLE LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTF4ZZ | PX | RESECTION OF RIGHT LOWER LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTG4ZZ | PX | RESECTION OF LEFT UPPER LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTJ4ZZ | PX | RESECTION OF LEFT LOWER LUNG LOBE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTC0ZZ | PX | RESECTION OF RIGHT UPPER LUNG LOBE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTD0ZZ | PX | RESECTION OF RIGHT MIDDLE LUNG LOBE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTF0ZZ | PX | RESECTION OF RIGHT LOWER LUNG LOBE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTG0ZZ | PX | RESECTION OF LEFT UPPER LUNG LOBE, OPEN APPROACH | ICD-10-CM |
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 1 | Open Pulmonary Lobectomy | 0BTJ0ZZ | PX | RESECTION OF LEFT LOWER LUNG LOBE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | V45.86 | DX | BARIATRIC SURGERY STATUS | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 539.01 | DX | INFECTION DUE TO GASTRIC BAND PROCEDURE | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 539.09 | DX | COMPLICATION OF GASTRIC BAND PROCEDURE | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 539.81 | DX | INFECTION DUE TO BARIATRIC PROCEDURE | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 539.89 | DX | COMPLICATION OF BARIATRIC PROCEDURE | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | Z98.84 | DX | BARIATRIC SURGERY STATUS | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | K95.01 | DX | INFECTION DUE TO GASTRIC BAND PROCEDURE | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | K95.09 | DX | OTHER COMPLICATIONS OF GASTRIC BAND PROCEDURE | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | K95.81 | DX | INFECTION DUE TO OTHER BARIATRIC PROCEDURE | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | K95.89 | DX | OTHER COMPLICATIONS OF OTHER BARIATRIC PROCEDURE | ICD-10-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------|----|-----------------------------------------------------------------------------------------------------------|-----------|
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43.89 | PX | OPEN AND OTHER PARTIAL GASTRECTOMY | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 44.31 | PX | HIGH GASTRIC BYPASS | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 44.38 | PX | LAPAROSCOPIC GASTROENTEROSTOMY | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 44.39 | PX | OTHER GASTROENTEROSTOMY WITHOUT GASTRECTOMY | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 44.68 | PX | LAPAROSCOPIC GASTROPLASTY | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 44.94 | PX | REMOVAL OF GASTRIC BUBBLE (BALLOON) | ICD-9-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0DB60ZZ | PX | EXCISION OF STOMACH, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0DB63ZZ | PX | EXCISION OF STOMACH, PERCUTANEOUS APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0DB67ZZ | PX | EXCISION OF STOMACH, VIA NATURAL OR ARTIFICIAL OPENING | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D1607A | PX | BYPASS STOMACH TO JEJUNUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D1607B | PX | BYPASS STOMACH TO ILEUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D1607L | PX | BYPASS STOMACH TO TRANSVERSE COLON WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160JA | PX | BYPASS STOMACH TO JEJUNUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160JB | PX | BYPASS STOMACH TO ILEUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160JL | PX | BYPASS STOMACH TO TRANSVERSE COLON WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160KA | PX | BYPASS STOMACH TO JEJUNUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160KB | PX | BYPASS STOMACH TO ILEUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160KL | PX | BYPASS STOMACH TO TRANSVERSE COLON WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160ZA | PX | BYPASS STOMACH TO JEJUNUM, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160ZB | PX | BYPASS STOMACH TO ILEUM, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160ZL | PX | BYPASS STOMACH TO TRANSVERSE COLON, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D1687A | PX | BYPASS STOMACH TO JEJUNUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |

[illegible]

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------|----|-----------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D164KL | PX | BYPASS STOMACH TO TRANSVERSE COLON WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D164Z9 | PX | BYPASS STOMACH TO DUODENUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D164ZA | PX | BYPASS STOMACH TO JEJUNUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D164ZB | PX | BYPASS STOMACH TO ILEUM, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D164ZL | PX | BYPASS STOMACH TO TRANSVERSE COLON, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D16079 | PX | BYPASS STOMACH TO DUODENUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160J9 | PX | BYPASS STOMACH TO DUODENUM WITH SYNTHETIC SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160K9 | PX | BYPASS STOMACH TO DUODENUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D160Z9 | PX | BYPASS STOMACH TO DUODENUM, OPEN APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D16879 | PX | BYPASS STOMACH TO DUODENUM WITH AUTOLOGOUS TISSUE SUBSTITUTE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D168J9 | PX | BYPASS STOMACH TO DUODENUM WITH SYNTHETIC SUBSTITUTE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D168K9 | PX | BYPASS STOMACH TO DUODENUM WITH NONAUTOLOGOUS TISSUE SUBSTITUTE, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0D168Z9 | PX | BYPASS STOMACH TO DUODENUM, VIA NATURAL OR ARTIFICIAL OPENING ENDOSCOPIC | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 0DQ64ZZ | PX | REPAIR STOMACH, PERCUTANEOUS ENDOSCOPIC APPROACH | ICD-10-CM |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43770 | PX | LAPAROSCOPY, SURGICAL, GASTRIC RESTRICTIVE PROCEDURE: PLACEMENT OF ADJUSTABLE GASTRIC BAND | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43644 | PX | LAPAROSCOPY, SURGICAL, GASTRIC RESTRICTIVE PROCEDURE WITH GASTRIC BYPASS AND ROUX-EN-Y GASTROENTEROSTOMY (ROUX LIMB 150 CM OR LESS) | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43645 | PX | LAPAROSCOPY, SURGICAL, GASTRIC RESTRICTIVE WITH GASTRIC BYPASS AND SMALL INTESTINE RECONSTRUCTION TO LIMIT ABSORPTION | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43842 | PX | GASTRIC RESTRICTIVE PROCEDURE, WITHOUT GASTRIC BYPASS, FOR MORBID OBESITY, VERTICAL BANDED GASTROPLASTY | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43843 | PX | OTHER GASTRIC RESTRICTIVE PROCEDURES, WITHOUT GASTRIC BYPASS, AND OTHER THAN VERTICAL BANDED GASTROPLASTY | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43844 | PX | LAPAROSCOPIC GASTRIC RESTRICTIVE PROCEDURE WITH GASTRIC BYPASS AND ROUX EN Y GASTROENTEROSTOMY | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43845 | PX | GASTRIC RESTRICTIVE PROCEDURE WITH PARTIAL GASTRECTOMY, PYLORUS-PRESERVING DUODENOILEOSTOMY AND ILEOLIEOSTOMY TO LIMIT ABSORPTION (BPD) | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43846 | PX | GASTRIC RESTRICTIVE PROCEDURE, WITH GASTRIC BYPASS, FOR MORBID OBESITY; WITH SHORT LIMB (LESS THAN 100 CM) ROUX-EN-Y GASTROENTEROSTOMY | CPT/HCPCS |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|----------------------------------------------------------------------------------------------------------------------------|-----------|
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43847 | PX | GASTRIC RESTRICTIVE PROCEDURE, WITH SMALL INTESTINE RECONSTRUCTION TO LIMIT ABSORPTION; WITH LONG LIMB (>150 CM) ROUX-EN-Y | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43659 | PX | GASTRECTOMY, TOTAL; WITH ROUX-EN-Y RECONSTRUCTION; MINI-GASTRIC BYPASS | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | S2082 | PX | LAPAROSCOPY, SURGICAL; GASTRIC RESTRICTIVE PROCEDURE, ADJUSTABLE GASTRIC BAND INCLUDES PLACEMENT OF SUBCUTANEOUS PORT | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | S2085 | PX | LAPAROSCOPIC GASTRIC BYPASS | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43775 | PX | LAPAROSCOPY, SURGICAL; GASTRIC RESTRICTIVE PROCEDURE; LONGITUDINAL GASTRECTOMY (E.G., SLEEVE GASTRECTOMY) | CPT/HCPCS |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric surgeries | 43848 | PX | REVISION RYGB | CPT/HCPCS |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | V45.3 | DX | INTESTINAL BYPASS OR ANASTOMOSIS STATUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | Z98.0 | DX | INTESTINAL BYPASS AND ANASTOMOSIS STATUS | ICD-10-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.01 | PX | INCISION OF ESOPHAGEAL WEB | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.09 | PX | OTHER INCISION OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.10 | PX | ESOPHAGOSTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.11 | PX | CERVICAL ESOPHAGOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.12 | PX | EXTERIORIZATION OF ESOPHAGEAL POUCH | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.19 | PX | OTHER EXTERNAL FISTULIZATION OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.40 | PX | ESOPHAGECTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.41 | PX | PARTIAL ESOPHAGECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.42 | PX | TOTAL ESOPHAGECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.51 | PX | INTRATHORACIC ESOPHAGUESOPHAGOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.52 | PX | INTRATHORACIC ESOPHAGOGASTROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.53 | PX | INTRATHORACIC ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF SMALL BOWEL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.54 | PX | OTHER INTRATHORACIC ESOPHAGOENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.55 | PX | INTRATHORACIC ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF COLON | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|----------------------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.56 | PX | OTHER INTRATHORACIC ESOPHAGOCOLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.58 | PX | INTRATHORACIC ESOPHAGEAL ANASTOMOSIS WITH OTHER INTERPOSITION | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.59 | PX | OTHER INTRATHORACIC ANASTOMOSIS OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.61 | PX | ANTESTERNAL ESOPHAGUESOPHAGOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.62 | PX | ANTESTERNAL ESOPHAGOGASTROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.63 | PX | ANTESTERNAL ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF SMALL BOWEL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.64 | PX | OTHER ANTESTERNAL ESOPHAGOENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.65 | PX | ANTESTERNAL ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.66 | PX | OTHER ANTESTERNAL ESOPHAGOCOLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.68 | PX | OTHER ANTESTERNAL ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.69 | PX | OTHER ANTESTERNAL ANASTOMOSIS OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.7 | PX | ESOPHAGOMYOTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.81 | PX | INSERTION OF PERMANENT TUBE INTO ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.83 | PX | CLOSURE OF ESOPHAGOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.84 | PX | REPAIR OF ESOPHAGEAL FISTULA, NOT ELSEWHERE CLASSIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.0 | PX | GASTROTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.11 | PX | PERCUTANEOUS [ENDOSCOPIC] GASTROSTOMY [PEG] | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.19 | PX | OTHER GASTROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.5 | PX | PARTIAL GASTRECTOMY WITH ANASTOMOSIS TO ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.6 | PX | PARTIAL GASTRECTOMY WITH ANASTOMOSIS TO DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.7 | PX | PARTIAL GASTRECTOMY WITH ANASTOMOSIS TO JEJUNUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.81 | PX | PARTIAL GASTRECTOMY WITH JEJUNAL TRANSPOSITION | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|----------------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.82 | PX | LAPAROSCOPIC VERTICAL (SLEEVE) GASTRECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.91 | PX | TOTAL GASTRECTOMY WITH INTESTINAL INTERPOSITION | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.99 | PX | OTHER TOTAL GASTRECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.50 | PX | ISOLATION OF INTESTINAL SEGMENT, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.51 | PX | ISOLATION OF SEGMENT OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.52 | PX | ISOLATION OF SEGMENT OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.61 | PX | MULTIPLE SEGMENTAL RESECTION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.62 | PX | OTHER PARTIAL RESECTION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.63 | PX | TOTAL REMOVAL OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.71 | PX | OPEN AND OTHER MULTIPLE SEGMENTAL RESECTION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.72 | PX | OPEN AND OTHER CECECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.73 | PX | OPEN AND OTHER RIGHT HEMICOLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.74 | PX | OPEN AND OTHER RESECTION OF TRANSVERSE COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.75 | PX | OPEN AND OTHER LEFT HEMICOLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.76 | PX | OPEN AND OTHER SIGMOIDECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.79 | PX | OTHER AND UNSPECIFIED PARTIAL EXCISION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.81 | PX | LAPAROSCOPIC TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.82 | PX | OPEN TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.83 | PX | OTHER AND UNSPECIFIED TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.90 | PX | INTESTINAL ANASTOMOSIS, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.91 | PX | SMALL-TO-SMALL INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.92 | PX | ANASTOMOSIS OF SMALL INTESTINE TO RECTAL STUMP | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|-------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.93 | PX | OTHER SMALL- TO-LARGE INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.94 | PX | LARGE-TO-LARGE INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.95 | PX | ANASTOMOSIS TO ANUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.01 | PX | EXTERIORIZATION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.02 | PX | RESECTION OF EXTERIORIZED SEGMENT OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.03 | PX | EXTERIORIZATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.04 | PX | RESECTION OF EXTERIORIZED SEGMENT OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.10 | PX | COLOSTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.11 | PX | TEMPORARY COLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.13 | PX | PERMANENT COLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.14 | PX | DELAYED OPENING OF COLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.20 | PX | ILEOSTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.21 | PX | TEMPORARY ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.22 | PX | CONTINENT ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.23 | PX | OTHER PERMANENT ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.24 | PX | DELAYED OPENING OF ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.31 | PX | DELAYED OPENING OF OTHER ENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.32 | PX | PERCUTANEOUS (ENDOSCOPIC) JEJUNOSTOMY [PEJ] | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.39 | PX | OTHER ENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.40 | PX | REVISION OF INTESTINAL STOMA, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.41 | PX | REVISION OF STOMA OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.42 | PX | REPAIR OF PERICOLOSTOMY HERNIA | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|--------------------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.43 | PX | OTHER REVISION OF STOMA OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.50 | PX | CLOSURE OF INTESTINAL STOMA, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.51 | PX | CLOSURE OF STOMA OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.52 | PX | CLOSURE OF STOMA OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.60 | PX | FIXATION OF INTESTINE, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.61 | PX | FIXATION OF SMALL INTESTINE TO ABDOMINAL WALL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.62 | PX | OTHER FIXATION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.63 | PX | FIXATION OF LARGE INTESTINE TO ABDOMINAL WALL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.64 | PX | OTHER FIXATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.71 | PX | SUTURE OF LACERATION OF DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.72 | PX | CLOSURE OF FISTULA OF DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.73 | PX | SUTURE OF LACERATION OF SMALL INTESTINE, EXCEPT DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.74 | PX | CLOSURE OF FISTULA OF SMALL INTESTINE, EXCEPT DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.75 | PX | SUTURE OF LACERATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.76 | PX | CLOSURE OF FISTULA OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.79 | PX | OTHER REPAIR OF INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.80 | PX | INTRA-ABDOMINAL MANIPULATION OF INTESTINE, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.81 | PX | INTRA-ABDOMINAL MANIPULATION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.82 | PX | INTRA-ABDOMINAL MANIPULATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.85 | PX | DILATION OF INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.86 | PX | ENDOSCOPIC INSERTION OF COLONIC STENT(S) | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.87 | PX | OTHER INSERTION OF COLONIC STENT(S) | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|--------------------------------------------|-----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.91 | PX | MYOTOMY OF SIGMOID COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.92 | PX | MYOTOMY OF OTHER PARTS OF COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.93 | PX | REVISION OF ANASTOMOSIS OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.94 | PX | REVISION OF ANASTOMOSIS OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.95 | PX | LOCAL PERFUSION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.96 | PX | LOCAL PERFUSION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.97 | PX | TRANSPLANT OF INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.99 | PX | OTHER OPERATIONS ON INTESTINES | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.0 | DX | ULCERATIVE (CHRONIC) ENTEROCOLITIS | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.1 | DX | ULCERATIVE (CHRONIC) ILEOCOLITIS | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.2 | DX | ULCERATIVE (CHRONIC) PROCTITIS | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.3 | DX | ULCERATIVE (CHRONIC) PROCTOSIGMOIDITIS | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.5 | DX | LEFT-SIDED ULCERATIVE (CHRONIC) COLITIS | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.6 | DX | UNIVERSAL ULCERATIVE (CHRONIC) COLITIS | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.8 | DX | OTHER ULCERATIVE COLITIS | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | 556.9 | DX | ULCERATIVE COLITIS, UNSPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | V45.3 | DX | INTESTINAL BYPASS OR ANASTOMOSIS STATUS | ICD-10-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | Z98.0 | DX | INTESTINAL BYPASS AND ANASTOMOSIS STATUS | ICD-10-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.01 | PX | INCISION OF ESOPHAGEAL WEB | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.09 | PX | OTHER INCISION OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.10 | PX | ESOPHAGOSTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.11 | PX | CERVICAL ESOPHAGOSTOMY | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|------------------------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.12 | PX | EXTERIORIZATION OF ESOPHAGEAL POUCH | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.19 | PX | OTHER EXTERNAL FISTULIZATION OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.40 | PX | ESOPHAGECTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.41 | PX | PARTIAL ESOPHAGECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.42 | PX | TOTAL ESOPHAGECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.51 | PX | INTRATHORACIC ESOPHAGUESOPHAGOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.52 | PX | INTRATHORACIC ESOPHAGOGASTROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.53 | PX | INTRATHORACIC ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF SMALL BOWEL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.54 | PX | OTHER INTRATHORACIC ESOPHAGOENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.55 | PX | INTRATHORACIC ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.56 | PX | OTHER INTRATHORACIC ESOPHAGOCOLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.58 | PX | INTRATHORACIC ESOPHAGEAL ANASTOMOSIS WITH OTHER INTERPOSITION | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.59 | PX | OTHER INTRATHORACIC ANASTOMOSIS OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.61 | PX | ANTESTERNAL ESOPHAGUESOPHAGOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.62 | PX | ANTESTERNAL ESOPHAGOGASTROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.63 | PX | ANTESTERNAL ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF SMALL BOWEL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.64 | PX | OTHER ANTESTERNAL ESOPHAGOENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.65 | PX | ANTESTERNAL ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION OF COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.66 | PX | OTHER ANTESTERNAL ESOPHAGOCOLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.68 | PX | OTHER ANTESTERNAL ESOPHAGEAL ANASTOMOSIS WITH INTERPOSITION | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.69 | PX | OTHER ANTESTERNAL ANASTOMOSIS OF ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.7 | PX | ESOPHAGOMYOTOMY | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|----------------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.81 | PX | INSERTION OF PERMANENT TUBE INTO ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.83 | PX | CLOSURE OF ESOPHAGOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 42.84 | PX | REPAIR OF ESOPHAGEAL FISTULA, NOT ELSEWHERE CLASSIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.0 | PX | GASTROTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.11 | PX | PERCUTANEOUS [ENDOSCOPIC] GASTROSTOMY [PEG] | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.19 | PX | OTHER GASTROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.5 | PX | PARTIAL GASTRECTOMY WITH ANASTOMOSIS TO ESOPHAGUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.6 | PX | PARTIAL GASTRECTOMY WITH ANASTOMOSIS TO DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.7 | PX | PARTIAL GASTRECTOMY WITH ANASTOMOSIS TO JEJUNUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.81 | PX | PARTIAL GASTRECTOMY WITH JEJUNAL TRANSPOSITION | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.82 | PX | LAPAROSCOPIC VERTICAL (SLEEVE) GASTRECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.91 | PX | TOTAL GASTRECTOMY WITH INTESTINAL INTERPOSITION | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 43.99 | PX | OTHER TOTAL GASTRECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.50 | PX | ISOLATION OF INTESTINAL SEGMENT, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.51 | PX | ISOLATION OF SEGMENT OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.52 | PX | ISOLATION OF SEGMENT OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.61 | PX | MULTIPLE SEGMENTAL RESECTION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.62 | PX | OTHER PARTIAL RESECTION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.63 | PX | TOTAL REMOVAL OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.71 | PX | OPEN AND OTHER MULTIPLE SEGMENTAL RESECTION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.72 | PX | OPEN AND OTHER CECECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.73 | PX | OPEN AND OTHER RIGHT HEMICOLECTOMY | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|-----------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.74 | PX | OPEN AND OTHER RESECTION OF TRANSVERSE COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.75 | PX | OPEN AND OTHER LEFT HEMICOLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.76 | PX | OPEN AND OTHER SIGMOIDECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.79 | PX | OTHER AND UNSPECIFIED PARTIAL EXCISION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.81 | PX | LAPAROSCOPIC TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.82 | PX | OPEN TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.83 | PX | OTHER AND UNSPECIFIED TOTAL INTRA-ABDOMINAL COLECTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.90 | PX | INTESTINAL ANASTOMOSIS, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.91 | PX | SMALL-TO-SMALL INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.92 | PX | ANASTOMOSIS OF SMALL INTESTINE TO RECTAL STUMP | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.93 | PX | OTHER SMALL-TO-LARGE INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.94 | PX | LARGE-TO-LARGE INTESTINAL ANASTOMOSIS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 45.95 | PX | ANASTOMOSIS TO ANUS | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.01 | PX | EXTERIORIZATION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.02 | PX | RESECTION OF EXTERIORIZED SEGMENT OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.03 | PX | EXTERIORIZATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.04 | PX | RESECTION OF EXTERIORIZED SEGMENT OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.10 | PX | COLOSTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.11 | PX | TEMPORARY COLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.13 | PX | PERMANENT COLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.14 | PX | DELAYED OPENING OF COLOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.20 | PX | ILEOSTOMY, NOT OTHERWISE SPECIFIED | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------|----|----------------------------------------------------------|----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.21 | PX | TEMPORARY ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.22 | PX | CONTINENT ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.23 | PX | OTHER PERMANENT ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.24 | PX | DELAYED OPENING OF ILEOSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.31 | PX | DELAYED OPENING OF OTHER ENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.32 | PX | PERCUTANEOUS (ENDOSCOPIC) JEJUNOSTOMY [PEJ] | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.39 | PX | OTHER ENTEROSTOMY | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.40 | PX | REVISION OF INTESTINAL STOMA, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.41 | PX | REVISION OF STOMA OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.42 | PX | REPAIR OF PERICOLOSTOMY HERNIA | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.43 | PX | OTHER REVISION OF STOMA OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.50 | PX | CLOSURE OF INTESTINAL STOMA, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.51 | PX | CLOSURE OF STOMA OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.52 | PX | CLOSURE OF STOMA OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.60 | PX | FIXATION OF INTESTINE, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.61 | PX | FIXATION OF SMALL INTESTINE TO ABDOMINAL WALL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.62 | PX | OTHER FIXATION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.63 | PX | FIXATION OF LARGE INTESTINE TO ABDOMINAL WALL | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.64 | PX | OTHER FIXATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.71 | PX | SUTURE OF LACERATION OF DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.72 | PX | CLOSURE OF FISTULA OF DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.73 | PX | SUTURE OF LACERATION OF SMALL INTESTINE, EXCEPT DUODENUM | ICD-9-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|---------|----|--------------------------------------------------------------------|-----------|
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.74 | PX | CLOSURE OF FISTULA OF SMALL INTESTINE, EXCEPT DUODENUM | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.75 | PX | SUTURE OF LACERATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.76 | PX | CLOSURE OF FISTULA OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.79 | PX | OTHER REPAIR OF INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.80 | PX | INTRA-ABDOMINAL MANIPULATION OF INTESTINE, NOT OTHERWISE SPECIFIED | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.81 | PX | INTRA-ABDOMINAL MANIPULATION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.82 | PX | INTRA-ABDOMINAL MANIPULATION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.85 | PX | DILATION OF INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.86 | PX | ENDOSCOPIC INSERTION OF COLONIC STENT(S) | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.87 | PX | OTHER INSERTION OF COLONIC STENT(S) | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.91 | PX | MYOTOMY OF SIGMOID COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.92 | PX | MYOTOMY OF OTHER PARTS OF COLON | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.93 | PX | REVISION OF ANASTOMOSIS OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.94 | PX | REVISION OF ANASTOMOSIS OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.95 | PX | LOCAL PERFUSION OF SMALL INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.96 | PX | LOCAL PERFUSION OF LARGE INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.97 | PX | TRANSPLANT OF INTESTINE | ICD-9-CM |
| 17.2 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | GI excision/Other Major Procedures | 46.99 | PX | OTHER OPERATIONS ON INTESTINES | ICD-9-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.0 | DX | ULCERATIVE (CHRONIC) PANCOLITIS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.00 | DX | ULCERATIVE (CHRONIC) PANCOLITIS WITHOUT COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.01 | DX | ULCERATIVE (CHRONIC) PANCOLITIS WITH COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.011 | DX | ULCERATIVE (CHRONIC) PANCOLITIS WITH RECTAL BLEEDING | ICD-10-CM |

[illegible]

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------|----|----------------------------------------------------------------------|-----------|
| | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.319 | DX | ULCERATIVE (CHRONIC) RECTOSIGMOIDITIS WITH UNSPECIFIED COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.5 | DX | LEFT SIDED COLITIS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.50 | DX | LEFT SIDED COLITIS WITHOUT COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.51 | DX | LEFT SIDED COLITIS WITH COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.511 | DX | LEFT SIDED COLITIS WITH RECTAL BLEEDING | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.512 | DX | LEFT SIDED COLITIS WITH INTESTINAL OBSTRUCTION | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.513 | DX | LEFT SIDED COLITIS WITH FISTULA | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.514 | DX | LEFT SIDED COLITIS WITH ABSCESS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.518 | DX | LEFT SIDED COLITIS WITH OTHER COMPLICATION | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.519 | DX | LEFT SIDED COLITIS WITH UNSPECIFIED COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.8 | DX | OTHER ULCERATIVE COLITIS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.80 | DX | OTHER ULCERATIVE COLITIS WITHOUT COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.81 | DX | OTHER ULCERATIVE COLITIS WITH COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.811 | DX | OTHER ULCERATIVE COLITIS WITH RECTAL BLEEDING | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.812 | DX | OTHER ULCERATIVE COLITIS WITH INTESTINAL OBSTRUCTION | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.813 | DX | OTHER ULCERATIVE COLITIS WITH FISTULA | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.814 | DX | OTHER ULCERATIVE COLITIS WITH ABSCESS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.818 | DX | OTHER ULCERATIVE COLITIS WITH OTHER COMPLICATION | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.819 | DX | OTHER ULCERATIVE COLITIS WITH UNSPECIFIED COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.9 | DX | ULCERATIVE COLITIS, UNSPECIFIED | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.90 | DX | ULCERATIVE COLITIS, UNSPECIFIED, WITHOUT COMPLICATIONS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.91 | DX | ULCERATIVE COLITIS, UNSPECIFIED, WITH COMPLICATIONS | ICD-10-CM |

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------|----|-------------------------------------------------------------------|-----------|
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.911 | DX | ULCERATIVE COLITIS, UNSPECIFIED WITH RECTAL BLEEDING | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.912 | DX | ULCERATIVE COLITIS, UNSPECIFIED WITH INTESTINAL OBSTRUCTION | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.913 | DX | ULCERATIVE COLITIS, UNSPECIFIED WITH FISTULA | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.914 | DX | ULCERATIVE COLITIS, UNSPECIFIED WITH ABSCESS | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.918 | DX | ULCERATIVE COLITIS, UNSPECIFIED WITH OTHER COMPLICATION | ICD-10-CM |
| 17.3 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Ulcerative colitis | K51.919 | DX | ULCERATIVE COLITIS, UNSPECIFIED WITH UNSPECIFIED COMPLICATIONS | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | 555.0 | DX | REGIONAL ENTERITIS OF SMALL INTESTINE | ICD-9-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | 555.1 | DX | REGIONAL ENTERITIS OF LARGE INTESTINE | ICD-9-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | 555.2 | DX | REGIONAL ENTERITIS OF SMALL INTESTINE WITH LARGE INTESTINE | ICD-9-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | 555.9 | DX | REGIONAL ENTERITIS OF UNSPECIFIED SITE | ICD-9-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50 | DX | CROHN'S DISEASE [REGIONAL ENTERITIS] | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.0 | DX | CROHN'S DISEASE OF SMALL INTESTINE | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.00 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITHOUT COMPLICATIONS | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.01 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITH COMPLICATIONS | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.011 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITH RECTAL BLEEDING | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.012 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITH INTESTINAL OBSTRUCTION | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.013 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITH FISTULA | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.014 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITH ABSCESS | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.018 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITH OTHER COMPLICATION | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.019 | DX | CROHN'S DISEASE OF SMALL INTESTINE WITH UNSPECIFIED COMPLICATIONS | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.1 | DX | CROHN'S DISEASE OF LARGE INTESTINE | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.10 | DX | CROHN'S DISEASE OF LARGE INTESTINE WITHOUT COMPLICATIONS | ICD-10-CM |

[illegible]

| | | | | | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------|----|--------------------------------------------------------------------------------------------------------------------|-----------|
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.914 | DX | CROHN'S DISEASE, UNSPECIFIED, WITH ABSCESS | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.918 | DX | CROHN'S DISEASE, UNSPECIFIED, WITH OTHER COMPLICATION | ICD-10-CM |
| 17.4 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Crohn's Disease | K50.919 | DX | CROHN'S DISEASE, UNSPECIFIED, WITH UNSPECIFIED COMPLICATIONS | ICD-10-CM |
| 17.5 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastroparesis | 536.3 | DX | GASTROPARESIS | ICD-9-CM |
| 17.5 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastroparesis | K31.84 | DX | GASTROPARESIS | ICD-10-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.00 | DX | ACUTE DUODENAL ULCER WITH HEMORRHAGE, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.01 | DX | ACUTE DUODENAL ULCER WITH HEMORRHAGE, WITH OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.10 | DX | ACUTE DUODENAL ULCER WITH PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.11 | DX | ACUTE DUODENAL ULCER WITH PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.20 | DX | ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.21 | DX | ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.30 | DX | ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.31 | DX | ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.9 | DX | DUODENAL ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT HEMORRHAGE OR PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | 532.91 | DX | DUODENAL ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT MENTION OF HEMORRHAGE OR PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | K26.0 | DX | ACUTE DUODENAL ULCER WITH HEMORRHAGE | ICD-10-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | K26.1 | DX | ACUTE DUODENAL ULCER WITH PERFORATION | ICD-10-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | K26.2 | DX | ACUTE DUODENAL ULCER WITH BOTH HEMORRHAGE AND PERFORATION | ICD-10-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | K26.3 | DX | ACUTE DUODENAL ULCER WITHOUT HEMORRHAGE OR PERFORATION | ICD-10-CM |
| 17.6 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Duodenal ulcers | K26.9 | DX | DUODENAL ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT HEMORRHAGE OR PERFORATION | ICD-10-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.00 | DX | ACUTE GASTRIC ULCER WITH HEMORRHAGE, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.01 | DX | ACUTE GASTRIC ULCER WITH HEMORRHAGE, WITH OBSTRUCTION | ICD-9-CM |

| | | | | | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------|----|------------------------------------------------------------------------------------------------------------------------------|-----------|
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.10 | DX | ACUTE GASTRIC ULCER WITH PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.11 | DX | ACUTE GASTRIC ULCER WITH PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.20 | DX | ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.21 | DX | ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.30 | DX | ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.31 | DX | ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.90 | DX | GASTRIC ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT MENTION OF HEMORRHAGE OR PERFORATION, WITHOUT MENTION OF OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | 531.91 | DX | GASTRIC ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT MENTION OF HEMORRHAGE OR PERFORATION, WITH OBSTRUCTION | ICD-9-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | K25.0 | DX | ACUTE GASTRIC ULCER WITH HEMORRHAGE | ICD-10-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | K25.1 | DX | ACUTE GASTRIC ULCER WITH PERFORATION | ICD-10-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | K25.2 | DX | ACUTE GASTRIC ULCER WITH BOTH HEMORRHAGE AND PERFORATION | ICD-10-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | K25.3 | DX | ACUTE GASTRIC ULCER WITHOUT HEMORRHAGE OR PERFORATION | ICD-10-CM |
| 17.7 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Gastric ulcer | K25.9 | DX | GASTRIC ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT HEMORRHAGE OR PERFORATION | ICD-10-CM |
| 17.8 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Other GI diseases | 579.3 | DX | OTHER AND UNSPECIFIED POSTSURGICAL NONABSORPTION | ICD-9-CM |
| 17.8 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Other GI diseases | K90.82 | DX | SHORT BOWEL SYNDROME | ICD-10-CM |
| 17.8 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Other GI diseases | K90.821 | DX | SHORT BOWEL SYNDROME WITH COLON IN CONTINUITY | ICD-10-CM |
| 17.8 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Other GI diseases | K90.822 | DX | SHORT BOWEL SYNDROME WITHOUT COLON IN CONTINUITY | ICD-10-CM |
| 17.8 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Other GI diseases | K90.829 | DX | SHORT BOWEL SYNDROME, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140 | DX | MALIGNANT NEOPLASM OF LIP | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.0 | DX | MALIGNANT NEOPLASM OF UPPER LIP, VERMILION BORDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.1 | DX | MALIGNANT NEOPLASM OF LOWER LIP, VERMILION BORDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.3 | DX | MALIGNANT NEOPLASM OF UPPER LIP, INNER ASPECT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.4 | DX | MALIGNANT NEOPLASM OF LOWER LIP, INNER ASPECT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.5 | DX | MALIGNANT NEOPLASM OF LIP, UNSPECIFIED, INNER ASPECT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.6 | DX | MALIGNANT NEOPLASM OF COMMISSURE OF LIP | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.8 | DX | MALIGNANT NEOPLASM OF OTHER SITES OF LIP | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 140.9 | DX | MALIGNANT NEOPLASM OF LIP, UNSPECIFIED, VERMILION BORDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 141 | DX | MALIGNANT NEOPLASM OF TONGUE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------|----|-----------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1410 | DX | MALIGNANT NEOPLASM OF BASE OF TONGUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1411 | DX | MALIGNANT NEOPLASM OF DORSAL SURFACE OF TONGUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1412 | DX | MALIGNANT NEOPLASM OF TIP AND LATERAL BORDER OF TONGUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1413 | DX | MALIGNANT NEOPLASM OF VENTRAL SURFACE OF TONGUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1414 | DX | MALIGNANT NEOPLASM OF ANTERIOR TWO-THIRDS OF TONGUE, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1415 | DX | MALIGNANT NEOPLASM OF JUNCTIONAL ZONE OF TONGUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1416 | DX | MALIGNANT NEOPLASM OF LINGUAL TONSIL | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1418 | DX | MALIGNANT NEOPLASM OF OTHER SITES OF TONGUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 1419 | DX | MALIGNANT NEOPLASM OF TONGUE, UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 142 | DX | MALIGNANT NEOPLASM OF MAJOR SALIVARY GLANDS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 142.0 | DX | MALIGNANT NEOPLASM OF PAROTID GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 142.1 | DX | MALIGNANT NEOPLASM OF SUBMANDIBULAR GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 142.2 | DX | MALIGNANT NEOPLASM OF SUBLINGUAL GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 142.8 | DX | MALIGNANT NEOPLASM OF OTHER MAJOR SALIVARY GLANDS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 142.9 | DX | MALIGNANT NEOPLASM OF SALIVARY GLAND, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 143 | DX | MALIGNANT NEOPLASM OF GUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 143.0 | DX | MALIGNANT NEOPLASM OF UPPER GUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 143.1 | DX | MALIGNANT NEOPLASM OF LOWER GUM | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 143.8 | DX | MALIGNANT NEOPLASM OF OTHER SITES OF GUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 143.9 | DX | MALIGNANT NEOPLASM OF GUM, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 144 | DX | MALIGNANT NEOPLASM OF FLOOR OF MOUTH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 144.0 | DX | MALIGNANT NEOPLASM OF ANTERIOR PORTION OF FLOOR OF MOUTH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 144.1 | DX | MALIGNANT NEOPLASM OF LATERAL PORTION OF FLOOR OF MOUTH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 144.8 | DX | MALIGNANT NEOPLASM OF OTHER SITES OF FLOOR OF MOUTH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 144.9 | DX | MALIGNANT NEOPLASM OF FLOOR OF MOUTH, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145 | DX | MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED PARTS OF MOUTH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.0 | DX | MALIGNANT NEOPLASM OF CHEEK MUCOSA | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.1 | DX | MALIGNANT NEOPLASM OF VESTIBULE OF MOUTH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.2 | DX | MALIGNANT NEOPLASM OF HARD PALATE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.3 | DX | MALIGNANT NEOPLASM OF SOFT PALATE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.4 | DX | MALIGNANT NEOPLASM OF UVULA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.5 | DX | MALIGNANT NEOPLASM OF PALATE, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.6 | DX | MALIGNANT NEOPLASM OF RETROMOLAR AREA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED PARTS OF MOUTH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 145.9 | DX | MALIGNANT NEOPLASM OF MOUTH, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146 | DX | MALIGNANT NEOPLASM OF OROPHARYNX | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.0 | DX | MALIGNANT NEOPLASM OF TONSIL | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.1 | DX | MALIGNANT NEOPLASM OF TONSILLAR FOSSA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.2 | DX | MALIGNANT NEOPLASM OF TONSILLAR PILLARS (ANTERIOR) (POSTERIOR) | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.3 | DX | MALIGNANT NEOPLASM OF VALLECULA EPIGLOTTICA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.4 | DX | MALIGNANT NEOPLASM OF ANTERIOR ASPECT OF EPIGLOTTIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.5 | DX | MALIGNANT NEOPLASM OF JUNCTIONAL REGION OF OROPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.6 | DX | MALIGNANT NEOPLASM OF LATERAL WALL OF OROPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.7 | DX | MALIGNANT NEOPLASM OF POSTERIOR WALL OF OROPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF OROPHARYNX | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 146.9 | DX | MALIGNANT NEOPLASM OF OROPHARYNX, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 147 | DX | MALIGNANT NEOPLASM OF NASOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 147.0 | DX | MALIGNANT NEOPLASM OF SUPERIOR WALL OF NASOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 147.1 | DX | MALIGNANT NEOPLASM OF POSTERIOR WALL OF NASOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 147.2 | DX | MALIGNANT NEOPLASM OF LATERAL WALL OF NASOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 147.3 | DX | MALIGNANT NEOPLASM OF ANTERIOR WALL OF NASOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 147.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NASOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 147.9 | DX | MALIGNANT NEOPLASM OF NASOPHARYNX, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 148 | DX | MALIGNANT NEOPLASM OF HYPOPHARYNX | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 148.0 | DX | MALIGNANT NEOPLASM OF POSTCRICOID REGION OF HYPOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 148.1 | DX | MALIGNANT NEOPLASM OF PYRIFORM SINUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 148.2 | DX | MALIGNANT NEOPLASM OF ARYEPIGLOTTIC FOLD, HYPOPHARYNGEAL ASPECT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 148.3 | DX | MALIGNANT NEOPLASM OF POSTERIOR HYPOPHARYNGEAL WALL | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 148.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF HYPOPHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 148.9 | DX | MALIGNANT NEOPLASM OF HYPOPHARYNX, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 149 | DX | MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES WITHIN THE LIP, ORAL CAVITY AND PHARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 149.0 | DX | MALIGNANT NEOPLASM OF PHARYNX, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 149.1 | DX | MALIGNANT NEOPLASM OF WALDEYER'S RING | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 149.8 | DX | MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE LIP AND ORAL CAVITY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 149.9 | DX | MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE LIP AND ORAL CAVITY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150 | DX | MALIGNANT NEOPLASM OF OESOPHAGUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.0 | DX | MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.1 | DX | MALIGNANT NEOPLASM OF THORACIC ESOPHAGUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.2 | DX | MALIGNANT NEOPLASM OF ABDOMINAL ESOPHAGUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.3 | DX | MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.4 | DX | MALIGNANT NEOPLASM OF MIDDLE THIRD OF ESOPHAGUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.5 | DX | MALIGNANT NEOPLASM OF LOWER THIRD OF ESOPHAGUS | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED PART OF ESOPHAGUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 150.9 | DX | MALIGNANT NEOPLASM OF ESOPHAGUS, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151 | DX | MALIGNANT NEOPLASM OF STOMACH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.0 | DX | MALIGNANT NEOPLASM OF CARDIA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.1 | DX | MALIGNANT NEOPLASM OF PYLORUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.2 | DX | MALIGNANT NEOPLASM OF PYLORIC ANTRUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.3 | DX | MALIGNANT NEOPLASM OF FUNDUS OF STOMACH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.4 | DX | MALIGNANT NEOPLASM OF BODY OF STOMACH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.5 | DX | MALIGNANT NEOPLASM OF LESSER CURVATURE OF STOMACH, UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.6 | DX | MALIGNANT NEOPLASM OF GREATER CURVATURE OF STOMACH, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF STOMACH | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 151.9 | DX | MALIGNANT NEOPLASM OF STOMACH, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 152 | DX | MALIGNANT NEOPLASM OF SMALL INTESTINE, INCLUDING DUODENUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 152.0 | DX | MALIGNANT NEOPLASM OF DUODENUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 152.1 | DX | MALIGNANT NEOPLASM OF JEJUNUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 152.2 | DX | MALIGNANT NEOPLASM OF ILEUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 152.3 | DX | MALIGNANT NEOPLASM OF MECKEL'S DIVERTICULUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 152.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SMALL INTESTINE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 152.9 | DX | MALIGNANT NEOPLASM OF SMALL INTESTINE, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153 | DX | MALIGNANT NEOPLASM OF COLON | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.0 | DX | MALIGNANT NEOPLASM OF HEPATIC FLEXURE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.1 | DX | MALIGNANT NEOPLASM OF TRANSVERSE COLON | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.2 | DX | MALIGNANT NEOPLASM OF DESCENDING COLON | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.3 | DX | MALIGNANT NEOPLASM OF SIGMOID COLON | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.4 | DX | MALIGNANT NEOPLASM OF CECUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.5 | DX | MALIGNANT NEOPLASM OF APPENDIX VERMIFORMIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.6 | DX | MALIGNANT NEOPLASM OF ASCENDING COLON | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.7 | DX | MALIGNANT NEOPLASM OF SPLENIC FLEXURE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARGE INTESTINE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 153.9 | DX | MALIGNANT NEOPLASM OF COLON, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 154 | DX | MALIGNANT NEOPLASM OF RECTUM, RECTOSIGMOID JUNCTION AND ANUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 154.0 | DX | MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 154.1 | DX | MALIGNANT NEOPLASM OF RECTUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 154.2 | DX | MALIGNANT NEOPLASM OF ANAL CANAL | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 154.3 | DX | MALIGNANT NEOPLASM OF ANUS, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 154.8 | DX | MALIGNANT NEOPLASM OF OTHER SITES OF RECTUM, RECTOSIGMOID JUNCTION, AND ANUS | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 155 | DX | MALIGNANT NEOPLASM OF LIVER AND INTRAHEPATIC BILE DUCTS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 155.0 | DX | MALIGNANT NEOPLASM OF LIVER, PRIMARY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 155.1 | DX | MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 155.2 | DX | MALIGNANT NEOPLASM OF LIVER, NOT SPECIFIED AS PRIMARY OR SECONDARY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 156 | DX | MALIGNANT NEOPLASM OF GALLBLADDER AND EXTRAHEPATIC BILE DUCTS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 156.0 | DX | MALIGNANT NEOPLASM OF GALLBLADDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 156.1 | DX | MALIGNANT NEOPLASM OF EXTRAHEPATIC BILE DUCTS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 156.2 | DX | MALIGNANT NEOPLASM OF AMPULLA OF VATER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 156.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF GALLBLADDER AND EXTRAHEPATIC BILE DUCTS | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 156.9 | DX | MALIGNANT NEOPLASM OF BILIARY TRACT, PART UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157 | DX | MALIGNANT NEOPLASM OF PANCREAS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157.0 | DX | MALIGNANT NEOPLASM OF HEAD OF PANCREAS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157.1 | DX | MALIGNANT NEOPLASM OF BODY OF PANCREAS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157.2 | DX | MALIGNANT NEOPLASM OF TAIL OF PANCREAS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157.3 | DX | MALIGNANT NEOPLASM OF PANCREATIC DUCT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157.4 | DX | MALIGNANT NEOPLASM OF ISLETS OF LANGERHANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PANCREAS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 157.9 | DX | MALIGNANT NEOPLASM OF PANCREAS, PART UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 158 | DX | MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 158.0 | DX | MALIGNANT NEOPLASM OF RETROPERITONEUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 158.8 | DX | MALIGNANT NEOPLASM OF SPECIFIED PARTS OF PERITONEUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 158.9 | DX | MALIGNANT NEOPLASM OF PERITONEUM, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 159 | DX | MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES WITHIN THE DIGESTIVE ORGANS AND PERITONEUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 159.0 | DX | MALIGNANT NEOPLASM OF INTESTINAL TRACT, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 159.1 | DX | MALIGNANT NEOPLASM OF SPLEEN, NOT ELSEWHERE CLASSIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 159.8 | DX | MALIGNANT NEOPLASM OF OTHER SITES OF DIGESTIVE SYSTEM AND INTRA-ABDOMINAL ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 159.9 | DX | MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE DIGESTIVE ORGANS AND PERITONEUM | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160 | DX | MALIGNANT NEOPLASM OF NASAL CAVITIES, MIDDLE EAR AND ACCESSORY SINUSES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.0 | DX | MALIGNANT NEOPLASM OF NASAL CAVITIES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.1 | DX | MALIGNANT NEOPLASM OF AUDITORY TUBE, MIDDLE EAR, AND MASTOID AIR CELLS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.2 | DX | MALIGNANT NEOPLASM OF MAXILLARY SINUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.3 | DX | MALIGNANT NEOPLASM OF ETHMOIDAL SINUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.4 | DX | MALIGNANT NEOPLASM OF FRONTAL SINUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.5 | DX | MALIGNANT NEOPLASM OF SPHENOIDAL SINUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.8 | DX | MALIGNANT NEOPLASM OF OTHER ACCESSORY SINUSES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 160.9 | DX | MALIGNANT NEOPLASM OF ACCESSORY SINUS, UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 161 | DX | MALIGNANT NEOPLASM OF LARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 161.0 | DX | MALIGNANT NEOPLASM OF GLOTTIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 161.1 | DX | MALIGNANT NEOPLASM OF SUPRAGLOTTIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 161.2 | DX | MALIGNANT NEOPLASM OF SUBGLOTTIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 161.3 | DX | MALIGNANT NEOPLASM OF LARYNGEAL CARTILAGES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 161.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARYNX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 161.9 | DX | MALIGNANT NEOPLASM OF LARYNX, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162 | DX | MALIGNANT NEOPLASM OF TRACHEA, BRONCHUS AND LUNG | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162.0 | DX | MALIGNANT NEOPLASM OF TRACHEA | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162.2 | DX | MALIGNANT NEOPLASM OF MAIN BRONCHUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162.3 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, BRONCHUS OR LUNG | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162.4 | DX | MALIGNANT NEOPLASM OF MIDDLE LOBE, BRONCHUS OR LUNG | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162.5 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, BRONCHUS OR LUNG | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162.8 | DX | MALIGNANT NEOPLASM OF OTHER PARTS OF BRONCHUS OR LUNG | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 162.9 | DX | MALIGNANT NEOPLASM OF BRONCHUS AND LUNG, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 163 | DX | MALIGNANT NEOPLASM OF PLEURA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 163.0 | DX | MALIGNANT NEOPLASM OF PARIETAL PLEURA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 163.1 | DX | MALIGNANT NEOPLASM OF VISCERAL PLEURA | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 163.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PLEURA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 163.9 | DX | MALIGNANT NEOPLASM OF PLEURA, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 164 | DX | MALIGNANT NEOPLASM OF THYMUS, HEART AND MEDIASTINUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 164.0 | DX | MALIGNANT NEOPLASM OF THYMUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 164.1 | DX | MALIGNANT NEOPLASM OF HEART | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 164.2 | DX | MALIGNANT NEOPLASM OF ANTERIOR MEDIASTINUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 164.3 | DX | MALIGNANT NEOPLASM OF POSTERIOR MEDIASTINUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 164.8 | DX | MALIGNANT NEOPLASM OF OTHER PARTS OF MEDIASTINUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 164.9 | DX | MALIGNANT NEOPLASM OF MEDIASTINUM, PART UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 165 | DX | MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES WITHIN THE RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 165.0 | DX | MALIGNANT NEOPLASM OF UPPER RESPIRATORY TRACT, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 165.8 | DX | MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 165.9 | DX | MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE RESPIRATORY SYSTEM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170 | DX | MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.0 | DX | MALIGNANT NEOPLASM OF BONES OF SKULL AND FACE, EXCEPT MANDIBLE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.1 | DX | MALIGNANT NEOPLASM OF MANDIBLE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.2 | DX | MALIGNANT NEOPLASM OF VERTEBRAL COLUMN, EXCLUDING SACRUM AND COCCYX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.3 | DX | MALIGNANT NEOPLASM OF RIBS, STERNUM, AND CLAVICLE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.4 | DX | MALIGNANT NEOPLASM OF SCAPULA AND LONG BONES OF UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.5 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.6 | DX | MALIGNANT NEOPLASM OF PELVIC BONES, SACRUM, AND COCCYX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.7 | DX | MALIGNANT NEOPLASM OF LONG BONES OF LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.8 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 170.9 | DX | MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE, SITE UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.0 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.2 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF UPPER LIMB, INCLUDING SHOULDER | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.3 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF LOWER LIMB, INCLUDING HIP | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.4 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF THORAX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.5 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF ABDOMEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.6 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF PELVIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.7 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF TRUNK, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CONNECTIVE AND OTHER SOFT TISSUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 171.9 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE, SITE UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172 | DX | MALIGNANT MELANOMA OF SKIN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.0 | DX | MALIGNANT MELANOMA OF SKIN OF LIP | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.1 | DX | MALIGNANT MELANOMA OF SKIN OF EYELID, INCLUDING CANTHUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.2 | DX | MALIGNANT MELANOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.3 | DX | MALIGNANT MELANOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.4 | DX | MALIGNANT MELANOMA OF SKIN OF SCALP AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.5 | DX | MALIGNANT MELANOMA OF SKIN OF TRUNK, EXCEPT SCROTUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.6 | DX | MALIGNANT MELANOMA OF SKIN OF UPPER LIMB, INCLUDING SHOULDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.7 | DX | MALIGNANT MELANOMA OF SKIN OF LOWER LIMB, INCLUDING HIP | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.8 | DX | MALIGNANT MELANOMA OF OTHER SPECIFIED SITES OF SKIN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 172.9 | DX | MELANOMA OF SKIN, SITE UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174 | DX | MALIGNANT NEOPLASM OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.0 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.1 | DX | MALIGNANT NEOPLASM OF CENTRAL PORTION OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.2 | DX | MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.3 | DX | MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.4 | DX | MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.5 | DX | MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.6 | DX | MALIGNANT NEOPLASM OF AXILLARY TAIL OF FEMALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE BREAST | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 174.9 | DX | MALIGNANT NEOPLASM OF BREAST (FEMALE), UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 175 | DX | MALIGNANT NEOPLASM OF MALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 175.0 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF MALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 175.9 | DX | MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED SITES OF MALE BREAST | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176 | DX | KAPOSI'S SARCOMA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.0 | DX | KAPOSI'S SARCOMA, SKIN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.1 | DX | KAPOSI'S SARCOMA, SOFT TISSUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.2 | DX | KAPOSI'S SARCOMA, PALATE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.3 | DX | KAPOSI'S SARCOMA, GASTROINTESTINAL SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.4 | DX | KAPOSI'S SARCOMA, LUNG | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.5 | DX | KAPOSI'S SARCOMA, LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.8 | DX | KAPOSI'S SARCOMA, OTHER SPECIFIED SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 176.9 | DX | KAPOSI'S SARCOMA, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 179 | DX | MALIGNANT NEOPLASM OF UTERUS, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 179. | DX | MALIGNANT NEOPLASM OF UTERUS, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 180 | DX | MALIGNANT NEOPLASM OF CERVIX UTERI | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 180.0 | DX | MALIGNANT NEOPLASM OF ENDOCERVIX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 180.1 | DX | MALIGNANT NEOPLASM OF EXOCERVIX | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 180.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CERVIX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 180.9 | DX | MALIGNANT NEOPLASM OF CERVIX UTERI, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 181 | DX | MALIGNANT NEOPLASM OF PLACENTA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 181. | DX | MALIGNANT NEOPLASM OF PLACENTA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 182 | DX | MALIGNANT NEOPLASM OF BODY OF UTERUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 182.0 | DX | MALIGNANT NEOPLASM OF CORPUS UTERI, EXCEPT ISTHMUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 182.1 | DX | MALIGNANT NEOPLASM OF ISTHMUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 182.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BODY OF UTERUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183 | DX | MALIGNANT NEOPLASM OF OVARY AND OTHER UTERINE ADNEXA | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183.0 | DX | MALIGNANT NEOPLASM OF OVARY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183.2 | DX | MALIGNANT NEOPLASM OF FALLOPIAN TUBE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183.3 | DX | MALIGNANT NEOPLASM OF BROAD LIGAMENT OF UTERUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183.4 | DX | MALIGNANT NEOPLASM OF PARAMETRIUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183.5 | DX | MALIGNANT NEOPLASM OF ROUND LIGAMENT OF UTERUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF UTERINE ADNEXA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 183.9 | DX | MALIGNANT NEOPLASM OF UTERINE ADNEXA, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184 | DX | MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184.0 | DX | MALIGNANT NEOPLASM OF VAGINA | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184.1 | DX | MALIGNANT NEOPLASM OF LABIA MAJORA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184.2 | DX | MALIGNANT NEOPLASM OF LABIA MINORA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184.3 | DX | MALIGNANT NEOPLASM OF CLITORIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184.4 | DX | MALIGNANT NEOPLASM OF VULVA, UNSPECIFIED SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE GENITAL ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 184.9 | DX | MALIGNANT NEOPLASM OF FEMALE GENITAL ORGAN, SITE UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 185 | DX | MALIGNANT NEOPLASM OF PROSTATE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 185. | DX | MALIGNANT NEOPLASM OF PROSTATE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 186 | DX | MALIGNANT NEOPLASM OF TESTIS | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 186.0 | DX | MALIGNANT NEOPLASM OF UNDESCENDED TESTIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 186.9 | DX | MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED TESTIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187 | DX | MALIGNANT NEOPLASM OF PENIS AND OTHER MALE GENITAL ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.1 | DX | MALIGNANT NEOPLASM OF PREPUCE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.2 | DX | MALIGNANT NEOPLASM OF GLANS PENIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.3 | DX | MALIGNANT NEOPLASM OF BODY OF PENIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.4 | DX | MALIGNANT NEOPLASM OF PENIS, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.5 | DX | MALIGNANT NEOPLASM OF EPIDIDYMIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.6 | DX | MALIGNANT NEOPLASM OF SPERMATIC CORD | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.7 | DX | MALIGNANT NEOPLASM OF SCROTUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF MALE GENITAL ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 187.9 | DX | MALIGNANT NEOPLASM OF MALE GENITAL ORGAN, SITE UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188 | DX | MALIGNANT NEOPLASM OF BLADDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.0 | DX | MALIGNANT NEOPLASM OF TRIGONE OF URINARY BLADDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.1 | DX | MALIGNANT NEOPLASM OF DOME OF URINARY BLADDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.2 | DX | MALIGNANT NEOPLASM OF LATERAL WALL OF URINARY BLADDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.3 | DX | MALIGNANT NEOPLASM OF ANTERIOR WALL OF URINARY BLADDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.4 | DX | MALIGNANT NEOPLASM OF POSTERIOR WALL OF URINARY BLADDER | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.5 | DX | MALIGNANT NEOPLASM OF BLADDER NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.6 | DX | MALIGNANT NEOPLASM OF URETERIC ORIFICE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.7 | DX | MALIGNANT NEOPLASM OF URACHUS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BLADDER | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 188.9 | DX | MALIGNANT NEOPLASM OF BLADDER, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189 | DX | MALIGNANT NEOPLASM OF KIDNEY AND OTHER AND UNSPECIFIED URINARY ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189.0 | DX | MALIGNANT NEOPLASM OF KIDNEY, EXCEPT PELVIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189.1 | DX | MALIGNANT NEOPLASM OF RENAL PELVIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189.2 | DX | MALIGNANT NEOPLASM OF URETER | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189.3 | DX | MALIGNANT NEOPLASM OF URETHRA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189.4 | DX | MALIGNANT NEOPLASM OF PARAURETHRAL GLANDS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF URINARY ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 189.9 | DX | MALIGNANT NEOPLASM OF URINARY ORGAN, SITE UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190 | DX | MALIGNANT NEOPLASM OF EYE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.0 | DX | MALIGNANT NEOPLASM OF EYEBALL, EXCEPT CONJUNCTIVA, CORNEA, RETINA, AND CHOROID | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.1 | DX | MALIGNANT NEOPLASM OF ORBIT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.2 | DX | MALIGNANT NEOPLASM OF LACRIMAL GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.3 | DX | MALIGNANT NEOPLASM OF CONJUNCTIVA | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.4 | DX | MALIGNANT NEOPLASM OF CORNEA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.5 | DX | MALIGNANT NEOPLASM OF RETINA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.6 | DX | MALIGNANT NEOPLASM OF CHOROID | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.7 | DX | MALIGNANT NEOPLASM OF LACRIMAL DUCT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF EYE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 190.9 | DX | MALIGNANT NEOPLASM OF EYE, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191 | DX | MALIGNANT NEOPLASM OF BRAIN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.0 | DX | MALIGNANT NEOPLASM OF CEREBRUM, EXCEPT LOBES AND VENTRICLES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.1 | DX | MALIGNANT NEOPLASM OF FRONTAL LOBE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.2 | DX | MALIGNANT NEOPLASM OF TEMPORAL LOBE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.3 | DX | MALIGNANT NEOPLASM OF PARIETAL LOBE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.4 | DX | MALIGNANT NEOPLASM OF OCCIPITAL LOBE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.5 | DX | MALIGNANT NEOPLASM OF VENTRICLES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.6 | DX | MALIGNANT NEOPLASM OF CEREBELLUM NOS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.7 | DX | MALIGNANT NEOPLASM OF BRAIN STEM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.8 | DX | MALIGNANT NEOPLASM OF OTHER PARTS OF BRAIN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 191.9 | DX | MALIGNANT NEOPLASM OF BRAIN, UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 192 | DX | MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED PARTS OF NERVOUS SYSTEM | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 192.0 | DX | MALIGNANT NEOPLASM OF CRANIAL NERVES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 192.1 | DX | MALIGNANT NEOPLASM OF CEREBRAL MENINGES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 192.2 | DX | MALIGNANT NEOPLASM OF SPINAL CORD | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 192.3 | DX | MALIGNANT NEOPLASM OF SPINAL MENINGES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 192.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NERVOUS SYSTEM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 192.9 | DX | MALIGNANT NEOPLASM OF NERVOUS SYSTEM, PART UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 193 | DX | MALIGNANT NEOPLASM OF THYROID GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 193. | DX | MALIGNANT NEOPLASM OF THYROID GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194 | DX | MALIGNANT NEOPLASM OF OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.0 | DX | MALIGNANT NEOPLASM OF ADRENAL GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.1 | DX | MALIGNANT NEOPLASM OF PARATHYROID GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.3 | DX | MALIGNANT NEOPLASM OF PITUITARY GLAND AND CRANIOPHARYNGEAL DUCT | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.4 | DX | MALIGNANT NEOPLASM OF PINEAL GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.5 | DX | MALIGNANT NEOPLASM OF CAROTID BODY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.6 | DX | MALIGNANT NEOPLASM OF AORTIC BODY AND OTHER PARAGANGLIA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.8 | DX | MALIGNANT NEOPLASM OF OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 194.9 | DX | MALIGNANT NEOPLASM OF ENDOCRINE GLAND, SITE UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195 | DX | MALIGNANT NEOPLASM OF OTHER AND ILL-DEFINED SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195.0 | DX | MALIGNANT NEOPLASM OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195.1 | DX | MALIGNANT NEOPLASM OF THORAX | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195.2 | DX | MALIGNANT NEOPLASM OF ABDOMEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195.3 | DX | MALIGNANT NEOPLASM OF PELVIS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195.4 | DX | MALIGNANT NEOPLASM OF UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195.5 | DX | MALIGNANT NEOPLASM OF LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 195.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.0 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.1 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.2 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.3 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.5 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.6 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.8 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 196.9 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES, SITE UNSPECIFIED | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197 | DX | SECONDARY MALIGNANT NEOPLASM OF RESPIRATORY AND DIGESTIVE SYSTEMS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.0 | DX | SECONDARY MALIGNANT NEOPLASM OF LUNG | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.1 | DX | SECONDARY MALIGNANT NEOPLASM OF MEDIASTINUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.2 | DX | SECONDARY MALIGNANT NEOPLASM OF PLEURA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.3 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER RESPIRATORY ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.4 | DX | SECONDARY MALIGNANT NEOPLASM OF SMALL INTESTINE INCLUDING DUODENUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.5 | DX | SECONDARY MALIGNANT NEOPLASM OF LARGE INTESTINE AND RECTUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.6 | DX | SECONDARY MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.7 | DX | MALIGNANT NEOPLASM OF LIVER, SECONDARY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 197.8 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER DIGESTIVE ORGANS AND SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.0 | DX | SECONDARY MALIGNANT NEOPLASM OF KIDNEY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.1 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER URINARY ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.2 | DX | SECONDARY MALIGNANT NEOPLASM OF SKIN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.3 | DX | SECONDARY MALIGNANT NEOPLASM OF BRAIN AND SPINAL CORD | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.4 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER PARTS OF NERVOUS SYSTEM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.5 | DX | SECONDARY MALIGNANT NEOPLASM OF BONE AND BONE MARROW | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.6 | DX | SECONDARY MALIGNANT NEOPLASM OF OVARY | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.7 | DX | SECONDARY MALIGNANT NEOPLASM OF ADRENAL GLAND | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.81 | DX | SECONDARY MALIGNANT NEOPLASM OF BREAST | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.82 | DX | SECONDARY MALIGNANT NEOPLASM OF GENITAL ORGANS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 198.89 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 199 | DX | MALIGNANT NEOPLASM WITHOUT SPECIFICATION OF SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 199.0 | DX | DISSEMINATED MALIGNANT NEOPLASM WITHOUT SPECIFICATION OF SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 199.1 | DX | OTHER MALIGNANT NEOPLASM WITHOUT SPECIFICATION OF SITE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 199.2 | DX | MALIGNANT NEOPLASM ASSOCIATED WITH TRANSPLANT ORGAN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200 | DX | LYMPHOSARCOMA AND RETICULOSARCOMA AND OTHER SPECIFIED MALIGNANT TUMORS OF LYMPHATIC TISSUE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.00 | DX | RETICULOSARCOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.01 | DX | RETICULOSARCOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.02 | DX | RETICULOSARCOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.03 | DX | RETICULOSARCOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.04 | DX | RETICULOSARCOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.05 | DX | RETICULOSARCOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.06 | DX | RETICULOSARCOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.07 | DX | RETICULOSARCOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.08 | DX | RETICULOSARCOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.10 | DX | LYMPHOSARCOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.11 | DX | LYMPHOSARCOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.12 | DX | LYMPHOSARCOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.13 | DX | LYMPHOSARCOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.14 | DX | LYMPHOSARCOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.15 | DX | LYMPHOSARCOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.16 | DX | LYMPHOSARCOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.17 | DX | LYMPHOSARCOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.18 | DX | LYMPHOSARCOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.20 | DX | BURKITT'S TUMOR OR LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.21 | DX | BURKITT'S TUMOR OR LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.22 | DX | BURKITT'S TUMOR OR LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.23 | DX | BURKITT'S TUMOR OR LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.24 | DX | BURKITT'S TUMOR OR LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.25 | DX | BURKITT'S TUMOR OR LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.26 | DX | BURKITT'S TUMOR OR LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.27 | DX | BURKITT'S TUMOR OR LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.28 | DX | BURKITT'S TUMOR OR LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.30 | DX | MARGINAL ZONE LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.31 | DX | MARGINAL ZONE LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.32 | DX | MARGINAL ZONE LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.33 | DX | MARGINAL ZONE LYMPHOMA, INTRAABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.34 | DX | MARGINAL ZONE LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.35 | DX | MARGINAL ZONE LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.36 | DX | MARGINAL ZONE LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.37 | DX | MARGINAL ZONE LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.38 | DX | MARGINAL ZONE LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.40 | DX | MANTLE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.41 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.42 | DX | MANTLE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.43 | DX | MANTLE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.44 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.45 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.46 | DX | MANTLE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.47 | DX | MANTLE CELL LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.48 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.50 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.51 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.52 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.53 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.54 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.55 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.56 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.57 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.58 | DX | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.60 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.61 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.62 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.63 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.64 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.65 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.66 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.67 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.68 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.70 | DX | LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.71 | DX | LARGE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.72 | DX | LARGE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.73 | DX | LARGE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.74 | DX | LARGE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.75 | DX | LARGE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.76 | DX | LARGE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.77 | DX | LARGE CELL LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.78 | DX | LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.80 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.81 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.82 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.83 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.84 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.85 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.86 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.87 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 200.88 | DX | OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201 | DX | HODGKIN'S DISEASE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.00 | DX | HODGKIN'S PARAGRANULOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.01 | DX | HODGKIN'S PARAGRANULOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.02 | DX | HODGKIN'S PARAGRANULOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.03 | DX | HODGKIN'S PARAGRANULOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.04 | DX | HODGKIN'S PARAGRANULOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.05 | DX | HODGKIN'S PARAGRANULOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.06 | DX | HODGKIN'S PARAGRANULOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.07 | DX | HODGKIN'S PARAGRANULOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.08 | DX | HODGKIN'S PARAGRANULOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.10 | DX | HODGKIN'S GRANULOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20111 | DX | HODGKIN'S GRANULOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20112 | DX | HODGKIN'S GRANULOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20113 | DX | HODGKIN'S GRANULOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20114 | DX | HODGKIN'S GRANULOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20115 | DX | HODGKIN'S GRANULOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20116 | DX | HODGKIN'S GRANULOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20117 | DX | HODGKIN'S GRANULOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20118 | DX | HODGKIN'S GRANULOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20120 | DX | HODGKIN'S SARCOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20121 | DX | HODGKIN'S SARCOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20122 | DX | HODGKIN'S SARCOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20123 | DX | HODGKIN'S SARCOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20124 | DX | HODGKIN'S SARCOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20125 | DX | HODGKIN'S SARCOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20126 | DX | HODGKIN'S SARCOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20127 | DX | HODGKIN'S SARCOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20128 | DX | HODGKIN'S SARCOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20140 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20141 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20142 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20143 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20144 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20145 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20146 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20147 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20148 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20150 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20151 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20152 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20153 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20154 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20155 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20156 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20157 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20158 | DX | HODGKIN'S DISEASE, NODULAR SCLEROSIS, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 20160 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.61 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.62 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.63 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.64 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.65 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.66 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.67 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.68 | DX | HODGKIN'S DISEASE, MIXED CELLULARITY, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.70 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.71 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.72 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.73 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.74 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.75 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.76 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.77 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.78 | DX | HODGKIN'S DISEASE, LYMPHOCYTIC DEPLETION, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.90 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.91 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.92 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.93 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.94 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.95 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.96 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.97 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 201.98 | DX | HODGKIN'S DISEASE, UNSPECIFIED TYPE, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202 | DX | OTHER MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.00 | DX | NODULAR LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.01 | DX | NODULAR LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.02 | DX | NODULAR LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.03 | DX | NODULAR LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.04 | DX | NODULAR LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.05 | DX | NODULAR LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.06 | DX | NODULAR LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.07 | DX | NODULAR LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.08 | DX | NODULAR LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.10 | DX | MYCOSIS FUNGOIDES, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.11 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.12 | DX | MYCOSIS FUNGOIDES, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.13 | DX | MYCOSIS FUNGOIDES, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.14 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.15 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.16 | DX | MYCOSIS FUNGOIDES, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.17 | DX | MYCOSIS FUNGOIDES, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.18 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.20 | DX | SEZARY'S DISEASE, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.21 | DX | SEZARY'S DISEASE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.22 | DX | SEZARY'S DISEASE, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.23 | DX | SEZARY'S DISEASE, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.24 | DX | SEZARY'S DISEASE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.25 | DX | SEZARY'S DISEASE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.26 | DX | SEZARY'S DISEASE, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.27 | DX | SEZARY'S DISEASE, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.28 | DX | SEZARY'S DISEASE, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.30 | DX | MALIGNANT HISTIOCYTOSIS, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.31 | DX | MALIGNANT HISTIOCYTOSIS, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.32 | DX | MALIGNANT HISTIOCYTOSIS, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.33 | DX | MALIGNANT HISTIOCYTOSIS, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.34 | DX | MALIGNANT HISTIOCYTOSIS, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.35 | DX | MALIGNANT HISTIOCYTOSIS, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.36 | DX | MALIGNANT HISTIOCYTOSIS, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.37 | DX | MALIGNANT HISTIOCYTOSIS, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.38 | DX | MALIGNANT HISTIOCYTOSIS, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.40 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.41 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.42 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.43 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.44 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, LYMPH NODES OF AXILLA AND UPPER ARM | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.45 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.46 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.47 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.48 | DX | LEUKEMIC RETICULOENDOTHELIOSIS, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.50 | DX | LETTERER-SIWE DISEASE, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.51 | DX | LETTERER-SIWE DISEASE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.52 | DX | LETTERER-SIWE DISEASE, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.53 | DX | LETTERER-SIWE DISEASE, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.54 | DX | LETTERER-SIWE DISEASE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.55 | DX | LETTERER-SIWE DISEASE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.56 | DX | LETTERER-SIWE DISEASE, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.57 | DX | LETTERER-SIWE DISEASE, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.58 | DX | LETTERER-SIWE DISEASE, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.60 | DX | MALIGNANT MAST CELL TUMORS, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.61 | DX | MALIGNANT MAST CELL TUMORS, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.62 | DX | MALIGNANT MAST CELL TUMORS, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.63 | DX | MALIGNANT MAST CELL TUMORS, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.64 | DX | MALIGNANT MAST CELL TUMORS, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.65 | DX | MALIGNANT MAST CELL TUMORS, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.66 | DX | MALIGNANT MAST CELL TUMORS, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.67 | DX | MALIGNANT MAST CELL TUMORS, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.68 | DX | MALIGNANT MAST CELL TUMORS, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.70 | DX | PERIPHERAL T CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.71 | DX | PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.72 | DX | PERIPHERAL T CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.73 | DX | PERIPHERAL T CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.74 | DX | PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.75 | DX | PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.76 | DX | PERIPHERAL T CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.77 | DX | PERIPHERAL T CELL LYMPHOMA, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.78 | DX | PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.80 | DX | OTHER MALIGNANT LYMPHOMAS, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.81 | DX | OTHER MALIGNANT LYMPHOMAS, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.82 | DX | OTHER MALIGNANT LYMPHOMAS, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.83 | DX | OTHER MALIGNANT LYMPHOMAS, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.84 | DX | OTHER MALIGNANT LYMPHOMAS, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.85 | DX | OTHER MALIGNANT LYMPHOMAS, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.86 | DX | OTHER MALIGNANT LYMPHOMAS, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.87 | DX | OTHER MALIGNANT LYMPHOMAS, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.88 | DX | OTHER MALIGNANT LYMPHOMAS, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.90 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.91 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.92 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, INTRATHORACIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.93 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.94 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.95 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.96 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, INTRAPELVIC LYMPH NODES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.97 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, SPLEEN | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 202.98 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE, LYMPH NODES OF MULTIPLE SITES | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203 | DX | MULTIPLE MYELOMA AND IMMUNOPROLIFERATIVE NEOPLASMS | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.00 | DX | MULTIPLE MYELOMA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.01 | DX | MULTIPLE MYELOMA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.02 | DX | MULTIPLE MYELOMA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.10 | DX | PLASMA CELL LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.11 | DX | PLASMA CELL LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.12 | DX | PLASMA CELL LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.80 | DX | OTHER IMMUNOPROLIFERATIVE NEOPLASMS, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.81 | DX | OTHER IMMUNOPROLIFERATIVE NEOPLASMS, IN REMISSION | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 203.82 | DX | OTHER IMMUNOPROLIFERATIVE NEOPLASMS, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204 | DX | LYMPHOID LEUKEMIA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.00 | DX | ACUTE LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.01 | DX | ACUTE LYMPHOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.02 | DX | ACUTE LYMPHOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.10 | DX | CHRONIC LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.11 | DX | CHRONIC LYMPHOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.12 | DX | CHRONIC LYMPHOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.20 | DX | SUBACUTE LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.21 | DX | SUBACUTE LYMPHOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.22 | DX | SUBACUTE LYMPHOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.80 | DX | OTHER LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.81 | DX | OTHER LYMPHOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.82 | DX | OTHER LYMPHOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.90 | DX | UNSPECIFIED LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.91 | DX | UNSPECIFIED LYMPHOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 204.92 | DX | UNSPECIFIED LYMPHOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205 | DX | MYELOID LEUKEMIA | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.00 | DX | ACUTE MYELOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.01 | DX | ACUTE MYELOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.02 | DX | ACUTE MYELOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.10 | DX | CHRONIC MYELOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.11 | DX | CHRONIC MYELOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.12 | DX | CHRONIC MYELOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.20 | DX | SUBACUTE MYELOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.21 | DX | SUBACUTE MYELOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.22 | DX | SUBACUTE MYELOID LEUKEMIA, IN RELAPSE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.30 | DX | MYELOID SARCOMA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.31 | DX | MYELOID SARCOMA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.32 | DX | MYELOID SARCOMA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.80 | DX | OTHER MYELOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.81 | DX | OTHER MYELOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.82 | DX | OTHER MYELOID LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.90 | DX | UNSPECIFIED MYELOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.91 | DX | UNSPECIFIED MYELOID LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 205.92 | DX | UNSPECIFIED MYELOID LEUKEMIA, IN RELAPSE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206 | DX | MONOCYTIC LEUKEMIA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.00 | DX | ACUTE MONOCYTIC LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.01 | DX | ACUTE MONOCYTIC LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.02 | DX | ACUTE MONOCYTIC LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.10 | DX | CHRONIC MONOCYTIC LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.11 | DX | CHRONIC MONOCYTIC LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.12 | DX | CHRONIC MONOCYTIC LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.20 | DX | SUBACUTE MONOCYTIC LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.21 | DX | SUBACUTE MONOCYTIC LEUKEMIA, IN REMISSION | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.22 | DX | SUBACUTE MONOCYTIC LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.80 | DX | OTHER MONOCYTIC LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.81 | DX | OTHER MONOCYTIC LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.82 | DX | OTHER MONOCYTIC LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.90 | DX | UNSPECIFIED MONOCYTIC LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.91 | DX | UNSPECIFIED MONOCYTIC LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 206.92 | DX | UNSPECIFIED MONOCYTIC LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207 | DX | OTHER SPECIFIED LEUKEMIA | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.00 | DX | ACUTE ERYTHREMIA AND ERYTHROLEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.01 | DX | ACUTE ERYTHREMIA AND ERYTHROLEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.02 | DX | ACUTE ERYTHREMIA AND ERYTHROLEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.10 | DX | CHRONIC ERYTHREMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.11 | DX | CHRONIC ERYTHREMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.12 | DX | CHRONIC ERYTHREMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.20 | DX | MEGAKARYOCYTIC LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.21 | DX | MEGAKARYOCYTIC LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.22 | DX | MEGAKARYOCYTIC LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.80 | DX | OTHER SPECIFIED LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.81 | DX | OTHER SPECIFIED LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 207.82 | DX | OTHER SPECIFIED LEUKEMIA, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208 | DX | LEUKEMIA OF UNSPECIFIED CELL TYPE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.00 | DX | ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.01 | DX | ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.02 | DX | ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.10 | DX | CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.11 | DX | CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.12 | DX | CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE, IN RELAPSE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------------------|----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.20 | DX | SUBACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.21 | DX | SUBACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.22 | DX | SUBACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.80 | DX | OTHER LEUKEMIA OF UNSPECIFIED CELL TYPE, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.81 | DX | OTHER LEUKEMIA OF UNSPECIFIED CELL TYPE, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.82 | DX | OTHER LEUKEMIA OF UNSPECIFIED CELL TYPE, IN RELAPSE | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.90 | DX | UNSPECIFIED LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.91 | DX | UNSPECIFIED LEUKEMIA, IN REMISSION | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 208.92 | DX | UNSPECIFIED LEUKEMIA, IN RELAPSE | ICD-9-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.0 | DX | MALIGNANT NEOPLASM OF EXTERNAL UPPER LIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.1 | DX | MALIGNANT NEOPLASM OF EXTERNAL LOWER LIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.2 | DX | MALIGNANT NEOPLASM OF EXTERNAL LIP, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.3 | DX | MALIGNANT NEOPLASM OF UPPER LIP, INNER ASPECT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.4 | DX | MALIGNANT NEOPLASM OF LOWER LIP, INNER ASPECT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.5 | DX | MALIGNANT NEOPLASM OF LIP, UNSPECIFIED, INNER ASPECT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.6 | DX | MALIGNANT NEOPLASM OF COMMISSURE OF LIP, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF LIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C00.9 | DX | MALIGNANT NEOPLASM OF LIP, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C01 | DX | MALIGNANT NEOPLASM OF BASE OF TONGUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C02.0 | DX | MALIGNANT NEOPLASM OF DORSAL SURFACE OF TONGUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C02.1 | DX | MALIGNANT NEOPLASM OF BORDER OF TONGUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C02.2 | DX | MALIGNANT NEOPLASM OF VENTRAL SURFACE OF TONGUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C02.3 | DX | MALIGNANT NEOPLASM OF ANTERIOR TWO-THIRDS OF TONGUE, PART UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C02.4 | DX | MALIGNANT NEOPLASM OF LINGUAL TONSIL | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C02.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF TONGUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C02.9 | DX | MALIGNANT NEOPLASM OF TONGUE, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C03.0 | DX | MALIGNANT NEOPLASM OF UPPER GUM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C03.1 | DX | MALIGNANT NEOPLASM OF LOWER GUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C03.9 | DX | MALIGNANT NEOPLASM OF GUM, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C04.0 | DX | MALIGNANT NEOPLASM OF ANTERIOR FLOOR OF MOUTH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C04.1 | DX | MALIGNANT NEOPLASM OF LATERAL FLOOR OF MOUTH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C04.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF FLOOR OF MOUTH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C04.9 | DX | MALIGNANT NEOPLASM OF FLOOR OF MOUTH, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C05.0 | DX | MALIGNANT NEOPLASM OF HARD PALATE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C05.1 | DX | MALIGNANT NEOPLASM OF SOFT PALATE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C05.2 | DX | MALIGNANT NEOPLASM OF UVULA | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C05.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF PALATE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C05.9 | DX | MALIGNANT NEOPLASM OF PALATE, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C06.0 | DX | MALIGNANT NEOPLASM OF CHEEK MUCOSA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C06.1 | DX | MALIGNANT NEOPLASM OF VESTIBULE OF MOUTH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C06.2 | DX | MALIGNANT NEOPLASM OF RETROMOLAR AREA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C06.80 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF UNSPECIFIED PARTS OF MOUTH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C06.89 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF OTHER PARTS OF MOUTH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C06.9 | DX | MALIGNANT NEOPLASM OF MOUTH, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C07 | DX | MALIGNANT NEOPLASM OF PAROTID GLAND | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C08.0 | DX | MALIGNANT NEOPLASM OF SUBMANDIBULAR GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C08.1 | DX | MALIGNANT NEOPLASM OF SUBLINGUAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C08.9 | DX | MALIGNANT NEOPLASM OF MAJOR SALIVARY GLAND, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C09.0 | DX | MALIGNANT NEOPLASM OF TONSILLAR FOSSA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C09.1 | DX | MALIGNANT NEOPLASM OF TONSILLAR PILLAR (ANTERIOR) (POSTERIOR) | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C09.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF TONSIL | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C09.9 | DX | MALIGNANT NEOPLASM OF TONSIL, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C10.0 | DX | MALIGNANT NEOPLASM OF VALLECULA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C10.1 | DX | MALIGNANT NEOPLASM OF ANTERIOR SURFACE OF EPIGLOTTIS | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C10.2 | DX | MALIGNANT NEOPLASM OF LATERAL WALL OF OROPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C10.3 | DX | MALIGNANT NEOPLASM OF POSTERIOR WALL OF OROPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C10.4 | DX | MALIGNANT NEOPLASM OF BRANCHIAL CLEFT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C10.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF OROPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C10.9 | DX | MALIGNANT NEOPLASM OF OROPHARYNX, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C11.0 | DX | MALIGNANT NEOPLASM OF SUPERIOR WALL OF NASOPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C11.1 | DX | MALIGNANT NEOPLASM OF POSTERIOR WALL OF NASOPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C11.2 | DX | MALIGNANT NEOPLASM OF LATERAL WALL OF NASOPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C11.3 | DX | MALIGNANT NEOPLASM OF ANTERIOR WALL OF NASOPHARYNX | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C11.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF NASOPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C11.9 | DX | MALIGNANT NEOPLASM OF NASOPHARYNX, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C12 | DX | MALIGNANT NEOPLASM OF PYRIFORM SINUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C13.0 | DX | MALIGNANT NEOPLASM OF POSTCRICOID REGION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C13.1 | DX | MALIGNANT NEOPLASM OF ARYEPIGLOTTIC FOLD, HYPOPHARYNGEAL ASPECT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C13.2 | DX | MALIGNANT NEOPLASM OF POSTERIOR WALL OF HYPOPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C13.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF HYPOPHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C13.9 | DX | MALIGNANT NEOPLASM OF HYPOPHARYNX, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C14.0 | DX | MALIGNANT NEOPLASM OF PHARYNX, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C14.2 | DX | MALIGNANT NEOPLASM OF WALDEYER'S RING | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C14.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF LIP, ORAL CAVITY AND PHARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C15.3 | DX | MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C15.4 | DX | MALIGNANT NEOPLASM OF MIDDLE THIRD OF ESOPHAGUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C15.5 | DX | MALIGNANT NEOPLASM OF LOWER THIRD OF ESOPHAGUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C15.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF ESOPHAGUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C15.9 | DX | MALIGNANT NEOPLASM OF ESOPHAGUS, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.0 | DX | MALIGNANT NEOPLASM OF CARDIA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.1 | DX | MALIGNANT NEOPLASM OF FUNDUS OF STOMACH | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.2 | DX | MALIGNANT NEOPLASM OF BODY OF STOMACH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.3 | DX | MALIGNANT NEOPLASM OF PYLORIC ANTRUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.4 | DX | MALIGNANT NEOPLASM OF PYLORUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.5 | DX | MALIGNANT NEOPLASM OF LESSER CURVATURE OF STOMACH, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.6 | DX | MALIGNANT NEOPLASM OF GREATER CURVATURE OF STOMACH, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF STOMACH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C16.9 | DX | MALIGNANT NEOPLASM OF STOMACH, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C17.0 | DX | MALIGNANT NEOPLASM OF DUODENUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C17.1 | DX | MALIGNANT NEOPLASM OF JEJUNUM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C17.2 | DX | MALIGNANT NEOPLASM OF ILEUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C17.3 | DX | MECKEL'S DIVERTICULUM, MALIGNANT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C17.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF SMALL INTESTINE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C17.9 | DX | MALIGNANT NEOPLASM OF SMALL INTESTINE, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.0 | DX | MALIGNANT NEOPLASM OF CECUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.1 | DX | MALIGNANT NEOPLASM OF APPENDIX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.2 | DX | MALIGNANT NEOPLASM OF ASCENDING COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.3 | DX | MALIGNANT NEOPLASM OF HEPATIC FLEXURE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.4 | DX | MALIGNANT NEOPLASM OF TRANSVERSE COLON | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.5 | DX | MALIGNANT NEOPLASM OF SPLENIC FLEXURE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.6 | DX | MALIGNANT NEOPLASM OF DESCENDING COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.7 | DX | MALIGNANT NEOPLASM OF SIGMOID COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C18.9 | DX | MALIGNANT NEOPLASM OF COLON, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C19 | DX | MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C20 | DX | MALIGNANT NEOPLASM OF RECTUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C21.0 | DX | MALIGNANT NEOPLASM OF ANUS, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C21.1 | DX | MALIGNANT NEOPLASM OF ANAL CANAL | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C21.2 | DX | MALIGNANT NEOPLASM OF CLOACOGENIC ZONE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C21.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF RECTUM, ANUS AND ANAL CANAL | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.0 | DX | LIVER CELL CARCINOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.1 | DX | INTRAHEPATIC BILE DUCT CARCINOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.2 | DX | HEPATOBLASTOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.3 | DX | ANGIOSARCOMA OF LIVER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.4 | DX | OTHER SARCOMAS OF LIVER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.7 | DX | OTHER SPECIFIED CARCINOMAS OF LIVER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.8 | DX | MALIGNANT NEOPLASM OF LIVER, PRIMARY, UNSPECIFIED AS TO TYPE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C22.9 | DX | MALIGNANT NEOPLASM OF LIVER, NOT SPECIFIED AS PRIMARY OR SECONDARY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C23 | DX | MALIGNANT NEOPLASM OF GALLBLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C24.0 | DX | MALIGNANT NEOPLASM OF EXTRAHEPATIC BILE DUCT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C24.1 | DX | MALIGNANT NEOPLASM OF AMPULLA OF VATER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C24.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF BILIARY TRACT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C24.9 | DX | MALIGNANT NEOPLASM OF BILIARY TRACT, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.0 | DX | MALIGNANT NEOPLASM OF HEAD OF PANCREAS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.1 | DX | MALIGNANT NEOPLASM OF BODY OF PANCREAS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.2 | DX | MALIGNANT NEOPLASM OF TAIL OF PANCREAS | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.3 | DX | MALIGNANT NEOPLASM OF PANCREATIC DUCT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.4 | DX | MALIGNANT NEOPLASM OF ENDOCRINE PANCREAS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.7 | DX | MALIGNANT NEOPLASM OF OTHER PARTS OF PANCREAS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF PANCREAS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C25.9 | DX | MALIGNANT NEOPLASM OF PANCREAS, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C26.0 | DX | MALIGNANT NEOPLASM OF INTESTINAL TRACT, PART UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C26.1 | DX | MALIGNANT NEOPLASM OF SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C26.9 | DX | MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE DIGESTIVE SYSTEM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C30.0 | DX | MALIGNANT NEOPLASM OF NASAL CAVITY | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|--------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C30.1 | DX | MALIGNANT NEOPLASM OF MIDDLE EAR | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C31.0 | DX | MALIGNANT NEOPLASM OF MAXILLARY SINUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C31.1 | DX | MALIGNANT NEOPLASM OF ETHMOIDAL SINUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C31.2 | DX | MALIGNANT NEOPLASM OF FRONTAL SINUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C31.3 | DX | MALIGNANT NEOPLASM OF SPHENOID SINUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C31.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF ACCESSORY SINUSES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C31.9 | DX | MALIGNANT NEOPLASM OF ACCESSORY SINUS, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C32.0 | DX | MALIGNANT NEOPLASM OF GLOTTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C32.1 | DX | MALIGNANT NEOPLASM OF SUPRAGLOTTIS | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C32.2 | DX | MALIGNANT NEOPLASM OF SUBGLOTTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C32.3 | DX | MALIGNANT NEOPLASM OF LARYNGEAL CARTILAGE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C32.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF LARYNX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C32.9 | DX | MALIGNANT NEOPLASM OF LARYNX, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C33 | DX | MALIGNANT NEOPLASM OF TRACHEA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.00 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED MAIN BRONCHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.01 | DX | MALIGNANT NEOPLASM OF RIGHT MAIN BRONCHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.02 | DX | MALIGNANT NEOPLASM OF LEFT MAIN BRONCHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.10 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, UNSPECIFIED BRONCHUS OR LUNG | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.12 | DX | MALIGNANT NEOPLASM OF UPPER LOBE, LEFT BRONCHUS OR LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.2 | DX | MALIGNANT NEOPLASM OF MIDDLE LOBE, BRONCHUS OR LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.30 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, UNSPECIFIED BRONCHUS OR LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.31 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, RIGHT BRONCHUS OR LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.32 | DX | MALIGNANT NEOPLASM OF LOWER LOBE, LEFT BRONCHUS OR LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.80 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF UNSPECIFIED BRONCHUS AND LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.81 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF RIGHT BRONCHUS AND LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.82 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF LEFT BRONCHUS AND LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.90 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF UNSPECIFIED BRONCHUS OR LUNG | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.91 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF RIGHT BRONCHUS OR LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C34.92 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF LEFT BRONCHUS OR LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C37 | DX | MALIGNANT NEOPLASM OF THYMUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C38.0 | DX | MALIGNANT NEOPLASM OF HEART | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C38.1 | DX | MALIGNANT NEOPLASM OF ANTERIOR MEDIASTINUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C38.2 | DX | MALIGNANT NEOPLASM OF POSTERIOR MEDIASTINUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C38.3 | DX | MALIGNANT NEOPLASM OF MEDIASTINUM, PART UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C38.4 | DX | MALIGNANT NEOPLASM OF PLEURA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C38.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF HEART, MEDIASTINUM AND PLEURA | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C39.0 | DX | MALIGNANT NEOPLASM OF UPPER RESPIRATORY TRACT, PART UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C39.9 | DX | MALIGNANT NEOPLASM OF LOWER RESPIRATORY TRACT, PART UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.00 | DX | MALIGNANT NEOPLASM OF SCAPULA AND LONG BONES OF UNSPECIFIED UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.01 | DX | MALIGNANT NEOPLASM OF SCAPULA AND LONG BONES OF RIGHT UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.02 | DX | MALIGNANT NEOPLASM OF SCAPULA AND LONG BONES OF LEFT UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.10 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF UNSPECIFIED UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.11 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF RIGHT UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.12 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF LEFT UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.20 | DX | MALIGNANT NEOPLASM OF LONG BONES OF UNSPECIFIED LOWER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.21 | DX | MALIGNANT NEOPLASM OF LONG BONES OF RIGHT LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.22 | DX | MALIGNANT NEOPLASM OF LONG BONES OF LEFT LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.30 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF UNSPECIFIED LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.31 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF RIGHT LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.32 | DX | MALIGNANT NEOPLASM OF SHORT BONES OF LEFT LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.80 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF BONE AND ARTICULAR CARTILAGE OF UNSPECIFIED LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.81 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF BONE AND ARTICULAR CARTILAGE OF RIGHT LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.82 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF BONE AND ARTICULAR CARTILAGE OF LEFT LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.90 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED BONES AND ARTICULAR CARTILAGE OF UNSPECIFIED LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.91 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED BONES AND ARTICULAR CARTILAGE OF RIGHT LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C40.92 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED BONES AND ARTICULAR CARTILAGE OF LEFT LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C41.0 | DX | MALIGNANT NEOPLASM OF BONES OF SKULL AND FACE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C41.1 | DX | MALIGNANT NEOPLASM OF MANDIBLE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C41.2 | DX | MALIGNANT NEOPLASM OF VERTEBRAL COLUMN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C41.3 | DX | MALIGNANT NEOPLASM OF RIBS, STERNUM AND CLAVICLE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C41.4 | DX | MALIGNANT NEOPLASM OF PELVIC BONES, SACRUM AND COCCYX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C41.9 | DX | MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.0 | DX | MALIGNANT MELANOMA OF LIP | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.10 | DX | MALIGNANT MELANOMA OF UNSPECIFIED EYELID, INCLUDING CANTHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.111 | DX | MALIGNANT MELANOMA OF RIGHT UPPER EYELID, INCLUDING CANTHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.112 | DX | MALIGNANT MELANOMA OF RIGHT LOWER EYELID, INCLUDING CANTHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.12 | DX | MALIGNANT MELANOMA OF LEFT EYELID, INCLUDING CANTHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.121 | DX | MALIGNANT MELANOMA OF LEFT UPPER EYELID, INCLUDING CANTHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.122 | DX | MALIGNANT MELANOMA OF LEFT LOWER EYELID, INCLUDING CANTHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.20 | DX | MALIGNANT MELANOMA OF UNSPECIFIED EAR AND EXTERNAL AURICULAR CANAL | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.21 | DX | MALIGNANT MELANOMA OF RIGHT EAR AND EXTERNAL AURICULAR CANAL | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.22 | DX | MALIGNANT MELANOMA OF LEFT EAR AND EXTERNAL AURICULAR CANAL | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.30 | DX | MALIGNANT MELANOMA OF UNSPECIFIED PART OF FACE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.31 | DX | MALIGNANT MELANOMA OF NOSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.39 | DX | MALIGNANT MELANOMA OF OTHER PARTS OF FACE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.4 | DX | MALIGNANT MELANOMA OF SCALP AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.51 | DX | MALIGNANT MELANOMA OF ANAL SKIN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.52 | DX | MALIGNANT MELANOMA OF SKIN OF BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.59 | DX | MALIGNANT MELANOMA OF OTHER PART OF TRUNK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.60 | DX | MALIGNANT MELANOMA OF UNSPECIFIED UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.61 | DX | MALIGNANT MELANOMA OF RIGHT UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.62 | DX | MALIGNANT MELANOMA OF LEFT UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.70 | DX | MALIGNANT MELANOMA OF UNSPECIFIED LOWER LIMB, INCLUDING HIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.71 | DX | MALIGNANT MELANOMA OF RIGHT LOWER LIMB, INCLUDING HIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.72 | DX | MALIGNANT MELANOMA OF LEFT LOWER LIMB, INCLUDING HIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.8 | DX | MALIGNANT MELANOMA OF OVERLAPPING SITES OF SKIN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C43.9 | DX | MALIGNANT MELANOMA OF SKIN, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C45.0 | DX | MESOTHELIOMA OF PLEURA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C45.1 | DX | MESOTHELIOMA OF PERITONEUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C45.2 | DX | MESOTHELIOMA OF PERICARDIUM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C45.7 | DX | MESOTHELIOMA OF OTHER SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C45.9 | DX | MESOTHELIOMA, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.0 | DX | KAPOSI'S SARCOMA OF SKIN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.1 | DX | KAPOSI'S SARCOMA OF SOFT TISSUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.2 | DX | KAPOSI'S SARCOMA OF PALATE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.3 | DX | KAPOSI'S SARCOMA OF LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.4 | DX | KAPOSI'S SARCOMA OF GASTROINTESTINAL SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.50 | DX | KAPOSI'S SARCOMA OF UNSPECIFIED LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.51 | DX | KAPOSI'S SARCOMA OF RIGHT LUNG | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.52 | DX | KAPOSI'S SARCOMA OF LEFT LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.7 | DX | KAPOSI'S SARCOMA OF OTHER SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C46.9 | DX | KAPOSI'S SARCOMA, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.0 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF HEAD, FACE AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.10 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF UNSPECIFIED UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.11 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF RIGHT UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.12 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF LEFT UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.20 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF UNSPECIFIED LOWER LIMB, INCLUDING HIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.21 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF RIGHT LOWER LIMB, INCLUDING HIP | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.22 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF LEFT LOWER LIMB, INCLUDING HIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.3 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF THORAX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.4 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF ABDOMEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.5 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.6 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES OF TRUNK, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C47.9 | DX | MALIGNANT NEOPLASM OF PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C48.0 | DX | MALIGNANT NEOPLASM OF RETROPERITONEUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C48.1 | DX | MALIGNANT NEOPLASM OF SPECIFIED PARTS OF PERITONEUM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C48.2 | DX | MALIGNANT NEOPLASM OF PERITONEUM, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C48.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF RETROPERITONEUM AND PERITONEUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.0 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF HEAD, FACE AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.10 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF UNSPECIFIED UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.11 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF RIGHT UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.12 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF LEFT UPPER LIMB, INCLUDING SHOULDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.20 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF UNSPECIFIED LOWER LIMB, INCLUDING HIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.21 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF RIGHT LOWER LIMB, INCLUDING HIP | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.22 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF LEFT LOWER LIMB, INCLUDING HIP | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.3 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF THORAX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.4 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF ABDOMEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.5 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.6 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE OF TRUNK, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF CONNECTIVE AND SOFT TISSUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.9 | DX | MALIGNANT NEOPLASM OF CONNECTIVE AND SOFT TISSUE, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.A0 | DX | GASTROINTESTINAL STROMAL TUMOR, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.A1 | DX | GASTROINTESTINAL STROMAL TUMOR OF ESOPHAGUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.A2 | DX | GASTROINTESTINAL STROMAL TUMOR OF STOMACH | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.A3 | DX | GASTROINTESTINAL STROMAL TUMOR OF SMALL INTESTINE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.A4 | DX | GASTROINTESTINAL STROMAL TUMOR OF LARGE INTESTINE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.A5 | DX | GASTROINTESTINAL STROMAL TUMOR OF RECTUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C49.A9 | DX | GASTROINTESTINAL STROMAL TUMOR OF OTHER SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.011 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA, RIGHT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.012 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA, LEFT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.019 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA, UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.021 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA, RIGHT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.022 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA, LEFT MALE BREAST | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|-------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.029 | DX | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA, UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.111 | DX | MALIGNANT NEOPLASM OF CENTRAL PORTION OF RIGHT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.112 | DX | MALIGNANT NEOPLASM OF CENTRAL PORTION OF LEFT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.119 | DX | MALIGNANT NEOPLASM OF CENTRAL PORTION OF UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.211 | DX | MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF RIGHT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.212 | DX | MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF LEFT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.219 | DX | MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.221 | DX | MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF RIGHT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.222 | DX | MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF LEFT MALE BREAST | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|-------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.229 | DX | MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.311 | DX | MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF RIGHT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.312 | DX | MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF LEFT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.319 | DX | MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.321 | DX | MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF RIGHT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.322 | DX | MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF LEFT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.329 | DX | MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.411 | DX | MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF RIGHT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.412 | DX | MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF LEFT FEMALE BREAST | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|-------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.419 | DX | MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.421 | DX | MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF RIGHT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.422 | DX | MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF LEFT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.429 | DX | MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.511 | DX | MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF RIGHT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.512 | DX | MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF LEFT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.519 | DX | MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.521 | DX | MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF RIGHT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.522 | DX | MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF LEFT MALE BREAST | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|-----------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.529 | DX | MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.611 | DX | MALIGNANT NEOPLASM OF AXILLARY TAIL OF RIGHT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.612 | DX | MALIGNANT NEOPLASM OF AXILLARY TAIL OF LEFT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.619 | DX | MALIGNANT NEOPLASM OF AXILLARY TAIL OF UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.621 | DX | MALIGNANT NEOPLASM OF AXILLARY TAIL OF RIGHT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.622 | DX | MALIGNANT NEOPLASM OF AXILLARY TAIL OF LEFT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.629 | DX | MALIGNANT NEOPLASM OF AXILLARY TAIL OF UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.829 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.911 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF RIGHT FEMALE BREAST | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|---------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.912 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF LEFT FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.919 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF UNSPECIFIED FEMALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.921 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF RIGHT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.922 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF LEFT MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C50.929 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF UNSPECIFIED MALE BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C51.0 | DX | MALIGNANT NEOPLASM OF LABIUM MAJUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C51.1 | DX | MALIGNANT NEOPLASM OF LABIUM MINUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C51.2 | DX | MALIGNANT NEOPLASM OF CLITORIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C51.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF VULVA | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|---------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C51.9 | DX | MALIGNANT NEOPLASM OF VULVA, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C52 | DX | MALIGNANT NEOPLASM OF VAGINA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C53.0 | DX | MALIGNANT NEOPLASM OF ENDOCERVIX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C53.1 | DX | MALIGNANT NEOPLASM OF EXOCERVIX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C53.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF CERVIX UTERI | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C53.9 | DX | MALIGNANT NEOPLASM OF CERVIX UTERI, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C54.0 | DX | MALIGNANT NEOPLASM OF ISTHMUS UTERI | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C54.1 | DX | MALIGNANT NEOPLASM OF ENDOMETRIUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C54.2 | DX | MALIGNANT NEOPLASM OF MYOMETRIUM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C54.3 | DX | MALIGNANT NEOPLASM OF FUNDUS UTERI | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C54.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF CORPUS UTERI | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C54.9 | DX | MALIGNANT NEOPLASM OF CORPUS UTERI, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C55 | DX | MALIGNANT NEOPLASM OF UTERUS, PART UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C56.1 | DX | MALIGNANT NEOPLASM OF RIGHT OVARY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C56.2 | DX | MALIGNANT NEOPLASM OF LEFT OVARY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C56.9 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED OVARY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.00 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED FALLOPIAN TUBE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.01 | DX | MALIGNANT NEOPLASM OF RIGHT FALLOPIAN TUBE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.02 | DX | MALIGNANT NEOPLASM OF LEFT FALLOPIAN TUBE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.10 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED BROAD LIGAMENT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.11 | DX | MALIGNANT NEOPLASM OF RIGHT BROAD LIGAMENT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.12 | DX | MALIGNANT NEOPLASM OF LEFT BROAD LIGAMENT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.20 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED ROUND LIGAMENT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.21 | DX | MALIGNANT NEOPLASM OF RIGHT ROUND LIGAMENT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.22 | DX | MALIGNANT NEOPLASM OF LEFT ROUND LIGAMENT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.3 | DX | MALIGNANT NEOPLASM OF PARAMETRIUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.4 | DX | MALIGNANT NEOPLASM OF UTERINE ADNEXA, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.7 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED FEMALE GENITAL ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF FEMALE GENITAL ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C57.9 | DX | MALIGNANT NEOPLASM OF FEMALE GENITAL ORGAN, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C58 | DX | MALIGNANT NEOPLASM OF PLACENTA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C60.0 | DX | MALIGNANT NEOPLASM OF PREPUCE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C60.1 | DX | MALIGNANT NEOPLASM OF GLANS PENIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C60.2 | DX | MALIGNANT NEOPLASM OF BODY OF PENIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C60.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF PENIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C60.9 | DX | MALIGNANT NEOPLASM OF PENIS, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C61 | DX | MALIGNANT NEOPLASM OF PROSTATE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.00 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED UNDESCENDED TESTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.01 | DX | MALIGNANT NEOPLASM OF UNDESCENDED RIGHT TESTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.02 | DX | MALIGNANT NEOPLASM OF UNDESCENDED LEFT TESTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.10 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED DESCENDED TESTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.11 | DX | MALIGNANT NEOPLASM OF DESCENDED RIGHT TESTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.12 | DX | MALIGNANT NEOPLASM OF DESCENDED LEFT TESTIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.90 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED TESTIS, UNSPECIFIED WHETHER DESCENDED OR UNDESCENDED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.91 | DX | MALIGNANT NEOPLASM OF RIGHT TESTIS, UNSPECIFIED WHETHER DESCENDED OR UNDESCENDED | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C62.92 | DX | MALIGNANT NEOPLASM OF LEFT TESTIS, UNSPECIFIED WHETHER DESCENDED OR UNDESCENDED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.00 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED EPIDIDYMIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.01 | DX | MALIGNANT NEOPLASM OF RIGHT EPIDIDYMIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.02 | DX | MALIGNANT NEOPLASM OF LEFT EPIDIDYMIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.10 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SPERMATIC CORD | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.11 | DX | MALIGNANT NEOPLASM OF RIGHT SPERMATIC CORD | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.12 | DX | MALIGNANT NEOPLASM OF LEFT SPERMATIC CORD | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.2 | DX | MALIGNANT NEOPLASM OF SCROTUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.7 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED MALE GENITAL ORGANS | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|----------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF MALE GENITAL ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C63.9 | DX | MALIGNANT NEOPLASM OF MALE GENITAL ORGAN, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C64.1 | DX | MALIGNANT NEOPLASM OF RIGHT KIDNEY, EXCEPT RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C64.2 | DX | MALIGNANT NEOPLASM OF LEFT KIDNEY, EXCEPT RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C64.9 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED KIDNEY, EXCEPT RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C65.1 | DX | MALIGNANT NEOPLASM OF RIGHT RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C65.2 | DX | MALIGNANT NEOPLASM OF LEFT RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C65.9 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C66.1 | DX | MALIGNANT NEOPLASM OF RIGHT URETER | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C66.2 | DX | MALIGNANT NEOPLASM OF LEFT URETER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C66.9 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED URETER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.0 | DX | MALIGNANT NEOPLASM OF TRIGONE OF BLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.1 | DX | MALIGNANT NEOPLASM OF DOME OF BLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.2 | DX | MALIGNANT NEOPLASM OF LATERAL WALL OF BLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.3 | DX | MALIGNANT NEOPLASM OF ANTERIOR WALL OF BLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.4 | DX | MALIGNANT NEOPLASM OF POSTERIOR WALL OF BLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.5 | DX | MALIGNANT NEOPLASM OF BLADDER NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.6 | DX | MALIGNANT NEOPLASM OF URETERIC ORIFICE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.7 | DX | MALIGNANT NEOPLASM OF URACHUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF BLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C67.9 | DX | MALIGNANT NEOPLASM OF BLADDER, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C68.0 | DX | MALIGNANT NEOPLASM OF URETHRA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C68.1 | DX | MALIGNANT NEOPLASM OF PARAURETHRAL GLANDS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C68.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF URINARY ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C68.9 | DX | MALIGNANT NEOPLASM OF URINARY ORGAN, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.00 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED CONJUNCTIVA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.01 | DX | MALIGNANT NEOPLASM OF RIGHT CONJUNCTIVA | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.02 | DX | MALIGNANT NEOPLASM OF LEFT CONJUNCTIVA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.10 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED CORNEA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.11 | DX | MALIGNANT NEOPLASM OF RIGHT CORNEA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.12 | DX | MALIGNANT NEOPLASM OF LEFT CORNEA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.20 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED RETINA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.21 | DX | MALIGNANT NEOPLASM OF RIGHT RETINA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.22 | DX | MALIGNANT NEOPLASM OF LEFT RETINA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.30 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED CHOROID | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.31 | DX | MALIGNANT NEOPLASM OF RIGHT CHOROID | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.32 | DX | MALIGNANT NEOPLASM OF LEFT CHOROID | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.40 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED CILIARY BODY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.41 | DX | MALIGNANT NEOPLASM OF RIGHT CILIARY BODY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.42 | DX | MALIGNANT NEOPLASM OF LEFT CILIARY BODY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.50 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED LACRIMAL GLAND AND DUCT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.51 | DX | MALIGNANT NEOPLASM OF RIGHT LACRIMAL GLAND AND DUCT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.52 | DX | MALIGNANT NEOPLASM OF LEFT LACRIMAL GLAND AND DUCT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.60 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED ORBIT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.61 | DX | MALIGNANT NEOPLASM OF RIGHT ORBIT | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.62 | DX | MALIGNANT NEOPLASM OF LEFT ORBIT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.80 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF UNSPECIFIED EYE AND ADNEXA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.81 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF RIGHT EYE AND ADNEXA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.82 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF LEFT EYE AND ADNEXA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.90 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF UNSPECIFIED EYE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.91 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF RIGHT EYE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C69.92 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED SITE OF LEFT EYE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C70.0 | DX | MALIGNANT NEOPLASM OF CEREBRAL MENINGES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C70.1 | DX | MALIGNANT NEOPLASM OF SPINAL MENINGES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C70.9 | DX | MALIGNANT NEOPLASM OF MENINGES, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.0 | DX | MALIGNANT NEOPLASM OF CEREBRUM, EXCEPT LOBES AND VENTRICLES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.1 | DX | MALIGNANT NEOPLASM OF FRONTAL LOBE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.2 | DX | MALIGNANT NEOPLASM OF TEMPORAL LOBE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.3 | DX | MALIGNANT NEOPLASM OF PARIETAL LOBE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.4 | DX | MALIGNANT NEOPLASM OF OCCIPITAL LOBE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.5 | DX | MALIGNANT NEOPLASM OF CEREBRAL VENTRICLE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.6 | DX | MALIGNANT NEOPLASM OF CEREBELLUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.7 | DX | MALIGNANT NEOPLASM OF BRAIN STEM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.8 | DX | MALIGNANT NEOPLASM OF OVERLAPPING SITES OF BRAIN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C71.9 | DX | MALIGNANT NEOPLASM OF BRAIN, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.0 | DX | MALIGNANT NEOPLASM OF SPINAL CORD | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.1 | DX | MALIGNANT NEOPLASM OF CAUDA EQUINA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.20 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED OLFACTORY NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.21 | DX | MALIGNANT NEOPLASM OF RIGHT OLFACTORY NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.22 | DX | MALIGNANT NEOPLASM OF LEFT OLFACTORY NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.30 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED OPTIC NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.31 | DX | MALIGNANT NEOPLASM OF RIGHT OPTIC NERVE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.32 | DX | MALIGNANT NEOPLASM OF LEFT OPTIC NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.40 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED ACOUSTIC NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.41 | DX | MALIGNANT NEOPLASM OF RIGHT ACOUSTIC NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.42 | DX | MALIGNANT NEOPLASM OF LEFT ACOUSTIC NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.50 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED CRANIAL NERVE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.59 | DX | MALIGNANT NEOPLASM OF OTHER CRANIAL NERVES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C72.9 | DX | MALIGNANT NEOPLASM OF CENTRAL NERVOUS SYSTEM, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C73 | DX | MALIGNANT NEOPLASM OF THYROID GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.00 | DX | MALIGNANT NEOPLASM OF CORTEX OF UNSPECIFIED ADRENAL GLAND | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.01 | DX | MALIGNANT NEOPLASM OF CORTEX OF RIGHT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.02 | DX | MALIGNANT NEOPLASM OF CORTEX OF LEFT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.10 | DX | MALIGNANT NEOPLASM OF MEDULLA OF UNSPECIFIED ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.11 | DX | MALIGNANT NEOPLASM OF MEDULLA OF RIGHT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.12 | DX | MALIGNANT NEOPLASM OF MEDULLA OF LEFT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.90 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF UNSPECIFIED ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.91 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF RIGHT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C74.92 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED PART OF LEFT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.0 | DX | MALIGNANT NEOPLASM OF PARATHYROID GLAND | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.1 | DX | MALIGNANT NEOPLASM OF PITUITARY GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.2 | DX | MALIGNANT NEOPLASM OF CRANIOPHARYNGEAL DUCT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.3 | DX | MALIGNANT NEOPLASM OF PINEAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.4 | DX | MALIGNANT NEOPLASM OF CAROTID BODY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.5 | DX | MALIGNANT NEOPLASM OF AORTIC BODY AND OTHER PARAGANGLIA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.8 | DX | MALIGNANT NEOPLASM WITH PLURIGLANDULAR INVOLVEMENT, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C75.9 | DX | MALIGNANT NEOPLASM OF ENDOCRINE GLAND, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.0 | DX | MALIGNANT NEOPLASM OF HEAD, FACE AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.1 | DX | MALIGNANT NEOPLASM OF THORAX | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.2 | DX | MALIGNANT NEOPLASM OF ABDOMEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.3 | DX | MALIGNANT NEOPLASM OF PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.4 | DX | MALIGNANT NEOPLASM OF UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.40 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.41 | DX | MALIGNANT NEOPLASM OF RIGHT UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.42 | DX | MALIGNANT NEOPLASM OF LEFT UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.50 | DX | MALIGNANT NEOPLASM OF UNSPECIFIED LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.51 | DX | MALIGNANT NEOPLASM OF RIGHT LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.52 | DX | MALIGNANT NEOPLASM OF LEFT LOWER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C76.8 | DX | MALIGNANT NEOPLASM OF OTHER SPECIFIED ILL-DEFINED SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.0 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF HEAD, FACE AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.1 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.2 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.3 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF AXILLA AND UPPER LIMB LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.4 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INGUINAL AND LOWER LIMB LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.5 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.8 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF MULTIPLE REGIONS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C77.9 | DX | SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODE, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.00 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.01 | DX | SECONDARY MALIGNANT NEOPLASM OF RIGHT LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.02 | DX | SECONDARY MALIGNANT NEOPLASM OF LEFT LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.1 | DX | SECONDARY MALIGNANT NEOPLASM OF MEDIASTINUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.2 | DX | SECONDARY MALIGNANT NEOPLASM OF PLEURA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.30 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED RESPIRATORY ORGAN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.39 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER RESPIRATORY ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.4 | DX | SECONDARY MALIGNANT NEOPLASM OF SMALL INTESTINE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.5 | DX | SECONDARY MALIGNANT NEOPLASM OF LARGE INTESTINE AND RECTUM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.6 | DX | SECONDARY MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.7 | DX | SECONDARY MALIGNANT NEOPLASM OF LIVER AND INTRAHEPATIC BILE DUCT | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.8 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED DIGESTIVE ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.80 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED DIGESTIVE ORGAN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C78.89 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER DIGESTIVE ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.00 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED KIDNEY AND RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.01 | DX | SECONDARY MALIGNANT NEOPLASM OF RIGHT KIDNEY AND RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.02 | DX | SECONDARY MALIGNANT NEOPLASM OF LEFT KIDNEY AND RENAL PELVIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.10 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED URINARY ORGANS | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.11 | DX | SECONDARY MALIGNANT NEOPLASM OF BLADDER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.19 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER URINARY ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.2 | DX | SECONDARY MALIGNANT NEOPLASM OF SKIN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.31 | DX | SECONDARY MALIGNANT NEOPLASM OF BRAIN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.32 | DX | SECONDARY MALIGNANT NEOPLASM OF CEREBRAL MENINGES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.40 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED PART OF NERVOUS SYSTEM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.49 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER PARTS OF NERVOUS SYSTEM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.51 | DX | SECONDARY MALIGNANT NEOPLASM OF BONE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.52 | DX | SECONDARY MALIGNANT NEOPLASM OF BONE MARROW | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.60 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED OVARY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.61 | DX | SECONDARY MALIGNANT NEOPLASM OF RIGHT OVARY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.62 | DX | SECONDARY MALIGNANT NEOPLASM OF LEFT OVARY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.70 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.71 | DX | SECONDARY MALIGNANT NEOPLASM OF RIGHT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.72 | DX | SECONDARY MALIGNANT NEOPLASM OF LEFT ADRENAL GLAND | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.81 | DX | SECONDARY MALIGNANT NEOPLASM OF BREAST | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.82 | DX | SECONDARY MALIGNANT NEOPLASM OF GENITAL ORGANS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.89 | DX | SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|-------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C79.9 | DX | SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.0 | DX | MALIGNANT CARCINOID TUMORS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.00 | DX | MALIGNANT CARCINOID TUMOR OF UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.01 | DX | MALIGNANT CARCINOID TUMORS OF THE SMALL INTESTINE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.010 | DX | MALIGNANT CARCINOID TUMOR OF THE DUODENUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.011 | DX | MALIGNANT CARCINOID TUMOR OF THE JEJUNUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.012 | DX | MALIGNANT CARCINOID TUMOR OF THE ILEUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.019 | DX | MALIGNANT CARCINOID TUMOR OF THE SMALL INTESTINE, UNSPECIFIED PORTION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.02 | DX | MALIGNANT CARCINOID TUMORS OF THE APPENDIX, LARGE INTESTINE, AND RECTUM | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|-----------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.020 | DX | MALIGNANT CARCINOID TUMOR OF THE APPENDIX | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.021 | DX | MALIGNANT CARCINOID TUMOR OF THE CECUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.022 | DX | MALIGNANT CARCINOID TUMOR OF THE ASCENDING COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.023 | DX | MALIGNANT CARCINOID TUMOR OF THE TRANSVERSE COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.024 | DX | MALIGNANT CARCINOID TUMOR OF THE DESCENDING COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.025 | DX | MALIGNANT CARCINOID TUMOR OF THE SIGMOID COLON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.026 | DX | MALIGNANT CARCINOID TUMOR OF THE RECTUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.029 | DX | MALIGNANT CARCINOID TUMOR OF THE LARGE INTESTINE, UNSPECIFIED PORTION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.09 | DX | MALIGNANT CARCINOID TUMORS OF OTHER SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|----|-------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.090 | DX | MALIGNANT CARCINOID TUMOR OF THE BRONCHUS AND LUNG | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.091 | DX | MALIGNANT CARCINOID TUMOR OF THE THYMUS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.092 | DX | MALIGNANT CARCINOID TUMOR OF THE STOMACH | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.093 | DX | MALIGNANT CARCINOID TUMOR OF THE KIDNEY | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.094 | DX | MALIGNANT CARCINOID TUMOR OF THE FOREGUT, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.095 | DX | MALIGNANT CARCINOID TUMOR OF THE MIDGUT, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.096 | DX | MALIGNANT CARCINOID TUMOR OF THE HINDGUT, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.098 | DX | MALIGNANT CARCINOID TUMORS OF OTHER SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.1 | DX | MALIGNANT POORLY DIFFERENTIATED NEUROENDOCRINE TUMORS | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7A.8 | DX | OTHER MALIGNANT NEUROENDOCRINE TUMORS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B | DX | SECONDARY NEUROENDOCRINE TUMORS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.0 | DX | SECONDARY CARCINOID TUMORS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.00 | DX | SECONDARY CARCINOID TUMORS, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.01 | DX | SECONDARY CARCINOID TUMORS OF DISTANT LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.02 | DX | SECONDARY CARCINOID TUMORS OF LIVER | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.03 | DX | SECONDARY CARCINOID TUMORS OF BONE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.04 | DX | SECONDARY CARCINOID TUMORS OF PERITONEUM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.09 | DX | SECONDARY CARCINOID TUMORS OF OTHER SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.1 | DX | SECONDARY MERKEL CELL CARCINOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C7B.8 | DX | OTHER SECONDARY NEUROENDOCRINE TUMORS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C80.0 | DX | DISSEMINATED MALIGNANT NEOPLASM, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C80.1 | DX | MALIGNANT (PRIMARY) NEOPLASM, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C80.2 | DX | MALIGNANT NEOPLASM ASSOCIATED WITH TRANSPLANTED ORGAN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.00 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.01 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.02 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.03 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.04 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.05 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.06 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.07 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.08 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.09 | DX | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.10 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.11 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.12 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-----------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8113 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8114 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8115 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8116 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8117 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8118 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8119 | DX | NODULAR SCLEROSIS HODGKIN LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8120 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C8121 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.22 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.23 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.24 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.25 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.26 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.27 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.28 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.29 | DX | MIXED CELLULARITY HODGKIN LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.30 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.31 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.32 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.33 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.34 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.35 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.36 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.37 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.38 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.39 | DX | LYMPHOCYTE DEPLETED HODGKIN LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.40 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.41 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.42 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.43 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.44 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.45 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.46 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.47 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.48 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.49 | DX | LYMPHOCYTE-RICH HODGKIN LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.70 | DX | OTHER HODGKIN LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.71 | DX | OTHER HODGKIN LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.72 | DX | OTHER HODGKIN LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.73 | DX | OTHER HODGKIN LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.74 | DX | OTHER HODGKIN LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.75 | DX | OTHER HODGKIN LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.76 | DX | OTHER HODGKIN LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.77 | DX | OTHER HODGKIN LYMPHOMA, SPLEEN | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.78 | DX | OTHER HODGKIN LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.79 | DX | OTHER HODGKIN LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.90 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.91 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.92 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.93 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.94 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.95 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.96 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.97 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.98 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C81.99 | DX | HODGKIN LYMPHOMA, UNSPECIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.00 | DX | FOLLICULAR LYMPHOMA GRADE I, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.01 | DX | FOLLICULAR LYMPHOMA GRADE I, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.02 | DX | FOLLICULAR LYMPHOMA GRADE I, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.03 | DX | FOLLICULAR LYMPHOMA GRADE I, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.04 | DX | FOLLICULAR LYMPHOMA GRADE I, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.05 | DX | FOLLICULAR LYMPHOMA GRADE I, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.06 | DX | FOLLICULAR LYMPHOMA GRADE I, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.07 | DX | FOLLICULAR LYMPHOMA GRADE I, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.08 | DX | FOLLICULAR LYMPHOMA GRADE I, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.09 | DX | FOLLICULAR LYMPHOMA GRADE I, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.10 | DX | FOLLICULAR LYMPHOMA GRADE II, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.11 | DX | FOLLICULAR LYMPHOMA GRADE II, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.12 | DX | FOLLICULAR LYMPHOMA GRADE II, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.13 | DX | FOLLICULAR LYMPHOMA GRADE II, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.14 | DX | FOLLICULAR LYMPHOMA GRADE II, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.15 | DX | FOLLICULAR LYMPHOMA GRADE II, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.16 | DX | FOLLICULAR LYMPHOMA GRADE II, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.17 | DX | FOLLICULAR LYMPHOMA GRADE II, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.18 | DX | FOLLICULAR LYMPHOMA GRADE II, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.19 | DX | FOLLICULAR LYMPHOMA GRADE II, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.20 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.21 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.22 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.23 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.24 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.25 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.26 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.27 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.28 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.29 | DX | FOLLICULAR LYMPHOMA GRADE III, UNSPECIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.30 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.31 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.32 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, INTRATHORACIC LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.33 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.34 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.35 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.36 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.37 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.38 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.39 | DX | FOLLICULAR LYMPHOMA GRADE IIIA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.40 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.41 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.42 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.43 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.44 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.45 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.46 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.47 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.48 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.49 | DX | FOLLICULAR LYMPHOMA GRADE IIIB, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.81 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.82 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.83 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.84 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.85 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.86 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.87 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.88 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.89 | DX | OTHER TYPES OF FOLLICULAR LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.90 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, UNSPECIFIED SITE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.91 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.92 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.93 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.94 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.95 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.96 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.97 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.98 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C82.99 | DX | FOLLICULAR LYMPHOMA, UNSPECIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.00 | DX | SMALL CELL B-CELL LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.01 | DX | SMALL CELL B-CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.02 | DX | SMALL CELL B-CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.03 | DX | SMALL CELL B-CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.04 | DX | SMALL CELL B-CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.05 | DX | SMALL CELL B-CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.06 | DX | SMALL CELL B-CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.07 | DX | SMALL CELL B-CELL LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.08 | DX | SMALL CELL B-CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.09 | DX | SMALL CELL B-CELL LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.10 | DX | MANTLE CELL LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.11 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.12 | DX | MANTLE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.13 | DX | MANTLE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.14 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.15 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.16 | DX | MANTLE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.17 | DX | MANTLE CELL LYMPHOMA, SPLEEN | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.18 | DX | MANTLE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.19 | DX | MANTLE CELL LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.30 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.31 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.32 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.33 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.34 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.35 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.36 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.37 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.38 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.39 | DX | DIFFUSE LARGE B-CELL LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.50 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.51 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.52 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.53 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.54 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.55 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.56 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.57 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.58 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.59 | DX | LYMPHOBLASTIC (DIFFUSE) LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.70 | DX | BURKITT LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.71 | DX | BURKITT LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.72 | DX | BURKITT LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.73 | DX | BURKITT LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.74 | DX | BURKITT LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.75 | DX | BURKITT LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.76 | DX | BURKITT LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.77 | DX | BURKITT LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.78 | DX | BURKITT LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.79 | DX | BURKITT LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.80 | DX | OTHER NON-FOLLICULAR LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.81 | DX | OTHER NON-FOLLICULAR LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.82 | DX | OTHER NON-FOLLICULAR LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.83 | DX | OTHER NON-FOLLICULAR LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.84 | DX | OTHER NON-FOLLICULAR LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.85 | DX | OTHER NON-FOLLICULAR LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.86 | DX | OTHER NON-FOLLICULAR LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.87 | DX | OTHER NON-FOLLICULAR LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.88 | DX | OTHER NON-FOLLICULAR LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.89 | DX | OTHER NON-FOLLICULAR LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.90 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.91 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.92 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.93 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.94 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.95 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.96 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.97 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.98 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C83.99 | DX | NON-FOLLICULAR (DIFFUSE) LYMPHOMA, UNSPECIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.00 | DX | MYCOSIS FUNGOIDES, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.01 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.02 | DX | MYCOSIS FUNGOIDES, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.03 | DX | MYCOSIS FUNGOIDES, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.04 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.05 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.06 | DX | MYCOSIS FUNGOIDES, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.07 | DX | MYCOSIS FUNGOIDES, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.08 | DX | MYCOSIS FUNGOIDES, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.09 | DX | MYCOSIS FUNGOIDES, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.10 | DX | SEZARY DISEASE, UNSPECIFIED SITE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.11 | DX | SEZARY DISEASE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.12 | DX | SEZARY DISEASE, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.13 | DX | SEZARY DISEASE, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.14 | DX | SEZARY DISEASE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.15 | DX | SEZARY DISEASE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.16 | DX | SEZARY DISEASE, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.17 | DX | SEZARY DISEASE, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.18 | DX | SEZARY DISEASE, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.19 | DX | SEZARY DISEASE, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.40 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.41 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.42 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.43 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.44 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.45 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.46 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.47 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.48 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.49 | DX | PERIPHERAL T-CELL LYMPHOMA, NOT ELSEWHERE CLASSIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.60 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.61 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.62 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.63 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.64 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.65 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.66 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.67 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, SPLEEN | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.68 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.69 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.70 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.71 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.72 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.73 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.74 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.75 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.76 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, INTRAPELVIC LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.77 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.78 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.79 | DX | ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.90 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.91 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.92 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.93 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.94 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.95 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.96 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.97 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.98 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.99 | DX | MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A0 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A1 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A2 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A3 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A4 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A5 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A6 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A7 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A8 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.A9 | DX | CUTANEOUS T-CELL LYMPHOMA, UNSPECIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z0 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z1 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z2 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z3 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z4 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z5 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z6 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z7 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z8 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C84.Z9 | DX | OTHER MATURE T/NK-CELL LYMPHOMAS, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.10 | DX | UNSPECIFIED B-CELL LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.11 | DX | UNSPECIFIED B-CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.12 | DX | UNSPECIFIED B-CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.13 | DX | UNSPECIFIED B-CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.14 | DX | UNSPECIFIED B-CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.15 | DX | UNSPECIFIED B-CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.16 | DX | UNSPECIFIED B-CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.17 | DX | UNSPECIFIED B-CELL LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.18 | DX | UNSPECIFIED B-CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.19 | DX | UNSPECIFIED B-CELL LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.20 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.21 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.22 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.23 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.24 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.25 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.26 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.27 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.28 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.29 | DX | MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.80 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, UNSPECIFIED SITE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.81 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.82 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.83 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.84 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.85 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.86 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.87 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.88 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.89 | DX | OTHER SPECIFIED TYPES OF NON-HODGKIN LYMPHOMA, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.91 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF HEAD, FACE, AND NECK | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.92 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, INTRATHORACIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.93 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, INTRA-ABDOMINAL LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.94 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF AXILLA AND UPPER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.95 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.96 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, INTRAPELVIC LYMPH NODES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.97 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, SPLEEN | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.98 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, LYMPH NODES OF MULTIPLE SITES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C85.99 | DX | NON-HODGKIN LYMPHOMA, UNSPECIFIED, EXTRANODAL AND SOLID ORGAN SITES | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------|----|-------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C86.0 | DX | EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C86.1 | DX | HEPATOSPLENIC T-CELL LYMPHOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C86.2 | DX | ENTEROPATHY-TYPE (INTESTINAL) T-CELL LYMPHOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C86.3 | DX | SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C86.4 | DX | BLASTIC NK-CELL LYMPHOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C86.5 | DX | ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C86.6 | DX | PRIMARY CUTANEOUS CD30-POSITIVE T-CELL PROLIFERATIONS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C88.0 | DX | WALDENSTROM MACROGLOBULINEMIA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C88.2 | DX | HEAVY CHAIN DISEASE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C88.3 | DX | IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C88.4 | DX | EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE [MALT-LYMPHOMA] | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C88.8 | DX | OTHER MALIGNANT IMMUNOPROLIFERATIVE DISEASES | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C88.9 | DX | MALIGNANT IMMUNOPROLIFERATIVE DISEASE, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.00 | DX | MULTIPLE MYELOMA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.01 | DX | MULTIPLE MYELOMA IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.02 | DX | MULTIPLE MYELOMA IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.10 | DX | PLASMA CELL LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.11 | DX | PLASMA CELL LEUKEMIA IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.12 | DX | PLASMA CELL LEUKEMIA IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.20 | DX | EXTRAMEDULLARY PLASMACYTOMA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.21 | DX | EXTRAMEDULLARY PLASMACYTOMA IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.22 | DX | EXTRAMEDULLARY PLASMACYTOMA IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.30 | DX | SOLITARY PLASMACYTOMA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.31 | DX | SOLITARY PLASMACYTOMA IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C90.32 | DX | SOLITARY PLASMACYTOMA IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.00 | DX | ACUTE LYMPHOBLASTIC LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.01 | DX | ACUTE LYMPHOBLASTIC LEUKEMIA, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.02 | DX | ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.10 | DX | CHRONIC LYMPHOCYTIC LEUKEMIA OF B-CELL TYPE NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.11 | DX | CHRONIC LYMPHOCYTIC LEUKEMIA OF B-CELL TYPE IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.12 | DX | CHRONIC LYMPHOCYTIC LEUKEMIA OF B-CELL TYPE IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.30 | DX | PROLYMPHOCYTIC LEUKEMIA OF B-CELL TYPE NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.31 | DX | PROLYMPHOCYTIC LEUKEMIA OF B-CELL TYPE, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.32 | DX | PROLYMPHOCYTIC LEUKEMIA OF B-CELL TYPE, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.40 | DX | HAIRY CELL LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.41 | DX | HAIRY CELL LEUKEMIA, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.42 | DX | HAIRY CELL LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.50 | DX | ADULT T-CELL LYMPHOMA/LEUKEMIA (HTLV-1-ASSOCIATED) NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.51 | DX | ADULT T-CELL LYMPHOMA/LEUKEMIA (HTLV-1-ASSOCIATED), IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.52 | DX | ADULT T-CELL LYMPHOMA/LEUKEMIA (HTLV-1-ASSOCIATED), IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.60 | DX | PROLYMPHOCYTIC LEUKEMIA OF T-CELL TYPE NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.61 | DX | PROLYMPHOCYTIC LEUKEMIA OF T-CELL TYPE, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.62 | DX | PROLYMPHOCYTIC LEUKEMIA OF T-CELL TYPE, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.90 | DX | LYMPHOID LEUKEMIA, UNSPECIFIED NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.91 | DX | LYMPHOID LEUKEMIA, UNSPECIFIED, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91.92 | DX | LYMPHOID LEUKEMIA, UNSPECIFIED, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91A0 | DX | MATURE B-CELL LEUKEMIA BURKITT-TYPE NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91A1 | DX | MATURE B-CELL LEUKEMIA BURKITT-TYPE, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91A2 | DX | MATURE B-CELL LEUKEMIA BURKITT-TYPE, IN PERSON | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91Z0 | DX | OTHER LYMPHOID LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91Z1 | DX | OTHER LYMPHOID LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C91Z2 | DX | OTHER LYMPHOID LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.00 | DX | ACUTE MYELOBLASTIC LEUKEMIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.01 | DX | ACUTE MYELOBLASTIC LEUKEMIA, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.02 | DX | ACUTE MYELOBLASTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.10 | DX | CHRONIC MYELOID LEUKEMIA, BCR/ABL-POSITIVE, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.11 | DX | CHRONIC MYELOID LEUKEMIA, BCR/ABL-POSITIVE, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.12 | DX | CHRONIC MYELOID LEUKEMIA, BCR/ABL-POSITIVE, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.20 | DX | ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR/ABL-NEGATIVE, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.21 | DX | ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR/ABL-NEGATIVE, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.22 | DX | ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR/ABL-NEGATIVE, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.30 | DX | MYELOID SARCOMA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.31 | DX | MYELOID SARCOMA, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.32 | DX | MYELOID SARCOMA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.40 | DX | ACUTE PROMYELOCYTIC LEUKEMIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.41 | DX | ACUTE PROMYELOCYTIC LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.42 | DX | ACUTE PROMYELOCYTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.50 | DX | ACUTE MYELOMONOCYTIC LEUKEMIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.51 | DX | ACUTE MYELOMONOCYTIC LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.52 | DX | ACUTE MYELOMONOCYTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.60 | DX | ACUTE MYELOID LEUKEMIA WITH 11Q23-ABNORMALITY NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.61 | DX | ACUTE MYELOID LEUKEMIA WITH 11Q23-ABNORMALITY IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.62 | DX | ACUTE MYELOID LEUKEMIA WITH 11Q23-ABNORMALITY IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.90 | DX | MYELOID LEUKEMIA, UNSPECIFIED, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.91 | DX | MYELOID LEUKEMIA, UNSPECIFIED IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.92 | DX | MYELOID LEUKEMIA, UNSPECIFIED IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.A0 | DX | ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.A1 | DX | ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.A2 | DX | ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.Z0 | DX | OTHER MYELOID LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.Z1 | DX | OTHER MYELOID LEUKEMIA, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|---------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C92.Z2 | DX | OTHER MYELOID LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.00 | DX | ACUTE MONOBLASTIC/MONOCYTIC LEUKEMIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.01 | DX | ACUTE MONOBLASTIC/MONOCYTIC LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.02 | DX | ACUTE MONOBLASTIC/MONOCYTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.10 | DX | CHRONIC MYELOMONOCYTIC LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.11 | DX | CHRONIC MYELOMONOCYTIC LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.12 | DX | CHRONIC MYELOMONOCYTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.30 | DX | JUVENILE MYELOMONOCYTIC LEUKEMIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.31 | DX | JUVENILE MYELOMONOCYTIC LEUKEMIA, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|----------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.32 | DX | JUVENILE MYELOMONOCYTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.90 | DX | MONOCYTIC LEUKEMIA, UNSPECIFIED, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.91 | DX | MONOCYTIC LEUKEMIA, UNSPECIFIED IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.92 | DX | MONOCYTIC LEUKEMIA, UNSPECIFIED IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.Z0 | DX | OTHER MONOCYTIC LEUKEMIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.Z1 | DX | OTHER MONOCYTIC LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C93.Z2 | DX | OTHER MONOCYTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.00 | DX | ACUTE ERYTHROID LEUKEMIA, NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.01 | DX | ACUTE ERYTHROID LEUKEMIA, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|--------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.02 | DX | ACUTE ERYTHROID LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.20 | DX | ACUTE MEGAKARYOBLASTIC LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.21 | DX | ACUTE MEGAKARYOBLASTIC LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.22 | DX | ACUTE MEGAKARYOBLASTIC LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.30 | DX | MAST CELL LEUKEMIA NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.31 | DX | MAST CELL LEUKEMIA, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.32 | DX | MAST CELL LEUKEMIA, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.40 | DX | ACUTE PANMYELOSIS WITH MYELOFIBROSIS NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.41 | DX | ACUTE PANMYELOSIS WITH MYELOFIBROSIS, IN REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.42 | DX | ACUTE PANMYELOSIS WITH MYELOFIBROSIS, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.6 | DX | MYELOYDYSPLASTIC DISEASE, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.80 | DX | OTHER SPECIFIED LEUKEMIAS NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.81 | DX | OTHER SPECIFIED LEUKEMIAS, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C94.82 | DX | OTHER SPECIFIED LEUKEMIAS, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.00 | DX | ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.01 | DX | ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.02 | DX | ACUTE LEUKEMIA OF UNSPECIFIED CELL TYPE, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.10 | DX | CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE NOT HAVING ACHIEVED REMISSION | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.11 | DX | CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.12 | DX | CHRONIC LEUKEMIA OF UNSPECIFIED CELL TYPE, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.90 | DX | LEUKEMIA, UNSPECIFIED NOT HAVING ACHIEVED REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.91 | DX | LEUKEMIA, UNSPECIFIED, IN REMISSION | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C95.92 | DX | LEUKEMIA, UNSPECIFIED, IN RELAPSE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96 | DX | OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID, HEMATOPOIETIC AND RELATED TISSUE | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.0 | DX | MULTIFOCAL AND MULTISYSTEMIC (DISSEMINATED) LANGERHANS-CELL HISTIOCYTOSIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.2 | DX | MALIGNANT MAST CELL NEOPLASM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.20 | DX | MALIGNANT MAST CELL NEOPLASM, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|----|-----------------------------------------------------------------------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.21 | DX | AGGRESSIVE SYSTEMIC MASTOCYTOSIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.22 | DX | MAST CELL SARCOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.29 | DX | OTHER MALIGNANT MAST CELL NEOPLASM | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.4 | DX | SARCOMA OF DENDRITIC CELLS (ACCESSORY CELLS) | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.5 | DX | MULTIFOCAL AND UNISYSTEMIC LANGERHANS-CELL HISTIOCYTOSIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.6 | DX | UNIFOCAL LANGERHANS-CELL HISTIOCYTOSIS | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.9 | DX | MALIGNANT NEOPLASM OF LYMPHOID, HEMATOPOIETIC AND RELATED TISSUE, UNSPECIFIED | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.A | DX | HISTIOCYTIC SARCOMA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | C96.Z | DX | OTHER SPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID, HEMATOPOIETIC AND RELATED TISSUE | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------|-----|-------------------|-----------|
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | D45 | DX | POLYCYTHEMIA VERA | ICD-10-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | 789.51 | DX | MALIGNANT ASCITES | ICD-9-CM |
| 18 | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA < 10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | Cancer | R18.0 | DX | MALIGNANT ASCITES | ICD-10-CM |
| 19 | Presence of any other disease than heart failure with a life expectancy of <1 year in the investigator's opinion | CCI | N/A | N/A | N/A | N/A |
| 20 | Patients who must or wish to continue the intake of restricted medications (see Section 4.2.2) or any drug considered likely to interfere with the safe conduct of the trial | Intake of restricted medications that may interfere with the safe conduct | N/A | N/A | N/A | N/A |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | DAPAGLIF LOZIN PROPANE DIOL | RX | Generic | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | DAPAGLIF LOZIN PROPANE DIOL/MET FORMIN HCL | RX | Generic | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | DAPAGLIF LOZIN PROPANE DIOL/SAX AGLIPTIN HCL | RX | Generic | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | CANAGLIF LOZIN | RX | Generic | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | CANAGLIF LOZIN/ME TFORMIN HCL | RX | Generic | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | ERTUGLIF LOZIN PIDOLATE | RX | Generic | |

| | | | | | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|--------------------------------------------------------------------|-----|----------------------------------------------------------|----------|
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | ERTUGLIF LOZIN PIDOLATE/ METFORMI NHCL | RX | Generic | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | ERTUGLIF LOZIN PIDOLATE/ SITAGLIPT IN PHOSPHA TE | RX | Generic | |
| 21 | Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | SGLT2i | SOTAGLIF LOZIN | RX | Generic | |
| 21 | Current use or prior use of SGLT2i or combined SGLT1/2i or DPP-4i | DPP4i | ALOGLIPTI N BENZOATE | RX | Generic | |
| 21 | Current use or prior use of SGLT2i or combined SGLT1/2i or DPP-4i | DPP4i | ALOGLIPTI N BENZOATE /METFOR MINHCL | RX | Generic | |
| 21 | Current use or prior use of SGLT2i or combined SGLT1/2i or DPP-4i | DPP4i | ALOGLIPTI N BENZOATE /PIOGLITA ZONE HCL | RX | Generic | |
| 21 | Current use or prior use of SGLT2i or combined SGLT1/2i or DPP-4i | DPP4i | LINAGLIPT IN | RX | Generic | |
| 21 | Current use or prior use of SGLT2i or combined SGLT1/2i or DPP-4i | DPP4i | LINAGLIPT IN/METFO RMINHCL | RX | Generic | |
| 21 | Current use or prior use of SGLT2i or combined SGLT1/2i or DPP-4i | DPP4i | SAXAGLIP TIN HCL | RX | Generic | |
| 21 | Current use or prior use of SGLT2i or combined SGLT1/2i or DPP-4i | DPP4i | SAXAGLIP TIN HCL/METF ORMIN HCL | RX | Generic | |
| 22 | Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s). Patients participating in a purely observational trial will not be excluded | Enrolled in another trial | N/A | N/A | N/A | N/A |
| 23 | Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors | | N/A | N/A | N/A | N/A |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.0 | DX | ACUTE ALCOHOLIC INTOXICATION | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.01 | DX | ACUTE ALCOHOLIC INTOXICATION IN ALCOHOLISM, CONTINUOUS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.02 | DX | ACUTE ALCOHOLIC INTOXICATION IN ALCOHOLISM, EPISODIC | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.03 | DX | ACUTE ALCOHOLIC INTOXICATION IN ALCOHOLISM, IN REMISSION | ICD-9-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|--------|----|--------------------------------------------------------|----------|
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.9 | DX | OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.90 | DX | OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, UNSPECIFIED | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.91 | DX | OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, CONTINUOUS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.92 | DX | OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, EPISODIC | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 303.93 | DX | OTHER AND UNSPECIFIED ALCOHOL DEPENDENCE, IN REMISSION | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 305.0 | DX | NONDEPENDENT ALCOHOL ABUSE | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 305.01 | DX | ALCOHOL ABUSE, CONTINUOUS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 305.02 | DX | ALCOHOL ABUSE, EPISODIC | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 305.03 | DX | ALCOHOL ABUSE, IN REMISSION | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291 | DX | ALCOHOL-INDUCED MENTAL DISORDERS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.0 | DX | ALCOHOL WITHDRAWAL DELIRIUM | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.1 | DX | ALCOHOL-INDUCED PERSISTING AMNESTIC DISORDER | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.2 | DX | ALCOHOL-INDUCED PERSISTING DEMENTIA | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.3 | DX | ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.4 | DX | IDIOSYNCRATIC ALCOHOL INTOXICATION | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.5 | DX | ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.8 | DX | OTHER SPECIFIED ALCOHOL-INDUCED MENTAL DISORDERS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.81 | DX | ALCOHOL WITHDRAWAL | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.82 | DX | ALCOHOL INDUCED SLEEP DISORDERS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.89 | DX | OTHER ALCOHOL-INDUCED MENTAL DISORDERS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 291.9 | DX | UNSPECIFIED ALCOHOL-INDUCED MENTAL DISORDERS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 357.5 | DX | ALCOHOLIC POLYNEUROPATHY | ICD-9-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------|----|------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 425.5 | DX | ALCOHOLIC CARDIOMYOPATHY | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 571.0 | DX | ALCOHOLIC FATTY LIVER | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 571.1 | DX | ACUTE ALCOHOLIC HEPATITIS | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 571.2 | DX | ALCOHOLIC CIRRHOSIS OF LIVER | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | 571.3 | DX | ALCOHOLIC LIVER DAMAGE, UNSPECIFIED | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | V11.3 | DX | PERSONAL HISTORY OF ALCOHOLISM | ICD-9-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.1 | DX | ALCOHOL ABUSE | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.10 | DX | ALCOHOL ABUSE, UNCOMPLICATED (ALCOHOL USE DISORDER, MILD) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.11 | DX | ALCOHOL ABUSE, IN REMISSION | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.12 | DX | ALCOHOL ABUSE WITH INTOXICATION | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.120 | DX | ALCOHOL ABUSE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.121 | DX | ALCOHOL ABUSE WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.129 | DX | ALCOHOL ABUSE WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.13 | DX | ALCOHOL ABUSE WITH WITHDRAWAL | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.130 | DX | ALCOHOL ABUSE WITH WITHDRAWAL, UNCOMPLICATED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.131 | DX | ALCOHOL ABUSE WITH WITHDRAWAL DELIRIUM | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.132 | DX | ALCOHOL ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.139 | DX | ALCOHOL ABUSE WITH WITHDRAWAL, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.14 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED MOOD DISORDER (ALCOHOL USE DISORDER, MILD, WITH ALCOHOL-INDUCED BIPOLAR OR DEPRESSIVE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.15 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.150 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.151 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.159 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.18 | DX | ALCOHOL ABUSE WITH OTHER ALCOHOL-INDUCED DISORDERS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.180 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.181 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.182 | DX | ALCOHOL ABUSE WITH ALCOHOL-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.188 | DX | ALCOHOL ABUSE WITH OTHER ALCOHOL-INDUCED DISORDERS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.19 | DX | ALCOHOL ABUSE WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.2 | DX | ALCOHOL DEPENDENCE | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.20 | DX | ALCOHOL DEPENDENCE, UNCOMPLICATED (ALCOHOL USE DISORDER, MODERATE OR SEVERE) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.21 | DX | ALCOHOL DEPENDENCE, IN REMISSION | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.22 | DX | ALCOHOL DEPENDENCE WITH INTOXICATION (ACUTE DRUNKENNESS IN ALCOHOLISM) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.220 | DX | ALCOHOL DEPENDENCE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.221 | DX | ALCOHOL DEPENDENCE WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.229 | DX | ALCOHOL DEPENDENCE WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.23 | DX | ALCOHOL DEPENDENCE WITH WITHDRAWAL | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.230 | DX | ALCOHOL DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.231 | DX | ALCOHOL DEPENDENCE WITH WITHDRAWAL DELIRIUM | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.232 | DX | ALCOHOL DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.239 | DX | ALCOHOL DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.24 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED MOOD DISORDER (ALCOHOL USE DISORDER, MODERATE OR SEVERE, WITH ALCOHOL-INDUCED BIPOLAR OR DEPRESSIVE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.25 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.250 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.251 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.259 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.26 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING AMNESTIC DISORDER (ALCOHOL USE DISORDER, MODERATE OR SEVERE, WITH ALCOHOL-INDUCED MAJOR NEUROCOGNITIVE DISORDER, AMNESTIC-CONFABULATORY TYPE) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.27 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING DEMENTIA (ALCOHOL USE DISORDER, MODERATE OR SEVERE, WITH ALCOHOL-INDUCED MAJOR NEUROCOGNITIVE DISORDER, NONAMNESTIC-CONFABULATORY TYPE) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.28 | DX | ALCOHOL DEPENDENCE WITH OTHER ALCOHOL-INDUCED DISORDERS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.280 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.281 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.282 | DX | ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.288 | DX | ALCOHOL DEPENDENCE WITH OTHER ALCOHOL-INDUCED DISORDER (ALCOHOL USE DISORDER, MODERATE OR SEVERE, WITH ALCOHOL-INDUCED MILD NEUROCOGNITIVE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.29 | DX | ALCOHOL DEPENDENCE WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.9 | DX | Alcohol use, unspecified | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.90 | DX | Alcohol use, unspecified, uncomplicated | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.91 | DX | Alcohol use, unspecified, in remission | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.92 | DX | ALCOHOL USE, UNSPECIFIED WITH INTOXICATION | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.920 | DX | ALCOHOL USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.921 | DX | ALCOHOL USE, UNSPECIFIED WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.929 | DX | ALCOHOL USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.93 | DX | ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.930 | DX | ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL, UNCOMPLICATED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.931 | DX | ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL DELIRIUM | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.932 | DX | ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.939 | DX | ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.94 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED MOOD DISORDER (ALCOHOL-INDUCED BIPOLAR OR DEPRESSIVE DISORDER WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.95 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.950 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.951 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.959 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED (ALCOHOL-INDUCED PSYCHOTIC DISORDER WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.96 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PERSISTING AMNESTIC DISORDER (ALCOHOL-INDUCED MAJOR NEUROCOGNITIVE DISORDER, AMNESTIC-CONFABULATORY TYPE WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.97 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PERSISTING DEMENTIA (ALCOHOL-INDUCED MAJOR NEUROCOGNITIVE DISORDER, NONAMNESTIC-CONFABULATORY TYPE WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.98 | DX | ALCOHOL USE, UNSPECIFIED WITH OTHER ALCOHOL-INDUCED DISORDERS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.980 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED ANXIETY DISORDER (ALCOHOL-INDUCED ANXIETY DISORDER WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.981 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION (ALCOHOL-INDUCED SEXUAL DYSFUNCTION WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.982 | DX | ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED SLEEP DISORDER (ALCOHOL-INDUCED SLEEP DISORDER WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.988 | DX | ALCOHOL USE, UNSPECIFIED WITH OTHER ALCOHOL-INDUCED DISORDER (ALCOHOL-INDUCED MILD NEUROCOGNITIVE DISORDER WITHOUT USE DISORDER) | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | F10.99 | DX | ALCOHOL USE, UNSPECIFIED WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.0 | DX | ALCOHOLIC FATTY LIVER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.1 | DX | ALCOHOLIC HEPATITIS | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.10 | DX | ALCOHOLIC HEPATITIS WITHOUT ASCITES | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.11 | DX | ALCOHOLIC HEPATITIS WITH ASCITES | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.2 | DX | ALCOHOLIC FIBROSIS AND SCLEROSIS OF LIVER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.3 | DX | ALCOHOLIC CIRRHOSIS OF LIVER | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.30 | DX | ALCOHOLIC CIRRHOSIS OF LIVER WITHOUT ASCITES | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.31 | DX | ALCOHOLIC CIRRHOSIS OF LIVER WITH ASCITES | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.4 | DX | ALCOHOLIC HEPATIC FAILURE | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|--------|----|-----------------------------------------------------------|-----------|
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.40 | DX | ALCOHOLIC HEPATIC FAILURE WITHOUT COMA | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.41 | DX | ALCOHOLIC HEPATIC FAILURE WITH COMA | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | K70.9 | DX | ALCOHOLIC LIVER DISEASE, UNSPECIFIED | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | G62.1 | DX | ALCOHOLIC POLYNEUROPATHY | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | I42.6 | DX | ALCOHOLIC CARDIOMYOPATHY | ICD-10-CM |
| 24.1 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Alcohol Abuse | Z71.41 | DX | ALCOHOL ABUSE COUNSELING AND SURVEILLANCE OF ALCOHOLIC | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.0 | DX | OPIOID TYPE DEPENDENCE | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.00 | DX | OPIOID TYPE DEPENDENCE, UNSPECIFIED | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.01 | DX | OPIOID TYPE DEPENDENCE, CONTINUOUS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.02 | DX | OPIOID TYPE DEPENDENCE, EPISODIC | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.03 | DX | OPIOID TYPE DEPENDENCE, IN REMISSION | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.1 | DX | SEDATIVE, HYPNOTIC, OR ANXIOLYTIC DEPENDENCE | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.10 | DX | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNSPECIFIED | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.11 | DX | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, CONTINUOUS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.12 | DX | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, EPISODIC | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.13 | DX | SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.2 | DX | COCAINE DEPENDENCE | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.20 | DX | COCAINE DEPENDENCE, UNSPECIFIED | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.21 | DX | COCAINE DEPENDENCE, CONTINUOUS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.22 | DX | COCAINE DEPENDENCE, EPISODIC | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.23 | DX | COCAINE DEPENDENCE, IN REMISSION | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 304.3 | DX | CANNABIS DEPENDENCE | ICD-9-CM |

[illegible]

[illegible]

[illegible]

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|----|-------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.81 | DX | ANTIDEPRESSANT TYPE ABUSE, CONTINUOUS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.82 | DX | ANTIDEPRESSANT TYPE ABUSE, EPISODIC | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.83 | DX | ANTIDEPRESSANT TYPE ABUSE, IN REMISSION | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.9 | DX | NONDEPENDENT OTHER MIXED OR UNSPECIFIED DRUG ABUSE | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.90 | DX | OTHER, MIXED, OR UNSPECIFIED DRUG ABUSE, UNSPECIFIED | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.91 | DX | OTHER, MIXED, OR UNSPECIFIED DRUG ABUSE, CONTINUOUS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.92 | DX | OTHER, MIXED, OR UNSPECIFIED DRUG ABUSE, EPISODIC | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 305.93 | DX | OTHER, MIXED, OR UNSPECIFIED DRUG ABUSE, IN REMISSION | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292 | DX | DRUG WITHDRAWAL | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.11 | DX | DRUG-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.12 | DX | DRUG-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.2 | DX | PATHOLOGICAL DRUG INTOXICATION | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.81 | DX | DRUG-INDUCED DELIRIUM | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.82 | DX | DRUG-INDUCED PERSISTING DEMENTIA | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.83 | DX | DRUG-INDUCED PERSISTING AMNESTIC DISORDER | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.84 | DX | DRUG-INDUCED MOOD DISORDER | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.85 | DX | DRUG INDUCED SLEEP DISORDERS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.89 | DX | OTHER SPECIFIED DRUG-INDUCED MENTAL DISORDERS | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 292.9 | DX | UNSPECIFIED DRUG-INDUCED MENTAL DISORDER | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | V65.42 | DX | COUNSELING ON SUBSTANCE USE AND ABUSE | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.0 | DX | OPIOID DEPENDENCE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.02 | DX | OPIOID DEPENDENCE, WITH INTOXICATION | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|-------------------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.020 | DX | OPIOID DEPENDENCE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.09 | DX | OPIOID DEPENDENCE WITH UNSPECIFIED OPIOID-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.1 | DX | OPIOID ABUSE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.10 | DX | OPIOID ABUSE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.12 | DX | OPIOID ABUSE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.120 | DX | OPIOID ABUSE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.121 | DX | OPIOID ABUSE WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.122 | DX | OPIOID ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.129 | DX | OPIOID ABUSE WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.13 | DX | OPIOID ABUSE WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.14 | DX | OPIOID ABUSE WITH OPIOID-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.15 | DX | OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.150 | DX | OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.151 | DX | OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.159 | DX | OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.18 | DX | OPIOID ABUSE WITH OTHER OPIOID-INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.181 | DX | OPIOID ABUSE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.182 | DX | OPIOID ABUSE WITH OPIOID-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.188 | DX | OPIOID ABUSE WITH OTHER OPIOID-INDUCED DISORDERS (INCLUDES OPIOID-ASSOCIATED AMNESTIC SYNDROME WITH OPIOID ABUSE) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.19 | DX | OPIOID ABUSE WITH UNSPECIFIED OPIOID-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.2 | DX | OPIOID DEPENDENCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.20 | DX | OPIOID DEPENDENCE, UNCOMPLICATED | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|-----------------------------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.22 | DX | OPIOID DEPENDENCE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.220 | DX | OPIOID DEPENDENCE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.221 | DX | OPIOID DEPENDENCE WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.222 | DX | OPIOID DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.229 | DX | OPIOID DEPENDENCE WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.23 | DX | OPIOID DEPENDENCE WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.24 | DX | OPIOID DEPENDENCE WITH OPIOID-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.25 | DX | OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.250 | DX | OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.251 | DX | OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.259 | DX | OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.28 | DX | OPIOID DEPENDENCE WITH OTHER OPIOID-INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.281 | DX | OPIOID DEPENDENCE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.282 | DX | OPIOID DEPENDENCE WITH OPIOID-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.288 | DX | OPIOID DEPENDENCE WITH OTHER OPIOID-INDUCED DISORDERS (INCLUDES OPIOID-ASSOCIATED AMNESTIC SYNDROME WITH OPIOID DEPENDENCE) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.29 | DX | OPIOID DEPENDENCE WITH UNSPECIFIED OPIOID-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.9 | DX | OPIOID USE, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F12.10 | DX | CANNABIS ABUSE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F12.12 | DX | CANNABIS ABUSE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F12.120 | DX | CANNABIS ABUSE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F12.121 | DX | CANNABIS ABUSE WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F12.122 | DX | CANNABIS ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|-------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.129 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.13 | DX | SEDATIVE, HYPNOTIC, OR ANXIOLYTIC ABUSE WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.130 | DX | WITHDRAWAL, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.131 | DX | WITHDRAWAL DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.132 | DX | WITHDRAWAL WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.139 | DX | WITHDRAWAL, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.14 | DX | WITH INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.15 | DX | WITH PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.150 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.151 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.159 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.18 | DX | WITH OTHER INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.180 | DX | WITH INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.181 | DX | WITH INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.182 | DX | WITH INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.188 | DX | WITH OTHER INDUCED DISORDERS (INCLUDES AMNESTIC SYNDROME) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.19 | DX | WITH UNSPECIFIED INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.20 | DX | SEDATIVE, HYPNOTIC, OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.22 | DX | DEPENDENCE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.220 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.221 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.229 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|-----------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.23 | DX | DEPENDENCE WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.230 | DX | WITHDRAWAL, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.231 | DX | WITHDRAWAL DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.232 | DX | WITHDRAWAL WITH PERCEPTUAL DISTURBANCES | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.239 | DX | WITHDRAWAL, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.24 | DX | WITH INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.25 | DX | WITH PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.250 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.251 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.259 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.26 | DX | WITH PERSISTING AMNESTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.27 | DX | WITH PERSISTING DEMENTIA | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.28 | DX | WITH OTHER INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.280 | DX | WITH INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.281 | DX | WITH INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.282 | DX | WITH INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.288 | DX | WITH OTHER INDUCED DISORDERS (INCLUDES AMNESTIC SYNDROME) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.29 | DX | WITH UNSPECIFIED INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.90 | DX | USE, UNSPECIFIED, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.92 | DX | USE, UNSPECIFIED WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.920 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.921 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|----------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.929 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.93 | DX | USE, UNSPECIFIED WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.930 | DX | WITHDRAWAL, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.931 | DX | WITHDRAWAL DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.932 | DX | WITHDRAWAL WITH PERCEPTUAL DISTURBANCES | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.939 | DX | WITHDRAWAL, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.94 | DX | USE, UNSPECIFIED WITH MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.95 | DX | USE, UNSPECIFIED WITH PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.950 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.951 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.959 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.96 | DX | USE, UNSPECIFIED WITH PERSISTING AMNESTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.97 | DX | USE, UNSPECIFIED WITH PERSISTING DEMENTIA | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.98 | DX | USE, UNSPECIFIED WITH OTHER INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.980 | DX | WITH INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.981 | DX | WITH INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.982 | DX | WITH INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.988 | DX | WITH OTHER INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.99 | DX | USE, UNSPECIFIED WITH UNSPECIFIED INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.10 | DX | COCAINE ABUSE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.12 | DX | COCAINE ABUSE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.120 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|---------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.121 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.122 | DX | WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.129 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.13 | DX | COCAINE ABUSE WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.14 | DX | COCAINE ABUSE WITH COCAINE-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.15 | DX | COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.150 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.151 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.159 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.18 | DX | COCAINE ABUSE WITH OTHER COCAINE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.180 | DX | WITH COCAINE-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.181 | DX | WITH COCAINE-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.182 | DX | WITH COCAINE-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.188 | DX | WITH OTHER COCAINE-INDUCED DISORDER (INCLUDES COCAINE-INDUCED OBSESSIVE-COMPULSIVE OR RELATED DISORDER) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.19 | DX | WITH UNSPECIFIED COCAINE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.20 | DX | COCAINE DEPENDENCE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.22 | DX | COCAINE DEPENDENCE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.220 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.221 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.222 | DX | WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.229 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.23 | DX | COCAINE DEPENDENCE WITH WITHDRAWAL | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|---------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.24 | DX | COCAINE DEPENDENCE WITH COCAINE-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.25 | DX | COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.250 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.251 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.259 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.28 | DX | COCAINE DEPENDENCE WITH OTHER COCAINE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.280 | DX | WITH COCAINE-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.281 | DX | WITH COCAINE-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.282 | DX | WITH COCAINE-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.288 | DX | WITH OTHER COCAINE-INDUCED DISORDER (INCLUDES COCAINE-INDUCED OBSESSIVE-COMPULSIVE OR RELATED DISORDER) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.29 | DX | WITH UNSPECIFIED COCAINE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.90 | DX | COCAINE USE, UNSPECIFIED, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.92 | DX | COCAINE USE, UNSPECIFIED WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.920 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.921 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.922 | DX | WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.929 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.93 | DX | COCAINE USE, UNSPECIFIED WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.94 | DX | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.95 | DX | COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.950 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.951 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.98 | DX | COCAINE USE, UNSPECIFIED WITH OTHER COCAINE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.980 | DX | WITH COCAINE-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.981 | DX | WITH COCAINE-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.982 | DX | WITH COCAINE-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.988 | DX | WITH OTHER COCAINE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.99 | DX | COCAINE USE, UNSPECIFIED WITH UNSPECIFIED COCAINE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.10 | DX | OTHER STIMULANT ABUSE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.12 | DX | OTHER STIMULANT ABUSE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.120 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.121 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.122 | DX | WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.129 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.13 | DX | OTHER STIMULANT ABUSE WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.14 | DX | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.15 | DX | OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.150 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.151 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.159 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.18 | DX | OTHER STIMULANT ABUSE WITH OTHER STIMULANT-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.180 | DX | WITH STIMULANT-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.181 | DX | WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.182 | DX | WITH STIMULANT-INDUCED SLEEP DISORDER | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.188 | DX | WITH OTHER STIMULANT-INDUCED DISORDER (INCLUDES OBSESSIVE-COMPULSIVE OR RELATED DISORDER) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.19 | DX | WITH UNSPECIFIED STIMULANT-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.20 | DX | OTHER STIMULANT DEPENDENCE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.22 | DX | OTHER STIMULANT DEPENDENCE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.220 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.221 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.222 | DX | WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.229 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.23 | DX | OTHER STIMULANT DEPENDENCE WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.24 | DX | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.25 | DX | OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.250 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.251 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.259 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.26 | DX | OTHER STIMULANT DEPENDENCE WITH PERSISTING AMNESTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.28 | DX | OTHER STIMULANT DEPENDENCE WITH OTHER STIMULANT-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.280 | DX | WITH STIMULANT-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.281 | DX | WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.282 | DX | WITH STIMULANT-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.288 | DX | WITH OTHER STIMULANT-INDUCED DISORDERS (INCLUDES OBSESSIVE-COMPULSIVE OR RELATED DISORDER) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.29 | DX | OTHER STIMULANT DEPENDENCE WITH UNSPECIFIED STIMULANT-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.90 | DX | OTHER STIMULANT USE, UNSPECIFIED, UNCOMPLICATED | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.92 | DX | OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.920 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.921 | DX | WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.922 | DX | WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.929 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.93 | DX | OTHER STIMULANT USE, UNSPECIFIED WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.94 | DX | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.95 | DX | OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.950 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.951 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.959 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.98 | DX | OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.980 | DX | WITH STIMULANT-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.981 | DX | WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.982 | DX | WITH STIMULANT-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.988 | DX | WITH OTHER STIMULANT-INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.99 | DX | OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.1 | DX | HALLUCINOGEN ABUSE EXCLUDES1: HALLUCINOGEN DEPENDENCE (F16.2-), HALLUCINOGEN USE, UNSPECIFIED (F16.9-) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.10 | DX | HALLUCINOGEN ABUSE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.11 | DX | HALLUCINOGEN ABUSE, IN REMISSION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.12 | DX | HALLUCINOGEN ABUSE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.120 | DX | HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.983 | DX | HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.988 | DX | HALLUCINOGEN USE, UNSPECIFIED WITH OTHER HALLUCINOGEN-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.99 | DX | HALLUCINOGEN USE, UNSPECIFIED WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.10 | DX | INHALANT ABUSE, UNCOMPLICATED; INHALANT USE DISORDER, MILD | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.11 | DX | INHALANT ABUSE, IN REMISSION; INHALANT USE DISORDER, MILD, IN EARLY REMISSION; INHALANT USE DISORDER, MILD, IN SUSTAINED REMISSION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.12 | DX | INHALANT ABUSE WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.120 | DX | INHALANT ABUSE WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.121 | DX | INHALANT ABUSE WITH INTOXICATION DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.129 | DX | INHALANT ABUSE WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.14 | DX | INHALANT ABUSE WITH INHALANT-INDUCED MOOD DISORDER; INHALANT USE DISORDER, MILD, WITH INHALANT INDUCED DEPRESSIVE DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.15 | DX | INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.150 | DX | INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.151 | DX | INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.159 | DX | INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.17 | DX | INHALANT ABUSE WITH INHALANT-INDUCED DEMENTIA; INHALANT USE DISORDER, MILD, WITH INHALANT INDUCED MAJOR NEUROCOGNITIVE DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.18 | DX | INHALANT ABUSE WITH OTHER INHALANT-INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.180 | DX | INHALANT ABUSE WITH INHALANT-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.188 | DX | INHALANT ABUSE WITH OTHER INHALANT-INDUCED DISORDER; INHALANT USE DISORDER, MILD, WITH INHALANT INDUCED MILD NEUROCOGNITIVE DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F18.19 | DX | INHALANT ABUSE WITH UNSPECIFIED INHALANT-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.10 | DX | OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.11 | DX | OTHER PSYCHOACTIVE SUBSTANCE ABUSE, IN REMISSION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.12 | DX | OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.282 | DX | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.288 | DX | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER (INCLUDES OBSESSIVE-COMPULSIVE OR RELATED DISORDER) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.29 | DX | OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.90 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.91 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED, IN REMISSION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.92 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.920 | DX | WITH INTOXICATION, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.921 | DX | WITH INTOXICATION DELIRIUM (INCLUDES OTHER STIMULANT INTOXICATION DELIRIUM) | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.922 | DX | WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.929 | DX | WITH INTOXICATION, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.93 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.930 | DX | WITHDRAWAL, UNCOMPLICATED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.931 | DX | WITHDRAWAL DELIRIUM | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.932 | DX | WITHDRAWAL WITH PERCEPTUAL DISTURBANCES | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.939 | DX | WITHDRAWAL, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.94 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.95 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PSYCHOTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.950 | DX | WITH PSYCHOTIC DISORDER WITH DELUSIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.951 | DX | WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.959 | DX | WITH PSYCHOTIC DISORDER, UNSPECIFIED | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.96 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING AMNESTIC DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.97 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-INDUCED PERSISTING DEMENTIA | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|----|--------------------------------------------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.98 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDERS | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.980 | DX | WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.981 | DX | WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL DYSFUNCTION | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.982 | DX | WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.988 | DX | WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F19.99 | DX | OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-INDUCED DISORDER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | Z71.51 | DX | DRUG ABUSE COUNSELING AND SURVEILLANCE OF DRUG ABUSER | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.11 | DX | Opioid abuse, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.21 | DX | Opioid dependence, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.90 | DX | Opioid use, unspecified, uncomplicated | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F11.91 | DX | Opioid use, unspecified, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F12.11 | DX | Cannabis abuse, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F12.21 | DX | Cannabis dependence, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.11 | DX | Sedative, hypnotic, or anxiolytic abuse, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.21 | DX | Sedative, hypnotic, or anxiolytic dependence, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F13.91 | DX | Sedative, hypnotic, or anxiolytic use, unspecified, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.11 | DX | Cocaine abuse, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.21 | DX | Cocaine dependence, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F14.91 | DX | Cocaine use, unspecified, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.11 | DX | Other stimulant abuse, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.21 | DX | Other stimulant dependence, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F15.91 | DX | Other stimulant use, unspecified, in remission | ICD-10-CM |

| | | | | | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|----|------------------------------------------------------------------|-----------|
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.11 | DX | Hallucinogen abuse, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.21 | DX | Hallucinogen dependence, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | F16.91 | DX | Hallucinogen use, unspecified, in remission | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | G31.2 | DX | Degeneration of nervous system due to alcohol | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K29.2 | DX | Alcoholic gastritis | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K29.20 | DX | Alcoholic gastritis without bleeding | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K29.21 | DX | Alcoholic gastritis with bleeding | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K85.2 | DX | Alcohol-induced acute pancreatitis | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K85.20 | DX | Alcohol-induced acute pancreatitis without necrosis or infection | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K85.21 | DX | Alcohol-induced acute pancreatitis with uninfected necrosis | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K85.22 | DX | Alcohol-induced acute pancreatitis with infected necrosis | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | K86.0 | DX | Alcohol-induced chronic pancreatitis | ICD-10-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 331.7 | DX | Cerebral degeneration in diseases classified elsewhere | ICD-9-CM |
| 24.2 | Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial | Drug Abuse | 357.6 | DX | Polyneuropathy due to drugs | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 630 | DX | HYDATIDIFORM MOLE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 631 | DX | OTHER ABNORMAL PRODUCT OF CONCEPTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 632 | DX | MISSED ABORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 633 | DX | ECTOPIC PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 633.0 | DX | ABDOMINAL PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 633.1 | DX | TUBAL PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 633.2 | DX | OVARIAN PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 633.8 | DX | OTHER ECTOPIC PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 633.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 634 | DX | SPONTANEOUS ABORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 634.0 | DX | COMPLICATED BY GENITAL TRACT AND PELVIC INFECTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 634.1 | DX | COMPLICATED BY DELAYED OR EXCESSIVE HAEMORRHAGE | ICD-9-CM |

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|------------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.2 | DX | COMPLICATED BY DAMAGE TO PELVIC ORGANS AND TISSUES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.3 | DX | COMPLICATED BY RENAL FAILURE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.4 | DX | COMPLICATED BY METABOLIC DISORDER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.5 | DX | COMPLICATED BY SHOCK | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.6 | DX | COMPLICATED BY EMBOLISM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.7 | DX | WITH OTHER SPECIFIED COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.8 | DX | WITH UNSPECIFIED COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 637.9 | DX | WITHOUT MENTION OF COMPLICATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638 | DX | FAILED ATTEMPTED ABORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.0 | DX | COMPLICATED BY GENITAL TRACT AND PELVIC INFECTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.1 | DX | COMPLICATED BY DELAYED OR EXCESSIVE HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.2 | DX | COMPLICATED BY DAMAGE TO PELVIC ORGANS AND TISSUES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.3 | DX | COMPLICATED BY RENAL FAILURE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.4 | DX | COMPLICATED BY METABOLIC DISORDER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.5 | DX | COMPLICATED BY SHOCK | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.6 | DX | COMPLICATED BY EMBOLISM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.7 | DX | WITH OTHER SPECIFIED COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.8 | DX | WITH UNSPECIFIED COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 638.9 | DX | WITHOUT MENTION OF COMPLICATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639 | DX | COMPLICATIONS FOLLOWING ABORTION AND ECTOPIC AND MOLAR PREGNANCIES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.0 | DX | GENITAL TRACT AND PELVIC INFECTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.1 | DX | DELAYED OR EXCESSIVE HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.2 | DX | DAMAGE TO PELVIC ORGANS AND TISSUES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.3 | DX | RENAL FAILURE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.4 | DX | METABOLIC DISORDERS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.5 | DX | SHOCK | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.6 | DX | EMBOLISM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.8 | DX | OTHER SPECIFIED COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 639.9 | DX | UNSPECIFIED COMPLICATIONS FOLLOWING CONDITIONS CLASSIFIABLE TO 630-638 | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 640 | DX | HAEMORRHAGE IN EARLY PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 640.0 | DX | THREATENED ABORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 640.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 640.9 | DX | UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|--------------------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 641 | DX | ANTEPARTUM HAEMORRHAGE, ABRUPTIO PLACENTAE, AND PLACENTA PRAEVIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 641.0 | DX | PLACENTA PRAEVIA WITHOUT HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 641.1 | DX | HAEMORRHAGE FROM PLACENTA PRAEVIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 641.2 | DX | PREMATURE SEPARATION OF PLACENTA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 641.3 | DX | ANTEPARTUM HAEMORRHAGE ASSOCIATED WITH COAGULATION DEFECTS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 641.8 | DX | OTHER ANTEPARTUM HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 641.9 | DX | UNSPECIFIED ANTEPARTUM HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642 | DX | HYPERTENSION COMPLICATING PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.0 | DX | BENIGN ESSENTIAL HYPERTENSION COMPLICATING PREGNANCY, CHILDBIRTH | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.0 | DX | AND THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.1 | DX | HYPERTENSION SECONDARY TO RENAL DISEASE, COMPLICATING PREGNANCY, | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.2 | DX | OTHER PRE-EXISTING HYPERTENSION COMPLICATING PREGNANCY, CHILDBIRTH AND | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.2 | DX | THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.3 | DX | TRANSIENT HYPERTENSION OF PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.4 | DX | MILD OR UNSPECIFIED PRE-ECLAMPSIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.5 | DX | SEVERE PRE-ECLAMPSIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.6 | DX | ECLAMPSIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.7 | DX | PRE-ECLAMPSIA OR ECLAMPSIA SUPERIMPOSED ON PRE-EXISTING HYPERTENSION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 642.9 | DX | UNSPECIFIED HYPERTENSION COMPLICATING PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 643 | DX | EXCESSIVE VOMITING IN PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 643.0 | DX | MILD HYPEREMESIS GRAVIDARUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 643.1 | DX | HYPEREMESIS GRAVIDARUM WITH METABOLIC DISTURBANCE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 643.2 | DX | LATE VOMITING OF PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 643.8 | DX | OTHER VOMITING COMPLICATING PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 643.9 | DX | UNSPECIFIED VOMITING OF PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 644 | DX | EARLY OR THREATENED LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 644.0 | DX | THREATENED LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 644.1 | DX | EARLY ONSET OF DELIVERY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 645 | DX | PROLONGED PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646 | DX | OTHER COMPLICATIONS OF PREGNANCY, NOT ELSEWHERE CLASSIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.0 | DX | PAPYRACEOUS FETUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.1 | DX | OEDEMA OR EXCESSIVE WEIGHT GAIN IN PREGNANCY, WITHOUT MENTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.2 | DX | UNSPECIFIED RENAL DISEASE IN PREGNANCY, WITHOUT MENTION OF HYPERTENSION | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|-------------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.3 | DX | HABITUAL ABORTER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.4 | DX | PERIPHERAL NEURITIS IN PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.5 | DX | ASYMPTOMATIC BACTERIURIA IN PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.6 | DX | INFECTIONS OF GENITOURINARY TRACT IN PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.7 | DX | LIVER DISORDERS IN PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.8 | DX | OTHER SPECIFIED COMPLICATIONS OF PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 646.9 | DX | UNSPECIFIED COMPLICATION OF PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647 | DX | INFECTIVE AND PARASITIC CONDITIONS IN THE MOTHER CLASSIFIABLE ELSEWHERE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.0 | DX | SYPHILIS COMPLICATING PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.1 | DX | GONORRHOEA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.2 | DX | OTHER VENEREAL DISEASES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.3 | DX | TUBERCULOSIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.4 | DX | MALARIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.5 | DX | RUBELLA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.6 | DX | OTHER VIRAL DISEASES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.8 | DX | OTHER SPECIFIED INFECTIVE AND PARASITIC DISEASES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 647.9 | DX | UNSPECIFIED INFECTION OR INFESTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648 | DX | OTHER CURRENT CONDITIONS IN THE MOTHER CLASSIFIABLE ELSEWHERE BUT | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648 | DX | COMPLICATING PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.0 | DX | DIABETES MELLITUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.1 | DX | THYROID DYSFUNCTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.2 | DX | ANAEMIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.3 | DX | DRUG DEPENDENCE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.4 | DX | MENTAL DISORDERS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.5 | DX | CONGENITAL CARDIOVASCULAR DISORDERS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.6 | DX | OTHER CARDIOVASCULAR DISEASES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.7 | DX | BONE AND JOINT DISORDERS OF BACK, PELVIS AND LOWER LIMBS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.8 | DX | ABNORMAL GLUCOSE TOLERANCE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 648.9 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 650 | DX | DELIVERY IN A COMPLETELY NORMAL CASE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 651 | DX | MULTIPLE GESTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 651.0 | DX | TWIN PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 651.1 | DX | TRIPLET PREGNANCY | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|-------------------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 651.2 | DX | QUADRUPLET PREGNANCY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 651.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 651.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652 | DX | MALPOSITION AND MALPRESENTATION OF FETUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.0 | DX | UNSTABLE LIE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.1 | DX | BREECH OR OTHER MALPRESENTATION SUCCESSFULLY CONVERTED TO CEPHALIC | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.2 | DX | BREECH PRESENTATION WITHOUT MENTION OF VERSION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.3 | DX | TRANSVERSE OR OBLIQUE PRESENTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.4 | DX | FACE OR BROW PRESENTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.5 | DX | HIGH HEAD AT TERM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.6 | DX | MULTIPLE GESTATION WITH MALPRESENTATION OF ONE FETUS OR MORE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.7 | DX | PROLAPSED ARM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 652.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653 | DX | DISPROPORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.0 | DX | MAJOR ABNORMALITY OF BONY PELVIS, NOT FURTHER SPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.1 | DX | GENERALLY CONTRACTED PELVIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.2 | DX | INLET CONTRACTION OF PELVIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.3 | DX | OUTLET CONTRACTION OF PELVIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.4 | DX | FETOPELVIC DISPROPORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.5 | DX | UNUSUALLY LARGE FETUS CAUSING DISPROPORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.6 | DX | HYDROCEPHALIC FETUS CAUSING DISPROPORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.7 | DX | OTHER FETAL ABNORMALITY CAUSING DISPROPORTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.8 | DX | DISPROPORTION OF OTHER ORIGIN | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 653.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654 | DX | ABNORMALITY OF ORGANS AND SOFT TISSUES OF PELVIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.0 | DX | CONGENITAL ABNORMALITIES OF UTERUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.1 | DX | TUMOURS OF BODY OF UTERUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.2 | DX | UTERINE SCAR FROM PREVIOUS SURGERY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.3 | DX | RETROVERTED AND INCARCERATED GRAVID UTERUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.4 | DX | OTHER ABNORMALITIES IN SHAPE OR POSITION OF GRAVID UTERUS AND OF NEIGHBOURING | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.5 | DX | CERVICAL INCOMPETENCE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.6 | DX | OTHER CONGENITAL OR ACQUIRED ABNORMALITY OF CERVIX | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|------------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.7 | DX | CONGENITAL OR ACQUIRED ABNORMALITY OF VAGINA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.8 | DX | CONGENITAL OR ACQUIRED ABNORMALITY OF VULVA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 654.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655 | DX | KNOWN OR SUSPECTED FETAL ABNORMALITY AFFECTING MANAGEMENT OF MOTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.0 | DX | CENTRAL NERVOUS SYSTEM MALFORMATION IN FETUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.1 | DX | CHROMOSOMAL ABNORMALITY IN FETUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.2 | DX | HEREDITARY DISEASE IN FAMILY POSSIBLY AFFECTING FETUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.3 | DX | SUSPECTED DAMAGE TO FETUS FROM VIRAL DISEASE IN THE MOTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.4 | DX | SUSPECTED DAMAGE TO FETUS FROM OTHER DISEASE IN THE MOTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.5 | DX | SUSPECTED DAMAGE TO FETUS FROM DRUGS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.6 | DX | SUSPECTED DAMAGE TO FETUS FROM RADIATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.8 | DX | OTHER KNOWN OR SUSPECTED FETAL ABNORMALITY, NOT ELSEWHERE CLASSIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 655.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656 | DX | OTHER FETAL AND PLACENTAL PROBLEMS AFFECTING MANAGEMENT OF MOTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.0 | DX | FETAL-MATERNAL HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.1 | DX | RHESUS ISOIMMUNIZATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.2 | DX | ISOIMMUNIZATION FROM OTHER AND UNSPECIFIED BLOOD-GROUP INCOMPATIBILITY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.3 | DX | FETAL DISTRESS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.4 | DX | INTRAUTERINE DEATH | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.5 | DX | POOR FETAL GROWTH | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.6 | DX | EXCESSIVE FETAL GROWTH | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.7 | DX | OTHER PLACENTAL CONDITIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 656.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 657 | DX | POLYHYDRAMNIO | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658 | DX | OTHER PROBLEMS ASSOCIATED WITH AMNIOTIC CAVITY AND MEMBRANES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658.0 | DX | OLIGOHYDRAMNIO | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658.1 | DX | PREMATURE RUPTURE OF MEMBRANES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658.2 | DX | DELAYED DELIVERY AFTER SPONTANEOUS OR UNSPECIFIED RUPTURE OF MEMBRANES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658.3 | DX | DELAYED DELIVERY AFTER ARTIFICIAL RUPTURE OF MEMBRANES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658.4 | DX | INFECTION OF AMNIOTIC CAVITY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 658.9 | DX | UNSPECIFIED | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|-----------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659 | DX | OTHER INDICATIONS FOR CARE OR INTERVENTION RELATED TO LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.0 | DX | AND DELIVERY AND NOT ELSEWHERE CLASSIFIED FAILED MECHANICAL INDUCTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.1 | DX | FAILED MEDICAL OR UNSPECIFIED INDUCTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.2 | DX | MATERNAL PYREXIA DURING LABOUR, UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.3 | DX | GENERALIZED INFECTION DURING LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.4 | DX | GRAND MULTIPARITY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.5 | DX | ELDERLY PRIMIGRAVIDA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 659.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660 | DX | OBSTRUCTED LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.0 | DX | OBSTRUCTION CAUSED BY MALPOSITION OF FETUS AT ONSET OF LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.1 | DX | OBSTRUCTION BY BONY PELVIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.2 | DX | OBSTRUCTION BY ABNORMAL PELVIC SOFT TISSUES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.3 | DX | DEEP TRANSVERSE ARREST AND PERSISTENT OCCIPITOPOSTERIOR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.4 | DX | OR OCCIPITOANTERIOR POSITION SHOULDER DYSTOCIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.5 | DX | LOCKED TWINS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.6 | DX | FAILED TRIAL OF LABOUR, UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.7 | DX | FAILED FORCEPS OR VENTOUSE, UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 660.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 661 | DX | ABNORMALITY OF FORCES OF LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 661.0 | DX | PRIMARY UTERINE INERTIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 661.1 | DX | SECONDARY UTERINE INERTIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 661.2 | DX | OTHER AND UNSPECIFIED UTERINE INERTIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 661.3 | DX | PRECIPITATE LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 661.4 | DX | HYPERTONIC, INCOORDINATE, OR PROLONGED UTERINE CONTRACTIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 661.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 662 | DX | LONG LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 662.0 | DX | PROLONGED FIRST STAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 662.1 | DX | PROLONGED LABOUR, UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 662.2 | DX | PROLONGED SECOND STAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 662.3 | DX | DELAYED DELIVERY OF SECOND TWIN, TRIPLET, ETC. | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663 | DX | UMBILICAL CORD COMPLICATIONS | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|-------------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.0 | DX | PROLAPSE OF CORD | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.1 | DX | CORD AROUND NECK, WITH COMPRESSION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.2 | DX | OTHER AND UNSPECIFIED CORD ENTANGLEMENT, WITH COMPRESSION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.3 | DX | OTHER AND UNSPECIFIED CORD ENTANGLEMENT, WITHOUT MENTION OF COMPRESSION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.4 | DX | SHORT CORD | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.5 | DX | VASA PRAEVIA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.6 | DX | VASCULAR LESIONS OF CORD | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 663.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664 | DX | TRAUMA TO PERINEUM AND VULVA DURING DELIVERY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.0 | DX | FIRST-DEGREE PERINEAL LACERATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.1 | DX | SECOND-DEGREE PERINEAL LACERATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.2 | DX | THIRD-DEGREE PERINEAL LACERATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.3 | DX | FOURTH-DEGREE PERINEAL LACERATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.4 | DX | UNSPECIFIED PERINEAL LACERATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.5 | DX | VULVAL AND PERINEAL HAEMATOMA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 664.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665 | DX | OTHER OBSTETRICAL TRAUMA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.0 | DX | RUPTURE OF UTERUS BEFORE ONSET OF LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.1 | DX | RUPTURE OF UTERUS DURING AND AFTER LABOUR | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.2 | DX | INVERSION OF UTERUS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.3 | DX | LACERATION OF CERVIX | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.4 | DX | HIGH VAGINAL LACERATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.5 | DX | OTHER INJURY TO PELVIC ORGANS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.6 | DX | DAMAGE TO PELVIC JOINTS AND LIGAMENTS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.7 | DX | PELVIC HAEMATOMA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 665.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 666 | DX | POSTPARTUM HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 666.0 | DX | THIRD-STAGE HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 666.1 | DX | OTHER IMMEDIATE POSTPARTUM HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 666.2 | DX | DELAYED AND SECONDARY POSTPARTUM HAEMORRHAGE | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|-------|----|----------------------------------------------------------------------|----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 666.3 | DX | POSTPARTUM COAGULATION DEFECTS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 667 | DX | RETAINED PLACENTA OR MEMBRANES, WITHOUT HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 667.0 | DX | RETAINED PLACENTA WITHOUT HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 667.1 | DX | RETAINED PORTIONS OF PLACENTA OR MEMBRANES, WITHOUT HAEMORRHAGE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 668 | DX | COMPLICATIONS OF THE ADMINISTRATION OF ANAESTHETIC OR OTHER SEDATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 668.0 | DX | IN LABOUR AND DELIVERY PULMONARY COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 668.1 | DX | CARDIAC COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 668.2 | DX | CENTRAL NERVOUS SYSTEM COMPLICATIONS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 668.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 668.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669 | DX | OTHER COMPLICATIONS OF LABOUR AND DELIVERY, NOT ELSEWHERE CLASSIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.0 | DX | MATERNAL DISTRESS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.1 | DX | SHOCK DURING OR FOLLOWING LABOUR AND DELIVERY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.2 | DX | MATERNAL HYPOTENSION SYNDROME | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.3 | DX | ACUTE RENAL FAILURE FOLLOWING LABOUR AND DELIVERY | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.4 | DX | OTHER COMPLICATIONS OF OBSTETRICAL SURGERY AND PROCEDURES | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.5 | DX | FORCEPS OR VENTOUSE DELIVERY WITHOUT MENTION OF INDICATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.6 | DX | BREECH EXTRACTION, WITHOUT MENTION OF INDICATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.7 | DX | CAESAREAN DELIVERY, WITHOUT MENTION OF INDICATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 669.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 670 | DX | MAJOR PUERPERAL INFECTION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671 | DX | VENOUS COMPLICATIONS IN PREGNANCY AND THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.0 | DX | VARICOSE VEINS OF LEGS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.1 | DX | VARICOSE VEINS OF VULVA AND PERINEUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.2 | DX | SUPERFICIAL THROMBOPHLEBITIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.3 | DX | DEEP PHLEBOTHROMBOSIS, ANTEPARTUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.4 | DX | DEEP PHLEBOTHROMBOSIS, POSTPARTUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.5 | DX | OTHER PHLEBITIS AND THROMBOSIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 671.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 672 | DX | PYREXIA OF UNKNOWN ORIGIN DURING THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 673 | DX | OBSTETRICAL PULMONARY EMBOLISM | ICD-9-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|---------|----|-------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 673.0 | DX | OBSTETRICAL AIR EMBOLISM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 673.1 | DX | AMNIOTIC FLUID EMBOLISM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 673.2 | DX | OBSTETRICAL BLOOD-CLOT EMBOLISM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 673.3 | DX | OBSTETRICAL PYAEMIC AND SEPTIC EMBOLISM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 673.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674 | DX | OTHER AND UNSPECIFIED COMPLICATIONS OF THE PUERPERIUM, NOT | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674.0 | DX | ELSEWHERE CLASSIFIED CEREBROVASCULAR DISORDERS IN THE PUERPERIUM | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674.1 | DX | DISRUPTION OF CAESAREAN WOUND | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674.2 | DX | DISRUPTION OF PERINEAL WOUND | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674.3 | DX | OTHER COMPLICATIONS OF OBSTETRICAL SURGICAL WOUNDS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674.4 | DX | PLACENTAL POLYP | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 674.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 675 | DX | INFECTIONS OF THE BREAST AND NIPPLE ASSOCIATED WITH CHILDBIRTH | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 675.0 | DX | INFECTIONS OF NIPPLE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 675.1 | DX | ABSCESS OF BREAST | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 675.2 | DX | NONPURULENT MASTITIS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 675.8 | DX | OTHER | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 675.9 | DX | UNSPECIFIED | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676 | DX | OTHER DISORDERS OF THE BREAST ASSOCIATED WITH CHILDBIRTH, AND DISORDERS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676 | DX | OF LACTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.0 | DX | RETRACTED NIPPLE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.1 | DX | CRACKED NIPPLE | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.2 | DX | ENGORGEMENT OF BREASTS | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.3 | DX | OTHER AND UNSPECIFIED DISORDER OF BREAST | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.4 | DX | FAILURE OF LACTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.5 | DX | SUPPRESSED LACTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.6 | DX | GALACTORRHOEA | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.8 | DX | OTHER DISORDERS OF LACTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 676.9 | DX | UNSPECIFIED DISORDER OF LACTATION | ICD-9-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | H35.1 | DX | RETINOPATHY OF PREMATURITY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | H35.10 | DX | RETINOPATHY OF PREMATURITY, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | H35.101 | DX | RETINOPATHY OF PREMATURITY, UNSPECIFIED, RIGHT EYE | ICD-10-CM |

[illegible]

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|--------------------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 001 | DX | HYDATIDIFORM MOLE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 001.0 | DX | CLASSICAL HYDATIDIFORM MOLE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 001.1 | DX | INCOMPLETE AND PARTIAL HYDATIDIFORM MOLE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 001.9 | DX | HYDATIDIFORM MOLE, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 002 | DX | OTHER ABNORMAL PRODUCTS OF CONCEPTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 002.0 | DX | BLIGHTED OVUM AND NONHYDATIDIFORM MOLE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 002.1 | DX | MISSED ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 002.8 | DX | OTHER SPECIFIED ABNORMAL PRODUCTS OF CONCEPTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 002.81 | DX | INAPPROPRIATE CHANGE IN QUANTITATIVE HUMAN CHORIONIC GONADOTROPIN (HCG) IN EARLY PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 002.89 | DX | OTHER ABNORMAL PRODUCTS OF CONCEPTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 002.9 | DX | ABNORMAL PRODUCT OF CONCEPTION, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003 | DX | SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.0 | DX | GENITAL TRACT AND PELVIC INFECTION FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.1 | DX | DELAYED OR EXCESSIVE HEMORRHAGE FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.2 | DX | EMBOLISM FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.3 | DX | OTHER AND UNSPECIFIED COMPLICATIONS FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.30 | DX | UNSPECIFIED COMPLICATION FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.31 | DX | SHOCK FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.32 | DX | RENAL FAILURE FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.33 | DX | METABOLIC DISORDER FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.34 | DX | DAMAGE TO PELVIC ORGANS FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.35 | DX | OTHER VENOUS COMPLICATIONS FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.36 | DX | CARDIAC ARREST FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.37 | DX | SEPSIS FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.38 | DX | URINARY TRACT INFECTION FOLLOWING INCOMPLETE SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.39 | DX | INCOMPLETE SPONTANEOUS ABORTION WITH OTHER COMPLICATIONS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.4 | DX | INCOMPLETE SPONTANEOUS ABORTION WITHOUT COMPLICATION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.5 | DX | GENITAL TRACT AND PELVIC INFECTION FOLLOWING COMPLETE OR UNSPECIFIED SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.6 | DX | DELAYED OR EXCESSIVE HEMORRHAGE FOLLOWING COMPLETE OR UNSPECIFIED SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.7 | DX | EMBOLISM FOLLOWING COMPLETE OR UNSPECIFIED SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.8 | DX | OTHER AND UNSPECIFIED COMPLICATIONS FOLLOWING COMPLETE OR UNSPECIFIED SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.80 | DX | UNSPECIFIED COMPLICATION FOLLOWING COMPLETE OR UNSPECIFIED SPONTANEOUS ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 003.81 | DX | SHOCK FOLLOWING COMPLETE OR UNSPECIFIED SPONTANEOUS ABORTION | ICD-10-CM |

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|-----------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 007.34 | DX | DAMAGE TO PELVIC ORGANS FOLLOWING FAILED ATTEMPTED TERMINATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 007.35 | DX | OTHER VENOUS COMPLICATIONS FOLLOWING FAILED ATTEMPTED TERMINATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 007.36 | DX | CARDIAC ARREST FOLLOWING FAILED ATTEMPTED TERMINATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 007.37 | DX | SEPSIS FOLLOWING FAILED ATTEMPTED TERMINATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 007.38 | DX | URINARY TRACT INFECTION FOLLOWING FAILED ATTEMPTED TERMINATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 007.39 | DX | FAILED ATTEMPTED TERMINATION OF PREGNANCY WITH OTHER COMPLICATIONS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 007.4 | DX | FAILED ATTEMPTED TERMINATION OF PREGNANCY WITHOUT COMPLICATION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008 | DX | COMPLICATIONS FOLLOWING ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.0 | DX | GENITAL TRACT AND PELVIC INFECTION FOLLOWING ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.1 | DX | DELAYED OR EXCESSIVE HEMORRHAGE FOLLOWING ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.2 | DX | EMBOLISM FOLLOWING ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.3 | DX | SHOCK FOLLOWING ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.4 | DX | RENAL FAILURE FOLLOWING ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.5 | DX | METABOLIC DISORDERS FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.6 | DX | DAMAGE TO PELVIC ORGANS AND TISSUES FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.7 | DX | OTHER VENOUS COMPLICATIONS FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.8 | DX | OTHER COMPLICATIONS FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.81 | DX | CARDIAC ARREST FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.82 | DX | SEPSIS FOLLOWING ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.83 | DX | URINARY TRACT INFECTION FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.89 | DX | OTHER COMPLICATIONS FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 008.9 | DX | UNSPECIFIED COMPLICATION FOLLOWING AN ECTOPIC AND MOLAR PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009 | DX | SUPERVISION OF HIGH RISK PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.0 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.00 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.01 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.02 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.03 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.1 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.10 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.11 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.12 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 009.13 | DX | SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, THIRD TRIMESTER | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|----------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.05 | DX | MILD TO MODERATE PRE-ECLAMPSIA, COMPLICATING THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.1 | DX | SEVERE PRE-ECLAMPSIA | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.10 | DX | SEVERE PRE-ECLAMPSIA, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.12 | DX | SEVERE PRE-ECLAMPSIA, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.13 | DX | SEVERE PRE-ECLAMPSIA, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.14 | DX | SEVERE PRE-ECLAMPSIA, COMPLICATING CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.15 | DX | SEVERE PRE-ECLAMPSIA, COMPLICATING THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.2 | DX | HELLP SYNDROME | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.20 | DX | HELLP SYNDROME (HELLP), UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.22 | DX | HELLP SYNDROME (HELLP), SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.23 | DX | HELLP SYNDROME (HELLP), THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.24 | DX | HELLP SYNDROME, COMPLICATING CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.25 | DX | HELLP SYNDROME, COMPLICATING THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.9 | DX | UNSPECIFIED PRE-ECLAMPSIA | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.90 | DX | UNSPECIFIED PRE-ECLAMPSIA, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.92 | DX | UNSPECIFIED PRE-ECLAMPSIA, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.93 | DX | UNSPECIFIED PRE-ECLAMPSIA, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.94 | DX | UNSPECIFIED PRE-ECLAMPSIA, COMPLICATING CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O14.95 | DX | UNSPECIFIED PRE-ECLAMPSIA, COMPLICATING THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15 | DX | ECLAMPSIA | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15.0 | DX | ECLAMPSIA COMPLICATING PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15.00 | DX | ECLAMPSIA COMPLICATING PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15.02 | DX | ECLAMPSIA COMPLICATING PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15.03 | DX | ECLAMPSIA COMPLICATING PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15.1 | DX | ECLAMPSIA COMPLICATING LABOR | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15.2 | DX | ECLAMPSIA COMPLICATING THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O15.9 | DX | ECLAMPSIA, UNSPECIFIED AS TO TIME PERIOD | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O16 | DX | UNSPECIFIED MATERNAL HYPERTENSION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O16.1 | DX | UNSPECIFIED MATERNAL HYPERTENSION, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O16.2 | DX | UNSPECIFIED MATERNAL HYPERTENSION, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O16.3 | DX | UNSPECIFIED MATERNAL HYPERTENSION, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O16.4 | DX | UNSPECIFIED MATERNAL HYPERTENSION, COMPLICATING CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | O16.5 | DX | UNSPECIFIED MATERNAL HYPERTENSION, COMPLICATING THE PUERPERIUM | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|-----------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 016.9 | DX | UNSPECIFIED MATERNAL HYPERTENSION, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 020 | DX | HEMORRHAGE IN EARLY PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 020.0 | DX | THREATENED ABORTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 020.8 | DX | OTHER HEMORRHAGE IN EARLY PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 020.9 | DX | HEMORRHAGE IN EARLY PREGNANCY, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 021 | DX | EXCESSIVE VOMITING IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 021.0 | DX | MILD HYPEREMESIS GRAVIDARUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 021.1 | DX | HYPEREMESIS GRAVIDARUM WITH METABOLIC DISTURBANCE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 021.2 | DX | LATE VOMITING OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 021.8 | DX | OTHER VOMITING COMPLICATING PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 021.9 | DX | VOMITING OF PREGNANCY, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022 | DX | VENOUS COMPLICATIONS AND HEMORRHOIDS IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.0 | DX | VARICOSE VEINS OF LOWER EXTREMITY IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.00 | DX | VARICOSE VEINS OF LOWER EXTREMITY IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.01 | DX | VARICOSE VEINS OF LOWER EXTREMITY IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.02 | DX | VARICOSE VEINS OF LOWER EXTREMITY IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.03 | DX | VARICOSE VEINS OF LOWER EXTREMITY IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.1 | DX | GENITAL VARICES IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.10 | DX | GENITAL VARICES IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.11 | DX | GENITAL VARICES IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.12 | DX | GENITAL VARICES IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.13 | DX | GENITAL VARICES IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.2 | DX | SUPERFICIAL THROMBOPHLEBITIS IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.20 | DX | SUPERFICIAL THROMBOPHLEBITIS IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.21 | DX | SUPERFICIAL THROMBOPHLEBITIS IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.22 | DX | SUPERFICIAL THROMBOPHLEBITIS IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.23 | DX | SUPERFICIAL THROMBOPHLEBITIS IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.3 | DX | DEEP PHLEBOTHROMBOSIS IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.30 | DX | DEEP PHLEBOTHROMBOSIS IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.31 | DX | DEEP PHLEBOTHROMBOSIS IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.32 | DX | DEEP PHLEBOTHROMBOSIS IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.33 | DX | DEEP PHLEBOTHROMBOSIS IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 022.4 | DX | HEMORRHOIDS IN PREGNANCY | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|---------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026 | DX | MATERNAL CARE FOR OTHER CONDITIONS PREDOMINANTLY RELATED TO PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.0 | DX | EXCESSIVE WEIGHT GAIN IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.00 | DX | EXCESSIVE WEIGHT GAIN IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.01 | DX | EXCESSIVE WEIGHT GAIN IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.02 | DX | EXCESSIVE WEIGHT GAIN IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.03 | DX | EXCESSIVE WEIGHT GAIN IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.1 | DX | LOW WEIGHT GAIN IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.10 | DX | LOW WEIGHT GAIN IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.11 | DX | LOW WEIGHT GAIN IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.12 | DX | LOW WEIGHT GAIN IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.13 | DX | LOW WEIGHT GAIN IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.2 | DX | PREGNANCY CARE FOR PATIENT WITH RECURRENT PREGNANCY LOSS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.20 | DX | PREGNANCY CARE FOR PATIENT WITH RECURRENT PREGNANCY LOSS, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.21 | DX | PREGNANCY CARE FOR PATIENT WITH RECURRENT PREGNANCY LOSS, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.22 | DX | PREGNANCY CARE FOR PATIENT WITH RECURRENT PREGNANCY LOSS, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.23 | DX | PREGNANCY CARE FOR PATIENT WITH RECURRENT PREGNANCY LOSS, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.3 | DX | RETAINED INTRAUTERINE CONTRACEPTIVE DEVICE IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.30 | DX | RETAINED INTRAUTERINE CONTRACEPTIVE DEVICE IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.31 | DX | RETAINED INTRAUTERINE CONTRACEPTIVE DEVICE IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.32 | DX | RETAINED INTRAUTERINE CONTRACEPTIVE DEVICE IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.33 | DX | RETAINED INTRAUTERINE CONTRACEPTIVE DEVICE IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.4 | DX | HERPES GESTATIONIS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.40 | DX | HERPES GESTATIONIS, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.41 | DX | HERPES GESTATIONIS, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.42 | DX | HERPES GESTATIONIS, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.43 | DX | HERPES GESTATIONIS, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.5 | DX | MATERNAL HYPOTENSION SYNDROME | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.50 | DX | MATERNAL HYPOTENSION SYNDROME, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.51 | DX | MATERNAL HYPOTENSION SYNDROME, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.52 | DX | MATERNAL HYPOTENSION SYNDROME, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.53 | DX | MATERNAL HYPOTENSION SYNDROME, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.6 | DX | LIVER AND BILIARY TRACT DISORDERS IN PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.61 | DX | LIVER AND BILIARY TRACT DISORDERS IN PREGNANCY | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|---------|----|------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.611 | DX | LIVER AND BILIARY TRACT DISORDERS IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.612 | DX | LIVER AND BILIARY TRACT DISORDERS IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.613 | DX | LIVER AND BILIARY TRACT DISORDERS IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.619 | DX | LIVER AND BILIARY TRACT DISORDERS IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.62 | DX | LIVER AND BILIARY TRACT DISORDERS IN CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.63 | DX | LIVER AND BILIARY TRACT DISORDERS IN THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.7 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.71 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.711 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.712 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.713 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.719 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.72 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.73 | DX | SUBLUXATION OF SYMPHYSIS (PUBIS) IN THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.8 | DX | OTHER SPECIFIED PREGNANCY RELATED CONDITIONS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.81 | DX | PREGNANCY RELATED EXHAUSTION AND FATIGUE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.811 | DX | PREGNANCY RELATED EXHAUSTION AND FATIGUE, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.812 | DX | PREGNANCY RELATED EXHAUSTION AND FATIGUE, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.813 | DX | PREGNANCY RELATED EXHAUSTION AND FATIGUE, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.819 | DX | PREGNANCY RELATED EXHAUSTION AND FATIGUE, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.82 | DX | PREGNANCY RELATED PERIPHERAL NEURITIS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.821 | DX | PREGNANCY RELATED PERIPHERAL NEURITIS, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.822 | DX | PREGNANCY RELATED PERIPHERAL NEURITIS, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.823 | DX | PREGNANCY RELATED PERIPHERAL NEURITIS, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.829 | DX | PREGNANCY RELATED PERIPHERAL NEURITIS, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.83 | DX | PREGNANCY RELATED RENAL DISEASE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.831 | DX | PREGNANCY RELATED RENAL DISEASE, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.832 | DX | PREGNANCY RELATED RENAL DISEASE, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.833 | DX | PREGNANCY RELATED RENAL DISEASE, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.839 | DX | PREGNANCY RELATED RENAL DISEASE, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.84 | DX | UTERINE SIZE-DATE DISCREPANCY COMPLICATING PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.841 | DX | UTERINE SIZE-DATE DISCREPANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.842 | DX | UTERINE SIZE-DATE DISCREPANCY, SECOND TRIMESTER | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|---------|----|---------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.843 | DX | UTERINE SIZE-DATE DISCREPANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.849 | DX | UTERINE SIZE-DATE DISCREPANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.85 | DX | SPOTTING COMPLICATING PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.851 | DX | SPOTTING COMPLICATING PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.852 | DX | SPOTTING COMPLICATING PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.853 | DX | SPOTTING COMPLICATING PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.859 | DX | SPOTTING COMPLICATING PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.86 | DX | PRURITIC URTICARIAL PAPULES AND PLAQUES OF PREGNANCY (PUPPP) | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.87 | DX | CERVICAL SHORTENING | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.872 | DX | CERVICAL SHORTENING, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.873 | DX | CERVICAL SHORTENING, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.879 | DX | CERVICAL SHORTENING, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.89 | DX | OTHER SPECIFIED PREGNANCY RELATED CONDITIONS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.891 | DX | OTHER SPECIFIED PREGNANCY RELATED CONDITIONS, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.892 | DX | OTHER SPECIFIED PREGNANCY RELATED CONDITIONS, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.893 | DX | OTHER SPECIFIED PREGNANCY RELATED CONDITIONS, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.899 | DX | OTHER SPECIFIED PREGNANCY RELATED CONDITIONS, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.9 | DX | PREGNANCY RELATED CONDITIONS, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.90 | DX | PREGNANCY RELATED CONDITIONS, UNSPECIFIED, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.91 | DX | PREGNANCY RELATED CONDITIONS, UNSPECIFIED, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.92 | DX | PREGNANCY RELATED CONDITIONS, UNSPECIFIED, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 026.93 | DX | PREGNANCY RELATED CONDITIONS, UNSPECIFIED, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028 | DX | ABNORMAL FINDINGS ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.0 | DX | ABNORMAL HEMATOLOGICAL FINDING ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.1 | DX | ABNORMAL BIOCHEMICAL FINDING ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.2 | DX | ABNORMAL CYTOLOGICAL FINDING ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.3 | DX | ABNORMAL UL TRASONIC FINDING ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.4 | DX | ABNORMAL RADIOLOGICAL FINDING ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.5 | DX | ABNORMAL CHROMOSOMAL AND GENETIC FINDING ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.8 | DX | OTHER ABNORMAL FINDINGS ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 028.9 | DX | UNSPECIFIED ABNORMAL FINDINGS ON ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 029 | DX | COMPLICATIONS OF ANESTHESIA DURING PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 029.0 | DX | PULMONARY COMPLICATIONS OF ANESTHESIA DURING PREGNANCY | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|----------|----|-----------------------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.6XX2 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO HYDROCEPHALIC FETUS, FETUS 2 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.6XX3 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO HYDROCEPHALIC FETUS, FETUS 3 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.6XX4 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO HYDROCEPHALIC FETUS, FETUS 4 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.6XX5 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO HYDROCEPHALIC FETUS, FETUS 5 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.6XX9 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO HYDROCEPHALIC FETUS, OTHER FETUS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7XX0 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES, NOT APPLICABLE OR UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7XX1 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES, FETUS 1 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7XX2 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES, FETUS 2 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7XX3 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES, FETUS 3 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7XX4 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES, FETUS 4 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7XX5 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES, FETUS 5 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.7XX9 | DX | MATERNAL CARE FOR DISPROPORTION DUE TO OTHER FETAL DEFORMITIES, OTHER FETUS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.8 | DX | MATERNAL CARE FOR DISPROPORTION OF OTHER ORIGIN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 033.9 | DX | MATERNAL CARE FOR DISPROPORTION, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034 | DX | MATERNAL CARE FOR ABNORMALITY OF PELVIC ORGANS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.0 | DX | MATERNAL CARE FOR CONGENITAL MALFORMATION OF UTERUS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.00 | DX | MATERNAL CARE FOR UNSPECIFIED CONGENITAL MALFORMATION OF UTERUS, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.01 | DX | MATERNAL CARE FOR UNSPECIFIED CONGENITAL MALFORMATION OF UTERUS, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.02 | DX | MATERNAL CARE FOR UNSPECIFIED CONGENITAL MALFORMATION OF UTERUS, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.03 | DX | MATERNAL CARE FOR UNSPECIFIED CONGENITAL MALFORMATION OF UTERUS, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.1 | DX | MATERNAL CARE FOR BENIGN TUMOR OF CORPUS UTERI | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.10 | DX | MATERNAL CARE FOR BENIGN TUMOR OF CORPUS UTERI, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.11 | DX | MATERNAL CARE FOR BENIGN TUMOR OF CORPUS UTERI, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.12 | DX | MATERNAL CARE FOR BENIGN TUMOR OF CORPUS UTERI, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.13 | DX | MATERNAL CARE FOR BENIGN TUMOR OF CORPUS UTERI, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.2 | DX | MATERNAL CARE DUE TO UTERINE SCAR FROM PREVIOUS SURGERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.21 | DX | MATERNAL CARE FOR SCAR FROM PREVIOUS CESAREAN DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.211 | DX | MATERNAL CARE FOR LOW TRANSVERSE SCAR FROM PREVIOUS CESAREAN DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.212 | DX | MATERNAL CARE FOR VERTICAL SCAR FROM PREVIOUS CESAREAN DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.219 | DX | MATERNAL CARE FOR UNSPECIFIED TYPE SCAR FROM PREVIOUS CESAREAN DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.29 | DX | MATERNAL CARE DUE TO UTERINE SCAR FROM OTHER PREVIOUS SURGERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 034.3 | DX | MATERNAL CARE FOR CERVICAL INCOMPETENCE | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|----------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 060.14X9 | DX | PRETERM LABOR THIRD TRIMESTER WITH PRETERM DELIVERY THIRD TRIMESTER, OTHER FETUS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 061 | DX | FAILED INDUCTION OF LABOR | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 061.0 | DX | FAILED MEDICAL INDUCTION OF LABOR | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 061.1 | DX | FAILED INSTRUMENTAL INDUCTION OF LABOR | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 061.8 | DX | OTHER FAILED INDUCTION OF LABOR | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 061.9 | DX | FAILED INDUCTION OF LABOR, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 063.2 | DX | DELAYED DELIVERY OF SECOND TWIN, TRIPLET, ETC. | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 071.0 | DX | RUPTURE OF UTERUS (SPONTANEOUS) BEFORE ONSET OF LABOR | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 071.00 | DX | RUPTURE OF UTERUS BEFORE ONSET OF LABOR, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 071.02 | DX | RUPTURE OF UTERUS BEFORE ONSET OF LABOR, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 071.03 | DX | RUPTURE OF UTERUS BEFORE ONSET OF LABOR, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 072 | DX | POSTPARTUM HEMORRHAGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 072.0 | DX | THIRD-STAGE HEMORRHAGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 072.1 | DX | OTHER IMMEDIATE POSTPARTUM HEMORRHAGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 072.2 | DX | DELAYED AND SECONDARY POSTPARTUM HEMORRHAGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 072.3 | DX | POSTPARTUM COAGULATION DEFECTS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 073 | DX | RETAINED PLACENTA AND MEMBRANES, WITHOUT HEMORRHAGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 073.0 | DX | RETAINED PLACENTA WITHOUT HEMORRHAGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 073.1 | DX | RETAINED PORTIONS OF PLACENTA AND MEMBRANES, WITHOUT HEMORRHAGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075 | DX | OTHER COMPLICATIONS OF LABOR AND DELIVERY, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.0 | DX | MATERNAL DISTRESS DURING LABOR AND DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.1 | DX | SHOCK DURING OR FOLLOWING LABOR AND DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.2 | DX | PYREXIA DURING LABOR, NOT ELSEWHERE CLASSIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.3 | DX | OTHER INFECTION DURING LABOR | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.4 | DX | OTHER COMPLICATIONS OF OBSTETRIC SURGERY AND PROCEDURES | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.5 | DX | DELAYED DELIVERY AFTER ARTIFICIAL RUPTURE OF MEMBRANES | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.8 | DX | OTHER SPECIFIED COMPLICATIONS OF LABOR AND DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.81 | DX | MATERNAL EXHAUSTION COMPLICATING LABOR AND DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.82 | DX | ONSET (SPONTANEOUS) OF LABOR AFTER 37 COMPLETED WEEKS OF GESTATION BUT BEFORE 39 COMPLETED WEEKS GESTATION, WITH DELIVERY BY (PLANNED) CESAREAN SECTION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.89 | DX | OTHER SPECIFIED COMPLICATIONS OF LABOR AND DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 075.9 | DX | COMPLICATION OF LABOR AND DELIVERY, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 094 | DX | SEQUELAE OF COMPLICATION OF PREGNANCY, CHILDBIRTH, AND THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 098 | DX | MATERNAL INFECTIOUS AND PARASITIC DISEASES CLASSIFIABLE ELSEWHERE BUT COMPLICATING PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-10-CM |

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|---------|----|---------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.413 | DX | SEXUAL ABUSE COMPLICATING PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.419 | DX | SEXUAL ABUSE COMPLICATING PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.42 | DX | SEXUAL ABUSE COMPLICATING CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.43 | DX | SEXUAL ABUSE COMPLICATING THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.5 | DX | PSYCHOLOGICAL ABUSE COMPLICATING PREGNANCY, CHILDBIRTH AND THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.51 | DX | PSYCHOLOGICAL ABUSE COMPLICATING PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.511 | DX | PSYCHOLOGICAL ABUSE COMPLICATING PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.512 | DX | PSYCHOLOGICAL ABUSE COMPLICATING PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.513 | DX | PSYCHOLOGICAL ABUSE COMPLICATING PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.519 | DX | PSYCHOLOGICAL ABUSE COMPLICATING PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.52 | DX | PSYCHOLOGICAL ABUSE COMPLICATING CHILDBIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | 09A.53 | DX | PSYCHOLOGICAL ABUSE COMPLICATING THE PUERPERIUM | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P01.5 | DX | NEWBORN AFFECTED BY MULTIPLE PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.01 | DX | NEWBORN LIGHT FOR GESTATIONAL AGE, LESS THAN 500 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.02 | DX | NEWBORN LIGHT FOR GESTATIONAL AGE, 500-749 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.03 | DX | NEWBORN LIGHT FOR GESTATIONAL AGE, 750-999 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.04 | DX | NEWBORN LIGHT FOR GESTATIONAL AGE, 1000-1249 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.05 | DX | NEWBORN LIGHT FOR GESTATIONAL AGE, 1250-1499 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.06 | DX | NEWBORN LIGHT FOR GESTATIONAL AGE, 1500-1749 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.11 | DX | NEWBORN SMALL FOR GESTATIONAL AGE, LESS THAN 500 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.12 | DX | NEWBORN SMALL FOR GESTATIONAL AGE, 500-749 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.13 | DX | NEWBORN SMALL FOR GESTATIONAL AGE, 750-999 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.14 | DX | NEWBORN SMALL FOR GESTATIONAL AGE, 1000-1249 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.15 | DX | NEWBORN SMALL FOR GESTATIONAL AGE, 1250-1499 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P05.16 | DX | NEWBORN SMALL FOR GESTATIONAL AGE, 1500-1749 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.01 | DX | EXTREMELY LOW BIRTH WEIGHT NEWBORN, LESS THAN 500 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.02 | DX | EXTREMELY LOW BIRTH WEIGHT NEWBORN, 500-749 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.03 | DX | EXTREMELY LOW BIRTH WEIGHT NEWBORN, 750-999 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.14 | DX | OTHER LOW BIRTH WEIGHT NEWBORN, 1000-1249 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.15 | DX | OTHER LOW BIRTH WEIGHT NEWBORN, 1250-1499 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.16 | DX | OTHER LOW BIRTH WEIGHT NEWBORN, 1500-1749 GRAMS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.2 | DX | EXTREME IMMATURITY OF NEWBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.20 | DX | EXTREME IMMATURITY OF NEWBORN, UNSPECIFIED WEEKS OF GESTATION | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|-----------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.21 | DX | EXTREME IMMATURETY OF NEWBORN, GESTATIONAL AGE LESS THAN 23 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.22 | DX | EXTREME IMMATURETY OF NEWBORN, GESTATIONAL AGE 23 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.23 | DX | EXTREME IMMATURETY OF NEWBORN, GESTATIONAL AGE 24 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.24 | DX | EXTREME IMMATURETY OF NEWBORN, GESTATIONAL AGE 25 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.25 | DX | EXTREME IMMATURETY OF NEWBORN, GESTATIONAL AGE 26 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.26 | DX | EXTREME IMMATURETY OF NEWBORN, GESTATIONAL AGE 27 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.3 | DX | PRETERM [PREMATURE] NEWBORN [OTHER] | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.30 | DX | PRETERM NEWBORN, UNSPECIFIED WEEKS OF GESTATION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.31 | DX | PRETERM NEWBORN, GESTATIONAL AGE 28 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.32 | DX | PRETERM NEWBORN, GESTATIONAL AGE 29 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.33 | DX | PRETERM NEWBORN, GESTATIONAL AGE 30 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.34 | DX | PRETERM NEWBORN, GESTATIONAL AGE 31 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.35 | DX | PRETERM NEWBORN, GESTATIONAL AGE 32 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.36 | DX | PRETERM NEWBORN, GESTATIONAL AGE 33 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.37 | DX | PRETERM NEWBORN, GESTATIONAL AGE 34 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.38 | DX | PRETERM NEWBORN, GESTATIONAL AGE 35 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P07.39 | DX | PRETERM NEWBORN, GESTATIONAL AGE 36 COMPLETED WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P08.2 | DX | LATE NEWBORN, NOT HEAVY FOR GESTATIONAL AGE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P08.21 | DX | POST-TERM NEWBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P08.22 | DX | PROLONGED GESTATION OF NEWBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | P61.2 | DX | ANEMIA OF PREMATURITY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z32.01 | DX | ENCOUNTER FOR PREGNANCY TEST, RESULT POSITIVE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z33 | DX | PREGNANT STATE | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z33.1 | DX | PREGNANT STATE, INCIDENTAL | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z33.2 | DX | ENCOUNTER FOR ELECTIVE TERMINATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z33.3 | DX | PREGNANT STATE, GESTATIONAL CARRIER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.0 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL FIRST PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.00 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL FIRST PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.01 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL FIRST PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.02 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL FIRST PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.03 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL FIRST PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.8 | DX | ENCOUNTER FOR SUPERVISION OF OTHER NORMAL PREGNANCY | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|----------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.80 | DX | ENCOUNTER FOR SUPERVISION OF OTHER NORMAL PREGNANCY, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.81 | DX | ENCOUNTER FOR SUPERVISION OF OTHER NORMAL PREGNANCY, FIRST TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.82 | DX | ENCOUNTER FOR SUPERVISION OF OTHER NORMAL PREGNANCY, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.83 | DX | ENCOUNTER FOR SUPERVISION OF OTHER NORMAL PREGNANCY, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.9 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL PREGNANCY, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.1 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR RAISED ALPHAFETOPROTEIN LEVEL | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.3 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR MALFORMATIONS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.4 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR FETAL GROWTH RETARDATION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.84 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR FETAL LUNG MATURITY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.85 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR STREPTOCOCCUS B | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.87 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR UNCERTAIN DATES | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.89 | DX | ENCOUNTER FOR OTHER SPECIFIED ANTENATAL SCREENING | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.9 | DX | ENCOUNTER FOR ANTENATAL SCREENING, UNSPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.5 | DX | OTHER MULTIPLE BIRTHS, ALL LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.50 | DX | MULTIPLE BIRTHS, UNSPECIFIED, ALL LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.51 | DX | TRIPLETS, ALL LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.52 | DX | QUADRUPLETS, ALL LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.54 | DX | SEXTUPLETS, ALL LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.59 | DX | OTHER MULTIPLE BIRTHS, ALL LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.6 | DX | OTHER MULTIPLE BIRTHS, SOME LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.60 | DX | MULTIPLE BIRTHS, UNSPECIFIED, SOME LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.61 | DX | TRIPLETS, SOME LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.62 | DX | QUADRUPLETS, SOME LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.69 | DX | OTHER MULTIPLE BIRTHS, SOME LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.3 | DX | TWIN LIVEBORN INFANT, BORN IN HOSPITAL | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.31 | DX | TWIN LIVEBORN INFANT, DELIVERED BY CESAREAN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.4 | DX | TWIN LIVEBORN INFANT, BORN OUTSIDE HOSPITAL | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.5 | DX | TWIN LIVEBORN INFANT, UNSPECIFIED AS TO PLACE OF BIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.6 | DX | OTHER MULTIPLE LIVEBORN INFANT, BORN IN HOSPITAL | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.62 | DX | TRIPLET LIVEBORN INFANT, DELIVERED BY CESAREAN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.64 | DX | QUADRUPLET LIVEBORN INFANT, DELIVERED BY CESAREAN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.66 | DX | QUINTUPLET LIVEBORN INFANT, DELIVERED BY CESAREAN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.69 | DX | OTHER MULTIPLE LIVEBORN INFANT, DELIVERED BY CESAREAN | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|-----------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.7 | DX | OTHER MULTIPLE LIVEBORN INFANT, BORN OUTSIDE HOSPITAL | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.8 | DX | OTHER MULTIPLE LIVEBORN INFANT, UNSPECIFIED AS TO PLACE OF BIRTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z39 | DX | ENCOUNTER FOR MATERNAL POSTPARTUM CARE AND EXAMINATION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z39.0 | DX | ENCOUNTER FOR CARE AND EXAMINATION OF MOTHER IMMEDIATELY AFTER DELIVERY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z39.2 | DX | ENCOUNTER FOR ROUTINE POSTPARTUM FOLLOW-UP | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A | DX | WEEKS OF GESTATION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.0 | DX | WEEKS OF GESTATION OF PREGNANCY, UNSPECIFIED OR LESS THAN 10 WEEKS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.01 | DX | LESS THAN 8 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.09 | DX | 9 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.1 | DX | WEEKS OF GESTATION OF PREGNANCY, WEEKS 10-19 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.12 | DX | 12 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.13 | DX | 13 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.14 | DX | 14 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.16 | DX | 16 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.17 | DX | 17 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.18 | DX | 18 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.19 | DX | 19 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.24 | DX | 24 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.25 | DX | 25 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.26 | DX | 26 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.27 | DX | 27 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.28 | DX | 28 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.29 | DX | 29 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.3 | DX | WEEKS OF GESTATION OF PREGNANCY, WEEKS 30-29 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.32 | DX | 32 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.33 | DX | 33 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.34 | DX | 34 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.39 | DX | 39 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.40 | DX | 40 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.41 | DX | 41 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.49 | DX | GREATER THAN 42 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.90 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL PREGNANCY, UNSPECIFIED, UNSPECIFIED TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.91 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL PREGNANCY, UNSPECIFIED, FIRST TRIMESTER | ICD-10-CM |

| | | | | | | |
|----|------------------------------------------------------------------------------------|-----------|--------|----|------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.92 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL PREGNANCY, UNSPECIFIED, SECOND TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z34.93 | DX | ENCOUNTER FOR SUPERVISION OF NORMAL PREGNANCY, UNSPECIFIED, THIRD TRIMESTER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36 | DX | ENCOUNTER FOR ANTENATAL SCREENING OF MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.0 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR CHROMOSOMAL ANOMALIES | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.2 | DX | ENCOUNTER FOR OTHER ANTENATAL SCREENING FOLLOW-UP | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.5 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR ISOIMMUNIZATION | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.8 | DX | ENCOUNTER FOR OTHER ANTENATAL SCREENING | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.81 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR HYDROPS FETALIS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.82 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR NUCHAL TRANSLUCENCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.83 | DX | ENCOUNTER FOR FETAL SCREENING FOR CONGENITAL CARDIAC ABNORMALITIES | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.86 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR CERVICAL LENGTH | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.88 | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR FETAL MACROSOMIA | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z36.8A | DX | ENCOUNTER FOR ANTENATAL SCREENING FOR OTHER GENETIC DEFECTS | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.2 | DX | TWINS, BOTH LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.3 | DX | TWINS, ONE LIVEBORN AND ONE STILLBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.53 | DX | QUINTUPLETS, ALL LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.63 | DX | QUINTUPLETS, SOME LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z37.64 | DX | SEXTUPLETS, SOME LIVEBORN | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.30 | DX | TWIN LIVEBORN INFANT, DELIVERED VAGINALLY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.61 | DX | TRIPLET LIVEBORN INFANT, DELIVERED VAGINALLY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.63 | DX | QUADRUPLET LIVEBORN INFANT, DELIVERED VAGINALLY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.65 | DX | QUINTUPLET LIVEBORN INFANT, DELIVERED VAGINALLY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z38.68 | DX | OTHER MULTIPLE LIVEBORN INFANT, DELIVERED VAGINALLY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z39.1 | DX | ENCOUNTER FOR CARE AND EXAMINATION OF LACTATING MOTHER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.00 | DX | WEEKS OF GESTATION OF PREGNANCY NOT SPECIFIED | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.08 | DX | 8 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.10 | DX | 10 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.11 | DX | 11 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.15 | DX | 15 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.2 | DX | WEEKS OF GESTATION OF PREGNANCY, WEEKS 20-29 | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.20 | DX | 20 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.21 | DX | 21 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.22 | DX | 22 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |

| | | | | | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|---------|----|----------------------------------------------------------------------------------------|-----------|
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.23 | DX | 23 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.30 | DX | 30 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.31 | DX | 31 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.35 | DX | 35 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.36 | DX | 36 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.37 | DX | 37 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.38 | DX | 38 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.4 | DX | WEEKS OF GESTATION OF PREGNANCY, WEEKS 40 OR GREATER | ICD-10-CM |
| 25 | Women who are pregnant, nursing, or who plan to become pregnant while in the trial | Pregnancy | Z3A.42 | DX | 42 WEEKS GESTATION OF PREGNANCY | ICD-10-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | V15.81 | DX | PERSONAL HISTORY OF NONCOMPLIANCE WITH MEDICAL TREATMENT, PRESENTING HAZARDS TO HEALTH | ICD-9-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | V45.12 | DX | NONCOMPLIANCE WITH RENAL DIALYSIS | ICD-9-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | Z91.120 | DX | PATIENT'S INTENTIONAL UNDERDOSING OF MEDICATION REGIMEN DUE TO FINANCIAL HARDSHIP | ICD-10-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | Z91.128 | DX | PATIENT'S INTENTIONAL UNDERDOSING OF MEDICATION REGIMEN FOR OTHER REASON | ICD-10-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | Z91.13 | DX | PATIENT'S UNINTENTIONAL UNDERDOSING OF MEDICATION REGIMEN | ICD-10-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | Z91.14 | DX | PATIENT'S OTHER NONCOMPLIANCE WITH MEDICATION REGIMEN | ICD-10-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | Z91.15 | DX | PATIENT'S NONCOMPLIANCE WITH RENAL DIALYSIS | ICD-10-CM |
| 26 | Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol | Non-compliance/Non-adherence | Z91.19 | DX | PATIENT'S NONCOMPLIANCE WITH OTHER MEDICAL TREATMENT AND REGIMEN | ICD-10-CM |

| Category | Variable_Name | Code | Code_category | Description | Code_type | Notes |
|----------|-----------------------------------|--------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|
| 1 | Hospitalisation for heart failure | 398.91 | DX | RHEUMATIC HEART FAILURE (CONGESTIVE) | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 402.01 | DX | MALIGNANT HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 402.11 | DX | BENIGN HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 402.91 | DX | UNSPECIFIED HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-9-CM | |
| | | | | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 404.01 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 404.03 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 404.11 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 404.13 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 404.91 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 404.93 | DX | HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428 | DX | CONGESTIVE HEART FAILURE, UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.0 | DX | LEFT HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.1 | DX | SYSTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.2 | DX | ACUTE SYSTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.21 | DX | CHRONIC SYSTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.22 | DX | ACUTE ON CHRONIC SYSTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.23 | DX | DIASTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.3 | DX | ACUTE DIASTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.31 | DX | CHRONIC DIASTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.32 | DX | ACUTE ON CHRONIC DIASTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.33 | DX | COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE, UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.4 | DX | ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.41 | DX | CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.42 | DX | ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART FAILURE | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.43 | DX | HEART FAILURE, UNSPECIFIED | ICD-9-CM | |
| 1 | Hospitalization for heart failure | 428.9 | DX | RHEUMATIC HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalisation for heart failure | 109.81 | DX | HYPERTENSIVE HEART DISEASE WITH HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 111.0 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 113.0 | DX | HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE WITH HEART FAILURE AND WITH STAGE 5 CHRONIC KIDNEY DISEASE, OR END STAGE RENAL DISEASE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 113.2 | DX | HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150 | DX | LEFT VENTRICULAR FAILURE, UNSPECIFIED | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.1 | DX | SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.2 | DX | UNSPECIFIED SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.20 | DX | ACUTE SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.21 | DX | CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.22 | DX | ACUTE ON CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.23 | DX | DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.3 | DX | UNSPECIFIED DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.30 | DX | ACUTE DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.31 | DX | CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.32 | DX | ACUTE ON CHRONIC DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.33 | DX | COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.4 | DX | UNSPECIFIED COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 | Hospitalization for heart failure | 150.40 | DX | HEART FAILURE | ICD-10-CM | |

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----|---------------------------------------------------------------------------------------------------|-------------------------|---------------------------|
| 1 Hospitalization for heart failure | I50.41 | DX | ACUTE COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.42 | DX | CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.43 | DX | ACUTE ON CHRONIC COMBINED SYSTOLIC (CONGESTIVE) AND DIASTOLIC (CONGESTIVE) HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.8 | DX | OTHER HEART FAILURE | ICD-10-CM | |
| 1 Hospitalisation for heart failure | I50.810 | DX | RIGHT HEART FAILURE, UNSPECIFIED | ICD-10-CM | |
| 1 Hospitalisation for heart failure | I50.811 | DX | ACUTE RIGHT HEART FAILURE | ICD-10-CM | |
| 1 Hospitalisation for heart failure | I50.812 | DX | CHRONIC RIGHT HEART FAILURE | ICD-10-CM | |
| 1 Hospitalisation for heart failure | I50.813 | DX | ACUTE ON CHRONIC RIGHT HEART FAILURE | ICD-10-CM | |
| 1 Hospitalisation for heart failure | I50.814 | DX | RIGHT HEART FAILURE DUE TO LEFT HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.82 | DX | BIVENTRICULAR HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.83 | DX | HIGH OUTPUT HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.84 | DX | END STAGE HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.89 | DX | OTHER HEART FAILURE | ICD-10-CM | |
| 1 Hospitalization for heart failure | I50.9 | DX | HEART FAILURE, UNSPECIFIED | ICD-10-CM | |
| 2 Death | 20 | | | IP: Discharge status | All database |
| 2 Death | 41 | | | IP: Discharge status | All database |
| 2 Death | 42 | | | IP: Discharge status | All database |
| 2 Death | 21 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 22 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 23 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 24 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 25 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 26 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 27 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 28 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 29 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | 40 | | | IP: Discharge status | Marketscan/Optum database |
| 2 Death | BENE_DEATH_DT | | | file: | |
| 2 Death | BENE_DEATH_DT | | | mbsf_abdc_summary | Medicare database |
| 2 Death | YMDOD in DOD | | | file: vital_status_file | Medicare database |
| 2 Death | DEATHYRMO | | | file: member enrollment | Optum database |
| | | | | file: mortality file | Marketscan database |
| Medicare fee-for-service: information on mortality was available through the vital status file | | | | | |
| Optum Clinformatics: information on mortality was available through four sources: Centers for Medicare and Medicaid Services, Social Security Administration Master Death Files, in-hospital deaths, and death as a reason for insurance discontinuation | | | | | |
| IBM MarketScan: information on mortality was limited to in-hospital deaths. | | | | | |
| 3 Negative control outcome: cataract surgery | | | | | |
| 3 Cataract surgery | 13.3 | PX | EXTRACAPSULAR EXTRACTION OF LENS BY SIMPLE ASPIRATION (AND IRRIGATION) TECHNIQUE | ICD-9-CM | |
| 3 Cataract surgery | 13.2 | PX | EXTRACAPSULAR EXTRACTION OF LENS BY LINEAR EXTRACTION TECHNIQUE | ICD-9-CM | |
| 3 Cataract surgery | 13.3 | PX | EXTRACAPSULAR EXTRACTION OF LENS BY SIMPLE ASPIRATION TECHNIQUE; IRRIGATION OF TRAUMATIC CATARACT | ICD-9-CM | |
| 3 Cataract surgery | 13.5 | PX | OTHER EXTRACAPSULAR EXTRACTION OF LENS | ICD-9-CM | |
| 3 Cataract surgery | 13.51 | PX | EXTRACAPSULAR EXTRACTION OF LENS BY TEMPORAL INFERIOR ROUTE | ICD-9-CM | |
| 3 Cataract surgery | 13.59 | PX | OTHER EXTRACAPSULAR EXTRACTION OF LENS | ICD-9-CM | |
| 3 Cataract surgery | 13.1 | PX | INTRACAPSULAR EXTRACTION OF LENS | ICD-9-CM | |
| 3 Cataract surgery | 13.19 | PX | OTHER INTRACAPSULAR EXTRACTION OF LENS | ICD-9-CM | |
| 3 Cataract surgery | 13.4 | PX | EXTRACAPSULAR EXTRACTION OF LENS BY FRAGMENTATION AND ASPIRATION TECHNIQUE | ICD-9-CM | |
| 3 Cataract surgery | 13.41 | PX | PHACOEMULSIFICATION AND ASPIRATION OF CATARACT | ICD-9-CM | |
| 3 Cataract surgery | 13.43 | PX | MECHANICAL PHACOEMULSIFICATION AND OTHER ASPIRATION OF CATARACT | ICD-9-CM | |
| 3 Cataract surgery | 08DJ3ZZ | PX | EXTRACTION OF RIGHT LENS, PERCUTANEOUS APPROACH | ICD-10-CM | |

| | | | | | | |
|---|----------------------------------------|--------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------------|
| 3 | Cataract surgery | 08DK3ZZ 08RJ3JZ | PX | EXTRACTION OF LEFT LENS, PERCUTANEOUS APPROACH | ICD-10-CM | |
| 3 | Cataract surgery | | PX | REPLACEMENT OF RIGHT LENS WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM | |
| 3 | Cataract surgery | 08RK3JZ | PX | REPLACEMENT OF LEFT LENS WITH SYNTHETIC SUBSTITUTE, PERCUTANEOUS APPROACH | ICD-10-CM | |
| 3 | Cataract surgery | 66830 | PX | REMOVAL OF SECONDARY MEMBRANOUS CATARACT (OPACIFIED POSTERIOR LENS CAPSULE AND/OR ANTERIOR HYALOID) WITH CORNEO-SCLERAL SECTION, WITH OR WITHOUT IRIDECTOMY (IRIDOCAPSULOTOMY, IRIDOCAPSULECTOMY) | CPT / HCPCS | |
| 3 | Cataract surgery | 66840 | PX | REMOVAL OF LENS MATERIAL; ASPIRATION TECHNIQUE, ≥1 STAGES | CPT / HCPCS | |
| 3 | Cataract surgery | 66850 | PX | PHACOFRAGMENTATION TECHNIQUE (MECHANICAL OR ULTRASONIC) WITH ASPIRATION | CPT / HCPCS | |
| 3 | Cataract surgery | 66852 | PX | REMOVAL OF LENS MATERIAL | CPT / HCPCS | |
| 3 | Cataract surgery | 66920 | PX | INTRACAPSULAR | CPT / HCPCS | |
| 3 | Cataract surgery | 66930 | PX | INTRACAPSULAR, FOR DISLOCATED LENS | CPT / HCPCS | |
| 3 | Cataract surgery | 66940 | PX | EXTRACAPSULAR (OTHER THAN 66840, 66850, 66852) | CPT / HCPCS | |
| 3 | Cataract surgery | 66982 | PX | EXTRACAPSULAR CATARACT REMOVAL WITH INSERTION OF IOL PROSTHESIS (1-STAGE PROCEDURE), MANUAL OR MECHANICAL TECHNIQUE (E.G., IRRIGATION AND ASPIRATION OR PHACOEMULSIFICATION) COMPLEX, REQUIRING DEVICES OR TECHNIQUES NOT GENERALLY USED IN ROUTINE CATARACT SURGERY | CPT / HCPCS | |
| 3 | Cataract surgery | 66983 | PX | INTRACAPSULAR EXTRACTION WITH INSERTION OF IOL PROSTHESIS (1-STAGE PROCEDURE) | CPT / HCPCS | |
| 3 | Cataract surgery | 66984 | PX | EXTRACAPSULAR CATARACT REMOVAL WITH INSERTION OF IOL PROSTHESIS (1-STAGE PROCEDURE), MANUAL OR MECHANICAL TECHNIQUE (E.G., IRRIGATION AND ASPIRATION OR PHACOEMULSIFICATION) | CPT / HCPCS | |
| 3 | Cataract surgery | 66987 | PX | EXTRACAPSULAR CATARACT REMOVAL WITH INSERTION OF INTRAOCULAR LENS PROSTHESIS (1-STAGE PROCEDURE), MANUAL OR MECHANICAL TECHNIQUE (E.G., IRRIGATION AND ASPIRATION OR PHACOEMULSIFICATION), COMPLEX, REQUIRING DEVICES OR TECHNIQUES NOT GENERALLY USED IN ROUTINE CATARACT SURGERY (E.G., IRIS EXPANSION DEVICE, SUTURE SUPPORT FOR INTRAOCULAR LENS, OR PRIMARY POSTERIOR CAPSULORRHESIS) OR PERFORMED ON PATIENTS IN THE AMBLYOGENIC DEVELOPMENTAL STAGE; WITH ENDOSCOPIC | CPT / HCPCS | |
| 3 | Cataract surgery | 66988 | PX | CYCLOPHOTOACOAGULATION | CPT / HCPCS | |
| 3 | Cataract surgery | C1780 | PX | XCAPSL CTRC RMVL W/ECP | CPT / HCPCS | |
| 3 | Cataract surgery | Q1004 | PX | LENS, INTRAOCULAR (NEW TECHNOLOGY) | CPT / HCPCS | |
| 3 | Cataract surgery | Q1005 | PX | NEW TECHNOLOGY INTRAOCULAR LENS CATEGORY 4 AS DEFINED IN FEDERAL REGISTER NOTICE | CPT / HCPCS | |
| 3 | Cataract surgery | | PX | NEW TECHNOLOGY INTRAOCULAR LENS CATEGORY 5 AS DEFINED IN FEDERAL REGISTER NOTICE | CPT / HCPCS | |
| 3 | Cataract surgery | V2630 | PX | ANTERIOR CHAMBER INTRAOCULAR LENS | CPT / HCPCS | |
| 3 | Cataract surgery | V2631 | PX | IRIS SUPPORTED INTRAOCULAR LENS | CPT / HCPCS | |
| 3 | Cataract surgery | V2632 | PX | POSTERIOR CHAMBER INTRAOCULAR LENS | CPT / HCPCS | |
| 4 | Negative control: Lumbar radiculopathy | 724.4 | DX | Thoracic or lumbosacral neuritis or radiculitis, unspecified | ICD-9-CM | |
| 4 | Negative control: Lumbar radiculopathy | M54.15 | DX | RADICULOPATHY, THORACOLUMBAR REGION | ICD-10-CM | Inpatient and outpatient setting, any position |
| 4 | Negative control: Lumbar radiculopathy | M54.16 | DX | RADICULOPATHY, LUMBAR REGION | ICD-10-CM | Inpatient and outpatient setting, any position |
| 4 | Negative control: Lumbar radiculopathy | M54.17 | DX | RADICULOPATHY, LUMBOSACRAL REGION | ICD-10-CM | Inpatient and outpatient setting, any position |
| 5 | Negative control: Hernia | 550 | DX | Inguinal hernia | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.0 | DX | Inguinal hernia with gangrene | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.00 | DX | Inguinal hernia, with gangrene, unilateral or unspecified (not specified as recurrent) | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.01 | DX | Inguinal hernia, with gangrene, unilateral or unspecified, recurrent | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.02 | DX | Inguinal hernia, with gangrene, bilateral (not specified as recurrent) | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.03 | DX | Inguinal hernia, with gangrene, bilateral, recurrent | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.1 | DX | Inguinal hernia with obstruction without mention of gangrene | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.10 | DX | Inguinal hernia, with obstruction, without mention of gangrene, unilateral or unspecified (not specified as recurrent) | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.11 | DX | Inguinal hernia with obstruction, without mention of gangrene, unilateral or unspecified, recurrent | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.12 | DX | Inguinal hernia, with obstruction, without mention of gangrene, bilateral (not specified as recurrent) | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.13 | DX | Inguinal hernia, with obstruction, without mention of gangrene, bilateral, recurrent | ICD-9-CM | |
| 5 | Negative control: Hernia | 550.9 | DX | Inguinal hernia without mention of obstruction or gangrene | ICD-9-CM | |

| | | | | | |
|----------------------------|--------|----|---------------------------------------------------------------------------------------------------------------------|-----------|------------------------------------------------|
| 5 Negative control: Hernia | 550.90 | DX | Inguinal hernia, without mention of obstruction or gangrene, unilateral or unspecified (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 550.91 | DX | Inguinal hernia, without mention of obstruction or gangrene, unilateral or unspecified, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 550.92 | DX | Inguinal hernia, without mention of obstruction or gangrene, bilateral (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 550.93 | DX | Inguinal hernia, without mention of obstruction or gangrene, bilateral, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 551 | DX | Other hernia of abdominal cavity with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.0 | DX | Femoral hernia with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.00 | DX | Femoral hernia with gangrene, unilateral or unspecified (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 551.01 | DX | Femoral hernia with gangrene, unilateral or unspecified, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 551.02 | DX | Femoral hernia with gangrene, bilateral (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 551.03 | DX | Femoral hernia with gangrene, bilateral, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 551.1 | DX | Umbilical hernia with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.2 | DX | Ventral hernia with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.20 | DX | Ventral hernia, unspecified, with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.21 | DX | Incisional ventral hernia, with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.29 | DX | Other ventral hernia with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.3 | DX | Diaphragmatic hernia with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.8 | DX | Hernia of other specified sites, with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 551.9 | DX | Hernia of unspecified site, with gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 552 | DX | Other hernia of abdominal cavity with obstruction but without mention of gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 552.0 | DX | Femoral hernia with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.00 | DX | Femoral hernia with obstruction, unilateral or unspecified (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 552.01 | DX | Femoral hernia with obstruction, unilateral or unspecified, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 552.02 | DX | Femoral hernia with obstruction, bilateral (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 552.03 | DX | Femoral hernia with obstruction, bilateral, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 552.1 | DX | Umbilical hernia with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.2 | DX | Ventral hernia with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.20 | DX | Ventral, unspecified, hernia with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.21 | DX | Incisional ventral hernia with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.29 | DX | Other ventral hernia with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.3 | DX | Diaphragmatic hernia with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.8 | DX | Hernia of other specified sites, with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 552.9 | DX | Hernia of unspecified site, with obstruction | ICD-9-CM | |
| 5 Negative control: Hernia | 553 | DX | Other hernia of abdominal cavity without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.0 | DX | Femoral hernia without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.00 | DX | Femoral hernia without mention of obstruction of gangrene, unilateral or unspecified (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 553.01 | DX | Femoral hernia without mention of obstruction or gangrene, unilateral or unspecified, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 553.02 | DX | Femoral hernia without mention of obstruction or gangrene, bilateral (not specified as recurrent) | ICD-9-CM | |
| 5 Negative control: Hernia | 553.03 | DX | Femoral hernia without mention of obstruction or gangrene, bilateral, recurrent | ICD-9-CM | |
| 5 Negative control: Hernia | 553.1 | DX | Umbilical hernia without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.2 | DX | Ventral hernia without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.20 | DX | Ventral, unspecified, hernia without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.21 | DX | Incisional hernia without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.29 | DX | Other ventral hernia without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.3 | DX | Diaphragmatic hernia without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.8 | DX | Hernia of other specified sites without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | 553.9 | DX | Hernia of unspecified site without mention of obstruction or gangrene | ICD-9-CM | |
| 5 Negative control: Hernia | K40 | DX | INGUINAL HERNIA | ICD-10-CM | Inpatient and outpatient setting, any position |
| 5 Negative control: Hernia | K41 | DX | FEMORAL HERNIA | ICD-10-CM | Inpatient and outpatient setting, any position |
| 5 Negative control: Hernia | K41.0 | DX | BILATERAL FEMORAL HERNIA, WITH OBSTRUCTION, WITHOUT GANGRENE | ICD-10-CM | Inpatient and outpatient setting, any position |
| 5 Negative control: Hernia | K41.00 | DX | BILATERAL FEMORAL HERNIA, WITH OBSTRUCTION, WITHOUT GANGRENE, NOT SPECIFIED AS RECURRENT | ICD-10-CM | Inpatient and outpatient setting, any position |
| 5 Negative control: Hernia | K41.01 | DX | BILATERAL FEMORAL HERNIA, WITH OBSTRUCTION, WITHOUT GANGRENE, RECURRENT | ICD-10-CM | Inpatient and outpatient setting, any position |
| 5 Negative control: Hernia | K41.1 | DX | BILATERAL FEMORAL HERNIA, WITH GANGRENE | ICD-10-CM | Inpatient and outpatient setting, any position |
| 5 Negative control: Hernia | K41.10 | DX | BILATERAL FEMORAL HERNIA, WITH GANGRENE, NOT SPECIFIED AS RECURRENT | ICD-10-CM | Inpatient and outpatient setting, any position |

[illegible]

| Category | Subcategory | ICD | Validation source | Type of the source | Codes in the study | Codes in the emulation | Modification | Description of Modifications | Notes | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Outcomes | | | | | 398.91 Rheumatic heart failure 402.01 Malignant hypertensive heart disease with heart failure 402.1 Benign hypertensive heart disease 402.11 Benign hypertensive heart disease with heart failure 402.91 Hypertensive heart disease unspecified with heart failure 404.x3 404.00 Malignant heart and chronic kidney disease without heart failure and with chronic kidney disease stage I-stage IV or unspecified 404.01 Malignant hypertensive heart and chronic kidney disease with heart failure 404.03 Malignant hypertensive heart and chronic kidney disease with heart failure and chronic kidney disease stage V or end-stage renal disease 404.10 Benign hypertensive heart and chronic kidney disease without heart failure and with chronic kidney disease stage I-stage IV or unspecified 404.11 Benign hypertensive heart disease and chronic kidney disease with heart failure and with chronic kidney disease stage I-stage IV or unspecified 404.12 Benign hypertensive heart disease and chronic kidney disease without heart failure and with chronic kidney disease stage V or end-stage renal disease 404.13 Benign hypertensive heart disease and chronic kidney disease with heart failure and with chronic kidney disease stage V or end-stage renal disease | 398.91 402.x1 402.01 402.11 402.91 404.x3 404.01 404.03 404.11 404.13 404.91 404.93 428.x 428.1 428.2 428.21 428.22 428.23 428.3 428.31 428.32 428.33 428.4 428.41 428.42 428.43 428.9 | | | Myocardial infarction, 410.0-410.9 Ischemic heart disease, 416.9 Chronic pulmonary heart disease unspecified, 422 Acute myocarditis*, 425 Cardiomyopathy*, 425.0 Endomyocardial fibrosis, 425.1 Hypertrophic obstructive cardiomyopathy, 425.2 Obscure cardiomyopathy of Africa, 425.3 Endocardial fibroelastosis, 425.4 Other primary cardiomyopathies, 425.5 Alcoholic cardiomyopathy, 425.7 Metabolic cardiomyopathy, 425.8 Cardiomyopathy in other diseases classified elsewhere, 425.9 Secondary cardiomyopathy unspecified, 429.3 Cardiomegaly, 429.4 Heart disease following cardiac surgery, 514 Pulmonary congestion and hypostasis, 518.4 Acute lung edema unspecified, 785.51 Cardiogenic shock, 786.0 Dyspnea/respiratory abnormality*, 997.1 Cardiac complications during or resulting from a procedure, V42.1 Heart transplant status | | |
| 1 | Hospitalisation for heart failure | ICD-9-CM ICD-10-CM | A systematic review of validated methods for identifying heart failure using administrative data PROMISE team | Systematic review DoPE | | | Yes | | The reason for not adding these codes is that they are either part of the exclusion criteria (i.e., alcoholic cardiomyopathy, hypertrophic obstructive cardiomyopathy, heart transplant) or do not clearly refer to heart failure (i.e., dyspnea, pulmonary congestion) and can have different etiologies besides heart failure | | |
| 2 | All-cause mortality | N/A | Bias Implications of Outcome Misclassification in Observational Studies Evaluating Association Between Treatments and All-Cause or Cardiovascular Mortality Using Administrative Claims | N/A | | | | | | | |
| 3 | Cataract surgery | ICD-9-CM, ICD-10-CM | Investigator review of codes based on: https://pubmed.ncbi.nlm.nih.gov/32828874/ , https://pubmed.ncbi.nlm.nih.gov/29433851/ , https://pubmed.ncbi.nlm.nih.gov/29075781/ , https://pubmed.ncbi.nlm.nih.gov/34935591/ and https://pubmed.ncbi.nlm.nih.gov/23993357/ and department ICD-9 to ICD-10 conversion | N/A | | | | | | | |
| 4 | Lumbar radiculopathy | ICD-10-CM | Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes Association between chiropractic spinal manipulation and lumbar discectomy in adults with lumbar disc herniation and radiculopathy: retrospective cohort study using United States' data | Study w/ same criteria | | | | | | | |
| | | ICD-9-CM | Investigator reviewed codes, based on ICD-10-CM translations | N/A | | | | | | | |
| 5 | Hernia | ICD-10-CM | Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes | Study w/ same criteria | | | | | | | |
| | | ICD-9-CM | Investigator reviewed codes, based on ICD-10-CM translations | N/A | | | | | | | |
| | | ICD-10-CM | Investigator reviewed codes | N/A | | | | | | | |
| Inclusion criteria | | | | | | | | | | | |
| Male or female, age ≥ 18 years at screening. A woman is considered of childbearing potential must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information | | | | | | | | | | | |
| 1 | Chronic HF diagnosed for at least 3 months before screening, and currently in HF NYHA class II-IV | Male or Female, age > 18 y.o | Can't be validated | N/A | | | | | | | |
| 2 | Chronic HF with preserved EF defined as LVEF > 40 % and no prior measurement of LVEF ≤40% under stable conditions. | Heart Failure, NYHA II-IV | Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure | DoPE | | | | | | | |
| 3 | Elevated N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) > 300 pg/ml for patients without AF, OR > 900 pg/ml for patients with AF | Heart Failure, EF > 40% | Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure | DoPE | | | | | | | |
| 4 | Structural heart disease (left atrial enlargement and/or left ventricular hypertrophy) documented by echocardiogram at Visit1 or within 6 months prior to Visit1 | NT-proBNP | Can't be validated | N/A | | | | | | | |
| | | Structural heart disease (left atrial enlargement and/or left ventricular hypertrophy) | Investigator reviewed codes. | N/A | | | | | | | |
| 5 | | | Codes for cardiomegaly, hypertrophic cardiomyopathy and hypertensive heart disease with heart failure are also mentioned in the HF systematic review. | N/A | | | | | | | |

| | | | | | | | | | |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.2 | Documented HHF within 12 months prior to Visit 1 | HHF | ICD-9-CM ICD-10-CM | A systematic review of validated methods for identifying heart failure using administrative data PROMISE team | Systematic review DoPE | 398.91 Rheumatic heart failure 402.01 Malignant hypertensive heart disease with heart failure 402.x1 402.1 Benign hypertensive heart disease 402.01 402.11 Benign hypertensive heart disease with heart failure 402.91 402.91 Hypertensive heart disease unspecified with heart failure 404.x1 404.x3 404.00 Malignant heart and chronic kidney disease without heart failure and with chronic kidney disease stage I-stage IV or unspecified 404.01 404.01 Malignant hypertensive heart and chronic kidney disease with heart failure 404.91 404.03 Malignant hypertensive heart and chronic kidney disease with heart failure and chronic kidney disease stage V or end-stage renal disease 428.x 428.1 404.10 Benign hypertensive heart and chronic kidney disease without heart failure and with chronic kidney disease stage I-stage IV or unspecified 428.21 428.22 404.11 Benign hypertensive heart disease and chronic kidney disease with heart failure and with chronic kidney disease stage I-stage IV or unspecified 428.3 428.31 428.32 428.33 404.12 Benign hypertensive heart disease and chronic kidney disease without heart failure and with chronic kidney disease stage V or end-stage renal disease 428.41 428.42 428.43 404.13 Benign hypertensive heart disease and | Yes | ischemic heart disease, 416.9 Chronic pulmonary heart disease unspecified, 422 Acute myocarditis*, 425 Cardiomyopathy*, 425.0 Endomyocardial fibrosis, 425.1 Hypertrophic obstructive cardiomyopathy, 425.2 Obscure cardiomyopathy of Africa, 425.3 Endocardial fibroelastosis, 425.4 Other primary cardiomyopathies, 425.5 Alcoholic cardiomyopathy, 425.7 Metabolic cardiomyopathy, 425.8 Cardiomyopathy in other diseases classified elsewhere, 425.9 Secondary cardiomyopathy unspecified, 429.3 Cardiomegaly, 429.4 Heart disease following cardiac surgery, 514 Pulmonary congestion and hypostasis, 518.4 Acute lung edema unspecified, 785.51 Cardiogenic shock, 786.0 Dyspnea/respiratory abnormality*, 997.1 Cardiac complications during or resulting from a procedure, V42.1 Heart transplant status | The reason for not adding these codes is that they are either part of the exclusion criteria (i.e., alcoholic cardiomyopathy, hypertrophic obstructive cardiomyopathy, heart transplant) or do not clearly refer to heart failure (i.e., dyspnea, pulmonary congestion) and can have different etiologies besides heart failure |
| | | | | | | | | | |
| 6 | Oral diuretics, if prescribed to patient according to local guidelines and discretion of the Investigator, should be stable for at least 1 week prior to Visit 2 (Randomisation) | Oral diuretics | | Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data | N/A N/A | | Yes | Finerenone, Tolvaptan added. | |
| | | | | | | | | | |
| 7 | Body Mass Index (BMI) < 45 kg/m2 at Visit 1 | | ICD-9-CM ICD-10-CM | ICD-9 and ICD-10 codes Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data | Validation study | | No | | |
| | | | | | | | | | |
| 8 | Signed and dated written ICF in accordance with GCP and local legislation prior to admission to the trial | BMI | ICD-10-CM | ICD-9 and ICD-10 codes | Validation study | | No | | |
| | | | | | | | | | |
| 9 | Trial subgroup of patients with Type 2 Diabetes Mellitus (T2DM) | Signed informed consent | ICD-9-CM ICD-10-CM | N/A PROMISE team PROMISE team | N/A DoPE DoPE | | | N/A | |
| | | | | | | | | | |
| Exclusion criteria | | | | | | | | | |
| 1 | Myocardial infarction (previously defined as enzymes in combination with symptoms of ischaemia or newly developed ischaemic ECG changes), coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 90 days | Myocardial infarction | ICD-9-CM ICD-10-CM | Validity of Myocardial Infarction Diagnoses in Administrative Databases: A Systematic Review Specificity and NPV were available only from three studies and in these ranged from 89–99%, and 75–99% PROMISE team | Systematic review DoPE | 410.x ICD-9 diagnosis code 'V4581' ICD-9 procedure codes '3610' '3611' '3612' '3613' '3614' '3615' '3616' '3617' '3619' | 410.x V45.81 996.03 36.10 36.11 36.12 36.13 36.14 36.15 36.16 36.17 36.19 36.2 | No No | |
| | | | | | | | | | |
| | | CABG | ICD-9-CM ICD-10-CM | Validation of a claims-based algorithm identifying eligible study subjects in the ADAPTABLE pragmatic clinical trial PROMISE team Outcomes after left ventricular assist device implantation in patients with acute kidney injury | Validation study DoPE | | Yes No | Added: 996.03 Mechanical complication due to coronary bypass graft | This added code describes the consequences following coronary artery bypass grafting (CABG), which aligns closely with established exclusion criteria |
| | | | | | | | | | |
| | | Major CV surgery | ICD-10-CM | Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score Assessment of Potentially Preventable Hospital Readmissions After Major Surgery and Association With Public vs Private Health Insurance and Comorbidities | Study w/ same criteria Study w/ same criteria Study w/ same criteria | | | | |

[illegible]

37.66

V43.2
V43.21
V43.22
Z95.811
Z95.812
37.60
37.63
37.65
37.66

02HA0RS
02HA3RS
02HA4RS
5A02116
5A02216
02HA0QZ
02HA3QZ
02HA4QZ
02WA0QZ
02WA3QZ
02WA4QZ

V45.02
Z95.810
37.94
37.95
37.96
37.97
37.98
33223
33230
33231
33240
33241
33243
33244
33249
33262
33263
33264
33270
33271
33272
33273

Added: V43.2 HEART
REPLACED BY OTHER MEANS,
V43.21 ORGAN OR TISSUE
REPLACED BY OTHER MEANS,
HEART ASSIST DEVICE, V43.22
ORGAN OR TISSUE REPLACED
BY OTHER MEANS, FULLY
IMPLANTABLE ARTIFICIAL
HEART, Z95.811 PRESENCE OF
HEART ASSIST DEVICE, Z95.812
PRESENCE OF FULLY
IMPLANTABLE ARTIFICIAL
HEART, 37.60 IMPLANTATION
OR INSERTION OF
BIVENTRICULAR EXTERNAL
HEART ASSIST SYSTEM, 37.63
REPAIR OF HEART ASSIST
SYSTEM, 37.65 IMPLANT OF
SINGLE VENTRICULAR
(EXTRACORPOREAL)
EXTERNAL HEART ASSIST
SYSTEM, 37.66 INSERTION OF
IMPLANTABLE HEART ASSIST
SYSTEM

The added codes indicate the
presence of a heart assist system

Yes

Study w/ same criteria

ICD-9-CM

Trends in left ventricular assist device use and outcomes
among Medicare beneficiaries, 2004–2011

LVAD/Implantable Heart

ICD-10-CM

N/A

N/A

37.94
37.95
37.96
37.97
37.98
37.89
33223
33249
33230
33231
33240
33262
33263
33264
33271

33233 + 33249

IMPLANTABLE CARDIAC
DEFIBRILLATOR IN SITU,
Z95.810 PRESENCE OF
AUTOMATIC (IMPLANTABLE)
CARDIAC DEFIBRILLATOR,
33243 REMOVAL OF SINGLE OR
DUAL CHAMBER
IMPLANTABLE DEFIBRILLATOR
ELECTRODE(S); BY
THORACOTOMY, 33244
REMOVAL OF SINGLE OR DUAL
CHAMBER IMPLANTABLE
DEFIBRILLATOR
ELECTRODE(S); BY
TRANSVENOUS EXTRACTION,
33270 INSERTION OR
REPLACEMENT OF
PERMANENT SUBCUTANEOUS
IMPLANTABLE DEFIBRILLATOR
SYSTEM, WITH SUBCUTANEOUS
ELECTRODE, INCLUDING
DEFIBRILLATION THRESHOLD
EVALUATION, INDUCTION OF
ARRHYTHMIA, EVALUATION OF
SENSING FOR ARRHYTHMIA
TERMINATION, AND
PROGRAMMING OR
REPROGRAMMING OF SENSING
OR THERAPEUTIC

The added codes indicate the
presence of an ICD

Yes

Study w/ same criteria

ICD-9-CM

Use of healthcare claims to validate the Prevention of
Arrhythmia Device Infection Trial cardiac implantable
electronic device infection risk score

Implantation of cardioverter defibrillator (ICD)
3 within 3 months

| | | | | | | | | | |
|-------------------------------------------|-----|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | | 0JH608Z 0JH808Z 02H63KZ 02H64KZ 02H73KZ 02H74KZ 02HK3KZ 02HK4KZ | 02H43KZ 02H40KZ 02H43KZ 02H44KZ 02H60KZ 02H63KZ 02H64KZ 02H70KZ 02H73KZ 02H74KZ 02HK0KZ 02HK3KZ 02HK4KZ 02HLOKZ 02HL3KZ 02HL4KZ 02HN0KZ 02HN3KZ 02HN4KZ 0JH608Z 0JH60FZ 0JH638Z 0JH63FZ 0JH808Z 0JH838Z 0JPT0FZ 0JPT3FZ 02H40JZ 02H43JZ | | DEFIBRILLATOR LEAD INTO CORONARY VEIN, PERCUTANEOUS APPROACH, 02H40KZ INSERTION OF DEFIBRILLATOR LEAD INTO CORONARY VEIN, OPEN APPROACH, 02H44KZ INSERTION OF DEFIBRILLATOR LEAD INTO CORONARY VEIN, PERCUTANEOUS ENDOSCOPIC APPROACH, 02H60KZ INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT ATRIUM, OPEN APPROACH, 02H70KZ INSERTION OF DEFIBRILLATOR LEAD INTO LEFT ATRIUM, OPEN APPROACH, 02HK0KZ INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT VENTRICLE, OPEN APPROACH, 02HK3KZ INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT VENTRICLE, PERCUTANEOUS APPROACH, 02HK4KZ INSERTION OF DEFIBRILLATOR LEAD INTO RIGHT VENTRICLE, PERCUTANEOUS ENDOSCOPIC APPROACH, 02HLOKZ INSERTION OF DEFIBRILLATOR replacement of transvenous lead [electrode] into left ventricular coronary venous system, 37.71 Initial insertion of transvenous lead [electrode] into ventricle, 37.72 Initial insertion of transvenous leads [electrodes] into atrium and ventricle, 37.73 Initial insertion of transvenous lead [electrode] into atrium, 37.81 Initial insertion of single-chamber device, not specified as rate responsive, 37.83 Initial insertion of dual-chamber device, 37.85 Replacement of any type pacemaker device with single-chamber device, not specified as rate responsive, 37.87 Replacement of any type pacemaker device with dual-chamber device, 37.89 Revision or removal of pacemaker device, 37.94 Implantation or replacement of automatic cardioverter/defibrillator, total system [AICD], 37.96 Implantation of automatic cardioverter/defibrillator pulse generator only, 33206 Insertion | The added codes indicate the presence of an ICD |
| | ICD | ICD-10-CM | Device-related infection in de novo transvenous implantable cardioverter-defibrillator Medicare patients | Study w/ same criteria | CRT-P ICD-9 00.50 00.52 37.71 37.72 37.73 37.81 37.83 37.85 37.87 CPT-4 33206 33225 33207 33208 33212 33213 33221 33229 33214 CRT-D ICD-9 00.51 00.52 00.54 37.89 37.94 --- | | | | |
| 4 Cardiac resynchronisation therapy (CRT) | CRT | ICD-9-CM ICD-10-CM | Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score Cardiac pacemakers | Study w/ same criteria N/A | 425.4 425.9 | CRT 00.50 00.51 00.53 00.54 | Yes | Added: 425.5 ALCOHOLIC CARDIOMYOPATHY, 425.7 NUTRITIONAL AND METABOLIC CARDIOMYOPATHY, 425.8 CARDIOMYOPATHY IN OTHER DISEASES CLASSIFIED ELSEWHERE, 425.11 HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY (see validation study HOCM below) | Added codes clearly indicate cardiac resynchronization therapy (CRT), whereas the non-added codes include pacemakers, leads, and chamber devices that are not clearly related to CRT |
| 5.1 Cardiac constrictor | | ICD-9-CM | Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer | Validation study | | 425.4 425.5 425.7 425.8 425.9 425.11 | Yes | | |

| | | | | | | | | | | |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| 5.2 | Cardiomyopathy | ICD-10-CM | A systematic review of validated methods for identifying heart failure using administrative data | Validation study | I25.5 Ischemic cardiomyopathy I42.0 Dilated cardiomyopathy I42.5 Other restrictive cardiomyopathy I42.6 Alcoholic cardiomyopathy I42.7 Cardiomyopathy due to drugs and external causes I42.8 Other cardiomyopathies I42.9 Cardiomyopathy, unspecified I43 Cardiomyopathy in diseases classified elsewhere I43.0 Cardiomyopathy in infectious and parasitic diseases classified elsewhere I43.1 Cardiomyopathy in metabolic diseases I43.2 Cardiomyopathy in nutritional diseases I43.8 Cardiomyopathy in other diseases classified elsewhere | I421 - (HOCM validation study below) I42.5 I42.6 I42.7 I43 | N/A | | | |
| | | | Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data | Validation study | 277.30 277.39 | 277.30 277.39 | No | | | |
| | | | ICD-9-CM | Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data | Validation study | E85.8x E85.4x E84.9x | E85.0 E85.1 E85.2 E85.3 E85.4 E85.8 E85.81 E85.82 E85.89 E85.9 | Added: E85.0 Non-neuropathic heredofamilial amyloidosis, E85.1 Neuropathic heredofamilial amyloidosis, E85.2 Heredofamilial amyloidosis, unspecified, E85.3 Secondary systemic amyloidosis | Added codes indicate the presence of amyloidosis | |
| | | | | | | | | | | |
| ICD-10-CM | Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data | Validation study | | | | 275.0 275.01 275.02 275.03 275.09 | 275.01 275.02 275.03 275.09 | Disorders of iron metabolism are a broad category that may include iron deficiency and not just hemochromatosis. Individuals with these disorders will be excluded under the criterion of "Hb < 9 mg/dl" | | |
| | | | | | | | | | | |
| | | | ICD-9-CM | Health Care Utilization and Economic Burdens of Hemochromatosis in the United States: A Population-Based Claims Study | Study w/ same criteria | N/A | E83.11 E83.110 E83.111 E83.118 E83.119 | Not added: 275.0 Disorders of iron metabolism (non-billable code, not specific) | | |
| | | | | | | | | | | |
| ICD-10-CM | N/A | N/A | | | | 359.1 | | N/A | | |
| | | | | | | | | | | |
| | | | ICD-9-CM | Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims | Study w/ same criteria | G71.0 G71.01 | 359.0 359.1 | Yes | Added: 359.0 CONGENITAL HEREDITARY MUSCULAR DYSTROPHY | We are interested in different types of muscular dystrophies. The provided validation study has investigated "duchenne muscular dystrophy" |
| | | | | | | | | | | |
| ICD-10-CM | Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims | Study w/ same criteria | | | | 429.83 | G71x | Yes | Added: G71.02, G71.03, G71.031, G71.032, G71.033, G71.034, G71.0340, G71.0341, G71.0342, G71.0349, G71.035, G71.038, G71.039, G71.09 | We are interested in different types of muscular dystrophies. The provided validation study has investigated Duchenne muscular dystrophy. |
| | | | | | | | | | | |
| | | | ICD-9-CM | Trends in hospitalization for takotsubo cardiomyopathy in the United States | Study w/ same criteria | N/A | 429.83 I51.81 | No | | |
| | | | | | | | | | | |
| ICD-10-CM | N/A | N/A | | | | 425.11 | | No | | |
| | | | | | | | | | | |
| | | | ICD-9-CM | Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States | Study w/ same criteria | 425.11 | | No | | |
| | | | | | | | | | | |
| ICD-10-CM | Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States | Study w/ same criteria | | | | I42.1 | I42.1 | No | | |
| | | | | | | | | | | |
| | | | ICD-9-CM | N/A | N/A | N/A | N/A | N/A | | |
| | | | | | | | | | | |
| ICD-10-CM | N/A | N/A | | | | N/A | N/A | N/A | | |
| | | | | | | | | | | |

| | | | | | 148 | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Atrial fibrillation/flutter | ICD-10-CM | Sensitivity, specificity, positive and negative predictive values of identifying atrial fibrillation using administrative data; a systematic review and meta-analysis | Systematic review | | I48.x | No | The pooled performance metrics were sensitivity 80% (95% CI 72–86%), specificity 98% (96–99%); PPV 88% (82–94%); NPV 97% (94–99%) | |
| | | | | | 401.0 402.0 402.01 403.00 403.01 404.00 404.01 404.02 404.03 | | | | |
| Systolic blood pressure (SBP) ≥ 180 mmHg at Visit 2. If SBP >150 mmHg and <180 mmHg at Visit 2, the patient should be receiving at least 3 antihypertensive drugs | | ICD-9-CM | Burden of Hypertensive Crisis in Patients With End-Stage Kidney Disease on Maintenance Dialysis: Insights From United States Renal Data System Database | Study w/ same criteria | N/A | 404.03 405.01 405.09 | Yes | Added: 405.01 DX Malignant renovascular hypertension, 405.09 DX Other malignant secondary hypertension | Added codes for malignant hypertension, as these individuals have a higher risk for adverse outcomes |
| | Hypertensive crisis | ICD-10-CM | N/A | N/A | | I16.0 Hypertensive urgency I16.1 Hypertensive emergency I16.9 Hypertensive crisis, unspecified | N/A | | |
| | | | | | Exclusion: 458 458.1 458.21 ----- Inclusion: 453.29 458.8 458.9 | | | | |
| Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 2 | | ICD-9-CM | Utilization of Medical Codes for Hypotension in Shock Patients: A Retrospective Analysis | Study w/ same criteria | | 458.x | No | | |
| | | | | | Exclusion: I95.1 I95.2 I95.3 ----- Inclusion: I95.0 I95.81 I95.89 I95.9 | | | | |
| | Hypotension | ICD-10-CM | Utilization of Medical Codes for Hypotension in Shock Patients: A Retrospective Analysis | Study w/ same criteria | | I95.x | No | | |
| | Worsening Asthma/Status Asthmaticus | | | | 493.0 493.1 493.2 493.9 | 493.00 493.01 493.02 493.10 493.11 493.12 493.2 493.20 493.21 493.22 493.81 493.82 493.90 493.91 493.92 | | | |
| Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension (with oxygen OR oral steroid therapy) | | ICD-9-CM ICD-10-CM | Validation of Diagnostic Coding for Asthma in an Electronic Health Record System in Hong Kong N/A | Validation study N/A | N/A 491.x 492.x 496.x | | Yes N/A | Added: 493.81 DX Exercise induced bronchospasm, 493.82 DX Cough variant asthma | Study has been conducted in Hong Kong. The overall positive predictive value (PPV) was 85.0% (95% CI 80.1–89.9%) |
| | | | | | | 491.0 491.1 491.20 491.21 491.22 491.8 491.9 492.0 492.8 494.0 494.1 496 506.4 | | | |
| Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | | ICD-9-CM | An independently validated, portable algorithm for the rapid identification of COPD patients using electronic health records | Validation study | J40 J41 J42 J43 J44 | J40 J41 J42 J43 J44 J47.0 J47.1 J47.9 J68.4 | Yes | Added: 494.0 Bronchiectasis without acute exacerbation, 494.1 Bronchiectasis with acute exacerbation, 506.4 Chronic respiratory conditions due to fumes and vapors | Bronchiectasis and chronic respiratory conditions due to fumes have been added, as these individuals are at higher risk for adverse outcomes that may influence our results |
| | | | | | | | | | |
| | COPD/Chronic Tuberculosis (inpatient codes only) | ICD-10-CM | N/A | N/A | | | Yes | Added: J47.0 Bronchiectasis with acute lower respiratory infection, J47.1 Bronchiectasis with (acute) exacerbation, J47.9 Bronchiectasis, uncomplicated | Bronchiectasis and chronic respiratory conditions due to fumes have been added, as these individuals are at higher risk for adverse outcomes that may influence our results |
| | | ICD-9-CM | Clinical evaluation of code-based algorithms to identify patients with pulmonary arterial hypertension in healthcare databases | Validation study | 416.0 416.8 416.9 | | 416 Yes | Not added: 416.8, 416.9 | The criteria is primary hypertension only, which is why only codes for primary pulmonary hypertension have been used |

| | | | | | | | | |
|------------------------------------------------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------|--------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pulmonary Hypertension/Other Pulmonary Heart Disease | ICD-10-CM | Clinical evaluation of code-based algorithms to identify patients with pulmonary arterial hypertension in healthcare databases | Study w/ same criteria | I27.0 | I27.0 Primary pulmonary hypertension | Yes | Not added: I27.1, I27.2, I27.20, I27.21, I27.29 | The criteria is primary hypertension only, which is why only codes for primary pulmonary hypertension have been used |
| | | | | I27.1 | | | | |
| | | | | I27.2 | | | | |
| | | | | I27.20 | | | | |
| | | | | I27.21 | | | | |
| | | | | I27.29 | | | | |
| | | | | 162 | | | | |
| | | | | 163 | | | | |
| | | | | 165 | | | | |
| | | | | 165.0 | | | | |
| | | | | 165.8 | | | | |
| | | | | 165.9 | | | | |
| | | | | 176.4 | | | | |
| | | | | 197.0 | | | | |
| | | | | 197.1 | | | | |
| | | | | 197.2 | | | | |
| | | | | 197.3 | | | | |
| | | | | 198 | | | | |
| | | | | 199 | | | | |
| | | | | 199.0 | | | | |
| | | | | 199.1 | | | | |
| | | | | 230 | | | | |
| | | | | 231 | | | | |
| | | | | 231.1 | | | | |
| | | | | 231.2 | | | | |
| | | | | 231.8 | | | | |
| | | | | 231.9 | | | | |
| | | | | 234 | | | | |
| | | | | 235 | 162.2 | | | |
| | | | | 235.6 | 162.3 | | | |
| | | | | 235.7 | 162.4 | | | |
| | | | | 235.8 | 162.5 | | | |
| | | | | 235.9 | 162.8 | | | |
| | | | | 238 | 162.9 | | | |
| Lung/Pulmonary Malignancies | ICD-9-CM | Diagnosis of Pulmonary Malignancy after Hospitalization for Pneumonia | Study w/ same criteria | C34.00 | 231.2 | Yes | Not added: 163, 165, 165.0, 165.8, 165.9, 176.4, 197.0, 197.1, 197.2, 197.3, 198, 199, 199.0, 199.1, 230, 231, 231.1, 231.8, 231.9, 234, 235, 235.6, 235.7, 235.8, 235.9, 238 | Did not add indicated codes, as they represent cancer in different parts of the respiratory system, other than the lung and bronchus. Malignancy codes for other parts of the respiratory system have been included in the exclusion criteria for "cancer" |
| | | | | C34.01 | C34.00 | | | |
| | | | | C34.02 | C34.01 | | | |
| | | | | C34.10 | C34.02 | | | |
| | | | | C34.11 | C34.1 | | | |
| | | | | C34.12 | C34.10 | | | |
| | | | | C34.2 | C34.11 | | | |
| | | | | C34.30 | C34.12 | | | |
| | | | | C34.31 | C34.2 | | | |
| | | | | C34.32 | C34.3 | | | |
| | | | | C34.80 | C34.30 | | | |
| | | | | C34.81 | C34.31 | | | |
| | | | | C34.82 | C34.32 | | | |
| | | | | C34.90 | C34.8 | | | |
| | | | | C34.91 | C34.80 | | | |
| | | | | C34.92 | C34.81 | | | |
| | | | | | C34.82 | | | |
| | | | | | C34.9 | | Added: D02.2 Carcinoma in situ of bronchus and lung, D02.20 | |
| | | | | | C34.90 | | Carcinoma in situ of unspecified bronchus and lung, D02.21 | |
| | | | | | C34.91 | | Carcinoma in situ of right bronchus and lung, D02.22 | |
| | | | | | C34.92 | | Carcinoma in situ of left bronchus and lung | Added codes for cancer in the bronchus. |
| | ICD-10-CM | Development and Validation of Coding Algorithms to Identify Patients with Incident Non-Small Cell Lung Cancer in United States Healthcare Claims Data | Study w/ same criteria | D02.20 | D02.21 | Yes | | |
| | | | | D02.21 | D02.22 | | | |
| | | | | D02.22 | | | | |
| | ICD-9-CM diagnosis | The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States | Study w/ same criteria | V42.6 | V42.6 | Yes | Added: 996.84 Complications of transplanted lung | Added codes indicate the post-operative complications after lung transplantation |
| | | | | 996.84 | | | | |
| | | | | Z94.2 | Z94.2 | | | |
| | | | | Z94.3 | Z94.3 | | | |
| | | | | | T86.810 | | | |
| | ICD-10-CM diagnosis | The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States | Study w/ same criteria | | T86.811 | Yes | | |
| | | | | | T86.819 | | Added: T86.810, T86.811, T86.819 | The codes indicate different types of failure after lung transplant |
| | | | | 33.50 | 33.5 | | | |
| | | | | 33.51 | 33.50 | | | |
| | | | | 33.52 | 33.52 | | | |
| | | | | 33.6 | 33.51 | | | |
| | ICD-9-CM procedures | The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States | Study w/ same criteria | | 33.6 | No | | |

| | | | | | | | | | |
|------------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------------------------------------------------------------------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Cirrhosis/Chronic Hepatic Diseases | ICD-10-CM ICD-9-CM | Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications N/A | Validation study N/A | K70.41 K72.11 K72.90 K72.91 B19.0 B19.11 B19.21 G93.40 G93.41 | | B15.0 B16.0 B16.2 B17.11 B19.0 B19.11 B19.21 K70.41 K72.01 K72.11 K72.90 K72.91 | Yes | Added: B15.0 Hepatitis A with hepatic coma, B16.0 Acute hepatitis B with delta-agent with hepatic coma, B16.2 Acute hepatitis B without delta-agent with hepatic coma, B17.11 Acute hepatitis C with hepatic coma, K72.01 Acute and subacute hepatic failure with coma Not added: G93.40 Encephalopathy, unspecified, G93.41 Metabolic encephalopathy | Added codes that clearly indicate the presence of coma and did not include general codes for encephalopathy, as it may not have a hepatic etiology |
| | | | | K70.30 K70.31† K70.40 K71.7 K74.3 K74.4 K74.5 K74.60 K74.69 | | K70.30 K70.31 K70.40 K70.41 K70.9 K71.7 K73.0 K73.1 K73.2 K73.8 K73.9 K74.00 K74.01 K74.02 K74.1 K74.2 K74.3 K74.4 K74.5 K74.60 K74.69 K75.4 | | Added: K70.41 Alcoholic hepatic failure with coma, K70.9 Alcoholic liver disease, unspecified, K73.0 Chronic persistent hepatitis, not elsewhere classified, K73.1 Chronic lobular hepatitis, not elsewhere classified, K73.2 Chronic active hepatitis, not elsewhere classified, K73.8 Other chronic hepatitis, not elsewhere classified, K73.9 Chronic hepatitis, unspecified, K74.00 Hepatic fibrosis, unspecified, K74.01 Hepatic fibrosis, early fibrosis, K74.02 Hepatic fibrosis, advanced fibrosis, K74.1 Hepatic sclerosis, K74.2 Hepatic fibrosis with hepatic sclerosis, K75.4 Autoimmune hepatitis | |
| | | | | 155.x | | 155.0 155.1 155.2 | Yes | | |
| | | | | | C22.x | C22.0 C22.1 C22.2 C22.3 C22.4 C22.7 C22.8 C22.9 | No | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| Hepatic Cancer | ICD-10-CM | Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications | Validation study | | | | | | Added codes that fit well with the definition of cirrhosis/chronic hepatic disease |
| | ICD-9-CM | Risk of cancer in infertile women: analysis of US claims data | Study w/ same criteria | | | | | | |
| Hepatorenal Syndrome | ICD-10-CM | Risk of cancer in infertile women: analysis of US claims data | Study w/ same criteria | | | | | | No |
| | ICD-9-CM | N/A | N/A | | | | | | |
| Liver Transplant | ICD-10-CM | Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications | Validation study | | | | | | No |
| | ICD-9-CM | PROMISE Team | DoPE | | | | | | |
| Viral Hepatitis | ICD-10-CM | PROMISE Team | DoPE | | | | | | No |
| | ICD-9-CM | | N/A | | | | | | |
| Chronic Kidney Disease | ICD-10-CM | | | | | | | | No |
| | ICD-9-CM | Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data | Validation study | | | | | | |
| Chronic Kidney Disease | ICD-10-CM | Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data | Validation study | | | | | | No |
| | ICD-9-CM | | | | | | | | |

Impaired renal function, defined as eGFR < 20 mL/min/1.73 m² (CKD-EPi) or requiring dialysis, (CKD) - Stage IV and V
13 as determined at Visit 1

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|------|--|--|--|--|--|---------------------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| | ESRD | | | | | | 403.01 403.91 585.6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|------|--|--|--|--|--|---------------------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|

| | | | | | | | | | | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| 16 | Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit1 | | ICD-10-CM | Sociodemographic, Clinical, and Treatment-Related Factors Associated With Hyperglycemic Crises Among Adults With Type 1 or Type 2 Diabetes in the US From 2014 to 2020 | Study w/ same criteria | | | | Yes | Added: E08.10 Diabetes mellitus due to underlying condition with ketoacidosis without coma, E08.11 Diabetes mellitus due to underlying condition with ketoacidosis with coma, E09.10 Drug or chemical induced diabetes mellitus with ketoacidosis without coma, E09.11 Drug or chemical induced diabetes mellitus with ketoacidosis with coma | Added codes that mention ketoacidosis. Same codes without modification used in PROMISE team. |
| | | | ICD-9-CM | Readmission destination and risk of mortality after major surgery: an observational cohort study | Study w/ same criteria | | | | | | |
| | | | ICD-10-CM | Assessment of Potentially Preventable Hospital Readmissions After Major Surgery and Association With Public vs Private Health Insurance and Comorbidities | Study w/ same criteria | | | | | | Codes from the indicated study have been investigator reviewed, categorized, and translated from ICD-9 to ICD-10 and vice versa |
| 17.1 | Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | Bariatric Surgeries | ICD-9-CM | N/A | N/A | | | | | | |
| | | | ICD-10-CM | Antihypertensive Medication Use Trajectories After Bariatric Surgery: A Matched Cohort Study | DoPE | | | | No | | Codes from the indicated study have been investigator reviewed, categorized, and translated from ICD-9 to ICD-10 and vice versa |
| | | | | N/A | N/A | | | | | | |
| 17.2 | | GI Excision/Other Major Procedures | | | | 556.xx | | 556.0 556.1 556.2 556.3 556.5 556.6 556.8 556.9 | | | |
| 17.3 | Ulcerative Colitis | | ICD-9-CM | Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study | Study w/ same criteria | K51.xx | | K51.00 K51.01 K51.011 K51.012 K51.013 K51.014 K51.018 K51.019 K51.2 K51.20 K51.21 K51.211 K51.212 K51.213 K51.214 K51.218 K51.219 | No | | |
| | | | | | | | | K51.3 K51.30 K51.31 K51.311 K51.312 K51.313 K51.314 K51.318 K51.319 | | | |
| 17.4 | Crohn's Disease | | ICD-10-CM | Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study | Study w/ same criteria | 555.x | | K51.5 K51.50 K51.51 | No | | |
| | | | | | | | | 555.0 555.1 555.2 | | | |
| | | | ICD-9-CM | A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases | Systematic review | | | 555.9 | No | | |

| | | | | | | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| | | | | | K50.x | --- K50.0 K50.00 K50.01 K50.011 K50.012 K50.013 K50.014 K50.018 K50.019 K50.1 K50.10 K50.11 K50.111 K50.112 K50.113 K50.114 K50.118 K50.119 K50.8 K50.80 K50.81 K50.811 K50.812 K50.813 K50.814 K50.818 K50.819 K50.9 K50.90 | |
| | | Gastroparesis | ICD-10-CM | A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases | Systematic review | 536.3x | No |
| 17.5 | | | ICD-9-CM | Epidemiology, Etiology, and Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database | Study w/ same criteria | K31.84 | 536.3 No |
| | | Duodenal Ulcers | ICD-10-CM | Epidemiology, Etiology, and Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database | Study w/ same criteria | 532.x | No |
| | | | | | | K31.84 532.00 532.01 532.10 532.11 532.20 532.21 532.30 532.31 532.9 532.91 | |
| 17.6 | | | ICD-9-CM | Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study | Study w/ same criteria | K26.x | No |
| | | Gastric Ulcers | ICD-10-CM | Validity of peptic ulcer disease and upper gastrointestinal bleeding diagnoses in administrative databases: a systematic review protocol | Study w/ same criteria | 531.x | No |
| | | | | | | K26.0 K26.1 K26.2 K26.3 K26.9 531.00 531.01 531.10 531.11 531.20 531.21 531.30 531.31 531.90 531.91 | |
| 17.7 | | | ICD-9-CM | Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study | Study w/ same criteria | K25.x | No |
| | | History of malignant neoplasm | ICD-10-CM | Validity of peptic ulcer disease and upper gastrointestinal bleeding diagnoses in administrative databases: a systematic review protocol | Study w/ same criteria | K25.9 | No |
| | Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix or low risk prostate cancer (patients with pretreatment PSA <10 ng/mL and biopsy Gleason score of ≤ 6 and clinical stage T1c or T2a) | | ICD-9-CM | PROMISE Team | DoPE | | No |
| 18 | | | ICD-10-CM | PROMISE Team | DoPE | | No |
| | Presence of any other disease than heart failure with a life expectancy of <1 year in the investigator's opinion | CCI | | A combined comorbidity score predicted mortality in elderly patients better than existing scores | DoPE | | |
| 19 | Patients who must or wish to continue the intake of restricted medications (see Section 4.2.2) or any drug considered likely to interfere with the safe conduct of the trial | Intake of restricted medications that may interfere with the safe conduct | | | | | |
| 20 | | | | N/A | N/A | | |

| | | | | | | | |
|-----------|-----------------------------------------------------------------------------------------------------------------------------|------------------------|---------|---------|-----|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| ICD-10-CM | Alignment of diagnosis and pharmacy claims data coding of medication adherence among patients with diabetes or hypertension | Study w/ same criteria | Z91.120 | Z91.120 | Yes | Added: Z91.15 Patient's noncompliance with renal dialysis, I91.19 Patient's noncompliance with other medical treatment and regimen | As one of the exclusion criteria is renal dialysis, individuals who are noncompliant with dialysis are excluded. |
| | | | Z91.128 | Z91.128 | | | |
| | | | Z91.13 | Z91.13 | | | |
| | | | Z91.14 | Z91.14 | | | |
| | | | Z91.15 | Z91.15 | | | |
| | | | Z91.19 | Z91.19 | | | |

Flowchart for Cohort Assembly*

Link to Aetion reports:

CMS

<https://bwh-dope.aetion.com/substantiate/project/3085/cohort/79928/156141/comparative/basics>

OPTUM

<https://bwh-dope.aetion.com/substantiate/project/3061/cohort/79926/156139/comparative/basics>

MarketScan

<https://bwh-dope.aetion.com/substantiate/project/3074/cohort/79927/156140/comparative/basics>

Date conducted:

5/13/26

5/13/26

5/13/26

| | Optum (Aug 01, 2014 and Aug 31, 2024) | | Marketscan (Aug 01, 2014 and Sep 30, 2023) | | CMS (Aug 01, 2014 and Sep 30, 2020) | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|--------------------|-----------------------------------------------|--------------------|-----------------------------------------|--------------------|
| | Less Excluded Patients | Remaining Patients | Less Excluded Patients | Remaining Patients | Less Excluded Patients | Remaining Patients |
| Patients in dataset | | 97,451,572 | | 126,118,011 | | 28,874,258 |
| Patients meeting cohort entry criteria | | 1,286,333 | | 1,094,216 | | 1,704,189 |
| Excluded due to insufficient enrollment | -183,980 (14%) | 1,102,353 | -116,724 (11%) | 977,492 | -504,468 (30%) | 1,199,721 |
| Excluded due to prior use of referent | -345,763 (31%) | 756,590 | -520,386 (53%) | 457,106 | -830,275 (69%) | 369,446 |
| Excluded due to prior use of exposure | -559,043 (74%) | 197,547 | -316,472 (69%) | 140,634 | -185,678 (50%) | 183,768 |
| Excluded because patient qualified in >1 exposure category | -590 (<1%) | 196,957 | -476 (<1%) | 140,158 | -318 (<1%) | 183,450 |
| Excluded based on Incl 1.1 - Age | -23 (<1%) | 196,934 | -78 (<1%) | 140,080 | -0 (<1%) | 183,450 |
| Excluded based on Incl 1.2 - Gender | -86 (<1%) | 196,848 | -17 (<1%) | 140,063 | -0 (<1%) | 183,450 |
| Excluded based on Incl 2 - Chronic heart failure | -144,840 (74%) | 52,008 | -126,645 (90%) | 13,418 | -138,092 (75%) | 45,358 |
| Excluded based on Incl 3 - Chronic HF with preserved EF defined as LVEF > 40 % and no prior measurement of LVEF ≤40% under stable conditions. | -16,845 (32%) | 35,163 | -5,492 (41%) | 7,926 | -15,584 (34%) | 29,774 |
| Excluded based on Incl 6 - Oral diuretics | -0 (<1%) | 35,163 | -3,162 (40%) | 4,764 | -0 (<1%) | 29,774 |
| Excluded based on Incl 7 - Body Mass Index (BMI) < 45 kg/m2 at Visit 1 | -1,986 (6%) | 33,177 | -100 (2%) | 4,664 | -1,053 (4%) | 28,721 |
| Excluded based on Incl 9 - Type 2 Diabetes mellitus | -3,627 (11%) | 29,550 | -256 (5%) | 4,408 | -199 (<1%) | 28,522 |
| Excluded based on Excl 1 - Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischaemia or newly developed ischaemic ECG changes), coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 90 days | -2,208 (7%) | 27,342 | -212 (5%) | 4,196 | -1,919 (7%) | 26,603 |
| Excluded based on Excl 2 - Heart transplantation | -136 (<1%) | 27,206 | -26 (<1%) | 4,170 | -113 (<1%) | 26,490 |
| Excluded based on Excl 3 - ICD | -6 (<1%) | 27,200 | -2 (<1%) | 4,168 | -17 (<1%) | 26,473 |
| Excluded based on Excl 4 - CRT | -35 (<1%) | 27,165 | -4 (<1%) | 4,164 | -67 (<1%) | 26,406 |
| Excluded based on Excl 5 - Cardiomyopathy | -147 (<1%) | 27,018 | -22 (<1%) | 4,142 | -51 (<1%) | 26,355 |
| Excluded based on Excl 6 - Valvular heart disease | -167 (<1%) | 26,851 | -147 (4%) | 3,995 | -4,665 (18%) | 21,690 |
| Excluded based on Excl 7 - Acute decompensated HF | -2,065 (8%) | 24,786 | -127 (3%) | 3,868 | -288 (1%) | 21,402 |
| Excluded based on Excl 8 - Atrial fibrillation / flutter | -330 (1%) | 24,456 | -93 (2%) | 3,775 | -654 (3%) | 20,748 |
| Excluded based on Excl 9 - Systolic blood pressure (SBP) ≥ 180 mmHg | -79 (<1%) | 24,377 | -8 (<1%) | 3,767 | -73 (<1%) | 20,675 |
| Excluded based on Excl 10 - Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 2 | -404 (2%) | 23,973 | -33 (<1%) | 3,734 | -258 (1%) | 20,417 |
| Excluded based on Excl 11 - Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension | -676 (3%) | 23,297 | -64 (2%) | 3,670 | -301 (1%) | 20,116 |

| | | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|-----------|-------|------------|--------|
| Excluded based on Excl 12 - Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 8 | -295 (1%) | 23,002 | -0 (<1%) | 3,670 | -215 (1%) | 19,901 |
| Excluded based on Excl 13 - Impaired renal function | -871 (4%) | 22,131 | -73 (2%) | 3,597 | -651 (3%) | 19,250 |
| Excluded based on Excl 14 - Hb < 9mg/dl (ANY) | -535 (2%) | 21,596 | -51 (1%) | 3,546 | -405 (2%) | 18,845 |
| Excluded based on Excl 14 - Hb < 9mg/dl (PRIMARY ONLY) | -332 (2%) | 21,264 | -132 (4%) | 3,414 | -377 (2%) | 18,468 |
| Excluded based on Excl 14 - Hb < 9mg/dl (PROCEDURE; 91 days before CED) | -2 (<1%) | 21,262 | -1 (<1%) | 3,413 | -3 (<1%) | 18,465 |
| Excluded based on Excl 15 - History of ketoacidosis | -51 (<1%) | 21,211 | -10 (<1%) | 3,403 | -29 (<1%) | 18,436 |
| Excluded based on Excl 16 - Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1, or scheduled major elective surgery (e.g. hip replacement) within 90 days after visit 2 | -16 (<1%) | 21,195 | -1 (<1%) | 3,402 | -21 (<1%) | 18,415 |
| Excluded based on Excl 17 - Gastrointestinal (GI) surgery or GI disorder that could interfere with absorption of trial medication in the investigator's opinion | -106 (<1%) | 21,089 | -14 (<1%) | 3,388 | -53 (<1%) | 18,362 |
| Excluded based on Excl 18 - Cancer | -823 (4%) | 20,266 | -116 (3%) | 3,272 | -729 (4%) | 17,633 |
| Excluded based on Excl 19 - Combined comorbidity score (CCI), 365 days | -106 (<1%) | 20,160 | -1 (<1%) | 3,271 | -24 (<1%) | 17,609 |
| Excluded based on Excl 21 - Current use or prior use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12 weeks prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes of study enrolment is not permitted | -374 (2%) | 19,786 | -70 (2%) | 3,201 | -325 (2%) | 17,284 |
| Excluded based on Excl 24 - Chronic alcohol or drug abuse | -303 (2%) | 19,483 | -22 (<1%) | 3,179 | -120 (<1%) | 17,164 |
| Excluded based on Excl 25 - Pregnancy | -2 (<1%) | 19,481 | -0 (<1%) | 3,179 | -0 (<1%) | 17,164 |
| Excluded based on Excl 26 - Non-compliance/Non-adherence | -86 (<1%) | 19,395 | -8 (<1%) | 3,171 | -116 (<1%) | 17,048 |
| Patients in Exposure Group | | 12,409 | | 1,582 | | 3,333 |
| Patients in Referent Group | | 6,986 | | 1,589 | | 13,715 |
| Total Patients | | 19,395 | | 3,171 | | 17,048 |

*Prior to inferential analyses, cohorts will undergo an additional comprehensive quality-control review; therefore, cohort counts may be subject to changes.

Appendix 4. 1st Feasibility Assessment

Table of Contents

- A. Patient characteristics by treatment group
- B. Summary Parameters of Study Population
- C. Median Follow up Time in Overall Study Population
- D. Reasons for Censoring in Overall Study Population
- E. Initial Power Assessment
- F. Action Report Links
- G. Review by Principal Investigator and FDA

In order to complete the initial power analysis, a dummy outcome of a 90-day gap in database enrollment was used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. We completed a 1:1 PS-matched comparative analysis using this outcome. The PS included only 3 covariates: age, sex, and combined comorbidity index. Power calculations are based on the formulas from Chow et al. (2008).

Optum: Study period between (Aug 01, 2014 and Aug 31, 2024)

Marketscan: Study period between (Aug 01, 2014 and Sep 30, 2023)

Medicare: Study period between (Aug 01, 2014 and Sep 30, 2020)

A. Patient characteristics by treatment group (we start 1 days after CED, so we drop few patients and hence table 1 number of patients are little different than the attrition table)

| UNMATCHED | Optum | | | Marketscan | | | Medicare | | |
|--------------------------------|----------------------|----------------------|------------------------|----------------------|----------------------|-----------------------|----------------------|----------------------|-------------------------|
| Variable | Sitagliptin | Empagliflozin | Difference | Sitagliptin | Empagliflozin | Difference | Sitagliptin | Empagliflozin | Difference |
| Number of patients | 6,986 | 12,409 | - (-, -) | 1,585 | 1,580 | - (-, -) | 13,606 | 3,326 | - (-, -) |
| Age | | | | | | | | | |
| ...mean (sd) | 73.55 (8.27) | 71.27 (9.31) | 2.28 (2.02, 2.53) | 68.05 (13.09) | 65.20 (11.41) | 2.85 (2.00, 3.71) | 77.85 (7.94) | 74.09 (6.31) | 3.77 (3.51, 4.02) |
| ...median [IQR] | 75.00 [69.00, 80.00] | 72.00 [66.00, 78.00] | - (-, -) | 68.00 [59.00, 78.00] | 63.00 [57.00, 74.00] | - (-, -) | 77.00 [71.00, 84.00] | 73.00 [69.00, 78.00] | - (-, -) |
| ...Missing; n (%) | | | | 1 (0.1%) | 0 (0.0%) | 0.1% (-0.1%, 0.2%) | | | |
| Gender without unknown | | | | | | | | | |
| ...Male; n (%) | 2,775 (39.7%) | 6,296 (50.7%) | -11.0% (-12.5%, -9.6%) | 772 (48.7%) | 925 (58.5%) | -9.8% (-13.4%, -6.3%) | 4,269 (31.4%) | 1,514 (45.5%) | -14.1% (-16.0%, -12.3%) |
| CCI (365 days)- ICD9 and ICD10 | | | | | | | | | |
| ...mean (sd) | 4.30 (1.97) | 4.02 (1.83) | 0.28 (0.22, 0.34) | 3.19 (1.60) | 3.17 (1.47) | 0.02 (-0.09, 0.13) | 2.91 (2.06) | 2.74 (1.89) | 0.16 (0.09, 0.24) |
| ...median [IQR] | 4.00 [3.00, 6.00] | 4.00 [3.00, 5.00] | - (-, -) | 3.00 [2.00, 4.00] | 3.00 [2.00, 4.00] | - (-, -) | 3.00 [1.00, 4.00] | 3.00 [1.00, 4.00] | - (-, -) |

B. Summary Parameters of Overall Study Population (Step 1)

| UNMATCHED | Optum | Marketscan | Medicare |
|-------------------------------------------------|--------|------------|----------|
| Variable | Value | Value | Value |
| Number of patients in full cohort | 19,395 | 3,171 | 17,048 |
| Number of patients dropped as incomplete cases | 0 | 0 | 0 |
| Number of patients that did not begin follow-up | 0 | 6 | 116 |
| Number of patients in analytic cohort | 19,395 | 3,165 | 16,932 |
| Number of events | 610 | 78 | 618 |

| | | | |
|--------------------------------------------|----------|----------|----------|
| Number of person-years | 9,976.83 | 1,460.70 | 8,146.86 |
| Number of patients in group: Sitagliptin | 6,986 | 1,585 | 13,606 |
| Number of patients in group: Empagliflozin | 12,409 | 1,580 | 3,326 |
| Risk per 1,000 patients | 31.45 | 24.64 | 36.5 |
| Rate per 1,000 person-years | 61.14 | 53.4 | 75.86 |

C. Median Follow up Time in Overall Study Population (Step 1)

| UNMATCHED | Optum | Marketscan | Medicare |
|----------------------------|------------------------------------|------------------------------------|------------------------------------|
| Patient Group | Median Follow-Up Time (Days) [IQR] | Median Follow-Up Time (Days) [IQR] | Median Follow-Up Time (Days) [IQR] |
| Overall Patient Population | 146 [85, 333] | 110 [55, 286] | 127 [58, 296] |

D. Reasons for Censoring in Overall Study Population (Step 1)

| UNMATCHED | Optum | Marketscan | Medicare |
|-----------------------------------------------|----------------|---------------|---------------|
| Overall | Value | Value | Value |
| Outcome | 610 (3.1%) | 78 (2.5%) | 618 (3.6%) |
| Death | 0 (0.0%) | 0 (0.0%) | 99 (0.6%) |
| Start of an additional exposure | 373 (1.9%) | 67 (2.1%) | 232 (1.4%) |
| End of index exposure | 10,213 (52.7%) | 1,734 (54.8%) | 8,120 (48.0%) |
| Maximum follow-up time (365 days) | 4,465 (23.0%) | 609 (19.2%) | 3,322 (19.6%) |
| Specified date reached | 0 (0.0%) | 207 (6.5%) | 994 (5.9%) |
| End of patient enrollment | 1,623 (8.4%) | 379 (12.0%) | 711 (4.2%) |
| Censor: Other DPP-4i/SGLT2/Nursing home began | 2,111 (10.9%) | 91 (2.9%) | 2,836 (16.7%) |

| Weighted number | Optum | Marketscan | Medicare |
|-----------------|--------|------------|----------|
| Exposure | 11,841 | 1,548 | 3,286 |
| Reference | 6,883 | 1,544 | 11,211 |

E. Initial Power Assessment

| Number of patients weighted | |
|-----------------------------|--------|
| Reference | 16,675 |
| Exposed | 19,638 |
| Risk per 1,000 patients | 33.07 |
| Desired HR from RCT | 0.79 |
| Alpha (2-sided) | 0.05 |
| | |
| | |

| | |
|---------------------------|--------|
| Number of events expected | 1200.9 |
| Power | 0.98 |

F. Aetion Report Links

Aetion report link:

Optum

<https://bwh-dope.aetion.com/substantiate/project/3061/rwrs/156142>

<https://bwh-dope.aetion.com/substantiate/project/3061/rwrs/156143>

Marketscan

<https://bwh-dope.aetion.com/substantiate/project/3074/rwrs/156145>

<https://bwh-dope.aetion.com/substantiate/project/3074/rwrs/156146>

Medicare

<https://bwh-dope.aetion.com/substantiate/project/3085/rwrs/156147>

<https://bwh-dope.aetion.com/substantiate/project/3085/rwrs/156148>

G. Review by principal investigator and FDA

Stop analyses until feasibility and power are reviewed by primary investigators and FDA.

| | | |
|----------------------------------------------------------------|----------------|-----------------------------|
| First review by FDA | Date reviewed: | May 22, 2026; Marie Bradley |
| Final review and approval by FDA after comments were addressed | Date reviewed: | June 2, 2026; Marie Bradley |

Appendix 5. 2nd Feasibility Assessment

Table of Contents

- A. Median Follow up Time by Treatment Group
- B. Reasons for Censoring by Treatment Group
- C. Final Power Assessment
- D. Action report Links
- E. Review by Principal Investigator and FDA

In order to complete the initial power analysis, a dummy outcome of a 90-day gap in database enrollment was used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. We completed a 1:1 PS-matched comparative analysis using this outcome. The PS included only 3 covariates: age, sex, and combined comorbidity index. Power calculations are based on the formulas from Chow et al. (2008).

Optum: Study period between (Aug 01, 2014 and Aug 31, 2024)

Marketscan: Study period between (Aug 01, 2014 and Sep 30, 2023)

Medicare: Study period between (Aug 01, 2014 and Sep 30, 2020)

A. Median Follow Up Time by Treatment Group (Step 1)

| UNMATCHED | Optum | Marketscan | Medicare |
|----------------------------|------------------------------------|------------------------------------|------------------------------------|
| Patient Group | Median Follow-Up Time (Days) [IQR] | Median Follow-Up Time (Days) [IQR] | Median Follow-Up Time (Days) [IQR] |
| Overall Patient Population | 146 [85, 333] | 110 [55, 286] | 127 [58, 296] |

B. Summary Parameters of Overall Study Population (Step 1)

| UNMATCHED | Optum | Marketscan | Medicare |
|-------------------------------------------------|--------|------------|----------|
| Variable | Value | Value | Value |
| Number of patients in full cohort | 19,395 | 3,171 | 17,048 |
| Number of patients dropped as incomplete cases | 0 | 0 | 0 |
| Number of patients that did not begin follow-up | 0 | 6 | 116 |

| | | | |
|-----------------------------------------------------|----------|----------|----------|
| Number of patients in analytic cohort | 19,395 | 3,165 | 16,932 |
| Number of events | 610 | 78 | 618 |
| Number of person-years | 9,976.83 | 1,460.70 | 8,146.86 |
| Number of patients in group: Reference - Warfarin | 6,986 | 1,585 | 13,606 |
| Number of patients in group: Exposure - Rivaroxaban | 12,409 | 1,580 | 3,326 |
| Risk per 1,000 patients | 31.45 | 24.64 | 36.5 |
| Rate per 1,000 person-years | 61.14 | 53.4 | 75.86 |

C. Reasons for Censoring in Overall Study Population (Step 1)

| UNMATCHED | Optum | Marketscan | Medicare |
|-----------------------------------------------|----------------|---------------|---------------|
| Overall | Value | Value | Value |
| Outcome | 610 (3.1%) | 78 (2.5%) | 618 (3.6%) |
| Death | 0 (0.0%) | 0 (0.0%) | 99 (0.6%) |
| Start of an additional exposure | 373 (1.9%) | 67 (2.1%) | 232 (1.4%) |
| End of index exposure | 10,213 (52.7%) | 1,734 (54.8%) | 8,120 (48.0%) |
| Maximum follow-up time (365 days) | 4,465 (23.0%) | 609 (19.2%) | 3,322 (19.6%) |
| Specified date reached | 0 (0.0%) | 207 (6.5%) | 994 (5.9%) |
| End of patient enrollment | 1,623 (8.4%) | 379 (12.0%) | 711 (4.2%) |
| Censor: Other DPP-4i/SGLT2/Nursing home began | 2,111 (10.9%) | 91 (2.9%) | 2,836 (16.7%) |

| Weighted number | Optum | Marketscan | Medicare |
|-----------------|-------|------------|----------|
| Exposure | 4,156 | 649 | 2,765 |
| Reference | 3,217 | 638 | 6,077 |

E. Initial Power Assessment

| | |
|-----------------------------|-------|
| | |
| Number of patients weighted | |
| Reference | 7,570 |
| Exposed | 9,932 |
| Risk per 1,000 patients | 33.07 |
| Desired HR from RCT | 0.79 |
| Alpha (2-sided) | 0.05 |
| | |
| | |
| Number of events expected | 578.8 |
| Power | 0.81 |

F. Action Report Links

Action report link:

Optum

<https://bwh-dope.aetion.com/substantiate/project/3061/rwrs/156234>

Marketscan

<https://bwh-dope.aetion.com/substantiate/project/3074/rwrs/156235>

Medicare

<https://bwh-dope.aetion.com/substantiate/project/3085/rwrs/156236>



G. Review by principal investigator and FDA

Stop analyses until feasibility and power are reviewed by primary investigators and FDA.



| | | |
|----------------------------------------------------------------|----------------|-----------------------------|
| First review by FDA | Date reviewed: | May 22, 2026; Marie Bradley |
| Final review and approval by FDA after comments were addressed | Date reviewed: | June 2, 2026; Marie Bradley |

Appendix 6. Balance Assessment - PS Distribution and C-Statistic



Optum c-stat: Unmatched 0.936, matched 0.51



Marketscan c-stat: Unmatched 0.935, matched 0.518



Medicare c-stat: Unmatched 0.842, matched 0.498



| Variable_name | Optum: Unmatched | | | Optum: Weighted | | | Marketscan: Unmatched | | | Marketscan: Weighted | | | Medicare: Unmatched | | | Medicare: Weighted | | |
|---------------------------------------------------------------------------------------|-------------------------|--------------------------|----------|-------------------------|--------------------------|----------|-------------------------|--------------------------|----------|-------------------------|--------------------------|----------|-------------------------|--------------------------|----------|-------------------------|--------------------------|----------|
| | Reference - Sitagliptin | Exposure - Empagliflozin | Std diff | Reference - Sitagliptin | Exposure - Empagliflozin | Std diff | Reference - Sitagliptin | Exposure - Empagliflozin | Std diff | Reference - Sitagliptin | Exposure - Empagliflozin | Std diff | Reference - Sitagliptin | Exposure - Empagliflozin | Std diff | Reference - Sitagliptin | Exposure - Empagliflozin | Std diff |
| Variables | | | | | | | | | | | | | | | | | | |
| Number of patients | 6,886 | 12,325 | | 6,886 | 12,325 | | 1,571 | 1,576 | | 1,571 | 1,576 | | 13,565 | 3,319 | | 13,565 | 3,319 | |
| Age | 73.53 (8.26) | 71.26 (9.31) | 0.26 | 72.41 (8.82) | 72.41 (9.04) | 0.00 | 68.13 (13.10) | 65.22 (11.41) | 0.24 | 66.08 (12.51) | 66.08 (11.75) | 0.00 | 77.86 (7.94) | 74.08 (6.31) | 0.53 | 75.01 (6.94) | 75.01 (6.66) | 0.00 |
| Gender (male); n (%) | 2,743 (39.8%) | 6,264 (50.8%) | 0.22 | 795.5 (44.2%) | 795.5 (44.2%) | 0.00 | 764 (48.6%) | 921 (58.4%) | 0.20 | 168.1 (53.1%) | 168.1 (53.1%) | 0.00 | 4,254 (31.4%) | 1,512 (45.6%) | 0.30 | 775.6 (40.6%) | 775.6 (40.6%) | 0.00 |
| Race | | | | | | | | | | | | | | | | | | |
| ...White; n (%) | 3,954 (57.4%) | 7,453 (60.5%) | 0.06 | 1,036.6 (57.6%) | 1,036.6 (57.6%) | 0.00 | | | | | | | | | | 1,465.2 (76.8%) | 1,465.2 (76.8%) | 0.00 |
| ...Asian; n (%) | 302 (4.4%) | 401 (3.3%) | 0.06 | 67.9 (3.8%) | 67.9 (3.8%) | 0.00 | | | | | | | 590 (4.3%) | 120 (3.6%) | 0.04 | 74.8 (3.9%) | 74.8 (3.9%) | 0.00 |
| ...Black; n (%) | 1,522 (22.1%) | 2,326 (18.9%) | 0.08 | 388.3 (21.6%) | 388.3 (21.6%) | 0.00 | | | | | | | 1,950 (14.4%) | 345 (10.4%) | 0.12 | 218.5 (11.5%) | 218.5 (11.5%) | 0.00 |
| ...Hispanic/Unknown/Missing; n (%) | 1,108 (16.1%) | 2,145 (17.4%) | 0.04 | 306.0 (17.0%) | 306.0 (17.0%) | 0.00 | | | | | | | 1,016 (7.5%) | 261 (7.9%) | 0.01 | 150.3 (7.9%) | 150.3 (7.9%) | 0.00 |
| Region | | | | | | | | | | | | | | | | | | |
| ...Northeast; n (%) | 857 (12.4%) | 1,234 (10.0%) | 0.08 | 201.1 (11.2%) | 201.1 (11.2%) | 0.00 | 343 (21.8%) | 214 (13.6%) | 0.22 | 55.2 (17.4%) | 55.2 (17.4%) | 0.00 | 2,598 (19.2%) | 619 (18.7%) | 0.01 | 348.6 (18.3%) | 348.6 (18.3%) | 0.00 |
| ...Midwest/North central; n (%) | 969 (14.1%) | 2,579 (20.9%) | 0.18 | 297.2 (16.5%) | 297.2 (16.5%) | 0.00 | 496 (31.6%) | 530 (33.6%) | 0.04 | 103.9 (32.8%) | 103.9 (32.8%) | 0.00 | 2,820 (20.8%) | 653 (19.7%) | 0.03 | 378.0 (19.8%) | 378.0 (19.8%) | 0.00 |
| ...South; n (%) | 3,757 (54.6%) | 6,226 (50.5%) | 0.08 | 983.3 (54.7%) | 983.3 (54.7%) | 0.00 | 606 (38.6%) | 660 (41.9%) | 0.07 | 129.5 (40.9%) | 129.5 (40.9%) | 0.00 | 5,728 (42.2%) | 1,346 (40.6%) | 0.03 | 793.3 (41.6%) | 793.3 (41.6%) | 0.00 |
| ...West; n (%) | 1,303 (18.9%) | 2,286 (18.5%) | 0.01 | 317.2 (17.6%) | 317.2 (17.6%) | 0.00 | 126 (8.0%) | 172 (10.9%) | 0.10 | 28.0 (8.8%) | 28.0 (8.8%) | 0.00 | 2,419 (17.8%) | 701 (21.1%) | 0.08 | 388.9 (20.4%) | 388.9 (20.4%) | 0.00 |
| Year of Cohort Entry Date | | | | | | | | | | | | | | | | | | |
| ...2014-2018; n (%) | 2,801 (40.7%) | 700 (5.7%) | 0.91 | 299.5 (16.7%) | 299.5 (16.7%) | 0.00 | 963 (61.3%) | 251 (15.9%) | 1.05 | 110.4 (34.9%) | 110.4 (34.9%) | 0.00 | 10,240 (75.5%) | 1,080 (32.5%) | 0.96 | 833.4 (43.7%) | 833.4 (43.7%) | 0.00 |
| ...2019; n (%) | 786 (11.4%) | 689 (5.6%) | 0.21 | 180.5 (10.0%) | 180.5 (10.0%) | 0.00 | 188 (12.0%) | 155 (9.8%) | 0.07 | 44.1 (13.9%) | 44.1 (13.9%) | 0.00 | 2,062 (15.2%) | 1,240 (37.4%) | 0.52 | 627.8 (32.9%) | 627.8 (32.9%) | 0.00 |
| ...2020; n (%) | 776 (11.3%) | 975 (7.9%) | 0.11 | 215.6 (12.0%) | 215.6 (12.0%) | 0.00 | 129 (8.2%) | 181 (11.5%) | 0.11 | 40.3 (12.7%) | 40.3 (12.7%) | 0.00 | 1,263 (9.3%) | 999 (30.1%) | 0.54 | 447.5 (23.5%) | 447.5 (23.5%) | 0.00 |
| ...2021; n (%) | 798 (11.6%) | 1,410 (11.4%) | 0.01 | 261.4 (14.5%) | 261.4 (14.5%) | 0.00 | 121 (7.7%) | 242 (15.4%) | 0.24 | 43.0 (13.6%) | 43.0 (13.6%) | 0.00 | | | | | | |
| ...2022; n (%) | 635 (9.2%) | 2,371 (19.2%) | 0.29 | 281.8 (15.7%) | 281.8 (15.7%) | 0.00 | 97 (6.2%) | 378 (24.0%) | 0.51 | 40.9 (12.9%) | 40.9 (12.9%) | 0.00 | | | | | | |
| ...2023-2024; n (%) | 1,090 (15.8%) | 6,180 (50.1%) | 0.78 | 560.0 (31.1%) | 560.0 (31.1%) | 0.00 | 73 (4.6%) | 369 (23.4%) | 0.56 | 37.8 (12.0%) | 37.8 (12.0%) | 0.00 | | | | | | |
| Smoking; n (%) | 1,189 (17.3%) | 2,629 (21.3%) | 0.10 | 355.4 (19.8%) | 355.4 (19.8%) | 0.00 | 123 (7.8%) | 138 (8.8%) | 0.03 | 27.6 (8.7%) | 27.6 (8.7%) | 0.00 | 1,645 (12.1%) | 457 (13.8%) | 0.05 | 260.5 (13.6%) | 260.5 (13.6%) | 0.00 |
| Covariate: Overweight, BMI 25.0 to 29.9; n (%) | 579 (8.4%) | 913 (7.4%) | 0.04 | 158.1 (8.8%) | 158.1 (8.8%) | 0.00 | 37 (2.4%) | 40 (2.5%) | 0.01 | 7.3 (2.3%) | 7.3 (2.3%) | 0.00 | 276 (2.0%) | 87 (2.6%) | 0.04 | 53.9 (2.8%) | 53.9 (2.8%) | 0.00 |
| Covariate: Class 1 (low-risk) obesity, if BMI is 30.0 to 34.9; n (%) | 615 (8.9%) | 1,357 (11.0%) | 0.07 | 175.5 (9.8%) | 175.5 (9.8%) | 0.00 | 53 (3.4%) | 118 (7.5%) | 0.18 | 18.7 (5.9%) | 18.7 (5.9%) | 0.00 | 418 (3.1%) | 165 (5.0%) | 0.10 | 91.2 (4.8%) | 91.2 (4.8%) | 0.00 |
| Covariate: Class 2 (moderate-risk) obesity, if BMI is 35.0 to 39.9; n (%) | 471 (6.8%) | 1,322 (10.7%) | 0.14 | 155.1 (8.6%) | 155.1 (8.6%) | 0.00 | 61 (3.9%) | 77 (4.9%) | 0.05 | 14.9 (4.7%) | 14.9 (4.7%) | 0.00 | 352 (2.6%) | 184 (5.5%) | 0.15 | 85.9 (4.5%) | 85.9 (4.5%) | 0.00 |
| Covariate: Class 3 (high-risk) obesity if BMI is equal to or greater than 40.0; n (%) | 835 (12.1%) | 2,451 (19.9%) | 0.21 | 281.2 (15.6%) | 281.2 (15.6%) | 0.00 | 131 (8.3%) | 227 (14.4%) | 0.19 | 40.3 (12.7%) | 40.3 (12.7%) | 0.00 | 498 (3.7%) | 220 (6.6%) | 0.13 | 110.6 (5.8%) | 110.6 (5.8%) | 0.00 |
| Covariate: Unspecified obesity; n (%) | 943 (13.7%) | 2,387 (19.4%) | 0.15 | 284.8 (15.8%) | 284.8 (15.8%) | 0.00 | 207 (13.2%) | 379 (24.0%) | 0.28 | 55.7 (17.6%) | 55.7 (17.6%) | 0.00 | 839 (6.2%) | 352 (10.6%) | 0.16 | 175.7 (9.2%) | 175.7 (9.2%) | 0.00 |
| Diabetes complications; n (%) | 3,365 (48.9%) | 6,378 (51.7%) | 0.06 | 929.3 (51.7%) | 929.3 (51.7%) | 0.00 | 528 (33.6%) | 635 (40.3%) | 0.14 | 117.6 (37.1%) | 117.6 (37.1%) | 0.00 | 5,948 (43.8%) | 1,744 (52.5%) | 0.18 | 953.3 (49.9%) | 953.3 (49.9%) | 0.00 |
| Skin infections; n (%) | 541 (7.9%) | 992 (8.0%) | 0.01 | 139.1 (7.7%) | 139.1 (7.7%) | 0.00 | 127 (8.1%) | 100 (6.3%) | 0.07 | 23.9 (7.5%) | 23.9 (7.5%) | 0.00 | 1,066 (7.9%) | 236 (7.1%) | 0.03 | 140.3 (7.4%) | 140.3 (7.4%) | 0.00 |
| Erectile dysfunction; n (%) | 102 (1.5%) | 324 (2.6%) | 0.08 | 38.3 (2.1%) | 38.3 (2.1%) | 0.00 | 27 (1.7%) | 42 (2.7%) | 0.07 | 5.0 (1.6%) | 5.0 (1.6%) | 0.00 | 61 (0.4%) | 22 (0.7%) | 0.03 | 12.0 (0.6%) | 12.0 (0.6%) | 0.00 |
| Urinary tract infections; n (%) | 1,039 (15.1%) | 1,127 (9.1%) | 0.18 | 217.2 (12.1%) | 217.2 (12.1%) | 0.00 | 169 (10.8%) | 94 (6.0%) | 0.17 | 28.4 (9.0%) | 28.4 (9.0%) | 0.00 | 2,744 (20.2%) | 380 (11.4%) | 0.24 | 260.1 (13.6%) | 260.1 (13.6%) | 0.00 |
| Genital infections; n (%) | 126 (1.8%) | 201 (1.6%) | 0.02 | 33.0 (1.8%) | 33.0 (1.8%) | 0.00 | 27 (1.7%) | 31 (2.0%) | 0.02 | 6.7 (2.1%) | 6.7 (2.1%) | 0.00 | 248 (1.8%) | 71 (2.1%) | 0.02 | 40.7 (2.1%) | 40.7 (2.1%) | 0.00 |
| Hypoglycemia; n (%) | 1,256 (18.2%) | 2,624 (21.3%) | 0.08 | 376.2 (20.9%) | 376.2 (20.9%) | 0.00 | 119 (7.6%) | 209 (13.3%) | 0.19 | 34.6 (10.9%) | 34.6 (10.9%) | 0.00 | 811 (6.0%) | 264 (8.0%) | 0.08 | 138.2 (7.2%) | 138.2 (7.2%) | 0.00 |
| Hyperglycemia/DKA/HONK; n (%) | 2,736 (39.7%) | 5,379 (43.6%) | 0.08 | 800.5 (44.5%) | 800.5 (44.5%) | 0.00 | 550 (35.0%) | 701 (44.5%) | 0.19 | 136.0 (43.0%) | 136.0 (43.0%) | 0.00 | 3,920 (28.9%) | 1,406 (42.4%) | 0.28 | 720.4 (37.7%) | 720.4 (37.7%) | 0.00 |
| Unstable angina; n (%) | 213 (3.1%) | 436 (3.5%) | 0.03 | 60.1 (3.3%) | 60.1 (3.3%) | 0.00 | 45 (2.9%) | 52 (3.3%) | 0.03 | 10.5 (3.3%) | 10.5 (3.3%) | 0.00 | 242 (1.8%) | 78 (2.4%) | 0.04 | 39.4 (2.1%) | 39.4 (2.1%) | 0.00 |
| Stable angina; n (%) | 457 (6.6%) | 1,199 (9.7%) | 0.11 | 145.0 (8.1%) | 145.0 (8.1%) | 0.00 | 87 (5.5%) | 131 (8.3%) | 0.11 | 21.8 (6.9%) | 21.8 (6.9%) | 0.00 | 452 (3.3%) | 215 (6.5%) | 0.15 | 99.2 (5.2%) | 99.2 (5.2%) | 0.00 |

| | | | | | | | | | | | | | | | | | | |
|----------------------------------------------------------|------------------|----------------|------|-----------------|--------------------|------|---------------|---------------|------|------------------|---------------|------|----------------|---------------|------|--------------------|-----------------|------|
| Hypertension ; n (%) | 6,453 (93.7%) | 11,502 (93.3%) | 0.02 | 1,685.9 (93.7%) | 1,685.9 (93.7%) | 0.00 | 1,400 (89.1%) | 1,426 (90.5%) | 0.05 | 285.8 (90.3%) | 285.8 (90.3%) | 0.00 | 10,733 (79.1%) | 2,580 (77.7%) | 0.03 | 1,497.8 (78.5%) | 1,497.8 (78.5%) | 0.00 |
| | 100 (1.5%) | 161 (1.3%) | 0.01 | 21.8 (1.2%) | 21.8 (1.2%) | 0.00 | 18 (1.1%) | 11 (0.7%) | 0.05 | 3.2 (1.0%) | 3.2 (1.0%) | 0.00 | 114 (0.8%) | 27 (0.8%) | 0.00 | 15.4 (0.8%) | 15.4 (0.8%) | 0.00 |
| Hypotension ; n (%) | 5,333 (77.4%) | 9,881 (80.2%) | 0.07 | 1,433.1 (79.7%) | 1,433.1 (79.7%) | 0.00 | | | | 241.4 (76.3%) | 241.4 (76.3%) | 0.00 | | | | 1,088.0 (57.0%) | 1,088.0 (57.0%) | 0.00 |
| Hyperlipidemia ; n (%) | 1,578 (22.9%) | 3,352 (27.2%) | 0.10 | 423.1 (23.5%) | 423.1 (23.5%) | 0.00 | 258 (16.4%) | 295 (18.7%) | 0.06 | 50.7 (16.0%) | 50.7 (16.0%) | 0.00 | 2,641 (19.5%) | 650 (19.6%) | 0.00 | 377.5 (19.8%) | 377.5 (19.8%) | 0.00 |
| Atrial fibrillation ; n (%) | 534 (7.8%) | 1,102 (8.9%) | 0.04 | 138.8 (7.7%) | 138.8 (7.7%) | 0.00 | 70 (4.5%) | 79 (5.0%) | 0.03 | 14.7 (4.7%) | 14.7 (4.7%) | 0.00 | 883 (6.5%) | 283 (8.5%) | 0.08 | 148.9 (7.8%) | 148.9 (7.8%) | 0.00 |
| Previous MI (NEW); n (%) | 2,639 (38.3%) | 5,468 (44.4%) | 0.12 | 731.0 (40.6%) | 731.0 (40.6%) | 0.00 | 593 (37.7%) | 669 (42.4%) | 0.10 | 128.8 (40.7%) | 128.8 (40.7%) | 0.00 | 4,409 (32.5%) | 1,294 (39.0%) | 0.14 | 698.2 (36.6%) | 698.2 (36.6%) | 0.00 |
| Coronary atherosclerosis; n (%) | | | | | | | | | | | | | | | | | | |
| Previous cardiac procedure (CABG, PTCA, Stent); n (%) | 73 (1.1%) | 224 (1.8%) | 0.06 | 25.9 (1.4%) | 25.9 (1.4%) | 0.00 | 29 (1.8%) | 42 (2.7%) | 0.06 | 5.8 (1.8%) | 5.8 (1.8%) | 0.00 | 97 (0.7%) | 51 (1.5%) | 0.08 | 20.8 (1.1%) | 20.8 (1.1%) | 0.00 |
| Cardiac conduction disorder; n (%) | 495 (7.2%) | 1,087 (8.8%) | 0.06 | 141.4 (7.9%) | 141.4 (7.9%) | 0.00 | 89 (5.7%) | 112 (7.1%) | 0.06 | 18.0 (5.7%) | 18.0 (5.7%) | 0.00 | 894 (6.6%) | 227 (6.8%) | 0.01 | 128.5 (6.7%) | 128.5 (6.7%) | 0.00 |
| Cerebrovascular procedure ; n (%) | 5 (0.1%) | 5 (0.0%) | 0.01 | 2.2 (0.1%) | 2.9 (0.2%) | 0.01 | 1 (0.1%) | 0 (0.0%) | 0.04 | 0.5 (0.1%) | 0.0 (0.0%) | 0.05 | 6 (0.0%) | 2 (0.1%) | 0.01 | 0.6 (0.0%) | 1.1 (0.1%) | 0.01 |
| Ischemic stroke; n (%) | 766 (11.1%) | 1,213 (9.8%) | 0.04 | 184.9 (10.3%) | 184.9 (10.3%) | 0.00 | 169 (10.8%) | 116 (7.4%) | 0.12 | 28.0 (8.8%) | 28.0 (8.8%) | 0.00 | 1,154 (8.5%) | 240 (7.2%) | 0.05 | 147.8 (7.7%) | 147.8 (7.7%) | 0.00 |
| PVD diagnosis or surgery ; n (%) | 1,172 (17.0%) | 1,924 (15.6%) | 0.04 | 286.6 (15.9%) | 286.6 (15.9%) | 0.00 | 203 (12.9%) | 147 (9.3%) | 0.12 | 35.6 (11.3%) | 35.6 (11.3%) | 0.00 | 1,728 (12.7%) | 387 (11.7%) | 0.03 | 225.1 (11.8%) | 225.1 (11.8%) | 0.00 |
| Other cardiac dysrhythmia ; n (%) | 1,504 (21.8%) | 3,123 (25.3%) | 0.08 | 419.9 (23.3%) | 419.9 (23.3%) | 0.00 | 297 (18.9%) | 342 (21.7%) | 0.07 | 66.6 (21.0%) | 66.6 (21.0%) | 0.00 | 2,034 (15.0%) | 500 (15.1%) | 0.00 | 285.2 (14.9%) | 285.2 (14.9%) | 0.00 |
| Cardiomyopathy ; n (%) | 246 (3.6%) | 829 (6.7%) | 0.14 | 87.8 (4.9%) | 87.8 (4.9%) | 0.00 | 41 (2.6%) | 101 (6.4%) | 0.18 | 12.6 (4.0%) | 12.6 (4.0%) | 0.00 | 172 (1.3%) | 107 (3.2%) | 0.13 | 45.5 (2.4%) | 45.5 (2.4%) | 0.00 |
| Valve disorders ; n (%) | 1,208 (17.5%) | 2,486 (20.2%) | 0.07 | 344.0 (19.1%) | 344.0 (19.1%) | 0.00 | 222 (14.1%) | 262 (16.6%) | 0.07 | 46.6 (14.7%) | 46.6 (14.7%) | 0.00 | 271 (2.0%) | 69 (2.1%) | 0.01 | 41.3 (2.2%) | 41.3 (2.2%) | 0.00 |
| Valve replacement ; n (%) | 180 (2.6%) | 400 (3.2%) | 0.04 | 53.6 (3.0%) | 53.6 (3.0%) | 0.00 | 26 (1.7%) | 32 (2.0%) | 0.03 | 4.7 (1.5%) | 4.7 (1.5%) | 0.00 | 97 (0.7%) | 28 (0.8%) | 0.02 | 16.1 (0.9%) | 16.1 (0.9%) | 0.00 |
| TIA ; n (%) | 167 (2.4%) | 231 (1.9%) | 0.04 | 41.3 (2.3%) | 41.3 (2.3%) | 0.00 | 36 (2.3%) | 24 (1.5%) | 0.06 | 6.9 (2.2%) | 6.9 (2.2%) | 0.00 | 231 (1.7%) | 50 (1.5%) | 0.02 | 29.7 (1.6%) | 29.7 (1.6%) | 0.00 |
| Edema ; n (%) | 1,205 (17.5%) | 2,131 (17.3%) | 0.01 | 298.1 (16.6%) | 298.1 (16.6%) | 0.00 | 145 (9.2%) | 132 (8.4%) | 0.03 | 23.0 (7.3%) | 23.0 (7.3%) | 0.00 | 1,871 (13.8%) | 367 (11.1%) | 0.08 | 222.8 (11.7%) | 222.8 (11.7%) | 0.00 |
| Venous thromboembolism; n (%) | 166 (2.4%) | 283 (2.3%) | 0.01 | 39.6 (2.2%) | 39.6 (2.2%) | 0.00 | 52 (3.3%) | 19 (1.2%) | 0.14 | 5.9 (1.9%) | 5.9 (1.9%) | 0.00 | 360 (2.7%) | 67 (2.0%) | 0.04 | 38.2 (2.0%) | 38.2 (2.0%) | 0.00 |
| Pulmonary hypertension; n (%) | 406 (5.9%) | 935 (7.6%) | 0.07 | 113.8 (6.3%) | 113.8 (6.3%) | 0.00 | 51 (3.2%) | 45 (2.9%) | 0.02 | 7.8 (2.5%) | 7.8 (2.5%) | 0.00 | 278 (2.0%) | 77 (2.3%) | 0.02 | 41.8 (2.2%) | 41.8 (2.2%) | 0.00 |
| Insertion of pacemakers / removal of cardiac lead; n (%) | 5 (0.1%) | 25 (0.2%) | 0.04 | 0.5 (0.0%) | 4.4 (0.3%) | 0.06 | 67 (4.3%) | 68 (4.3%) | 0.00 | 13.5 (4.3%) | 9.4 (3.0%) | 0.07 | 14 (0.1%) | 3 (0.1%) | 0.00 | 1.6 (0.1%) | 1.9 (0.1%) | 0.01 |
| Implantable cardioverter defibrillator; n (%) | 24 (0.3%) | 11 (0.1%) | 0.06 | 3.3 (0.2%) | 1.6 (0.1%) | 0.03 | 3 (0.2%) | 1 (0.1%) | 0.04 | 0.3 (0.1%) | 0.0 (0.0%) | 0.04 | 2 (0.0%) | 3 (0.1%) | 0.03 | 0.3 (0.0%) | 1.7 (0.1%) | 0.03 |
| CKD Stage 1-2 ; n (%) | 511 (7.4%) | 806 (6.5%) | 0.04 | 129.4 (7.2%) | 129.4 (7.2%) | 0.00 | 30 (1.9%) | 52 (3.3%) | 0.09 | 8.4 (2.7%) | 8.4 (2.7%) | 0.00 | 333 (2.5%) | 78 (2.4%) | 0.01 | 44.2 (2.3%) | 44.2 (2.3%) | 0.00 |
| CKD Stage 3-4 ; n (%) | 1,689 (24.5%) | 3,137 (25.5%) | 0.02 | 421.7 (23.4%) | 421.7 (23.4%) | 0.00 | 163 (10.4%) | 192 (12.2%) | 0.06 | 28.2 (8.9%) | 28.2 (8.9%) | 0.00 | 1,791 (13.2%) | 360 (10.8%) | 0.07 | 210.5 (11.0%) | 210.5 (11.0%) | 0.00 |
| Unspecified CKD; n (%) | 647 (9.4%) | 968 (7.9%) | 0.06 | 139.0 (7.7%) | 139.0 (7.7%) | 0.00 | 63 (4.0%) | 48 (3.0%) | 0.05 | 10.3 (3.3%) | 10.3 (3.3%) | 0.00 | 1,476 (10.9%) | 265 (8.0%) | 0.10 | 160.7 (8.4%) | 160.7 (8.4%) | 0.00 |
| Acute kidney injury; n (%) | 464 (6.7%) | 689 (5.6%) | 0.05 | 107.8 (6.0%) | 107.8 (6.0%) | 0.00 | 66 (4.2%) | 43 (2.7%) | 0.08 | 10.5 (3.3%) | 10.5 (3.3%) | 0.00 | 755 (5.6%) | 88 (2.7%) | 0.15 | 59.2 (3.1%) | 59.2 (3.1%) | 0.00 |
| Urolithiasis; n (%) | 184 (2.7%) | 306 (2.5%) | 0.01 | 46.1 (2.6%) | 46.1 (2.6%) | 0.00 | 48 (3.1%) | 45 (2.9%) | 0.01 | 8.4 (2.7%) | 8.4 (2.7%) | 0.00 | 369 (2.7%) | 114 (3.4%) | 0.04 | 60.8 (3.2%) | 60.8 (3.2%) | 0.00 |
| Nephrotic syndrome ; n (%) | 6 (0.1%) | 12 (0.1%) | 0.00 | 2.0 (0.1%) | 1.6 (0.1%) | 0.01 | 0 (0.0%) | 0 (0.0%) | - | 0.0 (0.0%) | 0.0 (0.0%) | 0.00 | 8 (0.1%) | 1 (0.0%) | 0.01 | 0.4 (0.0%) | 0.2 (0.0%) | 0.01 |
| Other renal conditons; n (%) | 3,943 (57.3%) | 7,399 (60.0%) | 0.06 | 1,092.5 (60.7%) | 1,092.5 (60.7%) | 0.00 | 661 (42.1%) | 869 (55.1%) | 0.26 | 162.6 (51.3%) | 162.6 (51.3%) | 0.00 | 6,133 (45.2%) | 1,961 (59.1%) | 0.28 | 1,045.3 (54.8%) | 1,045.3 (54.8%) | 0.00 |
| Hypertensive nephropathy ; n (%) | 1,546 (22.5%) | 2,700 (21.9%) | 0.01 | 396.4 (22.0%) | 396.4 (22.0%) | 0.00 | 159 (10.1%) | 192 (12.2%) | 0.07 | 31.0 (9.8%) | 31.0 (9.8%) | 0.00 | 1,449 (10.7%) | 326 (9.8%) | 0.03 | 188.6 (9.9%) | 188.6 (9.9%) | 0.00 |
| COPD ; n (%) | 1,428 (20.7%) | 2,275 (18.5%) | 0.06 | 356.2 (19.8%) | 356.2 (19.8%) | 0.00 | 199 (12.7%) | 139 (8.8%) | 0.13 | 31.2 (9.9%) | 31.2 (9.9%) | 0.00 | 2,232 (16.5%) | 499 (15.0%) | 0.04 | 302.0 (15.8%) | 302.0 (15.8%) | 0.00 |
| Asthma; n (%) | 565 (8.2%) | 1,134 (9.2%) | 0.04 | 155.5 (8.6%) | 155.5 (8.6%) | 0.00 | 113 (7.2%) | 121 (7.7%) | 0.02 | 23.2 (7.3%) | 23.2 (7.3%) | 0.00 | 899 (6.6%) | 211 (6.4%) | 0.01 | 125.8 (6.6%) | 125.8 (6.6%) | 0.00 |
| Obstructive sleep apnea ; n (%) | 1,215 (17.6%) | 3,461 (28.1%) | 0.25 | 386.2 (21.5%) | 386.2 (21.5%) | 0.00 | 271 (17.3%) | 417 (26.5%) | 0.22 | 65.7 (20.8%) | 65.7 (20.8%) | 0.00 | 1,366 (10.1%) | 626 (18.9%) | 0.25 | 302.9 (15.9%) | 302.9 (15.9%) | 0.00 |
| Pneumonia ; n (%) | 459 (6.7%) | 604 (4.9%) | 0.08 | 100.4 (5.6%) | 100.4 (5.6%) | 0.00 | 105 (6.7%) | 59 (3.7%) | 0.13 | 16.5 (5.2%) | 16.5 (5.2%) | 0.00 | 784 (5.8%) | 143 (4.3%) | 0.07 | 86.7 (4.5%) | 86.7 (4.5%) | 0.00 |
| Influenza; n (%) | 71 (1.0%) | 106 (0.9%) | 0.02 | 16.1 (0.9%) | 16.1 (0.9%) | 0.00 | 21 (1.3%) | 11 (0.7%) | 0.06 | 3.5 (1.1%) | 3.5 (1.1%) | 0.00 | 178 (1.3%) | 41 (1.2%) | 0.01 | 24.0 (1.3%) | 24.0 (1.3%) | 0.00 |
| Hyperthyroidism and other thyroid gland disorders; n (%) | 1,622 (23.6%) | 2,833 (23.0%) | 0.01 | 438.2 (24.4%) | 438.2 (24.4%) | 0.00 | 277 (17.6%) | 311 (19.7%) | 0.05 | 59.8 (18.9%) | 59.8 (18.9%) | 0.00 | 3,632 (26.8%) | 1,017 (30.6%) | 0.09 | 572.5 (30.0%) | 572.5 (30.0%) | 0.00 |
| Hypothyroidism; n (%) | 1,481 (21.5%) | 2,315 (18.8%) | 0.07 | 369.8 (20.6%) | 369.8 (20.6%) | 0.00 | 263 (16.7%) | 238 (15.1%) | 0.05 | 47.8 (15.1%) | 47.8 (15.1%) | 0.00 | 3,826 (28.2%) | 866 (26.1%) | 0.05 | 504.9 (26.5%) | 504.9 (26.5%) | 0.00 |
| Urinary incontinence; n (%) | 411 (6.0%) | 533 (4.3%) | 0.08 | 92.8 (5.2%) | 92.8 (5.2%) | 0.00 | 60 (3.8%) | 27 (1.7%) | 0.13 | 8.4 (2.7%) | 8.4 (2.7%) | 0.00 | 1,020 (7.5%) | 186 (5.6%) | 0.08 | 119.4 (6.3%) | 119.4 (6.3%) | 0.00 |
| Serious infections; n (%) | 1,740 (25.3%) | 2,551 (20.7%) | 0.11 | 410.4 (22.8%) | 410.4 (22.8%) | 0.00 | 344 (21.9%) | 254 (16.1%) | 0.15 | 64.4 (20.3%) | 64.4 (20.3%) | 0.00 | 4,158 (30.7%) | 854 (25.7%) | 0.11 | 531.3 (27.8%) | 531.3 (27.8%) | 0.00 |
| Liver disease ; n (%) | 547 (7.9%) | 1,096 (8.9%) | 0.03 | 156.2 (8.7%) | 156.2 (8.7%) | 0.00 | 116 (7.4%) | 136 (8.6%) | 0.05 | 28.2 (8.9%) | 28.2 (8.9%) | 0.00 | 466 (3.4%) | 153 (4.6%) | 0.06 | 84.0 (4.4%) | 84.0 (4.4%) | 0.00 |
| Fractures / Falls; n (%) | 482 (7.0%) | 619 (5.0%) | 0.08 | 99.9 (5.6%) | 99.9 (5.6%) | 0.00 | 68 (4.3%) | 37 (2.3%) | 0.11 | 9.6 (3.1%) | 9.6 (3.1%) | 0.00 | 334 (2.5%) | 58 (1.7%) | 0.05 | 37.0 (1.9%) | 37.0 (1.9%) | 0.00 |

| | | | | | | | | | | | | | | | | | | |
|---------------------------------------------------------------------|---------------|----------------|------|-----------------|-----------------|------|---------------|---------------|------|---------------|---------------|------|---------------|---------------|------|-----------------|-----------------|------|
| Osteoporosis; n (%) | 395 (5.7%) | 628 (5.1%) | 0.03 | 99.4 (5.5%) | 99.4 (5.5%) | 0.00 | 44 (2.8%) | 34 (2.2%) | 0.04 | 8.8 (2.8%) | 8.8 (2.8%) | 0.00 | 1,262 (9.3%) | 232 (7.0%) | 0.09 | 147.0 (7.7%) | 147.0 (7.7%) | 0.00 |
| Osteoarthritis; n (%) | 1,810 (26.3%) | 2,798 (22.7%) | 0.08 | 447.8 (24.9%) | 447.8 (24.9%) | 0.00 | 274 (17.4%) | 219 (13.9%) | 0.10 | 43.3 (13.7%) | 43.3 (13.7%) | 0.00 | 4,593 (33.9%) | 963 (29.0%) | 0.11 | 592.0 (31.0%) | 592.0 (31.0%) | 0.00 |
| Depression ; n (%) | 1,280 (18.6%) | 1,909 (15.5%) | 0.08 | 302.4 (16.8%) | 302.4 (16.8%) | 0.00 | 178 (11.3%) | 159 (10.1%) | 0.04 | 34.0 (10.7%) | 34.0 (10.7%) | 0.00 | 1,903 (14.0%) | 372 (11.2%) | 0.09 | 221.3 (11.6%) | 221.3 (11.6%) | 0.00 |
| Anxiety; n (%) | 849 (12.3%) | 1,550 (12.6%) | 0.01 | 222.2 (12.4%) | 222.2 (12.4%) | 0.00 | 151 (9.6%) | 147 (9.3%) | 0.01 | 32.6 (10.3%) | 32.6 (10.3%) | 0.00 | 2,033 (15.0%) | 445 (13.4%) | 0.05 | 262.2 (13.7%) | 262.2 (13.7%) | 0.00 |
| Sleep disorder; n (%) | 1,866 (27.1%) | 3,192 (25.9%) | 0.03 | 471.3 (26.2%) | 471.3 (26.2%) | 0.00 | 312 (19.9%) | 243 (15.4%) | 0.12 | 51.8 (16.4%) | 51.8 (16.4%) | 0.00 | 4,366 (32.2%) | 1,073 (32.3%) | 0.00 | 627.8 (32.9%) | 627.8 (32.9%) | 0.00 |
| Dementia ; n (%) | 736 (10.7%) | 670 (5.4%) | 0.19 | 133.2 (7.4%) | 133.2 (7.4%) | 0.00 | 101 (6.4%) | 37 (2.3%) | 0.20 | 12.3 (3.9%) | 12.3 (3.9%) | 0.00 | 1,689 (12.5%) | 174 (5.2%) | 0.26 | 123.9 (6.5%) | 123.9 (6.5%) | 0.00 |
| Delirium; n (%) | 194 (2.8%) | 128 (1.0%) | 0.13 | 24.7 (1.4%) | 24.7 (1.4%) | 0.00 | 35 (2.2%) | 9 (0.6%) | 0.14 | 3.7 (1.2%) | 3.7 (1.2%) | 0.00 | 521 (3.8%) | 20 (0.6%) | 0.22 | 16.2 (0.9%) | 16.2 (0.9%) | 0.00 |
| Number of distinct medications; mean (SD) | 13.04 (5.30) | 13.58 (5.41) | 0.10 | 13.24 (5.36) | 13.24 (5.47) | 0.00 | 10.69 (4.99) | 11.21 (4.87) | 0.11 | 10.96 (4.88) | 10.96 (5.05) | 0.00 | 13.04 (5.34) | 13.44 (5.10) | 0.08 | 13.24 (5.34) | 13.24 (5.16) | 0.00 |
| Number of antidiabetic drugs at cohort entry; mean (SD) | 1.11 (0.83) | 2.09 (0.88) | 1.16 | 1.58 (0.82) | 1.58 (0.67) | 0.00 | 1.02 (0.81) | 1.99 (0.87) | 1.16 | 1.52 (0.85) | 1.52 (0.65) | 0.00 | 2.12 (0.81) | 2.34 (0.90) | 0.27 | 2.25 (0.85) | 2.25 (0.87) | 0.00 |
| Concomitant initiation or current use of metformin; n (%) | 2,654 (38.5%) | 5,586 (45.3%) | 0.14 | 892.1 (49.6%) | 417.3 (23.2%) | 0.57 | 554 (35.3%) | 610 (38.7%) | 0.07 | 157.5 (49.7%) | 68.1 (21.5%) | 0.62 | 5,276 (38.9%) | 1,708 (51.5%) | 0.26 | 859.0 (45.0%) | 936.8 (49.1%) | 0.08 |
| Concomitant initiation or current use of sulfonylureas; n (%) | 2,158 (31.3%) | 2,562 (20.8%) | 0.24 | 661.6 (36.8%) | 279.6 (15.5%) | 0.50 | 389 (24.8%) | 263 (16.7%) | 0.20 | 104.2 (32.9%) | 39.5 (12.5%) | 0.50 | 4,345 (32.0%) | 886 (26.7%) | 0.12 | 563.3 (29.5%) | 557.3 (29.2%) | 0.01 |
| Concomitant initiation or current use of GLP-1RAs; n (%) | 169 (2.5%) | 1,178 (9.6%) | 0.30 | 117.3 (6.5%) | 40.5 (2.3%) | 0.21 | 44 (2.8%) | 200 (12.7%) | 0.38 | 26.2 (8.3%) | 9.3 (2.9%) | 0.23 | 240 (1.8%) | 444 (13.4%) | 0.45 | 93.9 (4.9%) | 150.2 (7.9%) | 0.12 |
| Concomitant initiation or current use of insulins; n (%) | 1,292 (18.8%) | 3,146 (25.5%) | 0.16 | 532.5 (29.6%) | 217.5 (12.1%) | 0.44 | 229 (14.6%) | 369 (23.4%) | 0.23 | 82.4 (26.0%) | 33.1 (10.5%) | 0.41 | 2,821 (20.8%) | 1,054 (31.8%) | 0.25 | 501.5 (26.3%) | 519.9 (27.2%) | 0.02 |
| Concomitant initiation or current use of other antidiabetics; n (%) | 413 (6.0%) | 644 (5.2%) | 0.03 | 164.7 (9.2%) | 65.3 (3.6%) | 0.23 | 67 (4.3%) | 51 (3.2%) | 0.05 | 21.7 (6.9%) | 8.8 (2.8%) | 0.19 | 808 (6.0%) | 228 (6.9%) | 0.04 | 127.3 (6.7%) | 129.4 (6.8%) | 0.00 |
| Past use of metformin; n (%) | 3,376 (49.0%) | 6,733 (54.6%) | 0.11 | 908.1 (50.5%) | 908.1 (50.5%) | 0.00 | 762 (48.5%) | 853 (54.1%) | 0.11 | 170.1 (53.7%) | 170.1 (53.7%) | 0.00 | 7,237 (53.4%) | 2,169 (65.4%) | 0.25 | 1,184.4 (62.1%) | 1,184.4 (62.1%) | 0.00 |
| Past use of sulfonylureas; n (%) | 2,598 (37.7%) | 3,157 (25.6%) | 0.26 | 619.1 (34.4%) | 619.1 (34.4%) | 0.00 | 497 (31.6%) | 378 (24.0%) | 0.17 | 95.5 (30.2%) | 95.5 (30.2%) | 0.00 | 5,722 (42.2%) | 1,199 (36.1%) | 0.12 | 738.3 (38.7%) | 738.3 (38.7%) | 0.00 |
| Past use of GLP-1RAs; n (%) | 292 (4.2%) | 1,626 (13.2%) | 0.32 | 142.7 (7.9%) | 142.7 (7.9%) | 0.00 | 80 (5.1%) | 280 (17.8%) | 0.41 | 32.6 (10.3%) | 32.6 (10.3%) | 0.00 | 491 (3.6%) | 641 (19.3%) | 0.51 | 202.5 (10.6%) | 202.5 (10.6%) | 0.00 |
| Past use of insulins; n (%) | 1,627 (23.6%) | 4,002 (32.5%) | 0.20 | 518.5 (28.8%) | 518.5 (28.8%) | 0.00 | 316 (20.1%) | 503 (31.9%) | 0.27 | 79.8 (25.2%) | 79.8 (25.2%) | 0.00 | 3,924 (28.9%) | 1,397 (42.1%) | 0.28 | 688.2 (36.1%) | 688.2 (36.1%) | 0.00 |
| Past use of other antidiabetics; n (%) | 545 (7.9%) | 831 (6.7%) | 0.05 | 159.9 (8.9%) | 159.9 (8.9%) | 0.00 | 91 (5.8%) | 83 (5.3%) | 0.02 | 19.3 (6.1%) | 19.3 (6.1%) | 0.00 | 1,263 (9.3%) | 360 (10.8%) | 0.05 | 201.7 (10.6%) | 201.7 (10.6%) | 0.00 |
| ACE / ARB; n (%) | 4,816 (69.9%) | 8,434 (68.4%) | 0.03 | 1,249.9 (69.5%) | 1,249.9 (69.5%) | 0.00 | 999 (63.6%) | 1,016 (64.5%) | 0.02 | 206.8 (65.3%) | 206.8 (65.3%) | 0.00 | 8,990 (66.3%) | 2,296 (69.2%) | 0.06 | 1,301.8 (68.2%) | 1,301.8 (68.2%) | 0.00 |
| ARNI; n (%) | 126 (1.8%) | 748 (6.1%) | 0.22 | 58.8 (3.3%) | 58.8 (3.3%) | 0.00 | 26 (1.7%) | 113 (7.2%) | 0.27 | 13.2 (4.2%) | 13.2 (4.2%) | 0.00 | 79 (0.6%) | 100 (3.0%) | 0.18 | 33.7 (1.8%) | 33.7 (1.8%) | 0.00 |
| Mineralocorticoid receptor antagonist; n (%) | 614 (8.9%) | 2,111 (17.1%) | 0.25 | 198.6 (11.0%) | 198.6 (11.0%) | 0.00 | 41 (2.6%) | 76 (4.8%) | 0.12 | 10.3 (3.3%) | 10.3 (3.3%) | 0.00 | 1,102 (8.1%) | 357 (10.8%) | 0.09 | 187.2 (9.8%) | 187.2 (9.8%) | 0.00 |
| Thiazides; n (%) | 1,790 (26.0%) | 2,970 (24.1%) | 0.04 | 453.9 (25.2%) | 453.9 (25.2%) | 0.00 | 324 (20.6%) | 302 (19.2%) | 0.04 | 67.4 (21.3%) | 67.4 (21.3%) | 0.00 | 3,793 (28.0%) | 955 (28.8%) | 0.02 | 539.9 (28.3%) | 539.9 (28.3%) | 0.00 |
| Beta-blockers; n (%) | 4,445 (64.6%) | 8,713 (70.7%) | 0.13 | 1,196.8 (66.5%) | 1,196.8 (66.5%) | 0.00 | 889 (56.6%) | 1,001 (63.5%) | 0.14 | 194.0 (61.3%) | 194.0 (61.3%) | 0.00 | 8,668 (63.9%) | 2,291 (69.0%) | 0.11 | 1,288.6 (67.5%) | 1,288.6 (67.5%) | 0.00 |
| Calcium channel blockers; n (%) | 2,607 (37.9%) | 4,580 (37.2%) | 0.01 | 681.5 (37.9%) | 681.5 (37.9%) | 0.00 | 534 (34.0%) | 494 (31.3%) | 0.06 | 101.1 (31.9%) | 101.1 (31.9%) | 0.00 | 5,299 (39.1%) | 1,261 (38.0%) | 0.02 | 732.1 (38.4%) | 732.1 (38.4%) | 0.00 |
| DIGOXIN / DIGITOXIN; n (%) | 323 (4.7%) | 342 (2.8%) | 0.10 | 58.0 (3.2%) | 58.0 (3.2%) | 0.00 | 53 (3.4%) | 22 (1.4%) | 0.13 | 5.2 (1.7%) | 5.2 (1.7%) | 0.00 | 758 (5.6%) | 113 (3.4%) | 0.11 | 72.7 (3.8%) | 72.7 (3.8%) | 0.00 |
| Loop diuretics; n (%) | 3,152 (45.8%) | 6,295 (51.1%) | 0.11 | 832.9 (46.3%) | 832.9 (46.3%) | 0.00 | 254 (16.2%) | 278 (17.6%) | 0.04 | 48.9 (15.4%) | 48.9 (15.4%) | 0.00 | 6,893 (50.8%) | 1,627 (49.0%) | 0.04 | 934.2 (48.9%) | 934.2 (48.9%) | 0.00 |
| Other diuretics; n (%) | 723 (10.5%) | 2,265 (18.4%) | 0.23 | 224.5 (12.5%) | 224.5 (12.5%) | 0.00 | 43 (2.7%) | 79 (5.0%) | 0.12 | 10.5 (3.3%) | 10.5 (3.3%) | 0.00 | 1,398 (10.3%) | 421 (12.7%) | 0.08 | 227.8 (11.9%) | 227.8 (11.9%) | 0.00 |
| Intravenous diuretics; n (%) | 283 (4.1%) | 675 (5.5%) | 0.06 | 85.5 (4.8%) | 85.5 (4.8%) | 0.00 | 52 (3.3%) | 62 (3.9%) | 0.03 | 12.1 (3.8%) | 12.1 (3.8%) | 0.00 | 479 (3.5%) | 152 (4.6%) | 0.05 | 81.6 (4.3%) | 81.6 (4.3%) | 0.00 |
| Nitrates; n (%) | 903 (13.1%) | 1,775 (14.4%) | 0.04 | 239.6 (13.3%) | 239.6 (13.3%) | 0.00 | 156 (9.9%) | 177 (11.2%) | 0.04 | 31.8 (10.1%) | 31.8 (10.1%) | 0.00 | 1,745 (12.9%) | 483 (14.6%) | 0.05 | 266.7 (14.0%) | 266.7 (14.0%) | 0.00 |
| Anti-arrhythmics; n (%) | 232 (3.4%) | 509 (4.1%) | 0.04 | 65.5 (3.6%) | 65.5 (3.6%) | 0.00 | 43 (2.7%) | 53 (3.4%) | 0.04 | 8.8 (2.8%) | 8.8 (2.8%) | 0.00 | 443 (3.3%) | 137 (4.1%) | 0.05 | 74.2 (3.9%) | 74.2 (3.9%) | 0.00 |
| Statins; n (%) | 5,242 (76.1%) | 10,089 (81.9%) | 0.14 | 1,418.4 (78.9%) | 1,418.4 (78.9%) | 0.00 | 1,051 (66.9%) | 1,141 (72.4%) | 0.12 | 220.8 (69.7%) | 220.8 (69.7%) | 0.00 | 9,650 (71.1%) | 2,652 (79.9%) | 0.21 | 1,485.6 (77.8%) | 1,485.6 (77.8%) | 0.00 |
| Other lipid-lowering drugs; n (%) | 675 (9.8%) | 1,559 (12.6%) | 0.09 | 196.4 (10.9%) | 196.4 (10.9%) | 0.00 | 154 (9.8%) | 211 (13.4%) | 0.11 | 40.6 (12.8%) | 40.6 (12.8%) | 0.00 | 1,519 (11.2%) | 476 (14.3%) | 0.09 | 252.6 (13.2%) | 252.6 (13.2%) | 0.00 |
| Antiplatelet agents; n (%) | 1,215 (17.6%) | 2,384 (19.3%) | 0.04 | 330.8 (18.4%) | 330.8 (18.4%) | 0.00 | 308 (19.6%) | 326 (20.7%) | 0.03 | 62.2 (19.7%) | 62.2 (19.7%) | 0.00 | 2,470 (18.2%) | 708 (21.3%) | 0.08 | 380.0 (19.9%) | 380.0 (19.9%) | 0.00 |
| Oral anticoagulants; n (%) | 1,425 (20.7%) | 3,080 (25.0%) | 0.10 | 395.7 (22.0%) | 395.7 (22.0%) | 0.00 | 229 (14.6%) | 297 (18.8%) | 0.12 | 50.6 (16.0%) | 50.6 (16.0%) | 0.00 | 2,711 (20.0%) | 748 (22.5%) | 0.06 | 415.7 (21.8%) | 415.7 (21.8%) | 0.00 |
| COPD/Asthma medications; n (%) | 1,992 (28.9%) | 3,823 (31.0%) | 0.05 | 527.1 (29.3%) | 527.1 (29.3%) | 0.00 | 372 (23.7%) | 398 (25.3%) | 0.04 | 73.5 (23.2%) | 73.5 (23.2%) | 0.00 | 4,281 (31.6%) | 1,048 (31.6%) | 0.00 | 605.8 (31.7%) | 605.8 (31.7%) | 0.00 |

| | | | | | | | | | | | | | | | | | | |
|------------------------------------------------------------------------|--------------------|-----------------|------|-----------------|-----------------|------|--------------------|-----------------|------|--------------------|-----------------|------|--------------------|-----------------|------|--------------------|-----------------|------|
| NSAIDS ; n (%) | 1,223 (17.8%) | 2,191 (17.8%) | 0.00 | 339.9 (18.9%) | 339.9 (18.9%) | 0.00 | 289 (18.4%) | 271 (17.2%) | 0.03 | 64.4 (20.3%) | 64.4 (20.3%) | 0.00 | 2,736 (20.2%) | 609 (18.3%) | 0.05 | 368.2 (19.3%) | 368.2 (19.3%) | 0.00 |
| Oral corticosteroids ; n (%) | 845 (12.3%) | 1,683 (13.7%) | 0.04 | 226.1 (12.6%) | 226.1 (12.6%) | 0.00 | 205 (13.0%) | 208 (13.2%) | 0.00 | 42.8 (13.5%) | 42.8 (13.5%) | 0.00 | 1,884 (13.9%) | 479 (14.4%) | 0.02 | 284.3 (14.9%) | 284.3 (14.9%) | 0.00 |
| Osteoporosis agents (incl. bisphosphonates); n (%) | 270 (3.9%) | 440 (3.6%) | 0.02 | 70.0 (3.9%) | 70.0 (3.9%) | 0.00 | 43 (2.7%) | 30 (1.9%) | 0.06 | 5.8 (1.8%) | 5.8 (1.8%) | 0.00 | 715 (5.3%) | 125 (3.8%) | 0.07 | 80.1 (4.2%) | 80.1 (4.2%) | 0.00 |
| Opioids ; n (%) | 1,851 (26.9%) | 2,755 (22.4%) | 0.11 | 443.7 (24.7%) | 443.7 (24.7%) | 0.00 | 392 (25.0%) | 294 (18.7%) | 0.15 | 67.3 (21.3%) | 67.3 (21.3%) | 0.00 | 4,222 (31.1%) | 849 (25.6%) | 0.12 | 520.3 (27.3%) | 520.3 (27.3%) | 0.00 |
| Antidepressants Copy; n (%) | 2,174 (31.6%) | 3,994 (32.4%) | 0.02 | 562.7 (31.3%) | 562.7 (31.3%) | 0.00 | 407 (25.9%) | 400 (25.4%) | 0.01 | 76.5 (24.2%) | 76.5 (24.2%) | 0.00 | 4,806 (35.4%) | 1,148 (34.6%) | 0.02 | 663.5 (34.8%) | 663.5 (34.8%) | 0.00 |
| Benzodiazepines; n (%) | 787 (11.4%) | 1,082 (8.8%) | 0.09 | 167.9 (9.3%) | 167.9 (9.3%) | 0.00 | 154 (9.8%) | 119 (7.6%) | 0.08 | 27.4 (8.7%) | 27.4 (8.7%) | 0.00 | 2,107 (15.5%) | 386 (11.6%) | 0.11 | 244.2 (12.8%) | 244.2 (12.8%) | 0.00 |
| Dementia medications ; n (%) | 406 (5.9%) | 332 (2.7%) | 0.16 | 71.1 (4.0%) | 71.1 (4.0%) | 0.00 | 60 (3.8%) | 37 (2.3%) | 0.09 | 8.4 (2.7%) | 8.4 (2.7%) | 0.00 | 1,352 (10.0%) | 143 (4.3%) | 0.22 | 102.8 (5.4%) | 102.8 (5.4%) | 0.00 |
| Antipsychotics; n (%) | 303 (4.4%) | 431 (3.5%) | 0.05 | 68.6 (3.8%) | 68.6 (3.8%) | 0.00 | 51 (3.2%) | 37 (2.3%) | 0.06 | 7.5 (2.4%) | 7.5 (2.4%) | 0.00 | 1,016 (7.5%) | 136 (4.1%) | 0.15 | 90.5 (4.7%) | 90.5 (4.7%) | 0.00 |
| ED visit ; n (%) | 2,196 (31.9%) | 3,302 (26.8%) | 0.11 | 540.4 (30.0%) | 540.4 (30.0%) | 0.00 | 451 (28.7%) | 375 (23.8%) | 0.11 | 85.4 (27.0%) | 85.4 (27.0%) | 0.00 | 4,492 (33.1%) | 831 (25.0%) | 0.18 | 524.6 (27.5%) | 524.6 (27.5%) | 0.00 |
| Number of office visits; mean (SD) | 5.52 (4.01) | 6.03 (4.09) | 0.13 | 5.75 (4.09) | 5.75 (3.93) | 0.00 | 5.52 (3.98) | 5.73 (3.95) | 0.06 | 5.48 (3.92) | 5.48 (3.85) | 0.00 | 5.83 (4.62) | 6.82 (4.38) | 0.22 | 6.59 (4.72) | 6.59 (4.35) | 0.00 |
| Number of Endocrinologist visits; mean (SD) | 0.20 (0.94) | 0.30 (1.03) | 0.10 | 0.26 (0.94) | 0.26 (1.17) | 0.00 | 0.19 (0.69) | 0.32 (0.86) | 0.17 | 0.25 (0.77) | 0.25 (0.80) | 0.00 | 0.19 (0.71) | 0.45 (1.04) | 0.29 | 0.32 (0.93) | 0.32 (0.92) | 0.00 |
| Endocrinologist visit (within prior 30d); n (%) | 358 (5.2%) | 1,163 (9.4%) | 0.16 | 129.3 (7.2%) | 129.3 (7.2%) | 0.00 | 105 (6.7%) | 184 (11.7%) | 0.17 | 26.7 (8.4%) | 26.7 (8.4%) | 0.00 | 815 (6.0%) | 551 (16.6%) | 0.34 | 212.2 (11.1%) | 212.2 (11.1%) | 0.00 |
| Endocrinologist visit (31-183 d); n (%) | 495 (7.2%) | 1,334 (10.8%) | 0.13 | 164.0 (9.1%) | 164.0 (9.1%) | 0.00 | 111 (7.1%) | 187 (11.9%) | 0.17 | 29.8 (9.4%) | 29.8 (9.4%) | 0.00 | 1,023 (7.5%) | 543 (16.4%) | 0.27 | 226.2 (11.9%) | 226.2 (11.9%) | 0.00 |
| Number of Cardiologist visits; mean (SD) | 1.53 (2.31) | 1.87 (2.51) | 0.14 | 1.64 (2.27) | 1.64 (2.56) | 0.00 | 1.39 (2.30) | 1.69 (2.21) | 0.13 | 1.52 (2.24) | 1.52 (2.15) | 0.00 | 1.15 (1.92) | 1.34 (1.90) | 0.10 | 1.27 (1.93) | 1.27 (1.86) | 0.00 |
| Cardiologist visit (within prior 30 d); n (%) | 1,388 (20.2%) | 3,952 (32.1%) | 0.27 | 438.5 (24.4%) | 438.5 (24.4%) | 0.00 | 315 (20.1%) | 457 (29.0%) | 0.21 | 73.0 (23.1%) | 73.0 (23.1%) | 0.00 | 2,272 (16.7%) | 763 (23.0%) | 0.16 | 394.2 (20.7%) | 394.2 (20.7%) | 0.00 |
| Cardiologist visit (31-183 d); n (%) | 3,381 (49.1%) | 6,669 (54.1%) | 0.10 | 916.1 (50.9%) | 916.1 (50.9%) | 0.00 | 700 (44.6%) | 830 (52.7%) | 0.16 | 154.3 (48.7%) | 154.3 (48.7%) | 0.00 | 5,839 (43.0%) | 1,602 (48.3%) | 0.11 | 892.2 (46.7%) | 892.2 (46.7%) | 0.00 |
| Number of Internal medicine/Family medicine visits ; mean (SD) | 5.39 (5.64) | 4.63 (5.11) | 0.14 | 4.96 (5.61) | 4.96 (5.31) | 0.00 | 4.11 (4.63) | 3.25 (3.50) | 0.21 | | | | 4.05 (4.28) | 3.29 (3.44) | 0.20 | 3.50 (3.51) | 3.50 (3.63) | 0.00 |
| Internal medicine/Family medicine visit (within prior 30 d); n (%) | 4,858 (70.5%) | 7,938 (64.4%) | 0.13 | 1,220.8 (67.9%) | 1,220.8 (67.9%) | 0.00 | 970 (61.7%) | 928 (58.9%) | 0.06 | 197.3 (62.3%) | 197.3 (62.3%) | 0.00 | 8,355 (61.6%) | 1,856 (55.9%) | 0.12 | 1,114.4 (58.4%) | 1,114.4 (58.4%) | 0.00 |
| Internal medicine/Family medicine visit (31-183 d); n (%) | 5,828 (84.6%) | 10,121 (82.1%) | 0.07 | 1,491.6 (82.9%) | 1,491.6 (82.9%) | 0.00 | 1,174 (74.7%) | 1,182 (75.0%) | 0.01 | 232.8 (73.5%) | 232.8 (73.5%) | 0.00 | 10,560 (77.8%) | 2,462 (74.2%) | 0.09 | 1,428.6 (74.8%) | 1,428.6 (74.8%) | 0.00 |
| SES - Out-of-pocket medication cost; mean (SD) | 328.76 (456.71) | 389.82 (474.09) | 0.13 | 349.31 (518.37) | 349.31 (407.06) | 0.00 | 243.21 (302.75) | 323.15 (411.22) | 0.22 | 273.07 (333.20) | 273.07 (276.88) | 0.00 | 333.67 (470.55) | 551.37 (683.52) | 0.37 | 456.12 (586.48) | 456.12 (534.59) | 0.00 |
| SES - Unique brand medications; mean (SD) | 13.19 (5.44) | 13.74 (5.54) | 0.10 | 13.39 (5.50) | 13.38 (5.60) | 0.00 | 10.85 (5.13) | 11.35 (4.98) | 0.10 | 11.11 (5.02) | 11.11 (5.18) | 0.00 | 13.25 (5.51) | 13.61 (5.23) | 0.07 | 13.42 (5.50) | 13.41 (5.29) | 0.00 |
| SES - Unique generic medications; mean (SD) | 13.04 (5.30) | 13.58 (5.41) | 0.10 | 13.24 (5.36) | 13.24 (5.47) | 0.00 | 10.69 (4.99) | 11.21 (4.87) | 0.11 | 10.96 (4.88) | 10.96 (5.05) | 0.00 | 13.04 (5.34) | 13.44 (5.10) | 0.08 | 13.24 (5.34) | 13.24 (5.16) | 0.00 |
| Ratio (brand/generic); mean (SD) | 1.01 (0.03) | 1.01 (0.03) | 0.00 | 1.01 (0.03) | 1.01 (0.03) | 0.00 | 1.01 (0.04) | 1.01 (0.03) | 0.07 | 1.01 (0.04) | 1.01 (0.04) | 0.00 | 1.01 (0.04) | 1.01 (0.03) | 0.07 | 1.01 (0.03) | 1.01 (0.03) | 0.00 |
| Electrocardiograms (ECG/EKG) ; n (%) | 3,358 (48.8%) | 6,439 (52.2%) | 0.07 | 896.6 (49.8%) | 896.6 (49.8%) | 0.00 | 884 (56.3%) | 892 (56.6%) | 0.01 | 185.0 (58.4%) | 185.0 (58.4%) | 0.00 | 6,541 (48.2%) | 1,681 (50.6%) | 0.05 | 949.8 (49.8%) | 949.8 (49.8%) | 0.00 |
| Echocardiograms ; n (%) | 1,830 (26.6%) | 3,877 (31.5%) | 0.11 | 506.7 (28.2%) | 506.7 (28.2%) | 0.00 | 522 (33.2%) | 540 (34.3%) | 0.02 | 106.4 (33.6%) | 106.4 (33.6%) | 0.00 | 2,740 (20.2%) | 757 (22.8%) | 0.06 | 422.7 (22.1%) | 422.7 (22.1%) | 0.00 |
| Flexible sigmoidoscopy or colonoscopy or CT virtual colonoscopy; n (%) | 196 (2.8%) | 501 (4.1%) | 0.07 | 60.4 (3.4%) | 60.4 (3.4%) | 0.00 | 66 (4.2%) | 86 (5.5%) | 0.06 | 14.8 (4.7%) | 14.8 (4.7%) | 0.00 | 372 (2.7%) | 138 (4.2%) | 0.08 | 71.6 (3.8%) | 71.6 (3.8%) | 0.00 |
| Flu vaccine Copy; n (%) | 1,384 (20.1%) | 2,385 (19.4%) | 0.02 | 361.9 (20.1%) | 361.9 (20.1%) | 0.00 | 273 (17.4%) | 267 (16.9%) | 0.01 | 47.9 (15.1%) | 47.9 (15.1%) | 0.00 | 4,322 (31.9%) | 1,114 (33.6%) | 0.04 | 630.2 (33.0%) | 630.2 (33.0%) | 0.00 |
| Pneumococcal vaccine; n (%) | 390 (5.7%) | 606 (4.9%) | 0.03 | 90.9 (5.1%) | 90.9 (5.1%) | 0.00 | 87 (5.5%) | 77 (4.9%) | 0.03 | 13.0 (4.1%) | 13.0 (4.1%) | 0.00 | 1,161 (8.6%) | 303 (9.1%) | 0.02 | 172.0 (9.0%) | 172.0 (9.0%) | 0.00 |
| Hyperkalemia ; n (%) | 195 (2.8%) | 347 (2.8%) | 0.00 | 49.2 (2.7%) | 49.2 (2.7%) | 0.00 | 27 (1.7%) | 23 (1.5%) | 0.02 | 6.0 (1.9%) | 6.0 (1.9%) | 0.00 | 194 (1.4%) | 19 (0.6%) | 0.09 | 14.5 (0.8%) | 14.5 (0.8%) | 0.00 |
| Anemia ; n (%) | 1,129 (16.4%) | 1,712 (13.9%) | 0.07 | 284.4 (15.8%) | 284.4 (15.8%) | 0.00 | 101 (6.4%) | 107 (6.8%) | 0.02 | 21.6 (6.8%) | 21.6 (6.8%) | 0.00 | 2,210 (16.3%) | 417 (12.6%) | 0.11 | 264.3 (13.9%) | 264.3 (13.9%) | 0.00 |
| Microalbuminuria; n (%) | 2,869 (41.7%) | 5,783 (46.9%) | 0.11 | 803.8 (44.7%) | 803.8 (44.7%) | 0.00 | 438 (27.9%) | 655 (41.6%) | 0.29 | 108.6 (34.3%) | 108.6 (34.3%) | 0.00 | 4,723 (34.8%) | 1,492 (45.0%) | 0.21 | 798.0 (41.8%) | 798.0 (41.8%) | 0.00 |
| Glucose test ordered ; n (%) | 5,990 (87.0%) | 10,814 (87.7%) | 0.02 | 1,566.0 (87.1%) | 1,566.0 (87.1%) | 0.00 | 1,126 (71.7%) | 1,299 (82.4%) | 0.26 | 252.9 (79.9%) | 252.9 (79.9%) | 0.00 | 12,308 (90.7%) | 3,123 (94.1%) | 0.13 | 1,780.7 (93.3%) | 1,780.7 (93.3%) | 0.00 |
| Lipid panel ; n (%) | 4,623 (67.1%) | 8,485 (68.8%) | 0.04 | 1,235.7 (68.7%) | 1,235.7 (68.7%) | 0.00 | 802 (51.1%) | 1,015 (64.4%) | 0.27 | 190.3 (60.1%) | 190.3 (60.1%) | 0.00 | 9,337 (68.8%) | 2,480 (74.7%) | 0.13 | 1,404.5 (73.6%) | 1,404.5 (73.6%) | 0.00 |
| Creatinine tests ; n (%) | 218 (3.2%) | 295 (2.4%) | 0.05 | 48.9 (2.7%) | 48.9 (2.7%) | 0.00 | 44 (2.8%) | 44 (2.8%) | 0.00 | 10.5 (3.3%) | 10.5 (3.3%) | 0.00 | 536 (4.0%) | 142 (4.3%) | 0.02 | 79.1 (4.1%) | 79.1 (4.1%) | 0.00 |

| | | | | | | | | | | | | | | | | | | |
|-------------------------------------------------------------------------|---------------|----------------|------|-----------------|-----------------|------|---------------|---------------|------|---------------|---------------|------|----------------|---------------|------|-----------------|-----------------|------|
| Pap smear ; n (%) | 90 (1.3%) | 172 (1.4%) | 0.01 | 27.6 (1.5%) | 27.6 (1.5%) | 0.00 | 55 (3.5%) | 29 (1.8%) | 0.10 | 9.2 (2.9%) | 9.2 (2.9%) | 0.00 | 1,114 (8.2%) | 341 (10.3%) | 0.07 | 189.4 (9.9%) | 189.4 (9.9%) | 0.00 |
| PSA test ; n (%) | 726 (10.5%) | 1,677 (13.6%) | 0.09 | 217.6 (12.1%) | 217.6 (12.1%) | 0.00 | 160 (10.2%) | 245 (15.5%) | 0.16 | 41.0 (13.0%) | 41.0 (13.0%) | 0.00 | 1,280 (9.4%) | 436 (13.1%) | 0.12 | 232.1 (12.2%) | 232.1 (12.2%) | 0.00 |
| Fecal occult blood test ; n (%) | 291 (4.2%) | 341 (2.8%) | 0.08 | 62.0 (3.5%) | 62.0 (3.5%) | 0.00 | 43 (2.7%) | 39 (2.5%) | 0.02 | 8.0 (2.5%) | 8.0 (2.5%) | 0.00 | 430 (3.2%) | 107 (3.2%) | 0.00 | 58.5 (3.1%) | 58.5 (3.1%) | 0.00 |
| Urine tests ; n (%) | 4,190 (60.8%) | 7,487 (60.7%) | 0.00 | 1,109.8 (61.7%) | 1,109.8 (61.7%) | 0.00 | 768 (48.9%) | 865 (54.9%) | 0.12 | 167.7 (53.0%) | 167.7 (53.0%) | 0.00 | 8,181 (60.3%) | 2,061 (62.1%) | 0.04 | 1,171.8 (61.4%) | 1,171.8 (61.4%) | 0.00 |
| Combined comorbidity score, 180 days; mean (SD) | 4.29 (1.97) | 4.01 (1.83) | 0.15 | 4.12 (1.86) | 4.12 (1.89) | 0.00 | 3.20 (1.60) | 3.18 (1.47) | 0.02 | 3.15 (1.43) | 3.15 (1.52) | 0.00 | 2.91 (2.06) | 2.74 (1.89) | 0.08 | 2.77 (1.92) | 2.77 (1.94) | 0.00 |
| Frailty Score: Empirical Version 180 days (ICD-9 and ICD-10); mean (SD) | 0.20 (0.05) | 0.19 (0.05) | 0.23 | 0.19 (0.05) | 0.19 (0.05) | 0.00 | 0.19 (0.05) | 0.17 (0.04) | 0.30 | 0.18 (0.04) | 0.18 (0.04) | 0.00 | 0.23 (0.06) | 0.21 (0.05) | 0.31 | 0.22 (0.05) | 0.22 (0.05) | 0.00 |
| Number of hospitalizations (0, 1, 2 or more) | | | | | | | | | | | | | | | | | | |
| ...< 1; n (%) | 5,452 (79.2%) | 10,345 (83.9%) | 0.12 | 1,474.6 (82.0%) | 1,474.6 (82.0%) | 0.00 | 1,277 (81.3%) | 1,382 (87.7%) | 0.18 | 268.5 (84.8%) | 268.5 (84.8%) | 0.00 | 10,461 (77.1%) | 2,799 (84.3%) | 0.18 | 1,577.5 (82.6%) | 1,577.5 (82.6%) | 0.00 |
| ...1 - <2; n (%) | 921 (13.4%) | 1,444 (11.7%) | 0.05 | 226.8 (12.6%) | 226.8 (12.6%) | 0.00 | 16 (1.0%) | 14 (0.9%) | 0.01 | 2.6 (0.8%) | 2.6 (0.8%) | 0.00 | 2,261 (16.7%) | 412 (12.4%) | 0.12 | 256.3 (13.4%) | 256.3 (13.4%) | 0.00 |
| ...>= 2; n (%) | 513 (7.4%) | 536 (4.3%) | 0.13 | 97.4 (5.4%) | 97.4 (5.4%) | 0.00 | 278 (17.7%) | 180 (11.4%) | 0.18 | 45.6 (14.4%) | 45.6 (14.4%) | 0.00 | 843 (6.2%) | 108 (3.3%) | 0.14 | 75.0 (3.9%) | 75.0 (3.9%) | 0.00 |
| Number of hospitalizations for heart failure (0, 1, 2 or more) | | | | | | | | | | | | | | | | | | |
| ...< 1; n (%) | 3,149 (45.7%) | 5,752 (46.7%) | 0.02 | 895.4 (49.8%) | 895.4 (49.8%) | 0.00 | 1,412 (89.9%) | 1,473 (93.5%) | 0.13 | 293.4 (92.7%) | 293.4 (92.7%) | 0.00 | 13,302 (98.1%) | 3,265 (98.4%) | 0.02 | 1,874.5 (98.2%) | 1,874.5 (98.2%) | 0.00 |
| ...1 - <2; n (%) | 1,623 (23.6%) | 2,897 (23.5%) | 0.00 | 411.1 (22.9%) | 411.1 (22.9%) | 0.00 | 64 (4.1%) | 41 (2.6%) | 0.08 | 8.6 (2.7%) | 8.6 (2.7%) | 0.00 | 251 (1.9%) | 52 (1.6%) | 0.02 | 32.7 (1.7%) | 32.7 (1.7%) | 0.00 |
| ...>= 2; n (%) | 2,114 (30.7%) | 3,676 (29.8%) | 0.02 | 492.3 (27.4%) | 492.3 (27.4%) | 0.00 | 95 (6.0%) | 62 (3.9%) | 0.10 | 14.7 (4.6%) | 14.7 (4.6%) | 0.00 | 12 (0.1%) | 2 (0.1%) | 0.01 | 1.6 (0.1%) | 1.6 (0.1%) | 0.00 |
| Dual status/low income subsidy; n (%) | | | | | | | | | | | | | 5,858 (43.2%) | 1,004 (30.3%) | 0.27 | 644.1 (33.8%) | 644.1 (33.8%) | 0.00 |